Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
715600.0
|
2022-05-04 00:00:00 UTC
|
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/pacific-biosciences-of-california-pacb-reports-q1-loss-tops-revenue-estimates
|
nan
|
nan
|
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -15.63%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.28 per share when it actually produced a loss of $0.30, delivering a surprise of -7.14%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Pacific Biosciences, which belongs to the Zacks Medical - Instruments industry, posted revenues of $33.17 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.29%. This compares to year-ago revenues of $29 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Pacific Biosciences shares have lost about 66.6% since the beginning of the year versus the S&P 500's decline of -12.4%.
What's Next for Pacific Biosciences?
While Pacific Biosciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Pacific Biosciences: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $38.91 million in revenues for the coming quarter and -$1.30 on $164.3 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2022. The results are expected to be released on May 10.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of +19.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Delcath Systems, Inc.'s revenues are expected to be $1.26 million, up 223.1% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Pacific Biosciences, which belongs to the Zacks Medical - Instruments industry, posted revenues of $33.17 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.29%.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.32.
|
One other stock from the same industry, Delcath Systems, Inc. (DCTH), is yet to report results for the quarter ended March 2022. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Pacific Biosciences, which belongs to the Zacks Medical - Instruments industry, posted revenues of $33.17 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 1.29%.
|
1c5cb1d8-8195-4105-a009-10635f1938e3
|
715601.0
|
2022-04-13 00:00:00 UTC
|
Wednesday 4/13 Insider Buying Report: DCTH, CSPI
|
DCTH
|
https://www.nasdaq.com/articles/wednesday-4-13-insider-buying-report%3A-dcth-cspi
|
nan
|
nan
|
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
On Monday, Delcath Systems' Chief Operating Officer, John Purpura, made a $32,950 purchase of DCTH, buying 5,000 shares at a cost of $6.59 a piece. Delcath Systems is trading off about 1.1% on the day Wednesday. Before this latest buy, Purpura made one other buy in the past twelve months, purchasing $37,680 shares for a cost of $9.42 a piece.
And on Friday, Joseph R. Nerges purchased $18,318 worth of CSPI, purchasing 2,491 shares at a cost of $7.35 a piece. Before this latest buy, Nerges purchased CSPI on 2 other occasions during the past year, for a total cost of $57,582 at an average of $8.54 per share. CSPI is trading off about 1.2% on the day Wednesday. Investors are able to buy CSPI even cheaper than Nerges did, with the stock trading as low as $7.03 at last check today which is 4.4% below Nerges's purchase price.
VIDEO: Wednesday 4/13 Insider Buying Report: DCTH, CSPI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
On Monday, Delcath Systems' Chief Operating Officer, John Purpura, made a $32,950 purchase of DCTH, buying 5,000 shares at a cost of $6.59 a piece. VIDEO: Wednesday 4/13 Insider Buying Report: DCTH, CSPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
|
VIDEO: Wednesday 4/13 Insider Buying Report: DCTH, CSPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On Monday, Delcath Systems' Chief Operating Officer, John Purpura, made a $32,950 purchase of DCTH, buying 5,000 shares at a cost of $6.59 a piece. Before this latest buy, Purpura made one other buy in the past twelve months, purchasing $37,680 shares for a cost of $9.42 a piece.
|
On Monday, Delcath Systems' Chief Operating Officer, John Purpura, made a $32,950 purchase of DCTH, buying 5,000 shares at a cost of $6.59 a piece. VIDEO: Wednesday 4/13 Insider Buying Report: DCTH, CSPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Before this latest buy, Purpura made one other buy in the past twelve months, purchasing $37,680 shares for a cost of $9.42 a piece.
|
On Monday, Delcath Systems' Chief Operating Officer, John Purpura, made a $32,950 purchase of DCTH, buying 5,000 shares at a cost of $6.59 a piece. VIDEO: Wednesday 4/13 Insider Buying Report: DCTH, CSPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And on Friday, Joseph R. Nerges purchased $18,318 worth of CSPI, purchasing 2,491 shares at a cost of $7.35 a piece.
|
49f2b690-3855-4a2c-a245-23260f42d4d9
|
715602.0
|
2022-03-25 00:00:00 UTC
|
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc.-dcth-reports-q4-loss-tops-revenue-estimates
|
nan
|
nan
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 25.81%. A quarter ago, it was expected that this company would post a loss of $0.91 per share when it actually produced a loss of $0.94, delivering a surprise of -3.30%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.11 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 285.38%. This compares to year-ago revenues of $0.38 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Delcath Systems, Inc. Shares have lost about 18.5% since the beginning of the year versus the S&P 500's decline of -5.2%.
What's Next for Delcath Systems, Inc.
While Delcath Systems, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Delcath Systems, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.92 on $0.6 million in revenues for the coming quarter and -$2.98 on $2.36 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Edwards Lifesciences (EW), another stock in the same industry, has yet to report results for the quarter ended March 2022.
This medical device maker is expected to post quarterly earnings of $0.58 per share in its upcoming report, which represents a year-over-year change of +7.4%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level.
Edwards Lifesciences' revenues are expected to be $1.31 billion, up 7.6% from the year-ago quarter.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.93. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.93. Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.11 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 285.38%.
|
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.93. Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc., which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.11 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 285.38%.
|
Delcath Systems, Inc. (DCTH): Free Stock Analysis Report Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.93. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
|
3ebb5c8d-f3ec-44ff-b625-02de9cec3e4c
|
715603.0
|
2022-03-25 00:00:00 UTC
|
Delcath Systems Q4 21 Earnings Conference Call At 8:30 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-q4-21-earnings-conference-call-at-8%3A30-am-et
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on March 25, 2022, to discuss Q4 21 earnings results.
To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/
To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 938572.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on March 25, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 938572. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on March 25, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 938572. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on March 25, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 938572. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on March 25, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://www.delcath.com/investors/events-presentations/ To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 938572. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
a15b021d-dba3-49d2-a530-a1802bb21810
|
715604.0
|
2022-01-18 00:00:00 UTC
|
Delcath Systems Inc Shares Near 52-Week Low - Market Mover
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc-shares-near-52-week-low-market-mover
|
nan
|
nan
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. The stock is currently down 9.4% year-to-date, down 56.3% over the past 12 months, and up 1393.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%.
Trading Activity
Trading volume this week was 18.2% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by 7.4%
The company's stock price performance over the past 12 months lags the peer average by 6449.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.4% The company's stock price performance over the past 12 months lags the peer average by 6449.7%
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.4% The company's stock price performance over the past 12 months lags the peer average by 6449.7% This story was produced by the Kwhen Automated News Generator.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
5c3f787b-d5ee-43e9-860e-338f7ee6cfcb
|
715605.0
|
2022-01-17 00:00:00 UTC
|
Delcath Systems Inc Shares Close in on 52-Week Low - Market Mover
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc-shares-close-in-on-52-week-low-market-mover
|
nan
|
nan
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. The stock is currently down 9.4% year-to-date, down 56.3% over the past 12 months, and up 1633.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%.
Trading Activity
Trading volume this week was 16.0% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by 7.4%
The company's stock price performance over the past 12 months lags the peer average by 6449.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.4% The company's stock price performance over the past 12 months lags the peer average by 6449.7%
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.4% The company's stock price performance over the past 12 months lags the peer average by 6449.7% This story was produced by the Kwhen Automated News Generator.
|
Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
41ecf1c4-9374-45fd-ac56-11efe41c28af
|
715606.0
|
2022-01-14 00:00:00 UTC
|
Delcath Systems Inc Shares Approach 52-Week Low - Market Mover
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-inc-shares-approach-52-week-low-market-mover
|
nan
|
nan
|
Delcath Systems Inc (DCTH) shares closed today at 1.4% above its 52 week low of $7.00, giving the company a market cap of $52M. The stock is currently down 8.4% year-to-date, down 58.2% over the past 12 months, and up 1653.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%.
Trading Activity
Trading volume this week was 69.1% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6.
Technical Indicators
The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
MACD, a trend-following momentum indicator, indicates a downward trend.
The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis
The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis
Per Group Comparative Performance
The company's stock price performance year-to-date lags the peer average by 18.9%
The company's stock price performance over the past 12 months lags the peer average by -4896.6%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc (DCTH) shares closed today at 1.4% above its 52 week low of $7.00, giving the company a market cap of $52M. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 18.9% The company's stock price performance over the past 12 months lags the peer average by -4896.6%
|
Delcath Systems Inc (DCTH) shares closed today at 1.4% above its 52 week low of $7.00, giving the company a market cap of $52M. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
Delcath Systems Inc (DCTH) shares closed today at 1.4% above its 52 week low of $7.00, giving the company a market cap of $52M. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 18.9% The company's stock price performance over the past 12 months lags the peer average by -4896.6% This story was produced by the Kwhen Automated News Generator.
|
Delcath Systems Inc (DCTH) shares closed today at 1.4% above its 52 week low of $7.00, giving the company a market cap of $52M. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
|
6568eae4-60a5-4068-b777-58f45fedc973
|
715607.0
|
2021-11-11 00:00:00 UTC
|
Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt?
|
DCTH
|
https://www.nasdaq.com/articles/is-delcath-systems-nasdaq%3Adcth-using-too-much-debt
|
nan
|
nan
|
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We can see that Delcath Systems, Inc. (NASDAQ:DCTH) does use debt in its business. But should shareholders be worried about its use of debt?
When Is Debt A Problem?
Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company's use of debt, we first look at cash and debt together.
How Much Debt Does Delcath Systems Carry?
The image below, which you can click on for greater detail, shows that at September 2021 Delcath Systems had debt of US$15.4m, up from US$2.00m in one year. But it also has US$24.9m in cash to offset that, meaning it has US$9.43m net cash.
NasdaqCM:DCTH Debt to Equity History November 11th 2021
A Look At Delcath Systems' Liabilities
The latest balance sheet data shows that Delcath Systems had liabilities of US$5.36m due within a year, and liabilities of US$17.3m falling due after that. Offsetting this, it had US$24.9m in cash and US$69.0k in receivables that were due within 12 months. So it can boast US$2.24m more liquid assets than total liabilities.
This short term liquidity is a sign that Delcath Systems could probably pay off its debt with ease, as its balance sheet is far from stretched. Succinctly put, Delcath Systems boasts net cash, so it's fair to say it does not have a heavy debt load! The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately the future profitability of the business will decide if Delcath Systems can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
Over 12 months, Delcath Systems reported revenue of US$2.0m, which is a gain of 18%, although it did not report any earnings before interest and tax. That rate of growth is a bit slow for our taste, but it takes all types to make a world.
So How Risky Is Delcath Systems?
We have no doubt that loss making companies are, in general, riskier than profitable ones. And in the last year Delcath Systems had an earnings before interest and tax (EBIT) loss, truth be told. And over the same period it saw negative free cash outflow of US$22m and booked a US$27m accounting loss. With only US$9.43m on the balance sheet, it would appear that its going to need to raise capital again soon. Even though its balance sheet seems sufficiently liquid, debt always makes us a little nervous if a company doesn't produce free cash flow regularly. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately, every company can contain risks that exist outside of the balance sheet. Be aware that Delcath Systems is showing 4 warning signs in our investment analysis , and 1 of those is significant...
At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We can see that Delcath Systems, Inc. (NASDAQ:DCTH) does use debt in its business. NasdaqCM:DCTH Debt to Equity History November 11th 2021 A Look At Delcath Systems' Liabilities The latest balance sheet data shows that Delcath Systems had liabilities of US$5.36m due within a year, and liabilities of US$17.3m falling due after that. Even though its balance sheet seems sufficiently liquid, debt always makes us a little nervous if a company doesn't produce free cash flow regularly.
|
NasdaqCM:DCTH Debt to Equity History November 11th 2021 A Look At Delcath Systems' Liabilities The latest balance sheet data shows that Delcath Systems had liabilities of US$5.36m due within a year, and liabilities of US$17.3m falling due after that. We can see that Delcath Systems, Inc. (NASDAQ:DCTH) does use debt in its business. Succinctly put, Delcath Systems boasts net cash, so it's fair to say it does not have a heavy debt load!
|
NasdaqCM:DCTH Debt to Equity History November 11th 2021 A Look At Delcath Systems' Liabilities The latest balance sheet data shows that Delcath Systems had liabilities of US$5.36m due within a year, and liabilities of US$17.3m falling due after that. We can see that Delcath Systems, Inc. (NASDAQ:DCTH) does use debt in its business. When we think about a company's use of debt, we first look at cash and debt together.
|
We can see that Delcath Systems, Inc. (NASDAQ:DCTH) does use debt in its business. NasdaqCM:DCTH Debt to Equity History November 11th 2021 A Look At Delcath Systems' Liabilities The latest balance sheet data shows that Delcath Systems had liabilities of US$5.36m due within a year, and liabilities of US$17.3m falling due after that. When we think about a company's use of debt, we first look at cash and debt together.
|
931c334a-4242-4848-81ef-393ee05a81aa
|
715608.0
|
2021-11-09 00:00:00 UTC
|
Delcath Systems Q3 21 Earnings Conference Call At 8:30 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-q3-21-earnings-conference-call-at-8%3A30-am-et
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on November 9, 2021, to discuss Q3 21 earnings results.
To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/43392
To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 676028.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on November 9, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/43392 To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 676028. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on November 9, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/43392 To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 676028. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on November 9, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/43392 To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 676028. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on November 9, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/43392 To listen to the call, dial 888-506-0062 (US) or 973-528-0011 (International), Entry Code: 676028. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ab0cf2d9-dcbd-4ef3-9c60-4ea275f2ded2
|
715609.0
|
2021-08-10 00:00:00 UTC
|
EARNINGS SUMMARY: Details of Delcath Systems Inc. Q2 Earnings Report
|
DCTH
|
https://www.nasdaq.com/articles/earnings-summary%3A-details-of-delcath-systems-inc.-q2-earnings-report-2021-08-10
|
nan
|
nan
|
(RTTNews) - Below are the earnings highlights for Delcath Systems Inc. (DCTH):
-Earnings: -$6.43 million in Q2 vs. -$4.33 million in the same period last year. -EPS: -$0.96 in Q2 vs. -$1.90 in the same period last year. -Revenue: $0.40 million in Q2 vs. $0.26 million in the same period last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Below are the earnings highlights for Delcath Systems Inc. (DCTH): -Earnings: -$6.43 million in Q2 vs. -$4.33 million in the same period last year. -EPS: -$0.96 in Q2 vs. -$1.90 in the same period last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Below are the earnings highlights for Delcath Systems Inc. (DCTH): -Earnings: -$6.43 million in Q2 vs. -$4.33 million in the same period last year. -EPS: -$0.96 in Q2 vs. -$1.90 in the same period last year. -Revenue: $0.40 million in Q2 vs. $0.26 million in the same period last year.
|
(RTTNews) - Below are the earnings highlights for Delcath Systems Inc. (DCTH): -Earnings: -$6.43 million in Q2 vs. -$4.33 million in the same period last year. -Revenue: $0.40 million in Q2 vs. $0.26 million in the same period last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Below are the earnings highlights for Delcath Systems Inc. (DCTH): -Earnings: -$6.43 million in Q2 vs. -$4.33 million in the same period last year. -Revenue: $0.40 million in Q2 vs. $0.26 million in the same period last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
7ab35ebc-b766-42f5-82bf-ad633b88fc6d
|
715610.0
|
2021-08-10 00:00:00 UTC
|
Delcath Systems Q2 21 Earnings Conference Call At 8:30 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-q2-21-earnings-conference-call-at-8%3A30-am-et-2021-08-10
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on August 10, 2021, to discuss Q2 21 earnings results.
To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/42376
To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Entry Code: 148562.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on August 10, 2021, to discuss Q2 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/42376 To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Entry Code: 148562. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on August 10, 2021, to discuss Q2 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/42376 To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Entry Code: 148562. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on August 10, 2021, to discuss Q2 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/42376 To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Entry Code: 148562. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:30 AM ET on August 10, 2021, to discuss Q2 21 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/42376 To listen to the call, dial 877-545-0523 (US) or 973-528-0016 (International), Entry Code: 148562. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
a47e6add-d717-4230-8427-f5042f037f71
|
715611.0
|
2021-05-11 00:00:00 UTC
|
Delcath Systems Slips To Loss In Q1 - Quick Facts
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-slips-to-loss-in-q1-quick-facts-2021-05-11
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year.
Total operating expenses for the quarter were $7.0 million compared with $5.3 million in the prior year quarter. First quarter expenses included approximately $2.2 million of stock option expense compared to no material stock option expense in the prior year quarter.
Product revenue for the quarter was approximately $0.4 million, compared to $0.3 million for the prior year period from sales of CHEMOSAT procedures in Europe.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year. First quarter expenses included approximately $2.2 million of stock option expense compared to no material stock option expense in the prior year quarter. Product revenue for the quarter was approximately $0.4 million, compared to $0.3 million for the prior year period from sales of CHEMOSAT procedures in Europe.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year. Total operating expenses for the quarter were $7.0 million compared with $5.3 million in the prior year quarter. First quarter expenses included approximately $2.2 million of stock option expense compared to no material stock option expense in the prior year quarter.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year. Total operating expenses for the quarter were $7.0 million compared with $5.3 million in the prior year quarter. First quarter expenses included approximately $2.2 million of stock option expense compared to no material stock option expense in the prior year quarter.
|
(RTTNews) - Delcath Systems Inc. (DCTH) reported that its first-quarter net loss was $6.8 million or $1.04 per share, compared to a net income of $7.9 million last year. Total operating expenses for the quarter were $7.0 million compared with $5.3 million in the prior year quarter. First quarter expenses included approximately $2.2 million of stock option expense compared to no material stock option expense in the prior year quarter.
|
8e973038-4974-41f5-bc38-fe40fa557040
|
715612.0
|
2021-05-03 00:00:00 UTC
|
Read This Before Selling Delcath Systems, Inc. (NASDAQ:DCTH) Shares
|
DCTH
|
https://www.nasdaq.com/articles/read-this-before-selling-delcath-systems-inc.-nasdaq%3Adcth-shares-2021-05-03
|
nan
|
nan
|
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Delcath Systems, Inc. (NASDAQ:DCTH), you may well want to know whether insiders have been buying or selling.
What Is Insider Buying?
Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, rules govern insider transactions, and certain disclosures are required.
We don't think shareholders should simply follow insider transactions. But equally, we would consider it foolish to ignore insider transactions altogether. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.
The Last 12 Months Of Insider Transactions At Delcath Systems
Over the last year, we can see that the biggest insider purchase was by CEO & Director Gerard Michel for US$200k worth of shares, at about US$12.88 per share. That means that an insider was happy to buy shares at above the current price of US$11.11. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
Delcath Systems insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqCM:DCTH Insider Trading Volume May 3rd 2021
Delcath Systems is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insiders at Delcath Systems Have Bought Stock Recently
Over the last three months, we've seen significant insider buying at Delcath Systems. Specifically, CEO & Director Gerard Michel bought US$200k worth of shares in that time, and we didn't record any sales whatsoever. This makes one think the business has some good points.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Based on our data, Delcath Systems insiders have about 2.0% of the stock, worth approximately US$1.4m. I generally like to see higher levels of ownership.
What Might The Insider Transactions At Delcath Systems Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Delcath Systems stock. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Delcath Systems. For example, Delcath Systems has 5 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
So before you buy or sell Delcath Systems, Inc. (NASDAQ:DCTH), you may well want to know whether insiders have been buying or selling. NasdaqCM:DCTH Insider Trading Volume May 3rd 2021 Delcath Systems is not the only stock insiders are buying. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.
|
So before you buy or sell Delcath Systems, Inc. (NASDAQ:DCTH), you may well want to know whether insiders have been buying or selling. NasdaqCM:DCTH Insider Trading Volume May 3rd 2021 Delcath Systems is not the only stock insiders are buying. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
|
So before you buy or sell Delcath Systems, Inc. (NASDAQ:DCTH), you may well want to know whether insiders have been buying or selling. NasdaqCM:DCTH Insider Trading Volume May 3rd 2021 Delcath Systems is not the only stock insiders are buying. The Last 12 Months Of Insider Transactions At Delcath Systems Over the last year, we can see that the biggest insider purchase was by CEO & Director Gerard Michel for US$200k worth of shares, at about US$12.88 per share.
|
So before you buy or sell Delcath Systems, Inc. (NASDAQ:DCTH), you may well want to know whether insiders have been buying or selling. NasdaqCM:DCTH Insider Trading Volume May 3rd 2021 Delcath Systems is not the only stock insiders are buying. Delcath Systems insiders may have bought shares in the last year, but they didn't sell any.
|
b114cfce-dbec-407e-b42b-5950ecd97ea4
|
715613.0
|
2021-04-05 00:00:00 UTC
|
Monday 4/5 Insider Buying Report: DCTH, SRG
|
DCTH
|
https://www.nasdaq.com/articles/monday-4-5-insider-buying-report%3A-dcth-srg-2021-04-05
|
nan
|
nan
|
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At Delcath Systems, a filing with the SEC revealed that on Monday, Chief Executive Officer Gerard J. Michel bought 15,500 shares of DCTH, for a cost of $12.88 each, for a total investment of $199,640. Delcath Systems Inc is trading up about 12% on the day Monday. Before this latest buy, Michel made one other purchase in the past year, buying $99,375 shares for a cost of $13.25 each.
And on Wednesday, Allison Thrush purchased $98,318 worth of Seritage Growth Properties, purchasing 5,450 shares at a cost of $18.04 a piece. Seritage Growth Properties is trading up about 2.2% on the day Monday. So far Thrush is in the green, up about 9.2% on their buy based on today's trading high of $19.70.
VIDEO: Monday 4/5 Insider Buying Report: DCTH, SRG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
At Delcath Systems, a filing with the SEC revealed that on Monday, Chief Executive Officer Gerard J. Michel bought 15,500 shares of DCTH, for a cost of $12.88 each, for a total investment of $199,640. VIDEO: Monday 4/5 Insider Buying Report: DCTH, SRG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. So far Thrush is in the green, up about 9.2% on their buy based on today's trading high of $19.70.
|
VIDEO: Monday 4/5 Insider Buying Report: DCTH, SRG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Delcath Systems, a filing with the SEC revealed that on Monday, Chief Executive Officer Gerard J. Michel bought 15,500 shares of DCTH, for a cost of $12.88 each, for a total investment of $199,640. And on Wednesday, Allison Thrush purchased $98,318 worth of Seritage Growth Properties, purchasing 5,450 shares at a cost of $18.04 a piece.
|
At Delcath Systems, a filing with the SEC revealed that on Monday, Chief Executive Officer Gerard J. Michel bought 15,500 shares of DCTH, for a cost of $12.88 each, for a total investment of $199,640. VIDEO: Monday 4/5 Insider Buying Report: DCTH, SRG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Before this latest buy, Michel made one other purchase in the past year, buying $99,375 shares for a cost of $13.25 each.
|
At Delcath Systems, a filing with the SEC revealed that on Monday, Chief Executive Officer Gerard J. Michel bought 15,500 shares of DCTH, for a cost of $12.88 each, for a total investment of $199,640. VIDEO: Monday 4/5 Insider Buying Report: DCTH, SRG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.
|
03cb3b27-7943-4f4b-9b18-a02b6c71a1c9
|
715614.0
|
2021-03-31 00:00:00 UTC
|
Delcath Systems Reports Positive Preliminary Results From Phase 3 FOCUS Trial Of HEPZATO
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-reports-positive-preliminary-results-from-phase-3-focus-trial-of-hepzato
|
nan
|
nan
|
(RTTNews) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis, the Independent Review Committee assessed Overall Response Rate of 29.2% in the Intent to Treat population which exceeded the predefined success criteria (21.0%) for the primary Overall Response Rate endpoint.
"While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a significantly improved benefit-risk profile compared with Best Alternative Care that could form the basis of our NDA resubmission to the FDA," said Gerard Michel, CEO of Delcath.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis, the Independent Review Committee assessed Overall Response Rate of 29.2% in the Intent to Treat population which exceeded the predefined success criteria (21.0%) for the primary Overall Response Rate endpoint. "While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a significantly improved benefit-risk profile compared with Best Alternative Care that could form the basis of our NDA resubmission to the FDA," said Gerard Michel, CEO of Delcath.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis, the Independent Review Committee assessed Overall Response Rate of 29.2% in the Intent to Treat population which exceeded the predefined success criteria (21.0%) for the primary Overall Response Rate endpoint. "While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a significantly improved benefit-risk profile compared with Best Alternative Care that could form the basis of our NDA resubmission to the FDA," said Gerard Michel, CEO of Delcath.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis, the Independent Review Committee assessed Overall Response Rate of 29.2% in the Intent to Treat population which exceeded the predefined success criteria (21.0%) for the primary Overall Response Rate endpoint. "While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a significantly improved benefit-risk profile compared with Best Alternative Care that could form the basis of our NDA resubmission to the FDA," said Gerard Michel, CEO of Delcath.
|
(RTTNews) - Delcath Systems, Inc. (DCTH) reported positive top-line preliminary results from the phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma. Based on the preliminary analysis, the Independent Review Committee assessed Overall Response Rate of 29.2% in the Intent to Treat population which exceeded the predefined success criteria (21.0%) for the primary Overall Response Rate endpoint. "While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a significantly improved benefit-risk profile compared with Best Alternative Care that could form the basis of our NDA resubmission to the FDA," said Gerard Michel, CEO of Delcath.
|
4e1b20ef-5fa4-4c6d-b65a-30eb2e983a17
|
715615.0
|
2021-03-31 00:00:00 UTC
|
Delcath Systems Q4 20 Earnings Conference Call At 8:00 AM ET
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-q4-20-earnings-conference-call-at-8%3A00-am-et-2021-03-31
|
nan
|
nan
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:00 AM ET on March 31, 2021, to discuss Q4 20 earnings results.
To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/40544
To listen to the call, dial 877-407-8035 (US) or 201-689-8035 (International).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:00 AM ET on March 31, 2021, to discuss Q4 20 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/40544 To listen to the call, dial 877-407-8035 (US) or 201-689-8035 (International). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:00 AM ET on March 31, 2021, to discuss Q4 20 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/40544 To listen to the call, dial 877-407-8035 (US) or 201-689-8035 (International). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:00 AM ET on March 31, 2021, to discuss Q4 20 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/40544 To listen to the call, dial 877-407-8035 (US) or 201-689-8035 (International). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Delcath Systems Inc. (DCTH) will host a conference call at 8:00 AM ET on March 31, 2021, to discuss Q4 20 earnings results. To access the live webcast, log on to https://www.webcaster4.com/Webcast/Page/2475/40544 To listen to the call, dial 877-407-8035 (US) or 201-689-8035 (International). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ff6ef777-3654-4c09-b9df-a942804ad19c
|
715616.0
|
2020-12-09 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Disney, Pfizer, Eli Lilly
|
DCTH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-boeing-disney-pfizer-eli-lilly-2020-12-09
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and the Dow scaled record highs on Wednesday as hopes of a working COVID-19 vaccine and fresh economic stimulus before the end of the year lifted demand for economically sensitive energy and financial shares. .N
At 10:48 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 30,177.9. The S&P 500 .SPX was up 0.07% at 3,704.87 and the Nasdaq Composite .IXIC was down 0.05% at 12,576.416. The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings , up 7.2% ** Lowes Companies , up 4.9% ** Eli Lilly and Co , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Fortinet Inc , down 2.9% ** Brown-Forman Corp , down 2.8% ** Qorvo Inc , down 2.7% The top three NYSE .PG.N percentage gainers: ** QuantumScape Corp , up 27.3% ** Ashford Hosptality , up 15.9% ** Owens & Minor , up 13% The top three NYSE .PL.N percentage losers: ** Talos Energy Inc , down 18.2% ** GameStop Corp , down 17.4% ** United Natural Foods Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Xenetic Biosciences Inc , up 431.9% ** Greenwich LifeSciences Inc , up 288.6% ** Rocket Pharmaceuticals Inc , up 77.5% The top three Nasdaq .PL.O percentage losers: ** Sino-Global Shipping America Ltd , down 37.2% ** Pluristem Therapeutics Inc , down 37.1% ** Aytu Bioscience , down 20.1% ** Boeing Co BA.N: down 0.1%
BUZZ-Jefferies says 'MAX is almost back', raises PT
** Walt Disney Co DIS.N: up 1.6%
BUZZ-Rises as KeyBanc initiates with 'overweight'
** Pfizer Inc PFE.N: down 2.5%
BUZZ-Street View: Pfizer's COVID-19 vaccine all set for EUA
** Eli Lilly and Co LLY.N: up 4.3%
BUZZ-Gains on positive data from diabetes drug study ** Exxon Mobil Corp XOM.N: up 1.7% ** Hess Corp HES.N: up 1.2% ** EOG Resources Inc EOG.N: up 1.7% ** Diamondback Energy Inc FANG.O: up 2.5% ** Valero Energy Corp VLO.N: down 0.1% ** Occidental Petroleum Corp OXY.N: up 3.5% ** Phillips 66 PSX.N: up 0.8% ** PBF Energy Inc PBF.N: up 1.7%
BUZZ-U.S. energy cos up as crude climbs on vaccine hopes, weaker dollar ** GameStop Corp GME.N: down 17.4%
BUZZ-Drops as Q3 revenue misses estimates ** Sorrento Therapeutics Inc SRNE.O: up 3.0%
BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 18.2%
BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 7.1%
BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 37.1%
BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 4.9%
BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: up 2.0% ** Omnicell Inc OMCL.O: up 8.5%
BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 37.2%
BUZZ-Sino-Global to acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: down 0.9%
BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 12.7%
BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 5.7%
BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 8.5%
BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: up 1.1%
BUZZ-Falls on $126 mln share offering ** Check Point Software Technologies CHKP.O: down 1.5% ** Palo Alto Networks Inc PANW.N: down 1.0% ** Fortinet Inc FTNT.O: down 2.9%
BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** QuantumScape Corp QS.N: up 27.3%
BUZZ-Says its battery could power electric planes, shares jump ** Zimmer Biomet Holdings ZBH.N: down 0.3%
BUZZ-Smart knee implants could be first-to-market - Needham ** Delcath Systems DCTH.O: down 1.2%
BUZZ- Down on launch of public offering ** IGM BioSciences IGMS.O: down 7.2%
BUZZ-Drops after pricing upsized $200 mln stock deal ** Zoom Video Communications Inc ZM.O: down 2.8%
BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 77.5%
BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 4.1%
BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 11.9%
BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 6.3%
BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 57.7%
BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 19.7%
BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 60.3%
BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.3%
BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: down 0.2%
BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.6%
BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 5.5%
BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 8.5%
BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 16.3%
UZZ-Falls as Q1 results miss estimates ** Talos Energy Inc TALO.N: down 18.2%
BUZZ-Drops; announces pricing for 8.5 mln share offer ** Lipocine Inc LPCN.O: down 14.4%
BUZZ-Deletes web posts suggesting drug approval, shares drop ** Francesca's Holdings Corp FRAN.O: up 32.5%
BUZZ-Jumps on court approval to support ongoing finances ** Vera Bradley Inc VRA.O: down 7.7%
BUZZ-Falls as Q3 revenue misses estimates ** Cardtronics PLC CATM.O: up 31.4%
BUZZ-Soars on buyout offer ** Autodesk Inc ADSK.O: up 1.3%
BUZZ-Up as J.P. Morgan upgrades to 'overweight' on construction market promise ** GrowGeneration Corp GRWG.O: down 7.6%
BUZZ-Falls after upsized equity raise ** Encompass Health Corp EHC.N: up 5.0%
BUZZ-Up on exploring strategic alternatives for home health, hospice business ** Tattooed Chef Inc TTCF.O: up 5.1%
BUZZ-Gains on new plant-based meat alternatives ** MTS Systems Corp MTSC.O: up 50.5%
BUZZ-Highest in more than a year on Amphenol deal ** SuperCom Ltd SPCB.O: up 2.3%
BUZZ-Rises on new GPS monitoring contract ** Lowe's Companies Inc LOW.N: up 4.9%
BUZZ- Up on $15 bln share buyback plan ** Stratasys Ltd SSYS.O: up 4.4%
BUZZ-To acquire 3D printing startup Origin, shares rise ** Prothena Corp PRTA.O: up 2.5%
BUZZ-Up on positive data from early-stage immunotherapy study ** Designer Brands DBI.N: down 6.9%
BUZZ-Falls on disappointing Q3 results ** DoorDash Inc DASH.N: flat
BUZZ-Indicated to open well above IPO price ** Curis Inc CRIS.O: up 11.5%
BUZZ-Curis capitalizes, raises equity after shares catapult
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.55%
Consumer Discretionary
.SPLRCD
up 0.27%
Consumer Staples
.SPLRCS
down 0.38%
Energy
.SPNY
up 0.40%
Financial
.SPSY
down 0.18%
Health
.SPXHC
down 0.36%
Industrial
.SPLRCI
up 0.16%
Information Technology
.SPLRCT
down 0.12%
Materials
.SPLRCM
up 0.29%
Real Estate
.SPLRCR
down 1.14%
Utilities
.SPLRCU
down 0.55%
(Compiled by Trisha Roy in Bengaluru)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings , up 7.2% ** Lowes Companies , up 4.9% ** Eli Lilly and Co , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Fortinet Inc , down 2.9% ** Brown-Forman Corp , down 2.8% ** Qorvo Inc , down 2.7% The top three NYSE .PG.N percentage gainers: ** QuantumScape Corp , up 27.3% ** Ashford Hosptality , up 15.9% ** Owens & Minor , up 13% The top three NYSE .PL.N percentage losers: ** Talos Energy Inc , down 18.2% ** GameStop Corp , down 17.4% ** United Natural Foods Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Xenetic Biosciences Inc , up 431.9% ** Greenwich LifeSciences Inc , up 288.6% ** Rocket Pharmaceuticals Inc , up 77.5% The top three Nasdaq .PL.O percentage losers: ** Sino-Global Shipping America Ltd , down 37.2% ** Pluristem Therapeutics Inc , down 37.1% ** Aytu Bioscience , down 20.1% ** Boeing Co BA.N: down 0.1% BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% BUZZ-Rises as KeyBanc initiates with 'overweight' ** Pfizer Inc PFE.N: down 2.5% BUZZ-Street View: Pfizer's COVID-19 vaccine all set for EUA ** Eli Lilly and Co LLY.N: up 4.3% BUZZ-Gains on positive data from diabetes drug study ** Exxon Mobil Corp XOM.N: up 1.7% ** Hess Corp HES.N: up 1.2% ** EOG Resources Inc EOG.N: up 1.7% ** Diamondback Energy Inc FANG.O: up 2.5% ** Valero Energy Corp VLO.N: down 0.1% ** Occidental Petroleum Corp OXY.N: up 3.5% ** Phillips 66 PSX.N: up 0.8% ** PBF Energy Inc PBF.N: up 1.7% BUZZ-U.S. energy cos up as crude climbs on vaccine hopes, weaker dollar ** GameStop Corp GME.N: down 17.4% BUZZ-Drops as Q3 revenue misses estimates ** Sorrento Therapeutics Inc SRNE.O: up 3.0% BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 18.2% BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 7.1% BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 37.1% BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 4.9% BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: up 2.0% ** Omnicell Inc OMCL.O: up 8.5% BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 37.2% BUZZ-Sino-Global to acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: down 0.9% BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 12.7% BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 5.7% BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 8.5% BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: up 1.1% BUZZ-Falls on $126 mln share offering ** Check Point Software Technologies CHKP.O: down 1.5% ** Palo Alto Networks Inc PANW.N: down 1.0% ** Fortinet Inc FTNT.O: down 2.9% BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** QuantumScape Corp QS.N: up 27.3% BUZZ-Says its battery could power electric planes, shares jump ** Zimmer Biomet Holdings ZBH.N: down 0.3% BUZZ-Smart knee implants could be first-to-market - Needham ** Delcath Systems DCTH.O: down 1.2% BUZZ- Down on launch of public offering ** IGM BioSciences IGMS.O: down 7.2% BUZZ-Drops after pricing upsized $200 mln stock deal ** Zoom Video Communications Inc ZM.O: down 2.8% BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 77.5% BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 4.1% BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 11.9% BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 6.3% BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 57.7% BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 19.7% BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 60.3% BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.3% BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: down 0.2% BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.6% BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 5.5% BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 8.5% BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 16.3% UZZ-Falls as Q1 results miss estimates ** Talos Energy Inc TALO.N: down 18.2% BUZZ-Drops; announces pricing for 8.5 mln share offer ** Lipocine Inc LPCN.O: down 14.4% BUZZ-Deletes web posts suggesting drug approval, shares drop ** Francesca's Holdings Corp FRAN.O: up 32.5% BUZZ-Jumps on court approval to support ongoing finances ** Vera Bradley Inc VRA.O: down 7.7% BUZZ-Falls as Q3 revenue misses estimates ** Cardtronics PLC CATM.O: up 31.4% BUZZ-Soars on buyout offer ** Autodesk Inc ADSK.O: up 1.3% BUZZ-Up as J.P. Morgan upgrades to 'overweight' on construction market promise ** GrowGeneration Corp GRWG.O: down 7.6% BUZZ-Falls after upsized equity raise ** Encompass Health Corp EHC.N: up 5.0% BUZZ-Up on exploring strategic alternatives for home health, hospice business ** Tattooed Chef Inc TTCF.O: up 5.1% BUZZ-Gains on new plant-based meat alternatives ** MTS Systems Corp MTSC.O: up 50.5% BUZZ-Highest in more than a year on Amphenol deal ** SuperCom Ltd SPCB.O: up 2.3% BUZZ-Rises on new GPS monitoring contract ** Lowe's Companies Inc LOW.N: up 4.9% BUZZ- Up on $15 bln share buyback plan ** Stratasys Ltd SSYS.O: up 4.4% BUZZ-To acquire 3D printing startup Origin, shares rise ** Prothena Corp PRTA.O: up 2.5% BUZZ-Up on positive data from early-stage immunotherapy study ** Designer Brands DBI.N: down 6.9% BUZZ-Falls on disappointing Q3 results ** DoorDash Inc DASH.N: flat BUZZ-Indicated to open well above IPO price ** Curis Inc CRIS.O: up 11.5% BUZZ-Curis capitalizes, raises equity after shares catapult The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow scaled record highs on Wednesday as hopes of a working COVID-19 vaccine and fresh economic stimulus before the end of the year lifted demand for economically sensitive energy and financial shares. down 0.55% (Compiled by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings , up 7.2% ** Lowes Companies , up 4.9% ** Eli Lilly and Co , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Fortinet Inc , down 2.9% ** Brown-Forman Corp , down 2.8% ** Qorvo Inc , down 2.7% The top three NYSE .PG.N percentage gainers: ** QuantumScape Corp , up 27.3% ** Ashford Hosptality , up 15.9% ** Owens & Minor , up 13% The top three NYSE .PL.N percentage losers: ** Talos Energy Inc , down 18.2% ** GameStop Corp , down 17.4% ** United Natural Foods Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Xenetic Biosciences Inc , up 431.9% ** Greenwich LifeSciences Inc , up 288.6% ** Rocket Pharmaceuticals Inc , up 77.5% The top three Nasdaq .PL.O percentage losers: ** Sino-Global Shipping America Ltd , down 37.2% ** Pluristem Therapeutics Inc , down 37.1% ** Aytu Bioscience , down 20.1% ** Boeing Co BA.N: down 0.1% BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% BUZZ-Rises as KeyBanc initiates with 'overweight' ** Pfizer Inc PFE.N: down 2.5% BUZZ-Street View: Pfizer's COVID-19 vaccine all set for EUA ** Eli Lilly and Co LLY.N: up 4.3% BUZZ-Gains on positive data from diabetes drug study ** Exxon Mobil Corp XOM.N: up 1.7% ** Hess Corp HES.N: up 1.2% ** EOG Resources Inc EOG.N: up 1.7% ** Diamondback Energy Inc FANG.O: up 2.5% ** Valero Energy Corp VLO.N: down 0.1% ** Occidental Petroleum Corp OXY.N: up 3.5% ** Phillips 66 PSX.N: up 0.8% ** PBF Energy Inc PBF.N: up 1.7% BUZZ-U.S. energy cos up as crude climbs on vaccine hopes, weaker dollar ** GameStop Corp GME.N: down 17.4% BUZZ-Drops as Q3 revenue misses estimates ** Sorrento Therapeutics Inc SRNE.O: up 3.0% BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 18.2% BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 7.1% BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 37.1% BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 4.9% BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: up 2.0% ** Omnicell Inc OMCL.O: up 8.5% BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 37.2% BUZZ-Sino-Global to acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: down 0.9% BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 12.7% BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 5.7% BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 8.5% BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: up 1.1% BUZZ-Falls on $126 mln share offering ** Check Point Software Technologies CHKP.O: down 1.5% ** Palo Alto Networks Inc PANW.N: down 1.0% ** Fortinet Inc FTNT.O: down 2.9% BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** QuantumScape Corp QS.N: up 27.3% BUZZ-Says its battery could power electric planes, shares jump ** Zimmer Biomet Holdings ZBH.N: down 0.3% BUZZ-Smart knee implants could be first-to-market - Needham ** Delcath Systems DCTH.O: down 1.2% BUZZ- Down on launch of public offering ** IGM BioSciences IGMS.O: down 7.2% BUZZ-Drops after pricing upsized $200 mln stock deal ** Zoom Video Communications Inc ZM.O: down 2.8% BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 77.5% BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 4.1% BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 11.9% BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 6.3% BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 57.7% BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 19.7% BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 60.3% BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.3% BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: down 0.2% BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.6% BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 5.5% BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 8.5% BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 16.3% UZZ-Falls as Q1 results miss estimates ** Talos Energy Inc TALO.N: down 18.2% BUZZ-Drops; announces pricing for 8.5 mln share offer ** Lipocine Inc LPCN.O: down 14.4% BUZZ-Deletes web posts suggesting drug approval, shares drop ** Francesca's Holdings Corp FRAN.O: up 32.5% BUZZ-Jumps on court approval to support ongoing finances ** Vera Bradley Inc VRA.O: down 7.7% BUZZ-Falls as Q3 revenue misses estimates ** Cardtronics PLC CATM.O: up 31.4% BUZZ-Soars on buyout offer ** Autodesk Inc ADSK.O: up 1.3% BUZZ-Up as J.P. Morgan upgrades to 'overweight' on construction market promise ** GrowGeneration Corp GRWG.O: down 7.6% BUZZ-Falls after upsized equity raise ** Encompass Health Corp EHC.N: up 5.0% BUZZ-Up on exploring strategic alternatives for home health, hospice business ** Tattooed Chef Inc TTCF.O: up 5.1% BUZZ-Gains on new plant-based meat alternatives ** MTS Systems Corp MTSC.O: up 50.5% BUZZ-Highest in more than a year on Amphenol deal ** SuperCom Ltd SPCB.O: up 2.3% BUZZ-Rises on new GPS monitoring contract ** Lowe's Companies Inc LOW.N: up 4.9% BUZZ- Up on $15 bln share buyback plan ** Stratasys Ltd SSYS.O: up 4.4% BUZZ-To acquire 3D printing startup Origin, shares rise ** Prothena Corp PRTA.O: up 2.5% BUZZ-Up on positive data from early-stage immunotherapy study ** Designer Brands DBI.N: down 6.9% BUZZ-Falls on disappointing Q3 results ** DoorDash Inc DASH.N: flat BUZZ-Indicated to open well above IPO price ** Curis Inc CRIS.O: up 11.5% BUZZ-Curis capitalizes, raises equity after shares catapult The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow scaled record highs on Wednesday as hopes of a working COVID-19 vaccine and fresh economic stimulus before the end of the year lifted demand for economically sensitive energy and financial shares. up 0.16% Information Technology
|
The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings , up 7.2% ** Lowes Companies , up 4.9% ** Eli Lilly and Co , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Fortinet Inc , down 2.9% ** Brown-Forman Corp , down 2.8% ** Qorvo Inc , down 2.7% The top three NYSE .PG.N percentage gainers: ** QuantumScape Corp , up 27.3% ** Ashford Hosptality , up 15.9% ** Owens & Minor , up 13% The top three NYSE .PL.N percentage losers: ** Talos Energy Inc , down 18.2% ** GameStop Corp , down 17.4% ** United Natural Foods Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Xenetic Biosciences Inc , up 431.9% ** Greenwich LifeSciences Inc , up 288.6% ** Rocket Pharmaceuticals Inc , up 77.5% The top three Nasdaq .PL.O percentage losers: ** Sino-Global Shipping America Ltd , down 37.2% ** Pluristem Therapeutics Inc , down 37.1% ** Aytu Bioscience , down 20.1% ** Boeing Co BA.N: down 0.1% BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% BUZZ-Rises as KeyBanc initiates with 'overweight' ** Pfizer Inc PFE.N: down 2.5% BUZZ-Street View: Pfizer's COVID-19 vaccine all set for EUA ** Eli Lilly and Co LLY.N: up 4.3% BUZZ-Gains on positive data from diabetes drug study ** Exxon Mobil Corp XOM.N: up 1.7% ** Hess Corp HES.N: up 1.2% ** EOG Resources Inc EOG.N: up 1.7% ** Diamondback Energy Inc FANG.O: up 2.5% ** Valero Energy Corp VLO.N: down 0.1% ** Occidental Petroleum Corp OXY.N: up 3.5% ** Phillips 66 PSX.N: up 0.8% ** PBF Energy Inc PBF.N: up 1.7% BUZZ-U.S. energy cos up as crude climbs on vaccine hopes, weaker dollar ** GameStop Corp GME.N: down 17.4% BUZZ-Drops as Q3 revenue misses estimates ** Sorrento Therapeutics Inc SRNE.O: up 3.0% BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 18.2% BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 7.1% BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 37.1% BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 4.9% BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: up 2.0% ** Omnicell Inc OMCL.O: up 8.5% BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 37.2% BUZZ-Sino-Global to acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: down 0.9% BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 12.7% BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 5.7% BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 8.5% BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: up 1.1% BUZZ-Falls on $126 mln share offering ** Check Point Software Technologies CHKP.O: down 1.5% ** Palo Alto Networks Inc PANW.N: down 1.0% ** Fortinet Inc FTNT.O: down 2.9% BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** QuantumScape Corp QS.N: up 27.3% BUZZ-Says its battery could power electric planes, shares jump ** Zimmer Biomet Holdings ZBH.N: down 0.3% BUZZ-Smart knee implants could be first-to-market - Needham ** Delcath Systems DCTH.O: down 1.2% BUZZ- Down on launch of public offering ** IGM BioSciences IGMS.O: down 7.2% BUZZ-Drops after pricing upsized $200 mln stock deal ** Zoom Video Communications Inc ZM.O: down 2.8% BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 77.5% BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 4.1% BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 11.9% BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 6.3% BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 57.7% BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 19.7% BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 60.3% BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.3% BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: down 0.2% BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.6% BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 5.5% BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 8.5% BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 16.3% UZZ-Falls as Q1 results miss estimates ** Talos Energy Inc TALO.N: down 18.2% BUZZ-Drops; announces pricing for 8.5 mln share offer ** Lipocine Inc LPCN.O: down 14.4% BUZZ-Deletes web posts suggesting drug approval, shares drop ** Francesca's Holdings Corp FRAN.O: up 32.5% BUZZ-Jumps on court approval to support ongoing finances ** Vera Bradley Inc VRA.O: down 7.7% BUZZ-Falls as Q3 revenue misses estimates ** Cardtronics PLC CATM.O: up 31.4% BUZZ-Soars on buyout offer ** Autodesk Inc ADSK.O: up 1.3% BUZZ-Up as J.P. Morgan upgrades to 'overweight' on construction market promise ** GrowGeneration Corp GRWG.O: down 7.6% BUZZ-Falls after upsized equity raise ** Encompass Health Corp EHC.N: up 5.0% BUZZ-Up on exploring strategic alternatives for home health, hospice business ** Tattooed Chef Inc TTCF.O: up 5.1% BUZZ-Gains on new plant-based meat alternatives ** MTS Systems Corp MTSC.O: up 50.5% BUZZ-Highest in more than a year on Amphenol deal ** SuperCom Ltd SPCB.O: up 2.3% BUZZ-Rises on new GPS monitoring contract ** Lowe's Companies Inc LOW.N: up 4.9% BUZZ- Up on $15 bln share buyback plan ** Stratasys Ltd SSYS.O: up 4.4% BUZZ-To acquire 3D printing startup Origin, shares rise ** Prothena Corp PRTA.O: up 2.5% BUZZ-Up on positive data from early-stage immunotherapy study ** Designer Brands DBI.N: down 6.9% BUZZ-Falls on disappointing Q3 results ** DoorDash Inc DASH.N: flat BUZZ-Indicated to open well above IPO price ** Curis Inc CRIS.O: up 11.5% BUZZ-Curis capitalizes, raises equity after shares catapult The 11 major S&P 500 sectors: Communication Services up 0.55% Consumer Discretionary up 0.27% Consumer Staples
|
The top three S&P 500 .PG.INX percentage gainers: ** Nielsen Holdings , up 7.2% ** Lowes Companies , up 4.9% ** Eli Lilly and Co , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Fortinet Inc , down 2.9% ** Brown-Forman Corp , down 2.8% ** Qorvo Inc , down 2.7% The top three NYSE .PG.N percentage gainers: ** QuantumScape Corp , up 27.3% ** Ashford Hosptality , up 15.9% ** Owens & Minor , up 13% The top three NYSE .PL.N percentage losers: ** Talos Energy Inc , down 18.2% ** GameStop Corp , down 17.4% ** United Natural Foods Inc , down 16.3% The top three Nasdaq .PG.O percentage gainers: ** Xenetic Biosciences Inc , up 431.9% ** Greenwich LifeSciences Inc , up 288.6% ** Rocket Pharmaceuticals Inc , up 77.5% The top three Nasdaq .PL.O percentage losers: ** Sino-Global Shipping America Ltd , down 37.2% ** Pluristem Therapeutics Inc , down 37.1% ** Aytu Bioscience , down 20.1% ** Boeing Co BA.N: down 0.1% BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% BUZZ-Rises as KeyBanc initiates with 'overweight' ** Pfizer Inc PFE.N: down 2.5% BUZZ-Street View: Pfizer's COVID-19 vaccine all set for EUA ** Eli Lilly and Co LLY.N: up 4.3% BUZZ-Gains on positive data from diabetes drug study ** Exxon Mobil Corp XOM.N: up 1.7% ** Hess Corp HES.N: up 1.2% ** EOG Resources Inc EOG.N: up 1.7% ** Diamondback Energy Inc FANG.O: up 2.5% ** Valero Energy Corp VLO.N: down 0.1% ** Occidental Petroleum Corp OXY.N: up 3.5% ** Phillips 66 PSX.N: up 0.8% ** PBF Energy Inc PBF.N: up 1.7% BUZZ-U.S. energy cos up as crude climbs on vaccine hopes, weaker dollar ** GameStop Corp GME.N: down 17.4% BUZZ-Drops as Q3 revenue misses estimates ** Sorrento Therapeutics Inc SRNE.O: up 3.0% BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 18.2% BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 7.1% BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 37.1% BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 4.9% BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: up 2.0% ** Omnicell Inc OMCL.O: up 8.5% BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 37.2% BUZZ-Sino-Global to acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: down 0.9% BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 12.7% BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 5.7% BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 8.5% BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: up 1.1% BUZZ-Falls on $126 mln share offering ** Check Point Software Technologies CHKP.O: down 1.5% ** Palo Alto Networks Inc PANW.N: down 1.0% ** Fortinet Inc FTNT.O: down 2.9% BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** QuantumScape Corp QS.N: up 27.3% BUZZ-Says its battery could power electric planes, shares jump ** Zimmer Biomet Holdings ZBH.N: down 0.3% BUZZ-Smart knee implants could be first-to-market - Needham ** Delcath Systems DCTH.O: down 1.2% BUZZ- Down on launch of public offering ** IGM BioSciences IGMS.O: down 7.2% BUZZ-Drops after pricing upsized $200 mln stock deal ** Zoom Video Communications Inc ZM.O: down 2.8% BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 77.5% BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 4.1% BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 11.9% BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 6.3% BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 57.7% BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 19.7% BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 60.3% BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.3% BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: down 0.2% BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.6% BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 5.5% BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 8.5% BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 16.3% UZZ-Falls as Q1 results miss estimates ** Talos Energy Inc TALO.N: down 18.2% BUZZ-Drops; announces pricing for 8.5 mln share offer ** Lipocine Inc LPCN.O: down 14.4% BUZZ-Deletes web posts suggesting drug approval, shares drop ** Francesca's Holdings Corp FRAN.O: up 32.5% BUZZ-Jumps on court approval to support ongoing finances ** Vera Bradley Inc VRA.O: down 7.7% BUZZ-Falls as Q3 revenue misses estimates ** Cardtronics PLC CATM.O: up 31.4% BUZZ-Soars on buyout offer ** Autodesk Inc ADSK.O: up 1.3% BUZZ-Up as J.P. Morgan upgrades to 'overweight' on construction market promise ** GrowGeneration Corp GRWG.O: down 7.6% BUZZ-Falls after upsized equity raise ** Encompass Health Corp EHC.N: up 5.0% BUZZ-Up on exploring strategic alternatives for home health, hospice business ** Tattooed Chef Inc TTCF.O: up 5.1% BUZZ-Gains on new plant-based meat alternatives ** MTS Systems Corp MTSC.O: up 50.5% BUZZ-Highest in more than a year on Amphenol deal ** SuperCom Ltd SPCB.O: up 2.3% BUZZ-Rises on new GPS monitoring contract ** Lowe's Companies Inc LOW.N: up 4.9% BUZZ- Up on $15 bln share buyback plan ** Stratasys Ltd SSYS.O: up 4.4% BUZZ-To acquire 3D printing startup Origin, shares rise ** Prothena Corp PRTA.O: up 2.5% BUZZ-Up on positive data from early-stage immunotherapy study ** Designer Brands DBI.N: down 6.9% BUZZ-Falls on disappointing Q3 results ** DoorDash Inc DASH.N: flat BUZZ-Indicated to open well above IPO price ** Curis Inc CRIS.O: up 11.5% BUZZ-Curis capitalizes, raises equity after shares catapult The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow scaled record highs on Wednesday as hopes of a working COVID-19 vaccine and fresh economic stimulus before the end of the year lifted demand for economically sensitive energy and financial shares. .N At 10:48 ET, the Dow Jones Industrial Average .DJI was up 0.01% at 30,177.9.
|
a7fbc51a-853e-4d8c-92bc-f919ed5effd5
|
715617.0
|
2020-12-09 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Cybersecurity stocks, Boeing, Disney, Zoom
|
DCTH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-cybersecurity-stocks-boeing-disney-zoom-2020-12-09
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 was set to open at a record high on Wednesday as hopes for a vaccine-linked economic recovery and more domestic fiscal stimulus sparked demand for economically sensitive stocks such as banks and industrials. .N
At 8:41 ET, Dow e-minis 1YMc1 were up 0.27% at 30,251. S&P 500 e-minis ESc1 were up 0.15% at 3,707.5, while Nasdaq 100 e-minis NQc1 were down 0.08% at 12,627. The top three NYSE percentage gainers premarket .PRPG.NQ: ** QuantumScape Corp , up 36.4% ** Compania Cervecerias Unidas S.A. , up 20.0% ** Cabot Corp , up 19.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Talos Energy Inc , down 20.2% ** GameStop Corp , down 17.4% ** STMicroelectronics N.V. , down 10.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Xenetic Biosciences Inc , up 304.6% ** Intec Pharma Ltd , up 114.7% ** Zw Data Action Technologies Inc , up 93.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Pluristem Therapeutics Inc , down 42.2% ** Atossa Therapeutics Inc , down 41.9% ** Streamline Health Solutions Inc , down 31.8% ** Check Point Software Technologies CHKP.O: down 1.7% premarket ** Palo Alto Networks Inc PANW.N: down 1.6% premarket ** Fortinet Inc FTNT.O: down 2.1% premarket BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** Boeing Co BA.N: up 1.0% premarket BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% premarket BUZZ-Rises as KeyBanc initiates with 'overweight' ** GameStop Corp GME.N: down 17.4% premarket BUZZ-Drops as Q3 revenue misses estimates USN ** Sorrento Therapeutics Inc SRNE.O: up 9.5% premarket BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 20.2% premarket BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 8.2% premarket BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 42.2% premarket BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 1.6% premarket BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: down 0.6% premarket ** Omnicell Inc OMCL.O: up 13.1% premarket BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 6.5% premarket BUZZ-To acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: up 3.0% premarket BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 10.7% premarket BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 3.9% premarket BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 7.2% premarket BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: down 3.2% premarket BUZZ-Falls on $126 mln share offering ** QuantumScape Corp QS.N: up 36.4% premarket BUZZ-Says its battery could power electric planes, shares jump ** Delcath Systems DCTH.O: down 12.1% premarket BUZZ-Down on launch of public offering ** IGM BioSciences IGMS.O: up 10.4% premarket BUZZ-Drops after pricing upsized $200 mln stock deal ** Pluralsight Inc PS.O: down 2.8% premarket BUZZ-Falls as J.P. Morgan downgrades on likely revenue slowdown ** Zoom Video Communications Inc ZM.O: down 1.8% premarket BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 35.6% premarket BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 6.5% premarket BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 9.4% premarket BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 2.8% premarket BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 114.7% premarket BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 44.8% premarket BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 93.8% premarket BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.4% premarket BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: flat/untraded premarket BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.9% premarket BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 17.4% premarket BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 7.2% premarket BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 12.2% premarket BUZZ-Falls as Q1 results miss estimates
(Compiled by Trisha Roy in Bengaluru)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** QuantumScape Corp , up 36.4% ** Compania Cervecerias Unidas S.A. , up 20.0% ** Cabot Corp , up 19.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Talos Energy Inc , down 20.2% ** GameStop Corp , down 17.4% ** STMicroelectronics N.V. , down 10.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Xenetic Biosciences Inc , up 304.6% ** Intec Pharma Ltd , up 114.7% ** Zw Data Action Technologies Inc , up 93.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Pluristem Therapeutics Inc , down 42.2% ** Atossa Therapeutics Inc , down 41.9% ** Streamline Health Solutions Inc , down 31.8% ** Check Point Software Technologies CHKP.O: down 1.7% premarket ** Palo Alto Networks Inc PANW.N: down 1.6% premarket ** Fortinet Inc FTNT.O: down 2.1% premarket BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** Boeing Co BA.N: up 1.0% premarket BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% premarket BUZZ-Rises as KeyBanc initiates with 'overweight' ** GameStop Corp GME.N: down 17.4% premarket BUZZ-Drops as Q3 revenue misses estimates USN ** Sorrento Therapeutics Inc SRNE.O: up 9.5% premarket BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 20.2% premarket BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 8.2% premarket BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 42.2% premarket BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 1.6% premarket BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: down 0.6% premarket ** Omnicell Inc OMCL.O: up 13.1% premarket BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 6.5% premarket BUZZ-To acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: up 3.0% premarket BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 10.7% premarket BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 3.9% premarket BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 7.2% premarket BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: down 3.2% premarket BUZZ-Falls on $126 mln share offering ** QuantumScape Corp QS.N: up 36.4% premarket BUZZ-Says its battery could power electric planes, shares jump ** Delcath Systems DCTH.O: down 12.1% premarket BUZZ-Down on launch of public offering ** IGM BioSciences IGMS.O: up 10.4% premarket BUZZ-Drops after pricing upsized $200 mln stock deal ** Pluralsight Inc PS.O: down 2.8% premarket BUZZ-Falls as J.P. Morgan downgrades on likely revenue slowdown ** Zoom Video Communications Inc ZM.O: down 1.8% premarket BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 35.6% premarket BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 6.5% premarket BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 9.4% premarket BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 2.8% premarket BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 114.7% premarket BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 44.8% premarket BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 93.8% premarket BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.4% premarket BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: flat/untraded premarket BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.9% premarket BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 17.4% premarket BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 7.2% premarket BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 12.2% premarket BUZZ-Falls as Q1 results miss estimates (Compiled by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set to open at a record high on Wednesday as hopes for a vaccine-linked economic recovery and more domestic fiscal stimulus sparked demand for economically sensitive stocks such as banks and industrials. .N At 8:41 ET, Dow e-minis 1YMc1 were up 0.27% at 30,251.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** QuantumScape Corp , up 36.4% ** Compania Cervecerias Unidas S.A. , up 20.0% ** Cabot Corp , up 19.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Talos Energy Inc , down 20.2% ** GameStop Corp , down 17.4% ** STMicroelectronics N.V. , down 10.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Xenetic Biosciences Inc , up 304.6% ** Intec Pharma Ltd , up 114.7% ** Zw Data Action Technologies Inc , up 93.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Pluristem Therapeutics Inc , down 42.2% ** Atossa Therapeutics Inc , down 41.9% ** Streamline Health Solutions Inc , down 31.8% ** Check Point Software Technologies CHKP.O: down 1.7% premarket ** Palo Alto Networks Inc PANW.N: down 1.6% premarket ** Fortinet Inc FTNT.O: down 2.1% premarket BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** Boeing Co BA.N: up 1.0% premarket BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% premarket BUZZ-Rises as KeyBanc initiates with 'overweight' ** GameStop Corp GME.N: down 17.4% premarket BUZZ-Drops as Q3 revenue misses estimates USN ** Sorrento Therapeutics Inc SRNE.O: up 9.5% premarket BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 20.2% premarket BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 8.2% premarket BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 42.2% premarket BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 1.6% premarket BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: down 0.6% premarket ** Omnicell Inc OMCL.O: up 13.1% premarket BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 6.5% premarket BUZZ-To acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: up 3.0% premarket BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 10.7% premarket BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 3.9% premarket BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 7.2% premarket BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: down 3.2% premarket BUZZ-Falls on $126 mln share offering ** QuantumScape Corp QS.N: up 36.4% premarket BUZZ-Says its battery could power electric planes, shares jump ** Delcath Systems DCTH.O: down 12.1% premarket BUZZ-Down on launch of public offering ** IGM BioSciences IGMS.O: up 10.4% premarket BUZZ-Drops after pricing upsized $200 mln stock deal ** Pluralsight Inc PS.O: down 2.8% premarket BUZZ-Falls as J.P. Morgan downgrades on likely revenue slowdown ** Zoom Video Communications Inc ZM.O: down 1.8% premarket BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 35.6% premarket BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 6.5% premarket BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 9.4% premarket BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 2.8% premarket BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 114.7% premarket BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 44.8% premarket BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 93.8% premarket BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.4% premarket BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: flat/untraded premarket BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.9% premarket BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 17.4% premarket BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 7.2% premarket BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 12.2% premarket BUZZ-Falls as Q1 results miss estimates (Compiled by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set to open at a record high on Wednesday as hopes for a vaccine-linked economic recovery and more domestic fiscal stimulus sparked demand for economically sensitive stocks such as banks and industrials. S&P 500 e-minis ESc1 were up 0.15% at 3,707.5, while Nasdaq 100 e-minis NQc1 were down 0.08% at 12,627.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** QuantumScape Corp , up 36.4% ** Compania Cervecerias Unidas S.A. , up 20.0% ** Cabot Corp , up 19.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Talos Energy Inc , down 20.2% ** GameStop Corp , down 17.4% ** STMicroelectronics N.V. , down 10.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Xenetic Biosciences Inc , up 304.6% ** Intec Pharma Ltd , up 114.7% ** Zw Data Action Technologies Inc , up 93.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Pluristem Therapeutics Inc , down 42.2% ** Atossa Therapeutics Inc , down 41.9% ** Streamline Health Solutions Inc , down 31.8% ** Check Point Software Technologies CHKP.O: down 1.7% premarket ** Palo Alto Networks Inc PANW.N: down 1.6% premarket ** Fortinet Inc FTNT.O: down 2.1% premarket BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** Boeing Co BA.N: up 1.0% premarket BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% premarket BUZZ-Rises as KeyBanc initiates with 'overweight' ** GameStop Corp GME.N: down 17.4% premarket BUZZ-Drops as Q3 revenue misses estimates USN ** Sorrento Therapeutics Inc SRNE.O: up 9.5% premarket BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 20.2% premarket BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 8.2% premarket BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 42.2% premarket BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 1.6% premarket BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: down 0.6% premarket ** Omnicell Inc OMCL.O: up 13.1% premarket BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 6.5% premarket BUZZ-To acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: up 3.0% premarket BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 10.7% premarket BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 3.9% premarket BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 7.2% premarket BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: down 3.2% premarket BUZZ-Falls on $126 mln share offering ** QuantumScape Corp QS.N: up 36.4% premarket BUZZ-Says its battery could power electric planes, shares jump ** Delcath Systems DCTH.O: down 12.1% premarket BUZZ-Down on launch of public offering ** IGM BioSciences IGMS.O: up 10.4% premarket BUZZ-Drops after pricing upsized $200 mln stock deal ** Pluralsight Inc PS.O: down 2.8% premarket BUZZ-Falls as J.P. Morgan downgrades on likely revenue slowdown ** Zoom Video Communications Inc ZM.O: down 1.8% premarket BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 35.6% premarket BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 6.5% premarket BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 9.4% premarket BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 2.8% premarket BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 114.7% premarket BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 44.8% premarket BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 93.8% premarket BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.4% premarket BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: flat/untraded premarket BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.9% premarket BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 17.4% premarket BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 7.2% premarket BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 12.2% premarket BUZZ-Falls as Q1 results miss estimates (Compiled by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. .N At 8:41 ET, Dow e-minis 1YMc1 were up 0.27% at 30,251. S&P 500 e-minis ESc1 were up 0.15% at 3,707.5, while Nasdaq 100 e-minis NQc1 were down 0.08% at 12,627.
|
The top three NYSE percentage gainers premarket .PRPG.NQ: ** QuantumScape Corp , up 36.4% ** Compania Cervecerias Unidas S.A. , up 20.0% ** Cabot Corp , up 19.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** Talos Energy Inc , down 20.2% ** GameStop Corp , down 17.4% ** STMicroelectronics N.V. , down 10.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Xenetic Biosciences Inc , up 304.6% ** Intec Pharma Ltd , up 114.7% ** Zw Data Action Technologies Inc , up 93.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Pluristem Therapeutics Inc , down 42.2% ** Atossa Therapeutics Inc , down 41.9% ** Streamline Health Solutions Inc , down 31.8% ** Check Point Software Technologies CHKP.O: down 1.7% premarket ** Palo Alto Networks Inc PANW.N: down 1.6% premarket ** Fortinet Inc FTNT.O: down 2.1% premarket BUZZ-Cybersecurity stocks: JPM downgrades on slowing on-premise firewall spend ** Boeing Co BA.N: up 1.0% premarket BUZZ-Jefferies says 'MAX is almost back', raises PT ** Walt Disney Co DIS.N: up 1.6% premarket BUZZ-Rises as KeyBanc initiates with 'overweight' ** GameStop Corp GME.N: down 17.4% premarket BUZZ-Drops as Q3 revenue misses estimates USN ** Sorrento Therapeutics Inc SRNE.O: up 9.5% premarket BUZZ-Up on receiving CLIA license, plans to start COVID-19 testing ** Talos Energy TALO.N: down 20.2% premarket BUZZ-Drops; announces 8.5 mln share offer ** BRP Group Inc BRP.O: down 8.2% premarket BUZZ-Falls on discounted share offering ** Pluristem Therapeutics Inc PSTI.O: down 42.2% premarket BUZZ-Pluristem to close late-stage study of arterial disease treatment, shares plunge ** JinkoSolar Holding Co Ltd JKS.N: down 1.6% premarket BUZZ-Down on $100 mln equity offering ** Baxter International Inc BAX.N: down 0.6% premarket ** Omnicell Inc OMCL.O: up 13.1% premarket BUZZ-Credit Suisse says Omnicell deal can be potentially good ** Sino-Global Shipping America Ltd SINO.O: down 6.5% premarket BUZZ-To acquire 51% of Shenzhen Jiayoubao, shares drop ** Fuelcell Energy FCEL.O: up 3.0% premarket BUZZ-Canaccord Genuity initiates coverage with 'hold' ** Tricida Inc TCDA.O: down 10.7% premarket BUZZ-Drops after revising kidney disease drug trial protocol ** Xpeng Inc XPEV.N: down 3.9% premarket BUZZ-Chinese EV maker Xpeng slips after pricing upsized equity offering ** Vesper Healthcare Acquisition VSPR.O: up 7.2% premarket BUZZ-Jumps on report of merger with HydraFacial ** Sutro Biopharma STRO.O: down 3.2% premarket BUZZ-Falls on $126 mln share offering ** QuantumScape Corp QS.N: up 36.4% premarket BUZZ-Says its battery could power electric planes, shares jump ** Delcath Systems DCTH.O: down 12.1% premarket BUZZ-Down on launch of public offering ** IGM BioSciences IGMS.O: up 10.4% premarket BUZZ-Drops after pricing upsized $200 mln stock deal ** Pluralsight Inc PS.O: down 2.8% premarket BUZZ-Falls as J.P. Morgan downgrades on likely revenue slowdown ** Zoom Video Communications Inc ZM.O: down 1.8% premarket BUZZ-Slips as J.P. Morgan downgrades on high valuation ** Rocket Pharmaceuticals Inc RCKT.O: up 35.6% premarket BUZZ-Soars after muscle disorder therapy shows promise in early trial ** Orion Energy Systems Inc OESX.O: up 6.5% premarket BUZZ-Shares rise on contract extension ** Atara Biotherapeutics ATRA.O: down 9.4% premarket BUZZ-Dips on equity offering ** Roku Inc ROKU.O: up 2.8% premarket BUZZ-Set to open at record high after Citigroup raises PT ** Intec Pharma Ltd NTEC.O: up 114.7% premarket BUZZ-Hits two-month high on cannabinoid research deal ** Usio Inc USIO.O: up 44.8% premarket BUZZ-Gains on LOI to buy Information Management Solutions ** ZW Data Action Technologies Inc CNET.O: up 93.8% premarket BUZZ-More than doubles in value on live-streaming launch ** PTC Inc PTC.O: up 2.4% premarket BUZZ-Gains on JP Morgan upgrade, PT raise ** Syneos Health Inc SYNH.O: flat/untraded premarket BUZZ-Analysts hike PTs on promising outlook ** Photronics Inc PLAB.O: down 17.9% premarket BUZZ-Slumps on Q4 revenue, profit miss ** Evelo Biosciences Inc EVLO.O: up 17.4% premarket BUZZ-Rises on positive data from eczema drug study USN ** Vesper Healthcare Acquisition Corp VSPR.O: up 7.2% premarket BUZZ-Former Allergan CEO-backed Vesper Healthcare jumps on $1.1 bln HydraFacial merger deal ** United Natural Foods UNFI.N: down 12.2% premarket BUZZ-Falls as Q1 results miss estimates (Compiled by Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set to open at a record high on Wednesday as hopes for a vaccine-linked economic recovery and more domestic fiscal stimulus sparked demand for economically sensitive stocks such as banks and industrials. .N At 8:41 ET, Dow e-minis 1YMc1 were up 0.27% at 30,251.
|
6e678fb7-27b4-4ad6-a2c1-e06b424db8cc
|
715618.0
|
2020-05-21 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Akorn, scPharmaceuticals, Teekay Tankers
|
DCTH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-akorn-scpharmaceuticals-teekay-tankers-2020-05-21
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stock indexes eyed a weaker open on Thursday as growing Sino-U.S. tensions and weak retail earnings added to worries about the pace of a recovery from a coronavirus-fueled economic slump. .N
At 08:00 ET, Dow e-minis 1YMc1 were down 0.41% at 24,418. S&P 500 e-minis ESc1 were down 0.52% at 2,953, while Nasdaq 100 e-minis NQc1 were down 0.38% at 9,449.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Aurora Cannabis Inc , up 27.3% ** Cincinnati Bell Inc , up 22.6% ** DHI Group Inc , up 18.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** MRC Global Inc , down 21.9% ** Renren Inc , down 11.9% ** Flotek Industries Inc , down 10% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Seneca Biopharma Inc , up 36.3% ** CleanSpark Inc , up 30.2% ** Imv Inc , up 22.3% The top three Nasdaq percentage losers premarket .PRPL.O: ** Akorn Inc , down 25.9% ** Delcath Systems Inc , down 19% ** Shiftpixy Inc , down 18.7% ** Lowe's Companies Inc LOW.N: up 0.5% premarket BUZZ-Street View: Lowe's on track to become a relative winner ** Expedia Group Inc EXPE.O: up 3.1% premarket BUZZ-Rises after signaling May rebound ** Akorn Inc AKRX.O: down 25.9% premarket BUZZ-Plunges on filing for Chapter 11 bankruptcy protection ** scPharmaceuticals Inc SCPH.O: down 15.9% premarket BUZZ-scPharmaceuticals drops on stock offering ** Teekay Tankers Ltd TNK.N: up 3.9% premarket BUZZ-Rises on Q1 beat, minimal impact from COVID-19 ** Under Armour Inc UAA.N: down 2.4% premarket BUZZ-Slips as co plans $400 mln convertible debt offering ** BJ's Wholesale Club Holdings Inc BJ.N: up 3.8% premarket BUZZ-Jumps after results beat ** Medtronic Plc MDT.N: down 2.6% premarket BUZZ-Drops after Q4 profit misses estimates on COVID-19 hit
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes eyed a weaker open on Thursday as growing Sino-U.S. tensions and weak retail earnings added to worries about the pace of a recovery from a coronavirus-fueled economic slump. .N At 08:00 ET, Dow e-minis 1YMc1 were down 0.41% at 24,418. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Aurora Cannabis Inc , up 27.3% ** Cincinnati Bell Inc , up 22.6% ** DHI Group Inc , up 18.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** MRC Global Inc , down 21.9% ** Renren Inc , down 11.9% ** Flotek Industries Inc , down 10% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Seneca Biopharma Inc , up 36.3% ** CleanSpark Inc , up 30.2% ** Imv Inc , up 22.3% The top three Nasdaq percentage losers premarket .PRPL.O: ** Akorn Inc , down 25.9% ** Delcath Systems Inc , down 19% ** Shiftpixy Inc , down 18.7% ** Lowe's Companies Inc LOW.N: up 0.5% premarket BUZZ-Street View: Lowe's on track to become a relative winner ** Expedia Group Inc EXPE.O: up 3.1% premarket BUZZ-Rises after signaling May rebound ** Akorn Inc AKRX.O: down 25.9% premarket BUZZ-Plunges on filing for Chapter 11 bankruptcy protection ** scPharmaceuticals Inc SCPH.O: down 15.9% premarket BUZZ-scPharmaceuticals drops on stock offering ** Teekay Tankers Ltd TNK.N: up 3.9% premarket BUZZ-Rises on Q1 beat, minimal impact from COVID-19 ** Under Armour Inc UAA.N: down 2.4% premarket BUZZ-Slips as co plans $400 mln convertible debt offering ** BJ's Wholesale Club Holdings Inc BJ.N: up 3.8% premarket BUZZ-Jumps after results beat ** Medtronic Plc MDT.N: down 2.6% premarket BUZZ-Drops after Q4 profit misses estimates on COVID-19 hit (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes eyed a weaker open on Thursday as growing Sino-U.S. tensions and weak retail earnings added to worries about the pace of a recovery from a coronavirus-fueled economic slump. S&P 500 e-minis ESc1 were down 0.52% at 2,953, while Nasdaq 100 e-minis NQc1 were down 0.38% at 9,449.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Aurora Cannabis Inc , up 27.3% ** Cincinnati Bell Inc , up 22.6% ** DHI Group Inc , up 18.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** MRC Global Inc , down 21.9% ** Renren Inc , down 11.9% ** Flotek Industries Inc , down 10% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Seneca Biopharma Inc , up 36.3% ** CleanSpark Inc , up 30.2% ** Imv Inc , up 22.3% The top three Nasdaq percentage losers premarket .PRPL.O: ** Akorn Inc , down 25.9% ** Delcath Systems Inc , down 19% ** Shiftpixy Inc , down 18.7% ** Lowe's Companies Inc LOW.N: up 0.5% premarket BUZZ-Street View: Lowe's on track to become a relative winner ** Expedia Group Inc EXPE.O: up 3.1% premarket BUZZ-Rises after signaling May rebound ** Akorn Inc AKRX.O: down 25.9% premarket BUZZ-Plunges on filing for Chapter 11 bankruptcy protection ** scPharmaceuticals Inc SCPH.O: down 15.9% premarket BUZZ-scPharmaceuticals drops on stock offering ** Teekay Tankers Ltd TNK.N: up 3.9% premarket BUZZ-Rises on Q1 beat, minimal impact from COVID-19 ** Under Armour Inc UAA.N: down 2.4% premarket BUZZ-Slips as co plans $400 mln convertible debt offering ** BJ's Wholesale Club Holdings Inc BJ.N: up 3.8% premarket BUZZ-Jumps after results beat ** Medtronic Plc MDT.N: down 2.6% premarket BUZZ-Drops after Q4 profit misses estimates on COVID-19 hit (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes eyed a weaker open on Thursday as growing Sino-U.S. tensions and weak retail earnings added to worries about the pace of a recovery from a coronavirus-fueled economic slump. S&P 500 e-minis ESc1 were down 0.52% at 2,953, while Nasdaq 100 e-minis NQc1 were down 0.38% at 9,449.5. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Aurora Cannabis Inc , up 27.3% ** Cincinnati Bell Inc , up 22.6% ** DHI Group Inc , up 18.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** MRC Global Inc , down 21.9% ** Renren Inc , down 11.9% ** Flotek Industries Inc , down 10% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Seneca Biopharma Inc , up 36.3% ** CleanSpark Inc , up 30.2% ** Imv Inc , up 22.3% The top three Nasdaq percentage losers premarket .PRPL.O: ** Akorn Inc , down 25.9% ** Delcath Systems Inc , down 19% ** Shiftpixy Inc , down 18.7% ** Lowe's Companies Inc LOW.N: up 0.5% premarket BUZZ-Street View: Lowe's on track to become a relative winner ** Expedia Group Inc EXPE.O: up 3.1% premarket BUZZ-Rises after signaling May rebound ** Akorn Inc AKRX.O: down 25.9% premarket BUZZ-Plunges on filing for Chapter 11 bankruptcy protection ** scPharmaceuticals Inc SCPH.O: down 15.9% premarket BUZZ-scPharmaceuticals drops on stock offering ** Teekay Tankers Ltd TNK.N: up 3.9% premarket BUZZ-Rises on Q1 beat, minimal impact from COVID-19 ** Under Armour Inc UAA.N: down 2.4% premarket BUZZ-Slips as co plans $400 mln convertible debt offering ** BJ's Wholesale Club Holdings Inc BJ.N: up 3.8% premarket BUZZ-Jumps after results beat ** Medtronic Plc MDT.N: down 2.6% premarket BUZZ-Drops after Q4 profit misses estimates on COVID-19 hit (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes eyed a weaker open on Thursday as growing Sino-U.S. tensions and weak retail earnings added to worries about the pace of a recovery from a coronavirus-fueled economic slump. .N At 08:00 ET, Dow e-minis 1YMc1 were down 0.41% at 24,418. S&P 500 e-minis ESc1 were down 0.52% at 2,953, while Nasdaq 100 e-minis NQc1 were down 0.38% at 9,449.5.
|
7bee5513-3ead-4f47-a73b-2e4412ed44e2
|
715619.0
|
2020-05-01 00:00:00 UTC
|
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Medigus, Aemetis
|
DCTH
|
https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-tesla-medigus-aemetis-2020-05-01
|
nan
|
nan
|
Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
U.S. stocks fell on Friday after President Donald Trump threatened to impose new tariffs on Beijing over the coronavirus crisis, while business warnings from Amazon.com and big oil firms highlighted the pain inflicted by global lockdowns .N
At 12:38 p.m. ET, the Dow Jones Industrial Average .DJI was down 2.45% at 23,748.19. The S&P 500 .SPX was down 2.68% at 2,834.26 and the Nasdaq Composite .IXIC was down 3.35% at 8,591.362. The top three S&P 500 .PG.INX percentage gainers: ** Fortune Brands Home & Security Inc FBHS.N, up 6.1% ** Clorox Co CLX.N, up 4.7% ** Juniper Networks Inc JNPR.N, up 2.8% The top three S&P 500 .PL.INX percentage losers: ** Weyerhaeuser Co WY.N, down 15.3% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5% ** Western Digital Corp WDC.OQ, down 13.2% The top three NYSE .PG.N percentage gainers: ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7% ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4% ** North European Oil Royalty Trust NRT.N, up 20.2% The top three NYSE .PL.N percentage losers: ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6% ** Mallinckrodt Plc MNK.N, down 19.2% ** Oceaneering International Inc OII.N, down 19.1% The top three Nasdaq .PG.O percentage gainers: ** Discovery Inc DISCB.O, up 63.2% ** Medigus Ltd MDGS.O, up 44.9% ** International Money Express Inc IMXI.O, up 22% The top three Nasdaq .PL.O percentage losers: ** Delcath Systems Inc DCTH.O, down 43.5% ** Pixelworks Inc PXLW.O, down 21.1% ** Marlin Business Services Corp MRLN.O, down 20.9% ** Wisdom Tree Investments Inc WETF.O: down 10.0%
BUZZ-WisdomTree Investments: Slides as Q1 revenue misses ** Prudential Financial Inc PRU.N: down 5.2% ** MetLife Inc MET.N: down 3.6% ** American International Group Inc AIG.N: down 5.2% ** Travelers Companies Inc TRV.N: down 3.5%
BUZZ-U.S. insurers: Fall as broker estimates COVID-19 losses to exceed 9/11 claims ** Restaurant Brands International Inc QSR.N: down 3.2%
BUZZ-Restaurant Brands: Falls on profit miss, Q2 warning ** Bel Fuse Inc BELFA.O: up 16.8%
BUZZ-Bel Fuse: Jumps on forecast of sequential sales growth ** Illumina Inc ILMN.O: down 4.3%
BUZZ-Illumina lacks near-term resiliency against COVID-19 pandemic - Canaccord Genuity ** Newell Brands Inc NWL.O: down 8.5%
BUZZ-Newell expects more damage from coronavirus, shares sink ** Molina Healthcare Inc MOH.N: up 3.0%
BUZZ-Molina: Rises on plans to buy Magellan Complete Care, Q1 profit beat ** Tandem Diabetes Care Inc TNDM.O: down 2.8%
BUZZ-Tandem Diabetes Care: Falls on Q1 profit miss ** Stryker Corp SYK.N: down 3.2%
BUZZ-Street View: Stryker's recovery after coronavirus crisis is tough to chart ** Medigus Ltd MDGS.O: up 44.9%
BUZZ-Medigus: Surges on first commercial order for COVID-19 test kits ** Goldman Sachs Group Inc GS.N: down 2.9% ** JPMorgan Chase & Co JPM.N>: down 3.3% ** Citigroup Inc C.N: down 5.5% ** Wells Fargo & Co WFC.N: down 5.4% ** Bank of America Corp BAC.N: down 4.7% ** Morgan Stanley MS.N: down 3.1%
BUZZ-U.S. banks track sliding yields amid risk-off sentiment ** United States Steel Corp X.N: down 2.9%
BUZZ-US Steel drops as shutdown triggers biggest adj loss in 12 qtrs ** Weyerhaeuser Co WY.N: down 15.4%
BUZZ-Weyerhaeuser eyes steepest fall in 6 weeks on suspending dividend, cutting production ** Tesla Inc TSLA.O: down 10.4%
BUZZ-Tesla continues slide as co drops price for China-made Model 3 cars by 10% BUZZ-Tesla shares move lower after Elon Musk tweet says 'stock price too high' ** Beyond Meat Inc BYND.O: down 7.7%
BUZZ-Beyond Meat: Falls after Wells Fargo downgrades on soft foodservice demand ** CURO Group Holdings Corp CURO.N: down 15.9%
BUZZ-CURO Group Holdings: Drops on disappointing Q1 profit ** Zendesk Inc ZEN.N: down 5.0%
BUZZ-Zendesk shares drop as co pulls 2020 forecast, post wider Q1 loss ** MGM Resorts International MGM.N: down 10.4% ** Wynn Resorts Ltd WYNN.O: down 6.7% ** Las Vegas Sands Corp LVS.N: down 5.7% ** Melco Resorts & Entertainment Ltd MLCO.O: down 5.1%
BUZZ-U.S. casinos: Tumble on weaker-than-expected Macau gaming revenue ** Caterpillar Inc CAT.N: down 4.4% ** Boeing Co BA.N: down 4.4% ** 3M Co MMM.N: down 1.4% ** Raytheon Technologies Corp RTX.N: down 6.4% ** Honeywell International Inc HON.N: down 4.7% ** General Electric Co GE.N: down 5.4%
BUZZ-U.S. industrials fall as Trump threatens new tariffs on China * Twitter Inc TWTR.N: down 4.9% BUZZ-Street View: Twitter's nest at risk as ad birds fly to peers ** HCA Healthcare Inc HCA.N: down 5.3% BUZZ-Bernstein expects COVID-19 to weigh on HCA Healthcare's profit, cuts PT ** L Brands Inc LB.N: down 3.2% BUZZ-L Brands: Jefferies urges to sell as J. Crew reportedly prepares for bankruptcy ** Comcast Corp CMCSA.O: down 1.5% BUZZ-Street view: Comcast's broadband business shines; TV unit struggles ** Western Digital Corp WDC.O: down 13.2% BUZZ-Western Digital: Slides as co suspends dividend, misses Q3 profit estimate ** Kraft Heinz Co KHC.O: down 2.1% BUZZ-Street View: Kraft Heinz's stockpiling-led growth could be short-lived ** MGM Resorts Internationals MGM.N: down 10.4% BUZZ-MGM Resorts: Slides after coronavirus knocks down Q1 topline ** Gilead Sciences Inc GILD.O: down 7.1% BUZZ-Gilead: Drops on flat profit; co plans to expand remdesivir production BUZZ-Street View: Too early to call shots on Gilead's remdesivir profits ** Amgen Inc AMGN.O: down 3.4% BUZZ-Street View: Amgen to see minimal disruption from COVID-19 ** Moderna Inc MRNA.O: up 3.2% BUZZ-Moderna: Rises on deal to accelerate COVID-19 vaccine manufacturing ** United Airlines Holdings Inc UAL.O: down 10.0% BUZZ-United Airlines: Falls after reporting $1.7 bln quarterly loss ** Clorox Co CLX.N: up 4.7% BUZZ-Clorox raises 2020 forecast on strong demand for cleaning products, shares up ** Aemetis Inc AMTX.O: up 95.9% BUZZ-Aemetis Inc: Surges as co begins CO2 deliveries to privately-held Messer ** Pixelworks Inc PXLW.O: down 21.1% BUZZ-Pixelworks slides on Q1 rev miss; Craig Hallum cuts PT on weak Q2 guidance ** Co-Diagnostics Inc CODX.O: up 16.6% BUZZ-Co-Diagnostics: Up on COVID-19 test performance data
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 1.78%
Consumer Discretionary
.SPLRCD
down 4.98%
Consumer Staples
.SPLRCS
down 0.57%
Energy
.SPNY
down 5.83%
Financial
.SPSY
down 3.52%
Health
.SPXHC
down 2.56%
Industrial
.SPLRCI
down 3.36%
Information Technology
.SPLRCT
down 2.66%
Materials
.SPLRCM
down 2.62%
Real Estate
.SPLRCR
down 3.30%
Utilities
.SPLRCU
down 2.46%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The top three S&P 500 .PG.INX percentage gainers: ** Fortune Brands Home & Security Inc FBHS.N, up 6.1% ** Clorox Co CLX.N, up 4.7% ** Juniper Networks Inc JNPR.N, up 2.8% The top three S&P 500 .PL.INX percentage losers: ** Weyerhaeuser Co WY.N, down 15.3% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5% ** Western Digital Corp WDC.OQ, down 13.2% The top three NYSE .PG.N percentage gainers: ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7% ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4% ** North European Oil Royalty Trust NRT.N, up 20.2% The top three NYSE .PL.N percentage losers: ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6% ** Mallinckrodt Plc MNK.N, down 19.2% ** Oceaneering International Inc OII.N, down 19.1% The top three Nasdaq .PG.O percentage gainers: ** Discovery Inc DISCB.O, up 63.2% ** Medigus Ltd MDGS.O, up 44.9% ** International Money Express Inc IMXI.O, up 22% The top three Nasdaq .PL.O percentage losers: ** Delcath Systems Inc DCTH.O, down 43.5% ** Pixelworks Inc PXLW.O, down 21.1% ** Marlin Business Services Corp MRLN.O, down 20.9% ** Wisdom Tree Investments Inc WETF.O: down 10.0% BUZZ-WisdomTree Investments: Slides as Q1 revenue misses ** Prudential Financial Inc PRU.N: down 5.2% ** MetLife Inc MET.N: down 3.6% ** American International Group Inc AIG.N: down 5.2% ** Travelers Companies Inc TRV.N: down 3.5% BUZZ-U.S. insurers: Fall as broker estimates COVID-19 losses to exceed 9/11 claims ** Restaurant Brands International Inc QSR.N: down 3.2% BUZZ-Restaurant Brands: Falls on profit miss, Q2 warning ** Bel Fuse Inc BELFA.O: up 16.8% BUZZ-Bel Fuse: Jumps on forecast of sequential sales growth ** Illumina Inc ILMN.O: down 4.3% BUZZ-Illumina lacks near-term resiliency against COVID-19 pandemic - Canaccord Genuity ** Newell Brands Inc NWL.O: down 8.5% BUZZ-Newell expects more damage from coronavirus, shares sink ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Molina: Rises on plans to buy Magellan Complete Care, Q1 profit beat ** Tandem Diabetes Care Inc TNDM.O: down 2.8% BUZZ-Tandem Diabetes Care: Falls on Q1 profit miss ** Stryker Corp SYK.N: down 3.2% BUZZ-Street View: Stryker's recovery after coronavirus crisis is tough to chart ** Medigus Ltd MDGS.O: up 44.9% BUZZ-Medigus: Surges on first commercial order for COVID-19 test kits ** Goldman Sachs Group Inc GS.N: down 2.9% ** JPMorgan Chase & Co JPM.N>: down 3.3% ** Citigroup Inc C.N: down 5.5% ** Wells Fargo & Co WFC.N: down 5.4% ** Bank of America Corp BAC.N: down 4.7% ** Morgan Stanley MS.N: down 3.1% BUZZ-U.S. banks track sliding yields amid risk-off sentiment ** United States Steel Corp X.N: down 2.9% BUZZ-US Steel drops as shutdown triggers biggest adj loss in 12 qtrs ** Weyerhaeuser Co WY.N: down 15.4% BUZZ-Weyerhaeuser eyes steepest fall in 6 weeks on suspending dividend, cutting production ** Tesla Inc TSLA.O: down 10.4% BUZZ-Tesla continues slide as co drops price for China-made Model 3 cars by 10% BUZZ-Tesla shares move lower after Elon Musk tweet says 'stock price too high' ** Beyond Meat Inc BYND.O: down 7.7% BUZZ-Beyond Meat: Falls after Wells Fargo downgrades on soft foodservice demand ** CURO Group Holdings Corp CURO.N: down 15.9% BUZZ-CURO Group Holdings: Drops on disappointing Q1 profit ** Zendesk Inc ZEN.N: down 5.0% BUZZ-Zendesk shares drop as co pulls 2020 forecast, post wider Q1 loss ** MGM Resorts International MGM.N: down 10.4% ** Wynn Resorts Ltd WYNN.O: down 6.7% ** Las Vegas Sands Corp LVS.N: down 5.7% ** Melco Resorts & Entertainment Ltd MLCO.O: down 5.1% BUZZ-U.S. casinos: Tumble on weaker-than-expected Macau gaming revenue ** Caterpillar Inc CAT.N: down 4.4% ** Boeing Co BA.N: down 4.4% ** 3M Co MMM.N: down 1.4% ** Raytheon Technologies Corp RTX.N: down 6.4% ** Honeywell International Inc HON.N: down 4.7% ** General Electric Co GE.N: down 5.4% BUZZ-U.S. industrials fall as Trump threatens new tariffs on China * Twitter Inc TWTR.N: down 4.9% BUZZ-Street View: Twitter's nest at risk as ad birds fly to peers ** HCA Healthcare Inc HCA.N: down 5.3% BUZZ-Bernstein expects COVID-19 to weigh on HCA Healthcare's profit, cuts PT ** L Brands Inc LB.N: down 3.2% BUZZ-L Brands: Jefferies urges to sell as J. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks fell on Friday after President Donald Trump threatened to impose new tariffs on Beijing over the coronavirus crisis, while business warnings from Amazon.com and big oil firms highlighted the pain inflicted by global lockdowns .N At 12:38 p.m. Crew reportedly prepares for bankruptcy ** Comcast Corp CMCSA.O: down 1.5% BUZZ-Street view: Comcast's broadband business shines; TV unit struggles ** Western Digital Corp WDC.O: down 13.2% BUZZ-Western Digital: Slides as co suspends dividend, misses Q3 profit estimate ** Kraft Heinz Co KHC.O: down 2.1% BUZZ-Street View: Kraft Heinz's stockpiling-led growth could be short-lived ** MGM Resorts Internationals MGM.N: down 10.4% BUZZ-MGM Resorts: Slides after coronavirus knocks down Q1 topline ** Gilead Sciences Inc GILD.O: down 7.1% BUZZ-Gilead: Drops on flat profit; co plans to expand remdesivir production BUZZ-Street View: Too early to call shots on Gilead's remdesivir profits ** Amgen Inc AMGN.O: down 3.4% BUZZ-Street View: Amgen to see minimal disruption from COVID-19 ** Moderna Inc MRNA.O: up 3.2% BUZZ-Moderna: Rises on deal to accelerate COVID-19 vaccine manufacturing ** United Airlines Holdings Inc UAL.O: down 10.0% BUZZ-United Airlines: Falls after reporting $1.7 bln quarterly loss ** Clorox Co CLX.N: up 4.7% BUZZ-Clorox raises 2020 forecast on strong demand for cleaning products, shares up ** Aemetis Inc AMTX.O: up 95.9% BUZZ-Aemetis Inc: Surges as co begins CO2 deliveries to privately-held Messer ** Pixelworks Inc PXLW.O: down 21.1% BUZZ-Pixelworks slides on Q1 rev miss; Craig Hallum cuts PT on weak Q2 guidance ** Co-Diagnostics Inc CODX.O: up 16.6% BUZZ-Co-Diagnostics: Up on COVID-19 test performance data The 11 major S&P 500 sectors: Communication Services
|
The top three S&P 500 .PG.INX percentage gainers: ** Fortune Brands Home & Security Inc FBHS.N, up 6.1% ** Clorox Co CLX.N, up 4.7% ** Juniper Networks Inc JNPR.N, up 2.8% The top three S&P 500 .PL.INX percentage losers: ** Weyerhaeuser Co WY.N, down 15.3% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5% ** Western Digital Corp WDC.OQ, down 13.2% The top three NYSE .PG.N percentage gainers: ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7% ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4% ** North European Oil Royalty Trust NRT.N, up 20.2% The top three NYSE .PL.N percentage losers: ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6% ** Mallinckrodt Plc MNK.N, down 19.2% ** Oceaneering International Inc OII.N, down 19.1% The top three Nasdaq .PG.O percentage gainers: ** Discovery Inc DISCB.O, up 63.2% ** Medigus Ltd MDGS.O, up 44.9% ** International Money Express Inc IMXI.O, up 22% The top three Nasdaq .PL.O percentage losers: ** Delcath Systems Inc DCTH.O, down 43.5% ** Pixelworks Inc PXLW.O, down 21.1% ** Marlin Business Services Corp MRLN.O, down 20.9% ** Wisdom Tree Investments Inc WETF.O: down 10.0% BUZZ-WisdomTree Investments: Slides as Q1 revenue misses ** Prudential Financial Inc PRU.N: down 5.2% ** MetLife Inc MET.N: down 3.6% ** American International Group Inc AIG.N: down 5.2% ** Travelers Companies Inc TRV.N: down 3.5% BUZZ-U.S. insurers: Fall as broker estimates COVID-19 losses to exceed 9/11 claims ** Restaurant Brands International Inc QSR.N: down 3.2% BUZZ-Restaurant Brands: Falls on profit miss, Q2 warning ** Bel Fuse Inc BELFA.O: up 16.8% BUZZ-Bel Fuse: Jumps on forecast of sequential sales growth ** Illumina Inc ILMN.O: down 4.3% BUZZ-Illumina lacks near-term resiliency against COVID-19 pandemic - Canaccord Genuity ** Newell Brands Inc NWL.O: down 8.5% BUZZ-Newell expects more damage from coronavirus, shares sink ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Molina: Rises on plans to buy Magellan Complete Care, Q1 profit beat ** Tandem Diabetes Care Inc TNDM.O: down 2.8% BUZZ-Tandem Diabetes Care: Falls on Q1 profit miss ** Stryker Corp SYK.N: down 3.2% BUZZ-Street View: Stryker's recovery after coronavirus crisis is tough to chart ** Medigus Ltd MDGS.O: up 44.9% BUZZ-Medigus: Surges on first commercial order for COVID-19 test kits ** Goldman Sachs Group Inc GS.N: down 2.9% ** JPMorgan Chase & Co JPM.N>: down 3.3% ** Citigroup Inc C.N: down 5.5% ** Wells Fargo & Co WFC.N: down 5.4% ** Bank of America Corp BAC.N: down 4.7% ** Morgan Stanley MS.N: down 3.1% BUZZ-U.S. banks track sliding yields amid risk-off sentiment ** United States Steel Corp X.N: down 2.9% BUZZ-US Steel drops as shutdown triggers biggest adj loss in 12 qtrs ** Weyerhaeuser Co WY.N: down 15.4% BUZZ-Weyerhaeuser eyes steepest fall in 6 weeks on suspending dividend, cutting production ** Tesla Inc TSLA.O: down 10.4% BUZZ-Tesla continues slide as co drops price for China-made Model 3 cars by 10% BUZZ-Tesla shares move lower after Elon Musk tweet says 'stock price too high' ** Beyond Meat Inc BYND.O: down 7.7% BUZZ-Beyond Meat: Falls after Wells Fargo downgrades on soft foodservice demand ** CURO Group Holdings Corp CURO.N: down 15.9% BUZZ-CURO Group Holdings: Drops on disappointing Q1 profit ** Zendesk Inc ZEN.N: down 5.0% BUZZ-Zendesk shares drop as co pulls 2020 forecast, post wider Q1 loss ** MGM Resorts International MGM.N: down 10.4% ** Wynn Resorts Ltd WYNN.O: down 6.7% ** Las Vegas Sands Corp LVS.N: down 5.7% ** Melco Resorts & Entertainment Ltd MLCO.O: down 5.1% BUZZ-U.S. casinos: Tumble on weaker-than-expected Macau gaming revenue ** Caterpillar Inc CAT.N: down 4.4% ** Boeing Co BA.N: down 4.4% ** 3M Co MMM.N: down 1.4% ** Raytheon Technologies Corp RTX.N: down 6.4% ** Honeywell International Inc HON.N: down 4.7% ** General Electric Co GE.N: down 5.4% BUZZ-U.S. industrials fall as Trump threatens new tariffs on China * Twitter Inc TWTR.N: down 4.9% BUZZ-Street View: Twitter's nest at risk as ad birds fly to peers ** HCA Healthcare Inc HCA.N: down 5.3% BUZZ-Bernstein expects COVID-19 to weigh on HCA Healthcare's profit, cuts PT ** L Brands Inc LB.N: down 3.2% BUZZ-L Brands: Jefferies urges to sell as J. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks fell on Friday after President Donald Trump threatened to impose new tariffs on Beijing over the coronavirus crisis, while business warnings from Amazon.com and big oil firms highlighted the pain inflicted by global lockdowns .N At 12:38 p.m. Crew reportedly prepares for bankruptcy ** Comcast Corp CMCSA.O: down 1.5% BUZZ-Street view: Comcast's broadband business shines; TV unit struggles ** Western Digital Corp WDC.O: down 13.2% BUZZ-Western Digital: Slides as co suspends dividend, misses Q3 profit estimate ** Kraft Heinz Co KHC.O: down 2.1% BUZZ-Street View: Kraft Heinz's stockpiling-led growth could be short-lived ** MGM Resorts Internationals MGM.N: down 10.4% BUZZ-MGM Resorts: Slides after coronavirus knocks down Q1 topline ** Gilead Sciences Inc GILD.O: down 7.1% BUZZ-Gilead: Drops on flat profit; co plans to expand remdesivir production BUZZ-Street View: Too early to call shots on Gilead's remdesivir profits ** Amgen Inc AMGN.O: down 3.4% BUZZ-Street View: Amgen to see minimal disruption from COVID-19 ** Moderna Inc MRNA.O: up 3.2% BUZZ-Moderna: Rises on deal to accelerate COVID-19 vaccine manufacturing ** United Airlines Holdings Inc UAL.O: down 10.0% BUZZ-United Airlines: Falls after reporting $1.7 bln quarterly loss ** Clorox Co CLX.N: up 4.7% BUZZ-Clorox raises 2020 forecast on strong demand for cleaning products, shares up ** Aemetis Inc AMTX.O: up 95.9% BUZZ-Aemetis Inc: Surges as co begins CO2 deliveries to privately-held Messer ** Pixelworks Inc PXLW.O: down 21.1% BUZZ-Pixelworks slides on Q1 rev miss; Craig Hallum cuts PT on weak Q2 guidance ** Co-Diagnostics Inc CODX.O: up 16.6% BUZZ-Co-Diagnostics: Up on COVID-19 test performance data The 11 major S&P 500 sectors: Communication Services
|
The top three S&P 500 .PG.INX percentage gainers: ** Fortune Brands Home & Security Inc FBHS.N, up 6.1% ** Clorox Co CLX.N, up 4.7% ** Juniper Networks Inc JNPR.N, up 2.8% The top three S&P 500 .PL.INX percentage losers: ** Weyerhaeuser Co WY.N, down 15.3% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5% ** Western Digital Corp WDC.OQ, down 13.2% The top three NYSE .PG.N percentage gainers: ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7% ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4% ** North European Oil Royalty Trust NRT.N, up 20.2% The top three NYSE .PL.N percentage losers: ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6% ** Mallinckrodt Plc MNK.N, down 19.2% ** Oceaneering International Inc OII.N, down 19.1% The top three Nasdaq .PG.O percentage gainers: ** Discovery Inc DISCB.O, up 63.2% ** Medigus Ltd MDGS.O, up 44.9% ** International Money Express Inc IMXI.O, up 22% The top three Nasdaq .PL.O percentage losers: ** Delcath Systems Inc DCTH.O, down 43.5% ** Pixelworks Inc PXLW.O, down 21.1% ** Marlin Business Services Corp MRLN.O, down 20.9% ** Wisdom Tree Investments Inc WETF.O: down 10.0% BUZZ-WisdomTree Investments: Slides as Q1 revenue misses ** Prudential Financial Inc PRU.N: down 5.2% ** MetLife Inc MET.N: down 3.6% ** American International Group Inc AIG.N: down 5.2% ** Travelers Companies Inc TRV.N: down 3.5% BUZZ-U.S. insurers: Fall as broker estimates COVID-19 losses to exceed 9/11 claims ** Restaurant Brands International Inc QSR.N: down 3.2% BUZZ-Restaurant Brands: Falls on profit miss, Q2 warning ** Bel Fuse Inc BELFA.O: up 16.8% BUZZ-Bel Fuse: Jumps on forecast of sequential sales growth ** Illumina Inc ILMN.O: down 4.3% BUZZ-Illumina lacks near-term resiliency against COVID-19 pandemic - Canaccord Genuity ** Newell Brands Inc NWL.O: down 8.5% BUZZ-Newell expects more damage from coronavirus, shares sink ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Molina: Rises on plans to buy Magellan Complete Care, Q1 profit beat ** Tandem Diabetes Care Inc TNDM.O: down 2.8% BUZZ-Tandem Diabetes Care: Falls on Q1 profit miss ** Stryker Corp SYK.N: down 3.2% BUZZ-Street View: Stryker's recovery after coronavirus crisis is tough to chart ** Medigus Ltd MDGS.O: up 44.9% BUZZ-Medigus: Surges on first commercial order for COVID-19 test kits ** Goldman Sachs Group Inc GS.N: down 2.9% ** JPMorgan Chase & Co JPM.N>: down 3.3% ** Citigroup Inc C.N: down 5.5% ** Wells Fargo & Co WFC.N: down 5.4% ** Bank of America Corp BAC.N: down 4.7% ** Morgan Stanley MS.N: down 3.1% BUZZ-U.S. banks track sliding yields amid risk-off sentiment ** United States Steel Corp X.N: down 2.9% BUZZ-US Steel drops as shutdown triggers biggest adj loss in 12 qtrs ** Weyerhaeuser Co WY.N: down 15.4% BUZZ-Weyerhaeuser eyes steepest fall in 6 weeks on suspending dividend, cutting production ** Tesla Inc TSLA.O: down 10.4% BUZZ-Tesla continues slide as co drops price for China-made Model 3 cars by 10% BUZZ-Tesla shares move lower after Elon Musk tweet says 'stock price too high' ** Beyond Meat Inc BYND.O: down 7.7% BUZZ-Beyond Meat: Falls after Wells Fargo downgrades on soft foodservice demand ** CURO Group Holdings Corp CURO.N: down 15.9% BUZZ-CURO Group Holdings: Drops on disappointing Q1 profit ** Zendesk Inc ZEN.N: down 5.0% BUZZ-Zendesk shares drop as co pulls 2020 forecast, post wider Q1 loss ** MGM Resorts International MGM.N: down 10.4% ** Wynn Resorts Ltd WYNN.O: down 6.7% ** Las Vegas Sands Corp LVS.N: down 5.7% ** Melco Resorts & Entertainment Ltd MLCO.O: down 5.1% BUZZ-U.S. casinos: Tumble on weaker-than-expected Macau gaming revenue ** Caterpillar Inc CAT.N: down 4.4% ** Boeing Co BA.N: down 4.4% ** 3M Co MMM.N: down 1.4% ** Raytheon Technologies Corp RTX.N: down 6.4% ** Honeywell International Inc HON.N: down 4.7% ** General Electric Co GE.N: down 5.4% BUZZ-U.S. industrials fall as Trump threatens new tariffs on China * Twitter Inc TWTR.N: down 4.9% BUZZ-Street View: Twitter's nest at risk as ad birds fly to peers ** HCA Healthcare Inc HCA.N: down 5.3% BUZZ-Bernstein expects COVID-19 to weigh on HCA Healthcare's profit, cuts PT ** L Brands Inc LB.N: down 3.2% BUZZ-L Brands: Jefferies urges to sell as J. Crew reportedly prepares for bankruptcy ** Comcast Corp CMCSA.O: down 1.5% BUZZ-Street view: Comcast's broadband business shines; TV unit struggles ** Western Digital Corp WDC.O: down 13.2% BUZZ-Western Digital: Slides as co suspends dividend, misses Q3 profit estimate ** Kraft Heinz Co KHC.O: down 2.1% BUZZ-Street View: Kraft Heinz's stockpiling-led growth could be short-lived ** MGM Resorts Internationals MGM.N: down 10.4% BUZZ-MGM Resorts: Slides after coronavirus knocks down Q1 topline ** Gilead Sciences Inc GILD.O: down 7.1% BUZZ-Gilead: Drops on flat profit; co plans to expand remdesivir production BUZZ-Street View: Too early to call shots on Gilead's remdesivir profits ** Amgen Inc AMGN.O: down 3.4% BUZZ-Street View: Amgen to see minimal disruption from COVID-19 ** Moderna Inc MRNA.O: up 3.2% BUZZ-Moderna: Rises on deal to accelerate COVID-19 vaccine manufacturing ** United Airlines Holdings Inc UAL.O: down 10.0% BUZZ-United Airlines: Falls after reporting $1.7 bln quarterly loss ** Clorox Co CLX.N: up 4.7% BUZZ-Clorox raises 2020 forecast on strong demand for cleaning products, shares up ** Aemetis Inc AMTX.O: up 95.9% BUZZ-Aemetis Inc: Surges as co begins CO2 deliveries to privately-held Messer ** Pixelworks Inc PXLW.O: down 21.1% BUZZ-Pixelworks slides on Q1 rev miss; Craig Hallum cuts PT on weak Q2 guidance ** Co-Diagnostics Inc CODX.O: up 16.6% BUZZ-Co-Diagnostics: Up on COVID-19 test performance data The 11 major S&P 500 sectors: Communication Services down 1.78% Consumer Discretionary
|
The top three S&P 500 .PG.INX percentage gainers: ** Fortune Brands Home & Security Inc FBHS.N, up 6.1% ** Clorox Co CLX.N, up 4.7% ** Juniper Networks Inc JNPR.N, up 2.8% The top three S&P 500 .PL.INX percentage losers: ** Weyerhaeuser Co WY.N, down 15.3% ** Norwegian Cruise Line Holdings Ltd NCLH.N, down 14.5% ** Western Digital Corp WDC.OQ, down 13.2% The top three NYSE .PG.N percentage gainers: ** Vesper US Large Cap Short-Term Reversal Strategy UTRN.N, up 27.7% ** John Hancock Multifactor Technology ETF JHMT.N, up 24.4% ** North European Oil Royalty Trust NRT.N, up 20.2% The top three NYSE .PL.N percentage losers: ** Microsectors U.S. Big Oil Index 3x NRGU.N, down 21.6% ** Mallinckrodt Plc MNK.N, down 19.2% ** Oceaneering International Inc OII.N, down 19.1% The top three Nasdaq .PG.O percentage gainers: ** Discovery Inc DISCB.O, up 63.2% ** Medigus Ltd MDGS.O, up 44.9% ** International Money Express Inc IMXI.O, up 22% The top three Nasdaq .PL.O percentage losers: ** Delcath Systems Inc DCTH.O, down 43.5% ** Pixelworks Inc PXLW.O, down 21.1% ** Marlin Business Services Corp MRLN.O, down 20.9% ** Wisdom Tree Investments Inc WETF.O: down 10.0% BUZZ-WisdomTree Investments: Slides as Q1 revenue misses ** Prudential Financial Inc PRU.N: down 5.2% ** MetLife Inc MET.N: down 3.6% ** American International Group Inc AIG.N: down 5.2% ** Travelers Companies Inc TRV.N: down 3.5% BUZZ-U.S. insurers: Fall as broker estimates COVID-19 losses to exceed 9/11 claims ** Restaurant Brands International Inc QSR.N: down 3.2% BUZZ-Restaurant Brands: Falls on profit miss, Q2 warning ** Bel Fuse Inc BELFA.O: up 16.8% BUZZ-Bel Fuse: Jumps on forecast of sequential sales growth ** Illumina Inc ILMN.O: down 4.3% BUZZ-Illumina lacks near-term resiliency against COVID-19 pandemic - Canaccord Genuity ** Newell Brands Inc NWL.O: down 8.5% BUZZ-Newell expects more damage from coronavirus, shares sink ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Molina: Rises on plans to buy Magellan Complete Care, Q1 profit beat ** Tandem Diabetes Care Inc TNDM.O: down 2.8% BUZZ-Tandem Diabetes Care: Falls on Q1 profit miss ** Stryker Corp SYK.N: down 3.2% BUZZ-Street View: Stryker's recovery after coronavirus crisis is tough to chart ** Medigus Ltd MDGS.O: up 44.9% BUZZ-Medigus: Surges on first commercial order for COVID-19 test kits ** Goldman Sachs Group Inc GS.N: down 2.9% ** JPMorgan Chase & Co JPM.N>: down 3.3% ** Citigroup Inc C.N: down 5.5% ** Wells Fargo & Co WFC.N: down 5.4% ** Bank of America Corp BAC.N: down 4.7% ** Morgan Stanley MS.N: down 3.1% BUZZ-U.S. banks track sliding yields amid risk-off sentiment ** United States Steel Corp X.N: down 2.9% BUZZ-US Steel drops as shutdown triggers biggest adj loss in 12 qtrs ** Weyerhaeuser Co WY.N: down 15.4% BUZZ-Weyerhaeuser eyes steepest fall in 6 weeks on suspending dividend, cutting production ** Tesla Inc TSLA.O: down 10.4% BUZZ-Tesla continues slide as co drops price for China-made Model 3 cars by 10% BUZZ-Tesla shares move lower after Elon Musk tweet says 'stock price too high' ** Beyond Meat Inc BYND.O: down 7.7% BUZZ-Beyond Meat: Falls after Wells Fargo downgrades on soft foodservice demand ** CURO Group Holdings Corp CURO.N: down 15.9% BUZZ-CURO Group Holdings: Drops on disappointing Q1 profit ** Zendesk Inc ZEN.N: down 5.0% BUZZ-Zendesk shares drop as co pulls 2020 forecast, post wider Q1 loss ** MGM Resorts International MGM.N: down 10.4% ** Wynn Resorts Ltd WYNN.O: down 6.7% ** Las Vegas Sands Corp LVS.N: down 5.7% ** Melco Resorts & Entertainment Ltd MLCO.O: down 5.1% BUZZ-U.S. casinos: Tumble on weaker-than-expected Macau gaming revenue ** Caterpillar Inc CAT.N: down 4.4% ** Boeing Co BA.N: down 4.4% ** 3M Co MMM.N: down 1.4% ** Raytheon Technologies Corp RTX.N: down 6.4% ** Honeywell International Inc HON.N: down 4.7% ** General Electric Co GE.N: down 5.4% BUZZ-U.S. industrials fall as Trump threatens new tariffs on China * Twitter Inc TWTR.N: down 4.9% BUZZ-Street View: Twitter's nest at risk as ad birds fly to peers ** HCA Healthcare Inc HCA.N: down 5.3% BUZZ-Bernstein expects COVID-19 to weigh on HCA Healthcare's profit, cuts PT ** L Brands Inc LB.N: down 3.2% BUZZ-L Brands: Jefferies urges to sell as J. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks fell on Friday after President Donald Trump threatened to impose new tariffs on Beijing over the coronavirus crisis, while business warnings from Amazon.com and big oil firms highlighted the pain inflicted by global lockdowns .N At 12:38 p.m. ET, the Dow Jones Industrial Average .DJI was down 2.45% at 23,748.19.
|
4c4281f7-171a-4544-8176-613abeb79dac
|
715620.0
|
2017-08-17 00:00:00 UTC
|
Health Care Sector Update for 08/17/2017: MYOV, DCTH, LAKE
|
DCTH
|
https://www.nasdaq.com/articles/health-care-sector-update-08172017-myov-dcth-lake-2017-08-17
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.44%
PFE -0.49%
ABT -0.28%
MRK -0.61%
AMGN-1.52%
Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking about 0.4% while shares of health care companies in the S&P 500 were down almost 0.6% as a group.
In company news, Myovant Sciences Ltd ( MYOV ) jumped on Thursday, reaching a session high of $12.47 a share, after analysts at Evercore ISI today began analyst coverage of the early-state biotech company with an outperform rating and a $35 price target.
Myovant last week reported a fiscal Q1 net loss of $0.39 per share, improving on a $0.47 loss during the same quarter last year.
In other sector news,
(+) DCTH, (+22.7%) Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11.
(-) LAKE, (-12.8%) Prices $10 mln public offering of 725,000 shares at $13.80 apiece, an 11.8% discount to Wednesday's closing price. Plans to use the expected $8.95 mln in net proceeds to build new manufacturing facilities overseas and repaying its line of credit.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In other sector news, (+) DCTH, (+22.7%) Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. In company news, Myovant Sciences Ltd ( MYOV ) jumped on Thursday, reaching a session high of $12.47 a share, after analysts at Evercore ISI today began analyst coverage of the early-state biotech company with an outperform rating and a $35 price target. Plans to use the expected $8.95 mln in net proceeds to build new manufacturing facilities overseas and repaying its line of credit.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) DCTH, (+22.7%) Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking about 0.4% while shares of health care companies in the S&P 500 were down almost 0.6% as a group.
|
In other sector news, (+) DCTH, (+22.7%) Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking about 0.4% while shares of health care companies in the S&P 500 were down almost 0.6% as a group. In company news, Myovant Sciences Ltd ( MYOV ) jumped on Thursday, reaching a session high of $12.47 a share, after analysts at Evercore ISI today began analyst coverage of the early-state biotech company with an outperform rating and a $35 price target.
|
In other sector news, (+) DCTH, (+22.7%) Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. Top Health Care Stocks Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking about 0.4% while shares of health care companies in the S&P 500 were down almost 0.6% as a group.
|
22d9cf2d-73ff-46b5-b7be-af5cff6715de
|
715621.0
|
2017-08-17 00:00:00 UTC
|
Close Update: Stocks Retreat as Dow Tumbles Most in Three Months and S&P 500 Hits Five-Week Low
|
DCTH
|
https://www.nasdaq.com/articles/close-update-stocks-retreat-dow-tumbles-most-three-months-and-sp-500-hits-five-week-low
|
nan
|
nan
|
Wall Street went into selloff mode on Thursday, with investors bailing out of stocks and looking for havens as the Dow Jones Industrial Average dropped the most since May 17 and the S&P 500 posted its lowest close in more than five weeks.
Concerns about political turmoil in Washington, D.C., had markets weaker from the start, while a terrorist attack in Barcelona, Spain, that left at least 13 people dead added to the selling pressure through the afternoon. Gold and US Treasuries prices rose.
A day after Donald Trump disbanded two business advisory councils as top chief executives quit in protest of his handling of violence in Charlottesville, Virginia, investors worried that the White House was getting distracted from the president's policy plans, including tax reforms. Markets were briefly relieved as a White House official said Gary Cohn, a Trump economic adviser, was staying on amid rumors to the contrary.
But the ease didn't last and the selling pressure grew as the day wore on. The CBOE Volatility Index surged 32% while on the S&P 500, losses were recored in all 11 of the industry sectors. The Dow was red from top to bottom.
An 1.9% decline in information technology sent the Nasdaq down the most among the benchmarks, as earnings from Cisco Systems ( CSCO ) disappointed and sent the shares down 4.5%. And although Wal-Mart Stores' ( WMT ) results topped expectations, investors were spooked by sluggish sales in its Sam's Club division and in-line guidance for 2018 and Q3, leading to a 1.6% decline in the stock and deep losses for the retail sector.
The day's economic data showed initial jobless claims were down a much greater-than-expected 12,000 for the week ended August 12 to 232,000 vs 240,000 estimates. The Philadelphia Fed manufacturing index dropped to its lowest level since November 2016 of 18.9 from 19.5 in July, but was above expectations of 17.
Friday's calendar has the preliminary August University of Michigan consumer sentiment due at 10 a.m. ET.
Here's where the markets stood by the close:
US MARKETS
Dow Jones Industrial Average was down 274.14 points (-1.24%)
S&P 500 was down 38.10 points (-1.54%)
Nasdaq Composite Index was down 123.19 points (-1.94%)
GLOBAL SENTIMENT
FTSE 100 was down 0.61%
Nikkei 225 was down 0.14%
Hang Seng Index was down 0.24%
Shanghai China Composite Index was up 0.68%
UPSIDE MOVERS
(+) SSI (+25.83%) Beat Q2 sales estimates, raised FY17 guidance
(+) DCTH (+19.15%) Ayrton Capital sold stake in company
(+) MYOV (+14.27%) Initiated at outperform at Evercore ISI Group
(+) HTHT (+9.61%) Q2 results top estimates with revenue guidance raised
(+) HSY (+1.71%) Bernstein raises to outperform; lifts PT to $127 from $109
DOWNSIDE MOVERS
(-) NLST (-28.57%) To sell shares in an underwritten offering
(-) BGG (-13.68%) Fiscal Q4 results lag street estimates, sets FY18 guidance below expectations
(-) ROKA (-8.76%) Sells assets to Institute for Environmental Health Subsidiary
(-) ADP (-5.78%) Disagrees with points raised in Pershing Square presentation
(-) RCII (-5.21%) July same store sales fall 5.7% in core US business
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(+) SSI (+25.83%) Beat Q2 sales estimates, raised FY17 guidance (+) DCTH (+19.15%) Ayrton Capital sold stake in company (+) MYOV (+14.27%) Initiated at outperform at Evercore ISI Group (+) HTHT (+9.61%) Q2 results top estimates with revenue guidance raised (+) HSY (+1.71%) Bernstein raises to outperform; lifts PT to $127 from $109 Wall Street went into selloff mode on Thursday, with investors bailing out of stocks and looking for havens as the Dow Jones Industrial Average dropped the most since May 17 and the S&P 500 posted its lowest close in more than five weeks. A day after Donald Trump disbanded two business advisory councils as top chief executives quit in protest of his handling of violence in Charlottesville, Virginia, investors worried that the White House was getting distracted from the president's policy plans, including tax reforms.
|
(+) SSI (+25.83%) Beat Q2 sales estimates, raised FY17 guidance (+) DCTH (+19.15%) Ayrton Capital sold stake in company (+) MYOV (+14.27%) Initiated at outperform at Evercore ISI Group (+) HTHT (+9.61%) Q2 results top estimates with revenue guidance raised (+) HSY (+1.71%) Bernstein raises to outperform; lifts PT to $127 from $109 Wall Street went into selloff mode on Thursday, with investors bailing out of stocks and looking for havens as the Dow Jones Industrial Average dropped the most since May 17 and the S&P 500 posted its lowest close in more than five weeks. And although Wal-Mart Stores' ( WMT ) results topped expectations, investors were spooked by sluggish sales in its Sam's Club division and in-line guidance for 2018 and Q3, leading to a 1.6% decline in the stock and deep losses for the retail sector.
|
(+) SSI (+25.83%) Beat Q2 sales estimates, raised FY17 guidance (+) DCTH (+19.15%) Ayrton Capital sold stake in company (+) MYOV (+14.27%) Initiated at outperform at Evercore ISI Group (+) HTHT (+9.61%) Q2 results top estimates with revenue guidance raised (+) HSY (+1.71%) Bernstein raises to outperform; lifts PT to $127 from $109 Dow Jones Industrial Average was down 274.14 points (-1.24%) S&P 500 was down 38.10 points (-1.54%) Nasdaq Composite Index was down 123.19 points (-1.94%) (-) NLST (-28.57%) To sell shares in an underwritten offering (-) BGG (-13.68%) Fiscal Q4 results lag street estimates, sets FY18 guidance below expectations (-) ROKA (-8.76%) Sells assets to Institute for Environmental Health Subsidiary (-) ADP (-5.78%) Disagrees with points raised in Pershing Square presentation (-) RCII (-5.21%) July same store sales fall 5.7% in core US business The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(+) SSI (+25.83%) Beat Q2 sales estimates, raised FY17 guidance (+) DCTH (+19.15%) Ayrton Capital sold stake in company (+) MYOV (+14.27%) Initiated at outperform at Evercore ISI Group (+) HTHT (+9.61%) Q2 results top estimates with revenue guidance raised (+) HSY (+1.71%) Bernstein raises to outperform; lifts PT to $127 from $109 Wall Street went into selloff mode on Thursday, with investors bailing out of stocks and looking for havens as the Dow Jones Industrial Average dropped the most since May 17 and the S&P 500 posted its lowest close in more than five weeks. Dow Jones Industrial Average was down 274.14 points (-1.24%) S&P 500 was down 38.10 points (-1.54%) Nasdaq Composite Index was down 123.19 points (-1.94%)
|
dc680baf-2e5d-4e56-9ea0-1ba98a73d7a3
|
715622.0
|
2017-08-17 00:00:00 UTC
|
Health Care Sector Update for 08/17/2017: ROKA, DCTH, LAKE
|
DCTH
|
https://www.nasdaq.com/articles/health-care-sector-update-08172017-roka-dcth-lake-2017-08-17
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.5%
PFE -0.7%
ABT -0.2%
MRK -0.9%
AMGN -1.8%
Health care stocks were finishing mostly lower this afternoon, with the NYSE Health Care Index (^NYP) sinking about 0.6% while shares of health care companies in the S&P 500 ( XLV ) were down almost 0.9% as a group. In company news, Roka Bioscience ( ROKA ) dropped to a record low on Thursday, dropping almost 17% to a worst-ever $1.83 a share after the molecular diagnostics company today said it was selling substantially all of its working assets to a newly-formed, wholly-owned subsidiary of the Institute for Environmental Health Inc - in what is being billed as the initial step in the liquidation of the company.
As part of the $17.5 million cash transaction, Roka will make a $2.5 million milestone payment pursuant to the new subsidiary under a license agreement. It also will provide transition services to the buyer through the end of the year.
The proposed sale will require Roka shareholder approval before closing.
In other sector news,
(+) DCTH, Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11.
(-) LAKE, Prices $10 mln public offering of 725,000 shares at $13.80 apiece, an 11.8% discount to Wednesday's closing price. Plans to use the expected $8.95 mln in net proceeds to build new manufacturing facilities overseas and repaying its line of credit.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In other sector news, (+) DCTH, Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. In company news, Roka Bioscience ( ROKA ) dropped to a record low on Thursday, dropping almost 17% to a worst-ever $1.83 a share after the molecular diagnostics company today said it was selling substantially all of its working assets to a newly-formed, wholly-owned subsidiary of the Institute for Environmental Health Inc - in what is being billed as the initial step in the liquidation of the company. Plans to use the expected $8.95 mln in net proceeds to build new manufacturing facilities overseas and repaying its line of credit.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) DCTH, Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. In company news, Roka Bioscience ( ROKA ) dropped to a record low on Thursday, dropping almost 17% to a worst-ever $1.83 a share after the molecular diagnostics company today said it was selling substantially all of its working assets to a newly-formed, wholly-owned subsidiary of the Institute for Environmental Health Inc - in what is being billed as the initial step in the liquidation of the company.
|
In other sector news, (+) DCTH, Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. Health care stocks were finishing mostly lower this afternoon, with the NYSE Health Care Index (^NYP) sinking about 0.6% while shares of health care companies in the S&P 500 ( XLV ) were down almost 0.9% as a group. In company news, Roka Bioscience ( ROKA ) dropped to a record low on Thursday, dropping almost 17% to a worst-ever $1.83 a share after the molecular diagnostics company today said it was selling substantially all of its working assets to a newly-formed, wholly-owned subsidiary of the Institute for Environmental Health Inc - in what is being billed as the initial step in the liquidation of the company.
|
In other sector news, (+) DCTH, Ayrton Capital cashes out 8.4% ownership stake, selling more than 41.7 mln of the company's shares between July 18 to Aug. 11. Health care stocks were finishing mostly lower this afternoon, with the NYSE Health Care Index (^NYP) sinking about 0.6% while shares of health care companies in the S&P 500 ( XLV ) were down almost 0.9% as a group. In company news, Roka Bioscience ( ROKA ) dropped to a record low on Thursday, dropping almost 17% to a worst-ever $1.83 a share after the molecular diagnostics company today said it was selling substantially all of its working assets to a newly-formed, wholly-owned subsidiary of the Institute for Environmental Health Inc - in what is being billed as the initial step in the liquidation of the company.
|
f16f23d1-9343-48da-88fd-1928a897d507
|
715623.0
|
2017-06-21 00:00:00 UTC
|
Health Care Sector Update for 06/21/2017: MBRX,DCTH,SGMO
|
DCTH
|
https://www.nasdaq.com/articles/health-care-sector-update-06212017-mbrxdcthsgmo-2017-06-21
|
nan
|
nan
|
Top Health Care Stocks
JNJ +0.37%
PFE +1.33%
ABT -0.43%
MRK +1.26%
AMGN +2.69%
Health care stocks easily were outpacing other industry sectors Wednesday, with the NYSE Health Care Index adding over 1.6% in value while shares of health care companies in the S&P 500 were up nearly 1.0% as a group.
In company news, Moleculin Biotech ( MBRX ) raced to large gains on Wednesday, climbing almost 53% to reach a session high of $1.30 after the specialty drugmaker today released more details of its discovery of a metabolic inhibitor with the potential to treat pancreatic cancer.
The prospective oncology medication works by starving tumors to death, exploiting their hyper-dependence on glycolysis for energy production. In particular, the company said, its WP1234 compound displays several other positive characteristics, including a 50-fold greater ability to kill pancreatic cancer cell lines compared with more traditional glycolysis inhibitors.
In other sector news,
(+) CXRX, (+12.2%) Hires Perella Weinberg Partners to assist with evaluating strategic alternatives. Company also says it is close to completing a long-term growth strategy and plans to soon release those results to shareholders.
(-) SGMO, (-1.2%) Prices $72.5 mln public offering of 10 mln shares at $7.25 apiece, a 12% discount to Tuesday's closing price. Net proceeds will be used for working capital and other general corporate purposes.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Moleculin Biotech ( MBRX ) raced to large gains on Wednesday, climbing almost 53% to reach a session high of $1.30 after the specialty drugmaker today released more details of its discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. The prospective oncology medication works by starving tumors to death, exploiting their hyper-dependence on glycolysis for energy production. In particular, the company said, its WP1234 compound displays several other positive characteristics, including a 50-fold greater ability to kill pancreatic cancer cell lines compared with more traditional glycolysis inhibitors.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Health care stocks easily were outpacing other industry sectors Wednesday, with the NYSE Health Care Index adding over 1.6% in value while shares of health care companies in the S&P 500 were up nearly 1.0% as a group.
|
Health care stocks easily were outpacing other industry sectors Wednesday, with the NYSE Health Care Index adding over 1.6% in value while shares of health care companies in the S&P 500 were up nearly 1.0% as a group. In company news, Moleculin Biotech ( MBRX ) raced to large gains on Wednesday, climbing almost 53% to reach a session high of $1.30 after the specialty drugmaker today released more details of its discovery of a metabolic inhibitor with the potential to treat pancreatic cancer. In particular, the company said, its WP1234 compound displays several other positive characteristics, including a 50-fold greater ability to kill pancreatic cancer cell lines compared with more traditional glycolysis inhibitors.
|
Top Health Care Stocks Health care stocks easily were outpacing other industry sectors Wednesday, with the NYSE Health Care Index adding over 1.6% in value while shares of health care companies in the S&P 500 were up nearly 1.0% as a group. In company news, Moleculin Biotech ( MBRX ) raced to large gains on Wednesday, climbing almost 53% to reach a session high of $1.30 after the specialty drugmaker today released more details of its discovery of a metabolic inhibitor with the potential to treat pancreatic cancer.
|
99c6ff3b-e5f6-466a-b7fb-80538b0da7d7
|
715624.0
|
2017-03-27 00:00:00 UTC
|
Wall Street Sees Lower Open after Trump's Failed Healthcare Bill
|
DCTH
|
https://www.nasdaq.com/articles/wall-street-sees-lower-open-after-trumps-failed-healthcare-bill-2017-03-27
|
nan
|
nan
|
U.S. stocks were poised to open sharply lower on Monday after President Donald Trump failed to push through with his healthcare agenda in Congress, raising doubts over his ability to deliver on his campaign promises.
Oil prices nudged lower with global benchmark Brent crude down 0.69% and U.S. benchmark West Texas Intermediate down 0.98% as the commodity got pressured by the rising production in the U.S. and after a meeting of the Organization of the Petroleum Exporting Countries' producers failed to impress investors.
At 10:00 a.m., data are expected to show the Dallas Fed general activity index at 22.0 in March, compared to February's 24.5 level.
Federal Reserve Presidents Charles Evans and Dennis Kaplan are scheduled to give speeches.
In equities, Delcath Systems ( DCTH ) shares were 22.2% higher pre-bell after the oncology company reached a special protocol assessment agreement with the U.S. Food and Drug Administration for the design of its pivotal trial of Melphalan Hydrochloride for Injection to treat patients with intrahepatic cholangiocarcinoma.
U.S. PRE-MARKET INDICATORS
-Dow Jones Industrial down 0.75%
-S&P 500 futures down 0.90%
-Nasdaq 100 futures down 0.78%
-Nasdaq 100 pre-market indicator down 0.54%
GLOBAL SENTIMENT
Nikkei down 1.44%
Hang Seng down 0.68%
Shanghai Composite down 0.08%
FTSE-100 down 0.86%
DAX-30 down 1.92%
PRE-MARKET SECTOR WATCH
(+/-) Large cap tech: mixed
(-) Chip stocks: lower
(+/-) Software stocks: mixed
(-) Hardware stocks: unchanged to lower
(-) Internet stocks: lower
(-) Oil stocks: unchanged to lower
(-) Biotech stocks: unchanged to lower
(+/-) Drug stocks: mixed
(-) Financial stocks: lower
(-) Retail stocks: lower
(-) Industrial stocks: lower
(-) Airlines: unchanged to lower
(-) Autos: unchanged to lower
UPSIDE MOVERS
(+) DDC (+4.4%) Forms special committee to review strategic alternatives
(+) APOP (+25.3%) Treated first cancer patient with stem cell transplant
(+) AZN (+1%) Says Tagrisso approved in China for certain types of non-small cell lung cancer
DOWNSIDE MOVERS
(-) AAPL (-0.7%) Wins iPhone patent infringement case in Beijing IP court
(-) GIII (-10.8%) Q4 results miss Street expectations
(-) ARQL (-14.9%) Cure for hepatocellular carcinoma fails to meet primary endpoint
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In equities, Delcath Systems ( DCTH ) shares were 22.2% higher pre-bell after the oncology company reached a special protocol assessment agreement with the U.S. Food and Drug Administration for the design of its pivotal trial of Melphalan Hydrochloride for Injection to treat patients with intrahepatic cholangiocarcinoma. U.S. stocks were poised to open sharply lower on Monday after President Donald Trump failed to push through with his healthcare agenda in Congress, raising doubts over his ability to deliver on his campaign promises. (-) AAPL (-0.7%) Wins iPhone patent infringement case in Beijing IP court (-) GIII (-10.8%) Q4 results miss Street expectations (-) ARQL (-14.9%) Cure for hepatocellular carcinoma fails to meet primary endpoint The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In equities, Delcath Systems ( DCTH ) shares were 22.2% higher pre-bell after the oncology company reached a special protocol assessment agreement with the U.S. Food and Drug Administration for the design of its pivotal trial of Melphalan Hydrochloride for Injection to treat patients with intrahepatic cholangiocarcinoma. (+/-) Large cap tech: mixed (-) Chip stocks: lower (+/-) Software stocks: mixed (-) Hardware stocks: unchanged to lower (-) Internet stocks: lower (-) Oil stocks: unchanged to lower (-) Biotech stocks: unchanged to lower (+/-) Drug stocks: mixed (-) Financial stocks: lower (-) Retail stocks: lower (-) Industrial stocks: lower (-) Airlines: unchanged to lower (-) Autos: unchanged to lower (-) AAPL (-0.7%) Wins iPhone patent infringement case in Beijing IP court (-) GIII (-10.8%) Q4 results miss Street expectations (-) ARQL (-14.9%) Cure for hepatocellular carcinoma fails to meet primary endpoint The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In equities, Delcath Systems ( DCTH ) shares were 22.2% higher pre-bell after the oncology company reached a special protocol assessment agreement with the U.S. Food and Drug Administration for the design of its pivotal trial of Melphalan Hydrochloride for Injection to treat patients with intrahepatic cholangiocarcinoma. Nikkei down 1.44% Hang Seng down 0.68% Shanghai Composite down 0.08% FTSE-100 down 0.86% DAX-30 down 1.92% (+/-) Large cap tech: mixed (-) Chip stocks: lower (+/-) Software stocks: mixed (-) Hardware stocks: unchanged to lower (-) Internet stocks: lower (-) Oil stocks: unchanged to lower (-) Biotech stocks: unchanged to lower (+/-) Drug stocks: mixed (-) Financial stocks: lower (-) Retail stocks: lower (-) Industrial stocks: lower (-) Airlines: unchanged to lower (-) Autos: unchanged to lower
|
In equities, Delcath Systems ( DCTH ) shares were 22.2% higher pre-bell after the oncology company reached a special protocol assessment agreement with the U.S. Food and Drug Administration for the design of its pivotal trial of Melphalan Hydrochloride for Injection to treat patients with intrahepatic cholangiocarcinoma. U.S. stocks were poised to open sharply lower on Monday after President Donald Trump failed to push through with his healthcare agenda in Congress, raising doubts over his ability to deliver on his campaign promises. Oil prices nudged lower with global benchmark Brent crude down 0.69% and U.S. benchmark West Texas Intermediate down 0.98% as the commodity got pressured by the rising production in the U.S. and after a meeting of the Organization of the Petroleum Exporting Countries' producers failed to impress investors.
|
5a4f2c4f-50be-408a-8036-07e03bc1ff7e
|
715625.0
|
2017-02-22 00:00:00 UTC
|
Close Update: Wall Street Mostly Lower After Fed But Dow Touches New Record
|
DCTH
|
https://www.nasdaq.com/articles/close-update-wall-street-mostly-lower-after-fed-dow-touches-new-record-2017-02-22
|
nan
|
nan
|
Stocks were mostly lower on Wednesday, with the S&P 500 and the Nasdaq Composite in the negative while the Dow Jones Industrial Average advanced on gains in component DuPont ( DD ) to send the blue-chip index to a new record high and a ninth straight day of increases.
Markets held on to their positions after the release of minutes from the Federal Open Market Committee's latest meeting that showed many participants thought another rate hike might be appropriate "fairly soon." The probability of a March increase rose to 22% on the CME Group's FedWatch tool from about 18% a day ago.
A decline in oil prices weighed on energy stocks, with the sector being the worst performer among the S&P 500 sectors. Benchmark US futures fell 1.6% late in the day to $53.56 a barrel. Utilities added 0.5% in the best increase among the 11 groups.
DuPont was up on a report that the European Union might be close to approving its merger with Dow Chemical ( DOW ), which also advanced in the session.
In economic data, the number of existing homes sold in January rose 3.3% to a seasonally-adjusted annual rate of 5.69 million, the highest number of homes sold since February 2007. This was above Wall Street expectations for a modest gain of 1.5%.
Thursday's calendar has initial weekly jobless claims and the January Chicago Fed National Activity Index at 8:30 a.m. ET, with the December Federal Housing Finance Agency house price index at 10 a.m.
Here's where the markets stood by the close:
US MARKETS
Dow Jones Industrial Average was up 32.6 points (+0.16%) to 20,775.60
S&P 500 was down 2.56 points (-0.11%) to 2,362.82
Nasdaq Composite Index was down 5.32 points (-0.09%) to 5,860.63
GLOBAL SENTIMENT
FTSE 100 was up 0.38%
Nikkei 225 was down 0.01%
Hang Seng Index was up 0.99%
Shanghai China Composite Index was up 0.24%
UPSIDE MOVERS
(+) DCTH (+10.8%) Study shows potential of PHP therapy
(+) GRMN (+7.3%) Posts Q4 beat and guides FY17 EPS in line with and sales above the Street view
(+) NVDQ (+3.55%) Cigna ( CI ) now covers costs for Dermacell
DOWNSIDE MOVERS
(-) ARGS (-66.5%) Independent monitoring committee recommends discontinuing trial for cancer drug
(-) CETX (-33.6%) Denies allegations of wrongdoing in Seeking Alpha article
(-) PKD (-17%) Launches offering of common and preferred stock
(-) GBT (-14.4%) Priced stock offering at $24.50 per share
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(+) DCTH (+10.8%) Study shows potential of PHP therapy (+) GRMN (+7.3%) Posts Q4 beat and guides FY17 EPS in line with and sales above the Street view (+) NVDQ (+3.55%) Cigna ( CI ) now covers costs for Dermacell Stocks were mostly lower on Wednesday, with the S&P 500 and the Nasdaq Composite in the negative while the Dow Jones Industrial Average advanced on gains in component DuPont ( DD ) to send the blue-chip index to a new record high and a ninth straight day of increases. (-) ARGS (-66.5%) Independent monitoring committee recommends discontinuing trial for cancer drug (-) CETX (-33.6%) Denies allegations of wrongdoing in Seeking Alpha article (-) PKD (-17%) Launches offering of common and preferred stock (-) GBT (-14.4%) Priced stock offering at $24.50 per share The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(+) DCTH (+10.8%) Study shows potential of PHP therapy (+) GRMN (+7.3%) Posts Q4 beat and guides FY17 EPS in line with and sales above the Street view (+) NVDQ (+3.55%) Cigna ( CI ) now covers costs for Dermacell Stocks were mostly lower on Wednesday, with the S&P 500 and the Nasdaq Composite in the negative while the Dow Jones Industrial Average advanced on gains in component DuPont ( DD ) to send the blue-chip index to a new record high and a ninth straight day of increases. (-) ARGS (-66.5%) Independent monitoring committee recommends discontinuing trial for cancer drug (-) CETX (-33.6%) Denies allegations of wrongdoing in Seeking Alpha article (-) PKD (-17%) Launches offering of common and preferred stock (-) GBT (-14.4%) Priced stock offering at $24.50 per share The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(+) DCTH (+10.8%) Study shows potential of PHP therapy (+) GRMN (+7.3%) Posts Q4 beat and guides FY17 EPS in line with and sales above the Street view (+) NVDQ (+3.55%) Cigna ( CI ) now covers costs for Dermacell Stocks were mostly lower on Wednesday, with the S&P 500 and the Nasdaq Composite in the negative while the Dow Jones Industrial Average advanced on gains in component DuPont ( DD ) to send the blue-chip index to a new record high and a ninth straight day of increases. Dow Jones Industrial Average was up 32.6 points (+0.16%) to 20,775.60 S&P 500 was down 2.56 points (-0.11%) to 2,362.82 Nasdaq Composite Index was down 5.32 points (-0.09%) to 5,860.63
|
(+) DCTH (+10.8%) Study shows potential of PHP therapy (+) GRMN (+7.3%) Posts Q4 beat and guides FY17 EPS in line with and sales above the Street view (+) NVDQ (+3.55%) Cigna ( CI ) now covers costs for Dermacell Stocks were mostly lower on Wednesday, with the S&P 500 and the Nasdaq Composite in the negative while the Dow Jones Industrial Average advanced on gains in component DuPont ( DD ) to send the blue-chip index to a new record high and a ninth straight day of increases. Here's where the markets stood by the close:
|
ffcdabab-a3df-4323-809d-613d06f33b2b
|
715626.0
|
2016-09-30 00:00:00 UTC
|
Mid-Day Market Update: Dow Surges Over 150 Points; Threshold Pharmaceuticals Shares Slide
|
DCTH
|
https://www.nasdaq.com/articles/mid-day-market-update-dow-surges-over-150-points-threshold-pharmaceuticals-shares-slide
|
nan
|
nan
|
Midway through trading Friday, the Dow traded up 0.96 percent to 18,317.91 while the NASDAQ climbed 0.83 percent to 5,312.77. The S&P also rose, gaining 0.80 percent to 2,168.40.
Leading and Lagging Sectors
On Friday, cyclical consumer goods & services shares surged 1.02 percent. Meanwhile, top gainers in the sector included Beasley Broadcast Group Inc (NASDAQ: BBGI ), and Sears Holdings Corp (NASDAQ: SHLD ).
In trading on Friday, utilities shares slipped by 0.30 percent. Meanwhile, top losers in the sector included Korea Electric Power Corporation (ADR) (NYSE: KEP ), down 3 percent, and Consolidated Edison, Inc. (NYSE: ED ), down 2 percent.
Top Headline
McCormick & Company, Incorporated (NYSE: MKC ) delivered better than expected EPS and inline revenue for the third quarter. The company boosted its full year adjusted EPS forecast and sees revenue at the upper end of earlier forecast.
The company reported net income of $127.7 million, or $1.00 per share, for the third quarter, up from $97.6 million, or $0.76 a share, in the year-ago quarter. On an adjusted basis too, net income advanced from $109.7 million to $131.1 million and EPS from $0.85 to $1.03. Street predicted an EPS of $0.94.
McCormick's net sales grew from $1.059 billion to $1.09 billion and came in line with the analysts' estimates.
Equities Trading UP
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares shot up 19 percent to $3.13 as the company disclosed that voclosporin achieved primary and all pre-specific secondary endpoints in Phase IIb AURA-LV study for LN.
Shares of Lexmark International Inc (NYSE: LXK ) got a boost, shooting up 14 percent to $39.93 after the company disclosed that it has received clearance from the Committee on Foreign Investment in the United States to proceed with proposed buyout.
Senomyx Inc. (NASDAQ: SNMX ) shares were also up, gaining 9 percent to $4.32 after the company disclosed that it has extended its Sweet Taste Program collaboration agreement with PepsiCo, Inc. for three additional years.
Equities Trading DOWN
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) shares dropped 43 percent to $0.675 after the company disclosed interim results from its Tarloxotinib program. The company announced that it will discontinue investment in its Tarloxotinib program and will focus on evofosfamide program and earlier-stage opportunities.
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 28 percent to $2.50. Delcath priced its 425,000 share offering at $3 per share.
Vectrus Inc (NYSE: VEC ) was down, falling around 46 percent to $15.00 on news of the government rejecting the company's contract proposal to provide comprehensive support services for all US Army facilities in Kuwait.
Commodities
In commodity news, oil traded up 0.44 percent to $48.04 while gold traded down 0.16 percent to $1,323.90.
Silver traded up 1.26 percent Friday to $19.43, while copper rose 1.12 percent to $2.21.
Eurozone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.06 percent, the Spanish Ibex Index fell 0.12 percent, while Italy's FTSE MIB Index climbed 0.38 percent. Meanwhile the German DAX rose 1.03 percent, and the French CAC 40 gained 0.18 percent while U.K. shares fell 0.29 percent.
Economics
U.S. consumer spending was flat for August, versus economists' expectations for a 0.1 percent growth. Personal income rose 0.20 percent in the month, versus expectations for a 0.20 percent increase.
The Chicago PMI increased to 54.20 in September, versus a prior reading of 51.50. Economists expected a reading of 52.50 for the month.
The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET.
Dallas Federal Reserve President Rob Kaplan is set to speak in Dallas at 1:00 p.m. ET.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 28 percent to $2.50. Equities Trading UP Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares shot up 19 percent to $3.13 as the company disclosed that voclosporin achieved primary and all pre-specific secondary endpoints in Phase IIb AURA-LV study for LN. Shares of Lexmark International Inc (NYSE: LXK ) got a boost, shooting up 14 percent to $39.93 after the company disclosed that it has received clearance from the Committee on Foreign Investment in the United States to proceed with proposed buyout.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 28 percent to $2.50. The company boosted its full year adjusted EPS forecast and sees revenue at the upper end of earlier forecast. The company reported net income of $127.7 million, or $1.00 per share, for the third quarter, up from $97.6 million, or $0.76 a share, in the year-ago quarter.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 28 percent to $2.50. Midway through trading Friday, the Dow traded up 0.96 percent to 18,317.91 while the NASDAQ climbed 0.83 percent to 5,312.77. The eurozone's STOXX 600 rose 0.06 percent, the Spanish Ibex Index fell 0.12 percent, while Italy's FTSE MIB Index climbed 0.38 percent.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 28 percent to $2.50. Equities Trading DOWN Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) shares dropped 43 percent to $0.675 after the company disclosed interim results from its Tarloxotinib program. Silver traded up 1.26 percent Friday to $19.43, while copper rose 1.12 percent to $2.21.
|
849f55b9-efb1-43ab-ba2c-fccf78e97236
|
715627.0
|
2016-09-30 00:00:00 UTC
|
Mid-Morning Market Update: Markets Open Higher; McCormick Profit Tops Estimates
|
DCTH
|
https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-mccormick-profit-tops-estimates-2016-09-30
|
nan
|
nan
|
Following the market opening Friday, the Dow traded up 0.49 percent to 18,232.21 while the NASDAQ climbed 0.24 percent to 5,282.04. The S&P also rose, gaining 0.34 percent to 2,158.54.
Leading and Lagging Sectors
Friday morning, non-cyclical consumer goods & services shares surged 0.78 percent.
In trading on Friday, telecommunications services shares slipped by 0.10 percent. Meanwhile, top losers in the sector included CalAmp Corp. (NASDAQ: CAMP ), down 16 percent, and Telefonica S.A. (ADR) (NYSE: TEF ), down 3 percent.
Top Headline
McCormick & Company, Incorporated (NYSE: MKC ) delivered better than expected EPS and inline revenue for the third quarter. The company boosted its full year adjusted EPS forecast and sees revenue at the upper end of earlier forecast.
The company reported net income of $127.7 million, or $1.00 per share, for the third quarter, up from $97.6 million, or $0.76 a share, in the year-ago quarter. On an adjusted basis too, net income advanced from $109.7 million to $131.1 million and EPS from $0.85 to $1.03. Street predicted an EPS of $0.94.
McCormick's net sales grew from $1.059 billion to $1.09 billion and came in line with the analysts' estimates.
Equities Trading UP
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares shot up 26 percent to $3.32 as the company disclosed that voclosporin achieved primary and all pre-specific secondary endpoints in Phase IIb AURA-LV study for LN.
Shares of Lexmark International Inc (NYSE: LXK ) got a boost, shooting up 14 percent to $39.91 after the company disclosed that it has received clearance from the Committee on Foreign Investment in the United States to proceed with proposed buyout.
Senomyx Inc. (NASDAQ: SNMX ) shares were also up, gaining 10 percent to $4.36 after the company disclosed that it has extended its Sweet Taste Program collaboration agreement with PepsiCo, Inc. for three additional years.
Equities Trading DOWN
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) shares dropped 46 percent to $0.640 after the company disclosed interim results from its Tarloxotinib program. The company announced that it will discontinue investment in its Tarloxotinib program and will focus on evofosfamide program and earlier-stage opportunities.
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 25 percent to $2.58. Delcath priced its 425,000 share offering at $3 per share.
Vectrus Inc (NYSE: VEC ) was down, falling around 48 percent to $14.33 on news of the government rejecting the company's contract proposal to provide comprehensive support services for all US Army facilities in Kuwait.
Commodities
In commodity news, oil traded up 0.27 percent to $47.96 while gold traded up 0.41 percent to $1,331.40.
Silver traded up 2.59 percent Friday to $19.69, while copper rose 0.80 percent to $2.21.
Eurozone
European shares were lower today. The eurozone's STOXX 600 slipped 0.59 percent, the Spanish Ibex Index fell 1.39 percent, while Italy's FTSE MIB Index declined 0.85 percent. Meanwhile the German DAX fell 0.50 percent, and the French CAC 40 dropped 1.01 percent while U.K. shares fell 0.51 percent.
Economics
U.S. consumer spending was flat for August, versus economists' expectations for a 0.1 percent growth. Personal income rose 0.20 percent in the month, versus expectations for a 0.20 percent increase.
The Chicago PMI increased to 54.20 in September, versus a prior reading of 51.50. Economists expected a reading of 52.50 for the month.
The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET.
Dallas Federal Reserve President Rob Kaplan is set to speak in Dallas at 1:00 p.m. ET.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Profit with More New & Research . Gain access to a streaming platform with all the information you need to invest better today. Click here to start your 14 Day Trial of Benzinga Professional
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 25 percent to $2.58. Equities Trading UP Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares shot up 26 percent to $3.32 as the company disclosed that voclosporin achieved primary and all pre-specific secondary endpoints in Phase IIb AURA-LV study for LN. Shares of Lexmark International Inc (NYSE: LXK ) got a boost, shooting up 14 percent to $39.91 after the company disclosed that it has received clearance from the Committee on Foreign Investment in the United States to proceed with proposed buyout.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 25 percent to $2.58. The company boosted its full year adjusted EPS forecast and sees revenue at the upper end of earlier forecast. Equities Trading DOWN Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) shares dropped 46 percent to $0.640 after the company disclosed interim results from its Tarloxotinib program.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 25 percent to $2.58. The eurozone's STOXX 600 slipped 0.59 percent, the Spanish Ibex Index fell 1.39 percent, while Italy's FTSE MIB Index declined 0.85 percent. Meanwhile the German DAX fell 0.50 percent, and the French CAC 40 dropped 1.01 percent while U.K. shares fell 0.51 percent.
|
Shares of Delcath Systems, Inc. (NASDAQ: DCTH ) were down 25 percent to $2.58. In trading on Friday, telecommunications services shares slipped by 0.10 percent. Equities Trading DOWN Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) shares dropped 46 percent to $0.640 after the company disclosed interim results from its Tarloxotinib program.
|
13007760-f9b2-4fe8-ab8f-23f7010e3364
|
715628.0
|
2016-09-30 00:00:00 UTC
|
Health Care Sector Update for 09/30/2016: DCTH,AUPH,VEC
|
DCTH
|
https://www.nasdaq.com/articles/health-care-sector-update-09302016-dcthauphvec-2016-09-30
|
nan
|
nan
|
Top Health Care Stocks
JNJ +0.95%
PFE +1.74%
MRK +2.43%
ABT +0.99%
AMGN +1.17%
Health care stocks were gaining this afternoon, with the NYSE Health Care Index rising over 0.9% while shares of health care companies in the S&P 500 were up nearly 1.3% as a group.
In company news, Delcath Systems ( DCTH ) shares dropped to a record low on Friday after the oncology drug company today priced a $1.3 million public offering of 425,000 shares of its common stock at $3 each, a 13% discount to Thursday's closing price.
The deal also included five-year warrants to buy up to 150,000 additional shares exercisable at $3 apiece, with investors receiving 0.35 of a warrant for each share they purchased in today's offering. Delcath expects to use the net proceeds to fund clinical trials and other regulatory and commercialization activities of its injection treatment for certain forms of liver cancer as well as for general corporate purposes.
DCTH shares were down over 28% at $2.48 each in late trade, earlier sinking to a worst-ever $2.45 a share.
In other sector news,
(+) AUPH, Voclosporin drug candidate meets primary endpoint of complete remission mid-way through a 48-week Phase IIb trial in patients with lupus nephritis. Also meet secondary endpoints.
(-) VEC, U.S. Army declines to renew support services contract for facilities in Kuwait.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Delcath Systems ( DCTH ) shares dropped to a record low on Friday after the oncology drug company today priced a $1.3 million public offering of 425,000 shares of its common stock at $3 each, a 13% discount to Thursday's closing price. DCTH shares were down over 28% at $2.48 each in late trade, earlier sinking to a worst-ever $2.45 a share. Delcath expects to use the net proceeds to fund clinical trials and other regulatory and commercialization activities of its injection treatment for certain forms of liver cancer as well as for general corporate purposes.
|
In company news, Delcath Systems ( DCTH ) shares dropped to a record low on Friday after the oncology drug company today priced a $1.3 million public offering of 425,000 shares of its common stock at $3 each, a 13% discount to Thursday's closing price. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DCTH shares were down over 28% at $2.48 each in late trade, earlier sinking to a worst-ever $2.45 a share.
|
In company news, Delcath Systems ( DCTH ) shares dropped to a record low on Friday after the oncology drug company today priced a $1.3 million public offering of 425,000 shares of its common stock at $3 each, a 13% discount to Thursday's closing price. DCTH shares were down over 28% at $2.48 each in late trade, earlier sinking to a worst-ever $2.45 a share. Health care stocks were gaining this afternoon, with the NYSE Health Care Index rising over 0.9% while shares of health care companies in the S&P 500 were up nearly 1.3% as a group.
|
In company news, Delcath Systems ( DCTH ) shares dropped to a record low on Friday after the oncology drug company today priced a $1.3 million public offering of 425,000 shares of its common stock at $3 each, a 13% discount to Thursday's closing price. DCTH shares were down over 28% at $2.48 each in late trade, earlier sinking to a worst-ever $2.45 a share. Health care stocks were gaining this afternoon, with the NYSE Health Care Index rising over 0.9% while shares of health care companies in the S&P 500 were up nearly 1.3% as a group.
|
0ef22c62-5422-4be7-846a-ee6d5c512740
|
715629.0
|
2015-05-29 00:00:00 UTC
|
Health Care Sector Update for 05/29/2015: DCTH,KBIO,SVON,XXII
|
DCTH
|
https://www.nasdaq.com/articles/health-care-sector-update-05292015-dcthkbiosvonxxii-2015-05-29
|
nan
|
nan
|
Top Health Care Stocks
JNJ -0.55%
PZE +1.29%
MRK -1.22%
ABT +2.27%
AMGN -0.56%
Health care stocks were lower today with the NYSE Health Care Sector Index sliding nearly 0.4% although shares of health care companies in the S&P 500 were down less than 0.1% as a group.
In company news, Delcath Systems ( DCTH ) shares surged Friday after the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting.
A total of 20 patients received 34 Chemosat treatments during the study, with 13 - or 65% - of the patients demonstrating a partial response in the liver, while another 2 patients had a complete response. Nine of the patients died from their diseases after a median 264 days after their first treatment.
DCTH shares were up almost 29% at $1.53 apiece, earlier climing to a session high of $1.92 a share. The stock has traded within a 52-week range of 80 cents to $3.00 a share, dropping 54% before today over the past 12 months.
In other sector news,
(+) HRTX, Reports positive, top-line results from Phase III testing of its Sustol drug candidate, with 64.7% of the cancer patients treated with the three-drug combination enjoying steep drops in their post-chemotherapy nausea and vomiting.
(-) XXII, (-8.6%) Prices $6 mln direct offering of 6 mln shares at $1 apiece, a 13.8% discount to Thursday's closing price. Investors also received one-half warrant to buy another share at $1.25 each before December 2020.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Delcath Systems ( DCTH ) shares surged Friday after the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting. DCTH shares were up almost 29% at $1.53 apiece, earlier climing to a session high of $1.92 a share. The stock has traded within a 52-week range of 80 cents to $3.00 a share, dropping 54% before today over the past 12 months.
|
In company news, Delcath Systems ( DCTH ) shares surged Friday after the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting. DCTH shares were up almost 29% at $1.53 apiece, earlier climing to a session high of $1.92 a share. Health care stocks were lower today with the NYSE Health Care Sector Index sliding nearly 0.4% although shares of health care companies in the S&P 500 were down less than 0.1% as a group.
|
In company news, Delcath Systems ( DCTH ) shares surged Friday after the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting. DCTH shares were up almost 29% at $1.53 apiece, earlier climing to a session high of $1.92 a share. Health care stocks were lower today with the NYSE Health Care Sector Index sliding nearly 0.4% although shares of health care companies in the S&P 500 were down less than 0.1% as a group.
|
In company news, Delcath Systems ( DCTH ) shares surged Friday after the drug-delivery company said it will present results from recent testing of its Hepatic chemosat delivery system with melanoma patients at the upcoming American Society of Clinical Oncology annual meeting. DCTH shares were up almost 29% at $1.53 apiece, earlier climing to a session high of $1.92 a share. Health care stocks were lower today with the NYSE Health Care Sector Index sliding nearly 0.4% although shares of health care companies in the S&P 500 were down less than 0.1% as a group.
|
7027876c-41e3-49f2-b330-3be0a1215fc1
|
715630.0
|
2014-05-12 00:00:00 UTC
|
Sirona Dental Q2 Earnings and Revs Beat Ests; Shares up - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/sirona-dental-q2-earnings-and-revs-beat-ests-shares-up-analyst-blog-2014-05-12
|
nan
|
nan
|
Sirona Dental Systems, Inc. ( SIRO ) posted a 6.7% rise in adjusted earnings of 80 cents per share for the second quarter of fiscal 2014 ended Mar 31, 2014 from 75 cents per share in the year-ago quarter. Adjusted earnings per share surpassed the Zacks Consensus Estimate by 2 cents.
Following the earnings release, shares of the company went up 1.2% to close at $74.70 on May 9.
Revenues
Revenues in the quarter grew 5.8% (or 2.9% on a constant currency basis) to $282.7 million, exceeding the Zacks Consensus Estimate of $267 million. Revenues in SIRO's CAD/CAM Systems segment rose 5.0% (or 2.5% on a constant currency basis); Imaging Systems segment revenues went up 5.0% (or 2.8% on a constant currency basis), Instruments segment sales increased 13.4% (9.3% on a constant currency basis), and Treatment Centers segment revenues grew 4.6% (up 0.8% on a constant currency basis) in the quarter.
Revenues in the U.S. improved 4.5% driven by continued demand for the company's Imaging and CAD/CAM products. Revenues in international markets rose 6.2% (or 2.3% in constant currency) on the back of growth in Asia Pacific, primarily in Japan.
Margins
Gross profit improved 4.7% to $151.5 million but gross margin fell 50 basis points (bps) to 53.6% in the quarter. The decline in gross margin was mainly caused by unfavorable foreign exchange rate, partially offset by general and product mix improvements.
Selling, general and administrative expenses (SG&A) stood at $87.2 million, up 26.9% from the prior-year quarter. Continued planned investments in sales and service infrastructure and cost of management transition, partially offset by favorable foreign exchange translation impacts led to the rise in expenses. As a percentage of sales, SG&A expenses contracted 80 bps to 30.8% from 31.6% a year ago.
Research and development (R&D) expenses were $16.4 million, up 8.6% year-over-year. The increase was a result of project timing and foreign currency translation. As a percentage of sales, R&D expenses expanded 20 bps to 5.8% from 5.6% in the second quarter of fiscal 2013.
Financial Position
SIRO exited the quarter with cash and cash equivalents of $255.3 million, up 5.6% from $241.7 million as of Sep 30, 2013. Total debt increased 5.6% to $79.6 million as of Mar 31, 2014, compared with $75.4 million as of Sep 30, 2013. Debt-to-capitalization ratio fell 20 bps to 5.9% as of Mar 31, 2014 from 6.1% as of Sep 30, 2013.
For the first six months of fiscal 2014 ended Mar 31, 2014, SIRO had cash flow from operations of $78.9 million, down 12.1% from $89.8 million in the same period last year. Capital expenditures surged by an astounding 179.0% to $61.1 million from $22.3 million in the first six months of fiscal 2013.
Guidance Reiterated
For fiscal 2014, SIRO retained its revenues and earnings guidance. The company anticipates adjusted earnings in the range of $3.60 to $3.70 per share, implying a year-over-year growth of 6-9%. The Zacks Consensus Estimate of $3.67 lies within the guided range.
SIRO continues to expect revenue growth in the range of 4-6% in constant currency. The growth assumed a 20% constant currency growth in two of its major markets, the U.S. and Germany.
For fiscal 2014, reported gross margin is expected to be higher than the prior year due to decrease in amortization expenses. SG&A as a percentage of revenues is anticipated between 29 and 30% for fiscal 2014. R&D expenses are anticipated between 5 and 6% of revenues.
The estimated effective tax rate for fiscal 2014 is projected in the band of 23 to 24%.
Zacks Rank
Currently, SIRO carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical instruments industry that warrant a look include RTI Surgical Inc. ( RTIX ), Accuray Incorporated ( ARAY ) and Delcath Systems, Inc. ( DCTH ). RTI Surgical sports a Zacks Rank #1 (Strong Buy), while both Accuray and Delcath Systems carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
SIRONA DENTAL (SIRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments industry that warrant a look include RTI Surgical Inc. ( RTIX ), Accuray Incorporated ( ARAY ) and Delcath Systems, Inc. ( DCTH ). Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report SIRONA DENTAL (SIRO): Free Stock Analysis Report To read this article on Zacks.com click here. The decline in gross margin was mainly caused by unfavorable foreign exchange rate, partially offset by general and product mix improvements.
|
Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report SIRONA DENTAL (SIRO): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical instruments industry that warrant a look include RTI Surgical Inc. ( RTIX ), Accuray Incorporated ( ARAY ) and Delcath Systems, Inc. ( DCTH ). Sirona Dental Systems, Inc. ( SIRO ) posted a 6.7% rise in adjusted earnings of 80 cents per share for the second quarter of fiscal 2014 ended Mar 31, 2014 from 75 cents per share in the year-ago quarter.
|
Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report SIRONA DENTAL (SIRO): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical instruments industry that warrant a look include RTI Surgical Inc. ( RTIX ), Accuray Incorporated ( ARAY ) and Delcath Systems, Inc. ( DCTH ). Revenues Revenues in the quarter grew 5.8% (or 2.9% on a constant currency basis) to $282.7 million, exceeding the Zacks Consensus Estimate of $267 million.
|
Some better-ranked stocks in the medical instruments industry that warrant a look include RTI Surgical Inc. ( RTIX ), Accuray Incorporated ( ARAY ) and Delcath Systems, Inc. ( DCTH ). Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report SIRONA DENTAL (SIRO): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues Revenues in the quarter grew 5.8% (or 2.9% on a constant currency basis) to $282.7 million, exceeding the Zacks Consensus Estimate of $267 million.
|
3f7e925e-e57c-4a4c-b9c2-970d2dd01bf3
|
715631.0
|
2014-05-09 00:00:00 UTC
|
ArthroCare Q1 Earnings Miss Ests; Revs In Line - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/arthrocare-q1-earnings-miss-ests-revs-in-line-analyst-blog-2014-05-09
|
nan
|
nan
|
ArthroCare Corp. ( ARTC ) posted a 13.5% drop in 2014-first-quarter adjusted earnings per share to 32 cents from 37 cents in the same quarter of 2013. Earnings also fell short of the Zacks Consensus Estimate of 35 cents. After the earnings release, shares of the company remained almost flat compared to its pre-earnings level.
Reported net earnings plummeted 64.7% to $3.6 million from $10.3 million in the first quarter of 2013. On a per share basis, earnings declined 66.7% to 10 cents from 30 cents a year ago.
Total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013. Revenues were in line with the Zacks Consensus Estimate.
Segments in Detail
Product revenues came in at $90.0 million, up 2.6% from $87.5 million a year ago.
Revenues from global sales of Sports Medicine products rose 7.0% to $63.8 million. Revenues from Sports Medicine products sales increased 13.8% in the international market, while it rose 3.4% in the U.S. Proprietary Sports Medicine product revenues in the Americas were flat with the prior-year quarter level.
Revenues from global ENT product sales declined 5.0% to $24.3 million in the quarter. Revenues from ENT product sales deteriorated 5.3% internationally while it decreased 4.9% in the U.S.
Other product revenues dropped 18.2% to $1.8 million in the quarter, accounting for less than 3% of the total product revenues.
Revenues from Royalties, fees and other segment spiked 24.8% to $6.1 million in the quarter. It accounted for 6.3% of total revenues in the first quarter of 2014.
Margins
On a year-over year basis, gross profit increased 5.6% to $67.6 million from $64.0 million and gross margin expanded 110 basis points (bps) to 70.4% from 69.3%.
Research and development (R&D) expenses decreased 4.9% to $8.0 million while as a percentage of sales, R&D expenses contracted 70 bps to 8.4%. The reduction was primarily due to lower prototype expenses and materials usage.
General and administrative (G&A) expenses surged 89.7% to $14.2 million while as a percentage of sales, it increased 660 bps to 14.7%. The increase was primarily related to the proposed merger expenses including legal fees, investment banker fees and proxy services.
Sales and marketing (S&M) expenses declined marginally by 0.6% to $30.5 million on lower severance related expenses in the quarter. As a percentage of sales, S&M expenses decreased 100 bps to 31.8%.
Operating earnings fell 31.7% to $9.2 million while operating margin contracted 500 bps to 9.6% from 14.6% in the first quarter of 2013. After adjusting for the investigation, restatement-related and merger related costs in the quarter, operating earnings improved 18.4% to $20.6 million from $17.4 million in the same quarter of 2013. Adjusted operating margin rose 260 bps to 21.4% from 18.8% in the year-earlier quarter.
Cash Balance and Cash Flow
Cash and cash equivalents were $191.0 million as of Mar 31, 2014, down 11.1% from $214.9 million as of Dec 31, 2013.
For the first three months ended Mar 31, 2014, cash flow from operating activities totaled $9.4 million, excluding a $30 million fine related to the resolution of the DOJ investigation, down 51.8% from $19.5 million in the prior-year period.
Cash used in investing activities during the quarter was $5.8 million compared with $10.4 million in the year-earlier quarter.
Zacks Rank
Currently ARTC retains a Zacks Rank #3 (Hold). Some better-ranked medical instruments stocks include RTI Surgical Inc. ( RTIX ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). While RTI Surgical sports a Zacks Rank #1 (Strong Buy), both Delcath Systems and Accuray carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACCURAY INC (ARAY): Free Stock Analysis Report
ARTHROCARE CORP (ARTC): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked medical instruments stocks include RTI Surgical Inc. ( RTIX ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. After the earnings release, shares of the company remained almost flat compared to its pre-earnings level.
|
Some better-ranked medical instruments stocks include RTI Surgical Inc. ( RTIX ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. While RTI Surgical sports a Zacks Rank #1 (Strong Buy), both Delcath Systems and Accuray carry a Zacks Rank #2 (Buy).
|
Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked medical instruments stocks include RTI Surgical Inc. ( RTIX ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
|
Some better-ranked medical instruments stocks include RTI Surgical Inc. ( RTIX ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Total revenues for the quarter stood at $96.1 million, reflecting an increase of 4.0% from $92.3 million in the first quarter of 2013.
|
fa86771b-b340-4dcc-a92d-d4e0d6883bbc
|
715632.0
|
2014-05-07 00:00:00 UTC
|
Mindray Medical Misses on Q1 Earnings - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/mindray-medical-misses-on-q1-earnings-analyst-blog-2014-05-07
|
nan
|
nan
|
Chinese medical devices maker, Mindray Medical International Ltd. ( MR ) posted a disappointing 34.0% fall in adjusted earnings per share to 33 cents for the 2014-first quarter from 50 cents a year ago and missed the Zacks Consensus Estimate by 3 cents per share.
Adjusted net earnings dipped 35.7% year-over-year to $38.5 million from $59.8 million in the first quarter of 2013. Reported earnings decreased 37.5% to 30 cents per share from 48 cents per share in the 2013-quarter or 37.9% to $35.6 million from $57.4 million in the year-ago quarter.
Net revenues grew 9.4% to $264.8 million, lying below the Zacks Consensus Estimate of $291 million. International sales continued to be stronger than the domestic market sales.
International revenues upped 13.9% to $148.9 million while revenues from China grew at a slower pace of 4.0% to $115.8 million due to sluggish purchasing and marketing activities in the healthcare sector.
Segment Revenues
Revenues from Patient Monitoring & Life Support Products fell 1.4% to $98.0 million, contributing 37.0% to overall net revenues. Revenues from In-Vitro Diagnostic Products went up 6.8% to $73.0 million, contributing 27.6% to net revenues. Reagents sales accounted for 38.1% of segment revenues.
Revenues from Medical Imaging Systems escalated 27.1% to $67.6 million, contributing 25.5% to net revenues. Revenues from Others (including sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period) zoomed 23.6% to $26.2 million, contributing 9.9% to overall net revenues.
Margins
Adjusted gross profit rose 5.3% to $148.0 million but adjusted gross margin declined 210 basis points (bps) to 55.9% in the quarter. Adjusted operating profit went down 16.5% to $34.7 million, while operating margin dipped 410 bps to 13.1% from 17.2% in the 2013 first quarter.
Financial Position
MR had $419.8 million in cash and cash equivalents as of Mar 31, 2014, up 9.0% from $385.2 million as of Dec 31, 2013. Total bank loans fell 10.6% to $425.2 million from $475.7 million as of Dec 31, 2013.
In the quarter, cash flow from operating activities plunged 53.6% to $19.7 million from $42.4 million in the 2013-quarter. Capital expenditure rose 39.1% to $27.9 million compared with $20.0 million a year ago.
2014 Guidance
MR continues to expect 2014 net revenues to grow at least 15% over 2013 based on strengths in Western Europe and some emerging markets as well as gradual improvement in China. The company also reiterated its capital expenditures guidance of $160 million for the year.
Our Take
MR is a bellwether in the Chinese MedTech industry with a solid international presence. A key distinction with domestic competitors is that the majority of its products have CE Mark and/or Food and Drug Administration (FDA) clearance.
However, falling earnings disappointed investors and the company's results fell short of both the earnings and revenues estimates. Currently, MR carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Edwards Lifesciences retain Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. 2014 Guidance MR continues to expect 2014 net revenues to grow at least 15% over 2013 based on strengths in Western Europe and some emerging markets as well as gradual improvement in China.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. Chinese medical devices maker, Mindray Medical International Ltd. ( MR ) posted a disappointing 34.0% fall in adjusted earnings per share to 33 cents for the 2014-first quarter from 50 cents a year ago and missed the Zacks Consensus Estimate by 3 cents per share.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. International revenues upped 13.9% to $148.9 million while revenues from China grew at a slower pace of 4.0% to $115.8 million due to sluggish purchasing and marketing activities in the healthcare sector.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MINDRAY MEDICAL (MR): Free Stock Analysis Report To read this article on Zacks.com click here. Chinese medical devices maker, Mindray Medical International Ltd. ( MR ) posted a disappointing 34.0% fall in adjusted earnings per share to 33 cents for the 2014-first quarter from 50 cents a year ago and missed the Zacks Consensus Estimate by 3 cents per share.
|
5d54f3e9-4e5f-4e0e-8830-9f82f20b3b9d
|
715633.0
|
2014-05-06 00:00:00 UTC
|
Volcano Slips into Loss, Misses Ests in Q1 - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/volcano-slips-into-loss-misses-ests-in-q1-analyst-blog-2014-05-06
|
nan
|
nan
|
Volcano Corporation 's ( VOLC ) first-quarter 2014 adjusted loss per share of 12 cents was 9.1% wider than the Zacks Consensus Estimate of loss of 11 cents. The loss also deteriorated from the prior-year quarter's adjusted earnings of 2 cents per share. However, without these adjustments, the company reported net loss of 21 cents per share, significantly below the year-ago loss of 6 cents.
With a lower-than-expected first quarter performance, following the earnings announcement Volcano's share price dropped 0.2% to $17.5 on May 5.
Revenues
Revenues of Volcano in the quarter climbed 1.4% year over year to $94.5 million. However, without considering a negative impact of $2.7 million due to unfavorable foreign currency, total revenue increased 4% at constant exchange rate or CER. However, reported revenues missed the Zacks Consensus Estimate of $96 million.
Year-over-year improvement in total revenues was driven by solid growth in the U.S. peripheral business, and FFR (Fractional Flow Reserve) and IVUS (intravascular ultrasound) disposables in Europe.
Geographic-region wise, Volcano experienced strong growth in Europe and the Middle East, with 21% year-over-year increase in total revenues. Moreover, apart from gaining traction in the emerging markets of Latin America and Asia-Pacific, console revenues escalated 52% year over year in Europe and the Middle East.
Segment Analysis
Revenues from Volcano's medical segment increased 1.4% (up 4% in CER) to $93 million in the first-quarter, driven by a solid 7.8% sales growth (up 9% in CER) in FFR single-procedure disposables offset by 3% decline (up 2% in CER) in sales of IVUS disposables and 4.5% decline (down 5% in CER) in sales of consoles.
FFR disposable sales increased 14% at CER in Japan, 16% in Europe and an impressive 47% in Rest of World. Revenues from IVUS disposables increased 9% at CER in U.S., 10% in Europe and 22% in Rest of World, while declined 9% in Japan at CER.
On the other hand, while console placement improved in Japan (up 14% at CER) and Europe (up 46%), it declined in the U.S. and the Rest of world (down 25% and 9%, respectively) compared with the year-ago quarter. Industrial segment revenue growth remained flat at $1.5 million in the reported quarter.
Margins
Gross margin deteriorated 160 basis points (bps) to 62.9% in the first quarter due to unfavorable foreign exchange rates and costs related to the ramping up of manufacturing activities at Costa Rica. Management expects gross margin to fluctuate through 2014, until the company completes the transfer of all its disposable manufacturing to Costa Rica.
Selling, general and administrative expenses spiked 14.8% year over year to $50.3 million, primarily driven by increased sales force headcount, litigation expenses, an increase in incentive compensation for non-executive employees and increased facility costs related to Volcano's expanded San Diego headquarters.
On the other hand, Volcano's research and development expenditure fell 10.8% year over year to $14 million, reflecting the strategic prioritization initiative implemented by the company last October. However, this decline was partly offset by increased investments in high-priority pipeline programs. Operating loss was $8.5 million in the reported quarter, compared to $1.8 million in the year ago quarter.
Financial Position
Volcano exited the first quarter with cash, cash equivalents and short-term investments of $345 million compared with $338 million at the end of 2013.
During the first quarter, cash used in operations declined 62% to $3.0 million from the prior-year quarter.
Outlook
For second-quarter 2014, Volcano expects revenues in the range of $102-$104 million and adjusted loss per share in the band of 4 to 6 cents. The Zacks Consensus Estimate of adjusted loss of 4 cents falls at the low end of the company's guided range. However, the Zacks Consensus Estimate of revenues of $105 million is pegged higher than the company's guidance.
For full-year 2014, the company reiterated its revenue guidance at $413-$421 million, with revenues at CER expected in the range of $417-$425 million. Volcano still expects adjusted loss per share to lie in the range of 16-19 cents in 2014. The Zacks Consensus Estimate for adjusted loss of 20 cents per share is higher than the company's expectations for the year. Meanwhile, the Zacks Consensus Estimate for revenues of $415 million lies within the company's guidance range.
Management also expects gross margin in the band of 64-65% in 2014 and operating expenses, including restructuring charges, in the range of 68-69% of revenues.
Our Take
We are disappointed with the company's first-quarter 2014 results, which failed to beat the Zacks Consensus Estimate on both the top and bottom-line front. Although overall medical segment revenues increased, a challenging coronary imaging business adversely affected total revenue growth in Japan. However, management is positive that the company's new pipeline products will be able to drive growth through 2014 and the scheduled launch of Sync Vision Co-Registration System Technology in Japan in the second half of 2014 will improve its position in Japan.
Zacks Rank
Volcano currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). Delcath and RTI Surgical sport a Zacks Rank #1 (Strong Buy), while Accuray carries a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. However, without considering a negative impact of $2.7 million due to unfavorable foreign currency, total revenue increased 4% at constant exchange rate or CER.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. Segment Analysis Revenues from Volcano's medical segment increased 1.4% (up 4% in CER) to $93 million in the first-quarter, driven by a solid 7.8% sales growth (up 9% in CER) in FFR single-procedure disposables offset by 3% decline (up 2% in CER) in sales of IVUS disposables and 4.5% decline (down 5% in CER) in sales of consoles.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues Revenues of Volcano in the quarter climbed 1.4% year over year to $94.5 million.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. However, reported revenues missed the Zacks Consensus Estimate of $96 million.
|
6e90ad54-d5b5-458e-9123-7300e0d01e98
|
715634.0
|
2014-05-06 00:00:00 UTC
|
DexCom Misses, Sees Broader Q1 Loss - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/dexcom-misses-sees-broader-q1-loss-analyst-blog-2014-05-06
|
nan
|
nan
|
DexCom, Inc. ( DXCM ) reported a broader loss of $12.5 million or 17 cents per share in the first quarter of 2014 compared with $11.1 million or 16 cents in the comparable quarter of 2013 as well as the Zacks Consensus Estimate of a loss of 8 cents.
The broader loss can be attributable to a significant increase in operating expenses in the quarter, mainly on account of a substantial rise in non-cash share-based compensation.
Revenues
DexCom's total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million, on a handsome 68.0% rise in product revenues to $46.7 million. However, a development grant and other revenues plunged 77.8% to $0.4 million in the quarter.
Expenses and Margins
Product gross profit nearly doubled to $29.8 million while product gross margin surged 760 basis points (bps) to 63.3% in the first quarter of 2014. The company continues to expect improvement in gross margin in the year as volumes continue to rise, mainly consumable product sales.
Operating expenses in the quarter jumped 53.6% to $42.1 million, driven by increased share-based compensation due to an uptrend in share price. Dexcom's non-cash equity related charges soared 86.8% to $9.9 million for the quarter from $5.3 million in the first quarter of 2013.
Research and development (R&D) expenses spiked 55.9% to $14.5 million in the quarter. The increase is partially attributable to a $2.1 million increase in non-cash equity related expense.
The remaining increase in R&D expenses relates to continued investment in the product pipeline, focusing upon higher accuracy, better connectivity, patient convenience and lower cost.
In the quarter, Dexcom conducted a number of clinical studies related to future technology, new sensors, new algorithms, enhance labeling, failure connectivity and general product improvements. The company has a few pending submissions with the FDA, including DexCom SHARE, the DexCom G4 system for professional use, the SweetSpot cloud-based system.
Selling, general and administrative (SG&A) expenses went up 52.5% to $27.6 million in the quarter, driven by increased headcount for commercial infrastructure. The increase in both R&D and SG&A expenses led to a broader operating loss of $12.3 million compared with $10.9 million loss in the 2013-first quarter.
Financial Status
DexCom had cash and cash equivalents of $45.7 million as of Mar 31, 2014 compared with $43.2 million as of Dec 31, 2013. Total long-term debt went down to $6.3 million from $6.8 million as of Dec 31, 2013.
Our Take
CA-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The company relies significantly on its base of recurring revenue which reflects increasing usage rate with existing patients. Thus, higher patient base will bolster top-line for DexCom.
However, we are concerned about its widening losses and disappointed about its earnings miss in the first quarter. DexCom currently retains a Zacks Rank #4 (Sell).
Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Natus Medical carry a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
NATUS MEDICAL (BABY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. The broader loss can be attributable to a significant increase in operating expenses in the quarter, mainly on account of a substantial rise in non-cash share-based compensation.
|
Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues DexCom's total revenues surged 59.1% to $47.1 million, topping the Zacks Consensus Estimate of $44.0 million, on a handsome 68.0% rise in product revenues to $46.7 million.
|
Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom, Inc. ( DXCM ) reported a broader loss of $12.5 million or 17 cents per share in the first quarter of 2014 compared with $11.1 million or 16 cents in the comparable quarter of 2013 as well as the Zacks Consensus Estimate of a loss of 8 cents.
|
Some better-ranked stocks in the medical instruments sector include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom, Inc. ( DXCM ) reported a broader loss of $12.5 million or 17 cents per share in the first quarter of 2014 compared with $11.1 million or 16 cents in the comparable quarter of 2013 as well as the Zacks Consensus Estimate of a loss of 8 cents.
|
616b89be-d7c3-48fb-b345-2ce750aa8378
|
715635.0
|
2014-05-05 00:00:00 UTC
|
Masimo Corporation Q1 Earnings Rise, Beat Ests - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/masimo-corporation-q1-earnings-rise-beat-ests-analyst-blog-2014-05-05
|
nan
|
nan
|
Masimo Corporation ( MASI ) posted a 39.3% rise in adjusted net earnings to 39 cents per share for the first quarter of 2014 from 28 cents for the same quarter of 2013 and beat the Zacks Consensus Estimate by 10 cents. Adjusted net earnings rose 37.8% to $22.6 million from $16.4 million in the first quarter of 2013.
Revenues in the quarter (including royalties) scaled up 2.8% to $139.8 million, missing the Zacks Consensus Estimate of $144.0 million.
Product revenues grew 2.8% to $132.2 million while global direct product revenues rose 3% in the first quarter, representing 84% of total product revenues. OEM sales, which accounted for 16% of product revenues, upped 2% in the quarter.
Revenues from sales of MASI rainbow products spiked 23% to $12.9 million in the first quarter. Revenues from Royalty went up 3.8% to $7.6 million in the quarter.
MASI shipped about 41,400 SET pulse oximetry and rainbow Pulse CO-Oximetry units in the quarter (excluding handheld units), up 5% year-over-year. MASI expects worldwide installed base of 1,231,000 units as of Mar 29, 2014, up 10% from 1,117,000 units as of Mar 30, 2013.
MASI had cash and cash equivalents of $117.5 million as of Mar 29, 2014, up 23.1% from $95.5 million as of Dec 28, 2013. Capital lease obligations amounted to $258 thousand as of Dec 28, 2013, down 23.2% compared with $336 thousand as of Dec 28, 2013.
In the quarter, cash flow from operating activities dipped 4.3% to $24.0 million from $25.1 million in the 2013-first quarter. Capital expenditure surged 54.4% to $2.8 million compared with $1.8 million a year ago.
For 2014, MASI expects revenues of $588 to $598 million, which includes Product revenues of $560 to $570 million and Royalty revenues of $28 million. Product revenue guidance includes rainbow revenues of $60 million. The current Zacks Consensus Estimate for 2014 revenues of $587 million lies within the guided range.
MASI also expects reported earnings in the range of $1.24 to $1.33 for 2014. The current Zacks Consensus Estimate of $1.23 lies below the outlook range.
MASI develops innovative monitoring technologies that significantly improve patient care -- helping solve unsolvable problems. The company sells its products to hospitals, emergency medical response organizations, and alternate care market through its direct sales force and distributors, as well as to original equipment manufacturer partners. Currently, it retains a Zacks Rank #2 (Buy).
Other players that worth a look in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. (ARAY ) and Edwards Lifesciences Corp. ( EW ). While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Edwards Lifesciences retain Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other players that worth a look in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. (ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. MASI develops innovative monitoring technologies that significantly improve patient care -- helping solve unsolvable problems.
|
Other players that worth a look in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. (ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. While Delcath Systems sports a Zacks Rank #1 (Strong Buy), both Accuray and Edwards Lifesciences retain Zacks Rank #2 (Buy).
|
Other players that worth a look in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. (ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter (including royalties) scaled up 2.8% to $139.8 million, missing the Zacks Consensus Estimate of $144.0 million.
|
Other players that worth a look in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. (ARAY ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter (including royalties) scaled up 2.8% to $139.8 million, missing the Zacks Consensus Estimate of $144.0 million.
|
35e8fca5-5500-4dc7-ab55-d6a54a1ba433
|
715636.0
|
2014-05-05 00:00:00 UTC
|
Accuray Posts Narrower-than-Expected Q3 Loss - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/accuray-posts-narrower-than-expected-q3-loss-analyst-blog-2014-05-05
|
nan
|
nan
|
Accuray Incorporated 's ( ARAY ) fiscal 2014-third-quarter loss of $4.7 million or 6 cents per share was significantly narrower than the year-ago loss of $31.2 million or 42 cents per share as well as the Zacks Consensus Estimate of a loss of 16 cents.
Total revenue for the quarter came in at $97.1 million, up 37.7% year over year. Revenues also surpassed the Zacks Consensus Estimate of $82 million.
Despite reporting bottom and top-line beat, third-quarter results failed to impress investors. Shares of ARAY fell 6.3% following the earnings release to close at $7.99 till the last reported session.
Revenue Details
Product revenues during the quarter surged 88.0% to $47.0 million, mainly driven by enhanced commercial effort and improvement in the company's order to revenue conversion process.
Service revenues stood at $50.0 million, up 10.0% from the year-ago quarter. The upside was driven by the increase in the company's installed base and shift of customers toward higher value service contracts.
Orders
Gross product orders declined 16.0% to $45.2 million during the quarter. Gross product orders, less cancellations and age-outs, totaled $38.6 million, a decrease of 12.5% from the third quarter of fiscal 2013.
Both gross and net order volumes were lower year over year due to the lack of new orders in the company's U.S. business.
Product backlog at the end of the reported quarter was $354 million, approximately 19% higher than the backlog at the end of the prior-year quarter.
Margins
Gross profit for the quarter escalated nearly 98.0% to $39.7 million. Gross margin expanded 1,250 basis points (bps) to 40.9% from 28.4% in the year-ago quarter. Product and services gross margins were 46.3% and 35.8%, respectively, in the third quarter versus 26.5% and 29.5% in the year-ago quarter.
Product gross margin improved on higher volume and stronger average product revenues. The significantly higher service gross margin represents continued improvement in TomoTherapy Systems reliability, which continues to drive demand for lower as well as higher-margin service contracts.
Total operating expenses decreased 10.9% to $40.2 million from $45.1 million a year ago. Operating expenses were close to the company's plan of spending $40 million on operational activities.
Research and Development (R&D) expenses declined 12.3% to $13.8 million during the quarter. As a percentage of sales, R&D expenses contracted 810 bps to 14.2% from 22.3% in the year-ago period.
Selling and marketing expenses rose 21.1% to $15.3 million, however, as a percentage of sales, it decreased 210 bps to 15.8% during the quarter. General and administrative expenses decreased 33.7% to $11.1 million, whereas, as a percentage of sales, it fell 1,230 bps to 11.4% from 23.7% in the year-ago period.
ARAY reported adjusted EBITDA of $7.8 million compared with a loss of $19.9 million in the third quarter of fiscal 2013, representing an impressive improvement of 139.3%. The improvement came on the back of revenue growth, margin expansion and operating expense control.
Financial Condition
ARAY exited the quarter with cash, cash equivalents and restricted cash of roughly $174.0 million, down 5.5% from $184.1 million in the year-earlier quarter. Long-term debt increased marginally by 0.6% to $198.8 million from $197.7 million a year ago.
ARAY generated a positive cash flow from operations of $13.7 million in the quarter under review.
Outlook
For fiscal 2014, ARAY raised its total revenue guidance to a range of $355 to $365 million from the previous range of $340 to $350 million provided on Jan 30, 2014. The current Zacks Consensus Estimate of $350 million lies below the revised guided range.
Our View
We are encouraged by ARAY's fiscal 2014-third-quarter results, which beat the Zacks Consensus Estimate at both fronts. Moreover, ARAY revised its fiscal 2014 revenue guidance upward, reflecting a favorable momentum in the business.
Additionally, the quarter was also marked by EBITDA profitability, positive cash flow from operations and working capital reduction. ARAY's CyberKnife and TomoTheray systems continue to generate positive feedback from customers and contribute to revenue growth.
However, with respect to orders, both gross and net order volumes were lower year over year in the quarter due to the lack of new orders in the U.S. ARAY remains susceptible to the weak U.S. and European markets, reimbursement uncertainties and faces stiff challenges from competitive product offerings.
Currently, ARAY carries a Zacks Rank #2 (Buy). Other medical instrument companies worth a look are Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Edwards Lifesciences Corp. ( EW ). While Delcath Systems and RTI Surgical sport a Zacks Rank #1 (Strong Buy), Edwards Lifesciences has the same Zacks Rank as ARAY.
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instrument companies worth a look are Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the quarter was also marked by EBITDA profitability, positive cash flow from operations and working capital reduction.
|
Other medical instrument companies worth a look are Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. While Delcath Systems and RTI Surgical sport a Zacks Rank #1 (Strong Buy), Edwards Lifesciences has the same Zacks Rank as ARAY.
|
Other medical instrument companies worth a look are Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Accuray Incorporated 's ( ARAY ) fiscal 2014-third-quarter loss of $4.7 million or 6 cents per share was significantly narrower than the year-ago loss of $31.2 million or 42 cents per share as well as the Zacks Consensus Estimate of a loss of 16 cents.
|
Other medical instrument companies worth a look are Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Edwards Lifesciences Corp. ( EW ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Product gross margin improved on higher volume and stronger average product revenues.
|
79e7ae2a-be9c-471d-89bd-54f133013722
|
715637.0
|
2014-04-30 00:00:00 UTC
|
Teleflex 1Q Earnings Rise, Beat Estimates - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/teleflex-1q-earnings-rise-beat-estimates-analyst-blog-2014-04-30
|
nan
|
nan
|
Teleflex Incorporated ( TFX ) posted a 15.1% rise in adjusted earnings to $1.22 per share for the first quarter of 2013 from $1.06 in the same quarter of 2013. With this, earnings beat the Zacks Consensus Estimate by 6 cents per share. Adjusted net earnings rose 19.6% to $53.0 million from $44.3 million in the year-ago quarter.
Net revenues went up 6.5% to $438.5 million, exceeding the Zacks Consensus Estimate of $434 million. Excluding foreign exchange fluctuations, net revenues rose 6.0% from the prior-year quarter.
The increase in revenues was attributable to contribution from the acquisitions of Vidacare Corporation in Dec 2013 and Mayo Healthcare in Feb 2014, an increase in the average selling price of products, and launch of new products.
Segment Overview
Effective Jan 1, 2014, Teleflex reorganized its operating segments. The reorganization in operating segments resulted from changes in the company's internal reporting structure. The Vascular, Anesthesia/Respiratory and Surgical businesses, which previously comprised much of the Americas reportable segment, are now treated as separate reportable segments. As a result, Teleflex currently has six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM.
Net revenues from Vascular North America rose 10.3% to $62.5 million. Excluding the impact of foreign currency movements, net revenues rose 10.8% from the prior year period. The increase in constant currency revenue was largely driven by Vidacare product sales, the introduction of new products to the market and price hikes, partially offset by lower sales volume of existing products.
Net revenues from Anesthesia/Respiratory North America dipped 5.9% to $54.7 million. Excluding the impact of foreign currency, net revenues fell 5.6% compared to the prior year quarter. The decline in constant currency revenue was largely driven by lower sales volume of existing products, partially offset by the introduction of new products and price increases.
Net revenues from Surgical North America slid 4.0% $35.2 million. Excluding the impact of foreign currency, net revenues fell 3.0% from the prior-year period. The decrease in constant currency revenue was largely due to lower sales volume of existing products, partially offset by price increases and the introduction of new products to the market.
Net revenues from EMEA rose 5.5% to $150.2 million. Excluding the impact of foreign currency, net revenues went up 2.5% from the prior-year period. The increase in constant currency revenue was largely driven by Vidacare product sales, price increases and the introduction of new products, partially offset by lower sales volume of existing products.
Net revenues from Asia rose 17.1% to $49.6 million from the prior-year quarter. Excluding the impact of foreign currency, net revenues increased 20.3% from the prior year period. The increase was attributable to Mayo Healthcare and Vidacare product sales, price increases and higher sales volume of existing products.
Net revenues from OEM and Development Services escalated 5.9% to $33.2 million. Excluding the impact of foreign currency, net revenues increased 5.3% compared to the prior year. The increase in constant currency revenues was driven by higher sales volume of existing products and the introduction of new products to the market, partially offset by lower average selling prices.
Restructuring Plan
On Apr 28, 2014, the Board of Directors of Teleflex approved a restructuring plan aimed at reducing costs, improve operating efficiencies and enhance the company's long term competitive position. The plan includes the relocation of manufacturing operations from some higher-cost locations to existing lower-cost locations. These measures will commence in the second quarter 2014 and are expected to be majorly completed by the end of 2017.
Teleflex estimated that that it will incur aggregate pre-tax charges of approximately $42 to $53 million in connection with the restructuring measures. Out of the total amount, the company expects approximately $22 to $23 million to be incurred in 2014 and most of the balance will be incurred prior to the end of 2016.
Further, Teleflex expects to incur $24 to $30 million in capital expenditures in connection with the plan, of which about $10 to $15 million will be made in 2014.
Financial Position
Teleflex had cash and cash equivalents of $421.6 million as of Mar 31, 2014, down 2.4% from $432.0 million as of Dec 31, 2013. Long-term borrowings increased marginally by 0.2% to $1,289.3 million from $1,286.3 million as of Dec 31, 2013.
In the quarter, cash flow from operating activities increased more than six-fold to $33.6 million from $5.3 million in the 2013-quarter, mainly driven by higher earnings and lower inventories. Capital expenditure fell 22.6% to $12.1 million compared with $15.6 million in the 2013-first quarter.
2014 Guidance
For 2014, Teleflex continues to expect revenue growth between 6.0 and 8.0% versus 2013. In constant currency, the company expects revenues to increase by 7.0 and 9.0%.
Teleflex also expects adjusted earnings per share in the range of $5.35 to $5.55. The current Zacks Consensus Estimate of $5.52 lies within the guided range.
Our Take
Headquartered in Limerick, PA, Teleflex is a leading provider of specialty medical devices for a range of procedures in critical care and surgery globally. We are encouraged about its significant earnings beat in the fourth quarter and higher EPS and revenue guidance. However, we are concerned about weak sales of some of its product lines. Currently, Teleflex retains a Zacks Rank #2 (Buy).
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). Delcath Systems carries a Zacks Rank #1 (Storng Buy), while both Accuray and Natus Medical retain a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
NATUS MEDICAL (BABY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Excluding the impact of foreign currency, net revenues fell 5.6% compared to the prior year quarter.
|
ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). The increase in constant currency revenue was largely driven by Vidacare product sales, the introduction of new products to the market and price hikes, partially offset by lower sales volume of existing products.
|
ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). The increase in constant currency revenue was largely driven by Vidacare product sales, the introduction of new products to the market and price hikes, partially offset by lower sales volume of existing products.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and Natus Medical Inc. ( BABY ). ACCURAY INC (ARAY): Free Stock Analysis Report NATUS MEDICAL (BABY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Adjusted net earnings rose 19.6% to $53.0 million from $44.3 million in the year-ago quarter.
|
951697c7-d745-496f-988c-caddd2f94dff
|
715638.0
|
2014-04-29 00:00:00 UTC
|
What Makes Intuitive Surgical (ISRG) a Strong Sell? - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/what-makes-intuitive-surgical-isrg-a-strong-sell-tale-of-the-tape-2014-04-29
|
nan
|
nan
|
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Intuitive Surgical, Inc. ( ISRG ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in ISRG.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 5 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from $14.86 a share a month ago to its current level of $11.77 per share.
Also, for the current quarter, Intuitive Surgical has seen 10 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to $2.83 a share from $3.76 over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 14.5% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical Instruments industry, you may instead consider some better-ranked stocks including Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). While Delcath Systems and RTI Surgical carry a Zacks Rank #1 (Strong Buy), Accuray holds a Zacks Rank #2 (Buy). With favorable Zacks Ranks, these stocks may be better selections at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If you are still interested in the Medical Instruments industry, you may instead consider some better-ranked stocks including Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). Click to get this free report >> ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns.
|
If you are still interested in the Medical Instruments industry, you may instead consider some better-ranked stocks including Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). Click to get this free report >> ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. While Delcath Systems and RTI Surgical carry a Zacks Rank #1 (Strong Buy), Accuray holds a Zacks Rank #2 (Buy).
|
Click to get this free report >> ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Medical Instruments industry, you may instead consider some better-ranked stocks including Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). One such stock that you may want to consider dropping is Intuitive Surgical, Inc. ( ISRG ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
|
If you are still interested in the Medical Instruments industry, you may instead consider some better-ranked stocks including Delcath Systems, Inc. ( DCTH ), RTI Surgical Inc. ( RTIX ) and Accuray Incorporated ( ARAY ). Click to get this free report >> ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report To read this article on Zacks.com click here. For the full year, we have seen 5 estimates moving down in the past 30 days, compared with no upward revision.
|
b90ba31c-a7a7-45c0-94e5-7b69dd174143
|
715639.0
|
2014-04-28 00:00:00 UTC
|
Bear of the Day: Intuitive Surgical (ISRG) - Bear of the Day
|
DCTH
|
https://www.nasdaq.com/articles/bear-day-intuitive-surgical-isrg-bear-day-2014-04-28
|
nan
|
nan
|
In the health care sector, investors have been laser focused on the biotech space. This corner of the market has faced severe pressure over the past few months as concerns over hot momentum stocks have reached a new level.
And yet while many have been focused on biotechnology, we have also seen some weakness in a few names in the medical device space. This is interesting because, by and large, many names in the segment have held up quite well despite the slump that many of their peers in the drug space were seeing.
However, unlike in the drug space, many companies in the medical device segment have been driven by fundamentals lately, instead of just sluggish momentum. This has been particularly the case for Intuitive Surgical ( ISRG ) which has been under severe pressure and may have significant trouble in keeping the sales up for its key da Vinci surgical system in the near future.
Recent Earnings & Outlook
This weakness in the da Vinci system sales was made abundantly clear in ISRG's most recent quarterly earnings report. In the release, ISRG put up a huge miss, posting earnings of just $2.67/share compared to estimates of $3.34/share. The firm cited the Affordable Care Act and uncertainty as the reasons for the big miss, and it also said that it may continue to have trouble selling in this environment for the future.
Thanks to this weakness, analysts have been slashing their estimates left and right on the shares of ISRG. Estimates have almost universally moved lower in the past week, including three estimates lower in the past seven days for the current year, and 10 lower for the next year time frame.
The magnitude of these revisions lower has also been intense for pretty much all time periods that we studied. For the current year in particular though, earnings estimates have moved from $16.70/share 90 days ago to just $14.01/share today, while next year figures have slumped by about 14% too.
Clearly, analysts are taking Intuitive Surgical's warnings to heart, and given the ever changing requirements and politics of the health care industry, many are betting that ISRG won't be able to turn things around any time soon. Instead, it looks as if ISRG's near term weakness will continue and that the pressure that has been building in this stock will lead to more underperformance.
That is why we have assigned ISRG our lowest ranking with a Zacks Rank #5 (Strong Sell), and are looking for more underperformance from this stock until estimates on the sales of their innovative da Vinci surgical system improve.
Better Picks
For investors seeking better selections in the medical instruments industry, a few such options do exist. Currently, both Delcath Systems ( DCTH ) and Globus Medical ( GMED ) have top ranks and may be better picks at this time.
Plus, both of these companies have beaten estimates in the most recent quarter, while they have moved to a top rank within the past week as well. So, now might be the time to let ISRG go and to look to the better positioned DCTH or GMED for now.
Want more insights from Zacks? See our latest free report 5 Stocks to Double . Click here to receive this free report now >>>
DELCATH SYS INC (DCTH): Free Stock Analysis Report
GLOBUS MEDICAL (GMED): Free Stock Analysis Report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Currently, both Delcath Systems ( DCTH ) and Globus Medical ( GMED ) have top ranks and may be better picks at this time. So, now might be the time to let ISRG go and to look to the better positioned DCTH or GMED for now. Click here to receive this free report now >>> DELCATH SYS INC (DCTH): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Currently, both Delcath Systems ( DCTH ) and Globus Medical ( GMED ) have top ranks and may be better picks at this time. Click here to receive this free report now >>> DELCATH SYS INC (DCTH): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. So, now might be the time to let ISRG go and to look to the better positioned DCTH or GMED for now.
|
Click here to receive this free report now >>> DELCATH SYS INC (DCTH): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, both Delcath Systems ( DCTH ) and Globus Medical ( GMED ) have top ranks and may be better picks at this time. So, now might be the time to let ISRG go and to look to the better positioned DCTH or GMED for now.
|
Currently, both Delcath Systems ( DCTH ) and Globus Medical ( GMED ) have top ranks and may be better picks at this time. So, now might be the time to let ISRG go and to look to the better positioned DCTH or GMED for now. Click here to receive this free report now >>> DELCATH SYS INC (DCTH): Free Stock Analysis Report GLOBUS MEDICAL (GMED): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here.
|
29f8696f-eea8-4c6b-bfda-34222a69b18b
|
715640.0
|
2014-04-24 00:00:00 UTC
|
Varian Medical Systems Beats, Earnings Flat Y/Y - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/varian-medical-systems-beats-earnings-flat-y-y-analyst-blog-2014-04-24
|
nan
|
nan
|
Varian Medical Systems ( VAR ) posted flat adjusted earnings per share of $1.04 (including a 16-cent charge related to a previously announced settlement of patent litigation) for the second quarter of fiscal 2014 ended Mar 28, 2014 compared with the same quarter in the prior fiscal year.
However, second quarter earnings edged past the Zacks Consensus Estimate by a couple of cents. With this, VAR also met its own guidance of earnings per share for the quarter in the range of $1.00 to $1.04.
Revenues in the quarter inched up 1.3% to $778.5 million during the quarter, beating the Zacks Consensus Estimate of $775 million. Thanks to the strong gross orders in Imaging Components segment and proton business as well as mid-single-digit growth in Oncology Systems segment.
VAR had backlog of $2,806.6 million at the end of the second quarter, up roughly 2.0% from $2,752.6 million in the comparable quarter a year ago.
Adjusted operating earnings (excluding litigation settlement) slid 2.0% to $152.6 million while adjusted operating margin dipped 70 basis points (bps) to 19.6% from 20.3% a year ago.
Segment Results
Revenues from Oncology Systems segment inched up 3.7% to $603.1 million in the quarter, driven by new multi-year agreements with large hospital systems. Oncology Systems gross orders grew 6.3% to $613.0 million while net orders rose 0.7% to $559.1 million.
Gross orders rose 3% in North America due to strong service growth. Gross orders upped 9% outside North America, driven by strength in Latin America and Australia that offset softness in Asia. Markets outside North America represented 58% of Oncology gross orders in the quarter.
During the quarter, VAR merged its X-Ray Products and Security and Inspection Products businesses into a single Imaging Components segment. Revenues from the segment went up 1.6% to $169.0 million in the quarter, driven by solid gains in gross orders.
Gross orders rose 13.8% to $205.0 million in the quarter while net orders upped 11.4% to $200.6 million in the quarter, driven by strong panel business, partially offset by weakness in the security and tube businesses.
Revenues from the Other segment (comprising Varian Particle Therapy businesses and the Ginzton Technology Center) plummeted 68.3% to $6.4 million, despite a $59.0 million increase in gross orders to $59.7 million and $58.2 million rise in net orders to $58.9 million for the quarter. The segment bagged orders for proton installations at the Cincinnati Children's Hospital Medical Center in Ohio and at the Paul Scherrer Institute in Switzerland during the quarter.
Financial Position
VAR exited the quarter with cash and cash equivalents of $939.0 million as of Mar 28, 2014 compared with $1,181 million as of Sep 27, 2013. Long-term debt (including current maturities) was $468.75 million compared with $506.25 million as of Sep 27, 2013. With this, long-term debt-to-capitalization ratio fell 10 bps to 21.8% compared with 22.8% as of Sep 27, 2013.
Cash flow from operations was $126 million for the quarter. During the quarter, VAR spent $159 million to repurchase about 2.0 million shares of common stock.
Guidance
For fiscal 2014, VAR reiterated its revenues growth in the range of 6 to 8%. The company also retained its earnings per share guidance between $4.22 and $4.34 for the year, including the 16 cents charge for the patent litigation settlement. The current Zacks Consensus Estimate of $4.29 lies within the guided range.
For the third quarter of fiscal 2014, VAR expects revenues to increase in the range of 5 to 6%. The company also expects earnings per share in the range of $1.06 to $1.10 for the quarter. The current Zacks Consensus Estimate of $1.12 lies above the guided range.
Zacks Rank
Currently, VAR carries a Zacks Rank #3 (Hold). Some better-ranked medical instrument stocks that currently worth a look include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). Delcath Systems sports a Zacks Rank #1 (Strong Buy), while both Accuray and IDEXX Laboratories carries a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
IDEXX LABS INC (IDXX): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked medical instrument stocks that currently worth a look include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. The segment bagged orders for proton installations at the Cincinnati Children's Hospital Medical Center in Ohio and at the Paul Scherrer Institute in Switzerland during the quarter.
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked medical instrument stocks that currently worth a look include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). Gross orders rose 13.8% to $205.0 million in the quarter while net orders upped 11.4% to $200.6 million in the quarter, driven by strong panel business, partially offset by weakness in the security and tube businesses.
|
Some better-ranked medical instrument stocks that currently worth a look include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter inched up 1.3% to $778.5 million during the quarter, beating the Zacks Consensus Estimate of $775 million.
|
Some better-ranked medical instrument stocks that currently worth a look include Delcath Systems, Inc. ( DCTH ), Accuray Inc. ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in the quarter inched up 1.3% to $778.5 million during the quarter, beating the Zacks Consensus Estimate of $775 million.
|
44e156a6-8887-4d8e-9d07-7134b3ffffa6
|
715641.0
|
2014-04-23 00:00:00 UTC
|
Intuitive Surgical Lags on Q1 Earnings - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/intuitive-surgical-lags-on-q1-earnings-analyst-blog-2014-04-23
|
nan
|
nan
|
Intuitive Surgical Inc. ( ISRG ) posted a 41.4% fall in adjusted earnings per share to $2.67 for the first quarter of the year from $4.56 in the same quarter of 2013. With this, the robotic surgical systems maker's earnings lagged the Zacks Consensus Estimate by a wide margin of 67 cents.
Net earnings ebbed 44.8% to $104.3 million from $188.9 million in the 2013-first quarter. The adjusted figures excluded the impact of deferral of revenues related to a customer trade-out program for their recently purchased da Vinci Si Surgical Systems with the company's recently announced da Vinci Xi Surgical System as well as product liability litigation charges.
The fall in earnings is attributable to lower System sales due to lower procedure volumes, changing hospital capital-spending priorities associated with the implementation of the Affordable Care Act and the anticipation of a new system affecting the healthcare capital-spending decisions.
Total Revenues
As projected by the company, revenues in the quarter dipped 24.0% to $464.7 million, missing the Zacks Consensus Estimate of $512 million. The decline is attributable to the $26 million deferral related to a customer trade-out program as discussed above. Excluding the impact of the trade-out program, revenues were $491 million in the quarter, still reflecting a 20% decline from the prior year on lower System sales.
Operating Income
Operating income was $124.0 million in the quarter, down 77.5% from $251.2 million in the year-ago quarter. With this, operating margin declined significantly by 2,890 basis points to 12.2% from 41.1% in the 2013-first quarter.
Adjusted operating income excluded a pre-tax charge of $67 million in the 2014-first quarter based on estimated costs of resolving a few product liability legal claims against the company.
The legal claims are related to alleged complications from surgeries performed with certain versions of Monopolar Curved Scissors (MCS) instruments that were associated with a recall in 2013 as well as with a first-generation MCS tip cover that was the subject of a market withdrawal in 2012.
Segment Results
Segment-wise revenues tally with the projected figures provided by Intuitive Surgical earlier this month.
Revenues from Instruments and Accessories slid 2.4% to $254.8 million in the quarter from $261.1 million in the prior-year quarter. The decrease is attributed to the fall in instruments and accessories stocking orders on the back of a decrease in system sales and the revenue deferral, partially offset by a 7% increase in procedure volumes, indicating growth in U.S. general surgery procedures and urologic procedures outside the U.S., despite a fall in U.S. gynecologic procedures.
Revenues from Systems plunged 58.6% to $106.0 million compared with $255.9 million in the first quarter of 2013. The drastic fall is attributable to lower system sales in the U.S. and the revenue deferral.
Intuitive Surgical shipped 87 da Vinci Surgical Systems in the 2014-first quarter, including 45 in the U.S. and 42 outside the U.S., nearly half compared with 164 shipped in the first quarter of 2013, including 115 in the U.S. and 49 outside the U.S. The significant 60.9% fall in system sales into the U.S. market was driven by the factors discussed above.
Revenues from Services rose 10.1% to $103.9 million compared with $94.4 million in the first quarter of 2013. The improvement is attributable to continued rise in installed base of da Vinci Surgical Systems.
Financial Position
Intuitive Surgical had cash, cash equivalents and investments of $2,963.6 million as of Mar 31, 2014, up 7.6% from $2,753.9 million as of Dec 31, 2013. Inventories scaled up 3.3% to $185.5 million as of Mar 31, 2014 from $179.6 million as of Dec 31, 2013.
Intuitive Surgical did not repurchase shares in the quarter. As of Mar 31, 2014, the company had 1 billion authorized shares for repurchase.
Our Take
Intuitive Surgical continues to be affected by stiff hospital capital spending environment. The company's robotic surgical systems came under fire in the past due to several incidents that raised doubts about the robotic surgical technology. Several reports have revealed that patients suffered complications or injuries owing to the robotic-assisted surgeries.
However, Intuitive Surgical is optimistic about its new da Vinci Xi Surgical System, which has been approved by the U.S. Food and Drug Administration (FDA). The company had revealed that the new and improved robotic system has longer instrument shafts enabling greater reach for surgery. The robotic arms of the system are also smaller and thinner and have a new joint design that improves their range of motion.
Currently, Intuitive Surgical retains a Zacks Rank #3 (Hold). Some better-ranked scrips in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Incorporated ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). Delcath Systems sports a Zacks Rank #1 (Strong Buy), while both Accuray and IDEXX Laboratories carries a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
IDEXX LABS INC (IDXX): Free Stock Analysis Report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked scrips in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Incorporated ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Excluding the impact of the trade-out program, revenues were $491 million in the quarter, still reflecting a 20% decline from the prior year on lower System sales.
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked scrips in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Incorporated ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). The adjusted figures excluded the impact of deferral of revenues related to a customer trade-out program for their recently purchased da Vinci Si Surgical Systems with the company's recently announced da Vinci Xi Surgical System as well as product liability litigation charges.
|
Some better-ranked scrips in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Incorporated ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. The adjusted figures excluded the impact of deferral of revenues related to a customer trade-out program for their recently purchased da Vinci Si Surgical Systems with the company's recently announced da Vinci Xi Surgical System as well as product liability litigation charges.
|
Some better-ranked scrips in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Accuray Incorporated ( ARAY ), and IDEXX Laboratories, Inc. ( IDXX ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report IDEXX LABS INC (IDXX): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Total Revenues As projected by the company, revenues in the quarter dipped 24.0% to $464.7 million, missing the Zacks Consensus Estimate of $512 million.
|
022a1d06-c9a8-47f3-9881-edd5c4949468
|
715642.0
|
2014-04-22 00:00:00 UTC
|
ABIOMED Up on License from Opsens - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/abiomed-up-on-license-from-opsens-analyst-blog-2014-04-22
|
nan
|
nan
|
Leading provider of heart support technologies, ABIOMED, Inc. ( ABMD ) announced its acquisition of an exclusive license from collaboration partner Opsens, to utilize the latter's breakthrough optical sensor technology in the field of cardio-circulatory assist devices. In a few trading sessions following the announcement, shares of ABIOMED climbed approximately 4.0% to close at $24.95 yesterday.
Per the licensing agreement, Opsens' miniature optical pressure sensors will be integrated into ABIOMED's flagship Impella heart pump catheters to provide robust blood pressure measurements that can help enhance Impella's performance and ease-of-use.
Opsens' optical sensors will allow for further improvements in set-up time, besides providing high-quality pressure monitoring capability that can eventually be used to help automate the control and operation of the Impella pump in the catheterization lab.
This licensing agreement - which secures ABIOMED's rights to the technology and gives the company the right to manufacture the sensors - is the continuation of an initial partnership entered between Opsens and ABIOMED in Jan 2010.
Last month, ABIOMED had announced successful completion of patient enrolment in the Recover Right clinical trial of its Impella RP in the U.S. The company plans to use the results from the trial to apply for a Humanitarian Device Exemption (HDE) approval, for which it has already received a Humanitarian Use Device (HUD) approval in Jul 2012.
More recently, ABIOMED secured CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union, following which, it anticipates the U.S. Food and Drug Administration (FDA) go-ahead for this novel product by Feb 2015.
ABIOMED is witnessing strong demand for its Impella line of products as an increasing number of patients are being treated with these devices. With the last reported quarter posting double-digit rise in Impella revenues, Impella utilization continues to grow at an impressive pace.
ABIOMED presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). While Syneron Medical and Delcath Systems both sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).
ABIOMED INC (ABMD): Free Stock Analysis Report
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Opsens' optical sensors will allow for further improvements in set-up time, besides providing high-quality pressure monitoring capability that can eventually be used to help automate the control and operation of the Impella pump in the catheterization lab.
|
Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. While Syneron Medical and Delcath Systems both sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).
|
ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Leading provider of heart support technologies, ABIOMED, Inc. ( ABMD ) announced its acquisition of an exclusive license from collaboration partner Opsens, to utilize the latter's breakthrough optical sensor technology in the field of cardio-circulatory assist devices.
|
ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Incorporated ( ARAY ). Per the licensing agreement, Opsens' miniature optical pressure sensors will be integrated into ABIOMED's flagship Impella heart pump catheters to provide robust blood pressure measurements that can help enhance Impella's performance and ease-of-use.
|
b1ff92a9-b177-475e-88a9-aa57e73dbc6a
|
715643.0
|
2014-04-22 00:00:00 UTC
|
Balanced Outlook on Accuray - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/balanced-outlook-on-accuray-analyst-blog-2014-04-22
|
nan
|
nan
|
On April 16, we have updated our research report on Accuray Incorporated ( ARAY ). Despite being a loss-making company, we expect the company's product revenues to improve further as medical centers continue to adopt the company's innovative radiosurgery and radiation therapy systems on a global basis.
Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter compared with a loss of $25.5 million, or 35 cents per share for the same quarter in the prior fiscal year as well as the Zacks Consensus Estimate of a loss of 20 cents per share. The narrower loss can be attributed to higher revenues and a substantial fall in operating expenses during the quarter.
Total revenues grew 20.4% to $93.6 million, surpassing the Zacks Consensus Estimate of $81.0 million significantly. Product revenues surged 36.1% to $45.1 million while Service revenues rose 8.7% to $45.5 million.
The improvement in Product revenues was attributable to impressive rise in product orders. Gross product orders almost doubled (102%) to $80.3 million in the quarter while net product orders (gross orders less cancellations and age-outs) soared 232% to $59.4 million in the second quarter.
At the end of the quarter, product backlog was $362 million, up roughly 30% from the backlog at the end of the fiscal 2013-second quarter. The increase in Service revenues was driven by the higher installed base and conversion of customers to emerald and diamond service contracts.
For fiscal 2014 ending June this year, Accuray upgraded its revenue guidance to a range of $340 to $350 million from the prior range of $325 to $345 million based on its performance in the first half of fiscal 2014 and optimism triggered by the continued momentum of converting orders to revenues. The current Zacks Consensus Estimate of $344 million lies within the guided range.
However, Accuray expects lower net orders in second half of fiscal 2014 compared with the net orders in the first half of the fiscal year. With this, Accuray expects to end the fiscal year with net product orders of $215 to $225 million, reflecting 25-31% growth over the prior fiscal year.
Currently, Accuray retains a Zacks Rank #2 (Buy). The company expects to release its fiscal 2014-third quarter results on April 29.
Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). Delcath Systems and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. The narrower loss can be attributed to higher revenues and a substantial fall in operating expenses during the quarter.
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter compared with a loss of $25.5 million, or 35 cents per share for the same quarter in the prior fiscal year as well as the Zacks Consensus Estimate of a loss of 20 cents per share.
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter compared with a loss of $25.5 million, or 35 cents per share for the same quarter in the prior fiscal year as well as the Zacks Consensus Estimate of a loss of 20 cents per share.
|
Other medical instrument stocks that are currently worth a look include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and DexCom, Inc. ( DXCM ). ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Accuray posted a narrower loss of $5.4 million, or 7 cents per share for the fiscal 2014-second quarter compared with a loss of $25.5 million, or 35 cents per share for the same quarter in the prior fiscal year as well as the Zacks Consensus Estimate of a loss of 20 cents per share.
|
ca684913-395f-4f6d-850f-09cc444ddebd
|
715644.0
|
2014-04-17 00:00:00 UTC
|
ABIOMED's Impella RP Bags CE Mark - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/abiomeds-impella-rp-bags-ce-mark-analyst-blog-2014-04-17
|
nan
|
nan
|
Leading provider of heart support technologies, ABIOMED, Inc. ( ABMD ) secured the CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union. Shares of ABIOMED climbed 2.8% following the announcement last week, to close at $24.48 till the last closing date.
ABIOMED's Impella RP is a percutaneous heart pump that can be planted into the heart via the femoral artery in the thigh without the need for a surgical procedure. It is designed to access the heart's right ventricle via the vena cava to provide temporary ventricular support for patients with right ventricular failure.
The device delivers over 4 liters of blood per minute from the lower right atrium to the pulmonary artery. As a result, the Impella RP enables surgeons to treat right ventricular dysfunction in a minimally invasive manner.
Impella RP is the latest in ABIOMED's line of Impella heart pumps. Impella 2.5, Impella 5.0, Impella CP and Impella LD have already secured the U.S. Food and Drug Administration (FDA) pre-market approval. The Impella RP, however, is not currently cleared for sale or use in the U.S.
Last month, ABIOMED had announced successful completion of patient enrolment in the Recover Right clinical trial of its Impella RP in the U.S. The company plans to use the results from the trial to apply for a Humanitarian Device Exemption (HDE) approval, for which it has already received a Humanitarian Use Device (HUD) approval in Jul 2012.
Following the commercial European availability of the new Impella RP device, ABIOMED anticipates the FDA go-ahead by Feb 2015. The company plans to introduce this novel product into its established hospital installed base.
ABIOMED is witnessing strong demand for its Impella line of products as an increasing number of patients are being treated with these devices. Impella utilization thus continues to grow at an impressive pace, with the last reported quarter posting double-digit rise in Impella revenues.
ABIOMED presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Inc. ( ARAY ). While Syneron Medical and Delcath Systems sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).
ABIOMED INC (ABMD): Free Stock Analysis Report
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Inc. ( ARAY ). ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. As a result, the Impella RP enables surgeons to treat right ventricular dysfunction in a minimally invasive manner.
|
Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Inc. ( ARAY ). ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. While Syneron Medical and Delcath Systems sport a Zacks Rank #1 (Strong Buy), Accuray retains a Zacks Rank #2 (Buy).
|
ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Inc. ( ARAY ). Impella 2.5, Impella 5.0, Impella CP and Impella LD have already secured the U.S. Food and Drug Administration (FDA) pre-market approval.
|
Some better-ranked stocks worth a look in the medical instruments industry are Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and Accuray Inc. ( ARAY ). ABIOMED INC (ABMD): Free Stock Analysis Report ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Leading provider of heart support technologies, ABIOMED, Inc. ( ABMD ) secured the CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union.
|
10c584dc-e291-4d9d-9b56-9ca0d846b4f8
|
715645.0
|
2014-04-16 00:00:00 UTC
|
Accuray Upped to Buy - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/accuray-upped-to-buy-analyst-blog-2014-04-16
|
nan
|
nan
|
On Apr 16, Zacks Investment Research upgraded Accuray Incorporated ( ARAY ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
Why the Upgrade?
The earnings estimates for this California-based developer of radiosurgery and radiation therapy systems have been revised upward following its improved fiscal 2014-second quarter results released on Jan 30.
Accuray reported adjusted loss per share of 7 cents for the quarter, narrower than the Zacks Consensus Estimate loss of 20 cents by 65.0% and the prior-year quarter's loss by 82.5%.
Year-over-year loss narrowed primarily due to robust top-line improvement of 20% from the year-ago period. Of the total revenue, Accuray's product revenues surged 36% in the reported quarter to $45.1 million, while service revenues totaled $48.5 million, representing an increase of 9%.
This happens to be the first quarter since the acquisition of TomoTherapy when the company has achieved year-over-year revenue growth. This revenue improvement is attributable to the company's strength in order backlog, along with internal improvements related to Accuray's revenue conversion management process.
In the second quarter, Accuray's total gross profit amounted to $38.2 million, increasing 43% year over year. Gross margin of 40.8% also reflected an improvement of 660 basis points (bps). Of the total gross margin, Accuray saw an enhanced product gross margin of 44.7%, resulting from higher volume and stronger average selling prices.
The company's service revenue margin also increased by 1020 bps in the reported quarter, on account of improvement in TomoTherapy Systems reliability, which drove lower parts consumption and sales of higher margin service contracts.
Based on its encouraging performance, Accuray raised its total revenue expectation for fiscal 2014 to $340-$350 million from the previous range of $325-$345 million. The Zacks Consensus Estimate of $344 million for the fiscal year lies within the current expected revenue range of the company.
The Zacks Consensus Estimate for fiscal 2014 was revised upward by 24% to a loss of 54 cents over the last three months. However, the Zacks Consensus Estimate for fiscal 2015 was revised downward by 43% to a loss of 10 cents over the same time frame.
Other Stocks to Consider
In the medical instruments space, Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and Hologic Inc. ( HOLX ) are performing well. While Delcath and Syneron sport a Zacks Rank #1 (Strong Buy), Hologic retains a Zacks Rank #2 (Buy).
ACCURAY INC (ARAY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other Stocks to Consider In the medical instruments space, Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and Hologic Inc. ( HOLX ) are performing well. ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. The earnings estimates for this California-based developer of radiosurgery and radiation therapy systems have been revised upward following its improved fiscal 2014-second quarter results released on Jan 30.
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider In the medical instruments space, Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and Hologic Inc. ( HOLX ) are performing well. On Apr 16, Zacks Investment Research upgraded Accuray Incorporated ( ARAY ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
|
ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider In the medical instruments space, Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and Hologic Inc. ( HOLX ) are performing well. Accuray reported adjusted loss per share of 7 cents for the quarter, narrower than the Zacks Consensus Estimate loss of 20 cents by 65.0% and the prior-year quarter's loss by 82.5%.
|
Other Stocks to Consider In the medical instruments space, Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ) and Hologic Inc. ( HOLX ) are performing well. ACCURAY INC (ARAY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. On Apr 16, Zacks Investment Research upgraded Accuray Incorporated ( ARAY ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
|
ada534af-0d03-4c54-b25e-3fcb521be074
|
715646.0
|
2014-04-14 00:00:00 UTC
|
Balanced View of Luminex Corporation - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/balanced-view-of-luminex-corporation-analyst-blog-2014-04-14
|
nan
|
nan
|
On April 11, we have updated our research report on Luminex Corporation ( LMNX ). Luminex disappointed investors by posting an 11.8% fall in adjusted net earnings to 15 cents per share and a 1.0% fall in revenues to $55.2 million. Nevertheless, the company beat the Zacks Consensus Estimate on earnings front by 8 cents per share but missed the Zacks Consensus Estimate revenues by $0.8 million.
The decline in Luminex earnings can be attributable to lower revenues and higher costs during the quarter. Poor assay revenues led to lower revenues during the quarter.
For full year 2013, adjusted net earnings fell about 11.0% to $16.9 million or 40 cents from $19.0 million or 45 cents in the prior year. However, revenues in the year grew 5.4% to $213.4 million, which is in line with the company's own guidance. Despite higher revenues, earnings in the year declined due to a considerable (15.9%) rise in operating expenses during the year.
For 2014, Luminex expects revenues in the range of $225 to $240 million, reflecting an increase of 5 to 12% over 2013. The Zacks Consensus Estimate of $231 million lies within the guided range.
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers. In the assay business line, the company expects growth in GPP, CF and PGx product lines apart from continuing positive momentum in its LDT strategy. Luminex believes that the presence of a direct molecular diagnostic sales force will provide significant momentum in 2014.
We appreciate Luminex's broad product portfolio. The company is renowned for its advanced xMAP and xTAG and MultiCode technology. Besides, the company possesses a healthy pipeline and develops several new assays
However, Luminex operates in the highly competitive life sciences industry. The industry is characterized by rapid and continuous technological innovation. Currently, it is facing significant competitive headwinds in the respiratory market.
Currently, Luminex retains a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ), and Teleflex Inc. ( TFX ). Delcath Systems and Syneron Medical carry a Zacks Rank #1 (Strong Buy) while Teleflex holds a Zacks Rank #2 (Buy).
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
LUMINEX CORP (LMNX): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ), and Teleflex Inc. ( TFX ). DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ), and Teleflex Inc. ( TFX ). DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Delcath Systems and Syneron Medical carry a Zacks Rank #1 (Strong Buy) while Teleflex holds a Zacks Rank #2 (Buy).
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ), and Teleflex Inc. ( TFX ). Luminex disappointed investors by posting an 11.8% fall in adjusted net earnings to 15 cents per share and a 1.0% fall in revenues to $55.2 million.
|
Some better-ranked stocks in the medical instruments industry include Delcath Systems, Inc. ( DCTH ), Syneron Medical Ltd. ( ELOS ), and Teleflex Inc. ( TFX ). DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report LUMINEX CORP (LMNX): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the company beat the Zacks Consensus Estimate on earnings front by 8 cents per share but missed the Zacks Consensus Estimate revenues by $0.8 million.
|
ada6d51f-5dd2-4d74-b082-abc9cfc31f55
|
715647.0
|
2014-04-14 00:00:00 UTC
|
Varian Medical Systems Settles Patent Dispute - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/varian-medical-systems-settles-patent-dispute-analyst-blog-2014-04-14
|
nan
|
nan
|
Medical device company Varian Medical Systems, Inc. ( VAR ) reported that it has settled a patent infringement lawsuit with the University of Pittsburg by agreeing to pay a lump sum of approximately $35 million. Shares of VAR dropped approximately 1.3% in the last trading session to close at $80.06 on April 11.
In 2007, the University of Pittsburgh had initiated the patent litigation against VAR alleging the company of infringement on two patents pertaining to the university's image-guided radiology technology. One patent deals with equipment that responds to patient movement during diagnosis and treatment, while the other allows the matching of X-ray images with previous images.
In April 2012, a U.S. district court in Pennsylvania ruled against VAR and initially awarded $37 million in damages to the university. It later increased the amount to more than $100 million on discovery of the infringement being willful, among other factors. The court also awarded $9.2 million in legal fees.
Subsequently, VAR challenged the ruling in the United States Court of Appeals for the Federal Circuit. In its ruling issued last week, the Federal Appeals Court disagreed with the lower court's decision on the multimillion-dollar damages, thus giving VAR a partial victory in its patent lawsuit against the University of Pittsburgh.
Earlier in the ongoing second quarter of fiscal 2014, VAR and the University of Pittsburgh had reached a settlement agreement that was contingent upon last week's ruling from the Appeals Court. Under the pre-negotiated settlement agreement, henceforth, VAR will not owe any future royalty payments associated with the sale of its products that incorporate the patent at issue. Customers of VAR will continue to have full use of the products.
VAR is currently reviewing the accounting treatment of this settlement. Per the company, part of the settlement will be expensed in the financial results of the second quarter while the balance will be recorded as a prepaid royalty in the third quarter of fiscal 2014.
Currently, VAR has a Zacks Rank #2 (Buy). Other stocks performing well in the medical instruments industry include Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and ArthroCare Corporation ( ARTC ). While Syneron Medical and Delcath Systems sport a Zacks Rank #1 (Strong Buy), ArthroCare carries a Zacks Rank #2 (Buy).
ARTHROCARE CORP (ARTC): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other stocks performing well in the medical instruments industry include Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and ArthroCare Corporation ( ARTC ). ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. In April 2012, a U.S. district court in Pennsylvania ruled against VAR and initially awarded $37 million in damages to the university.
|
ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Other stocks performing well in the medical instruments industry include Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and ArthroCare Corporation ( ARTC ). Medical device company Varian Medical Systems, Inc. ( VAR ) reported that it has settled a patent infringement lawsuit with the University of Pittsburg by agreeing to pay a lump sum of approximately $35 million.
|
ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Other stocks performing well in the medical instruments industry include Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and ArthroCare Corporation ( ARTC ). Medical device company Varian Medical Systems, Inc. ( VAR ) reported that it has settled a patent infringement lawsuit with the University of Pittsburg by agreeing to pay a lump sum of approximately $35 million.
|
Other stocks performing well in the medical instruments industry include Syneron Medical Ltd. ( ELOS ), Delcath Systems, Inc. ( DCTH ) and ArthroCare Corporation ( ARTC ). ARTHROCARE CORP (ARTC): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. In April 2012, a U.S. district court in Pennsylvania ruled against VAR and initially awarded $37 million in damages to the university.
|
a424b870-703a-4d4b-93ef-603da6502f24
|
715648.0
|
2014-04-10 00:00:00 UTC
|
Cepheid (CPHD) Looks Good: Stock Adds 5.3% in Session - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/cepheid-cphd-looks-good%3A-stock-adds-5.3-in-session-tale-of-the-tape-2014-04-10
|
nan
|
nan
|
Cepheid ( CPHD ) was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down nearly 6% since Apr 1, 2014.
The company has seen no estimate revision over the past 30 days, while the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Cepheid currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked medical stocks include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
CEPHEID INC (CPHD): Free Stock Analysis Report
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked medical stocks include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CEPHEID INC (CPHD): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Cepheid ( CPHD ) was a big mover last session, as the company saw its shares rise over 5% on the day.
|
Some better-ranked medical stocks include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CEPHEID INC (CPHD): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CEPHEID INC (CPHD): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked medical stocks include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked medical stocks include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CEPHEID INC (CPHD): Free Stock Analysis Report CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Cepheid ( CPHD ) was a big mover last session, as the company saw its shares rise over 5% on the day.
|
3ca19899-5ad0-497a-986c-37530eda57c2
|
715649.0
|
2014-04-10 00:00:00 UTC
|
Delcath (DCTH) Enters Oversold Territory - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/delcath-dcth-enters-oversold-territory-tale-of-the-tape-2014-04-10
|
nan
|
nan
|
Delcath Systems, Inc. 's ( DCTH ) share price has entered into oversold territory with an RSI value of 29.9. The Zacks Consensus Estimate for Delcath for the full year period has improved 4 cents over the past two months to -14 cents per share. Currently, Delcath has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( DCTH ) after its recent drop.
DELCATH SYS INC (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems, Inc. 's ( DCTH ) share price has entered into oversold territory with an RSI value of 29.9. Currently, Delcath has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( DCTH ) after its recent drop. DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Delcath Systems, Inc. 's ( DCTH ) share price has entered into oversold territory with an RSI value of 29.9. Currently, Delcath has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( DCTH ) after its recent drop. DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Delcath Systems, Inc. 's ( DCTH ) share price has entered into oversold territory with an RSI value of 29.9. Currently, Delcath has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( DCTH ) after its recent drop. DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Delcath Systems, Inc. 's ( DCTH ) share price has entered into oversold territory with an RSI value of 29.9. Currently, Delcath has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( DCTH ) after its recent drop. DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here.
|
6e08d371-27e2-4189-b40b-dd7a5e088a7b
|
715650.0
|
2014-04-10 00:00:00 UTC
|
Masimo Reports Encouraging PVI Study Results - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/masimo-reports-encouraging-pvi-study-results-analyst-blog-2014-04-10
|
nan
|
nan
|
Masimo Corporation ( MASI ) recently announced the results of a study which demonstrated that the company's non-invasive Pleth Variability Index (PVI) parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia (GEN-EPI).
The results of the study were published in the Journal of Monitoring and Computing as well. Following the announcement, shares of MASI rose 0.9% in the subsequent trading sessions to close at $26.92 yesterday.
GEN-EPI reduces the risk of respiratory complications and duration of stay in hospitals but requires proper fluid management. Multiple dynamic parameters are available to help clinicians predict fluid responsiveness and improve fluid management. However, most of these parameters require invasive and/or complex methods.
In contrast, MASI's PVI parameter is non-invasive and can be obtained with any Masimo SET or rainbow sensor. PVI helps clinicians to continuously assess the fluid status of patients in order to examine whether patients will benefit from fluid administration, thus enabling personalized and goal-directed fluid therapy.
The study was conducted at Shanghai First People's Hospital in Shanghai, China, to assess the impact of PVI as a goal-directed fluid parameter. It enrolled 30 patients who underwent elective abdominal surgery under GEN-EPI.
Investigators used a Masimo Radical-7 rainbow SET Pulse CO-Oximeter, which automatically calculated and displayed PVI. The total average amount of fluid infused in PVI-guided fluid therapy group was significantly lower than the amount of fluid in the control group.
Recent research has shown that higher blood lactate levels in the perioperative period are related with postoperative complications and the average hospitalization time. The study concluded that PVI-based goal-directed fluid management in major abdominal surgery patients under GEN-EPI helps in optimizing fluid management by reducing unnecessary fluid administration and blood lactate levels during surgery. It enables clinicians to understand the fluid level of their patients, thus improving patient outcomes.
MASI reported a 19.2% rise in earnings to 31 cents per share for the fourth quarter of 2013 which were in line with the Zacks Consensus Estimate. Revenues in the quarter (including royalties) increased 7.8% to $142.4 million, missing the Zacks Consensus Estimate of $145.0 million.
Currently, MASI carries a Zacks Rank #3 (Hold). Better-ranked stocks worth a look in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). All the three stocks sport a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks worth a look in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Masimo Corporation ( MASI ) recently announced the results of a study which demonstrated that the company's non-invasive Pleth Variability Index (PVI) parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia (GEN-EPI).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks worth a look in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). Masimo Corporation ( MASI ) recently announced the results of a study which demonstrated that the company's non-invasive Pleth Variability Index (PVI) parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia (GEN-EPI).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks worth a look in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). PVI helps clinicians to continuously assess the fluid status of patients in order to examine whether patients will benefit from fluid administration, thus enabling personalized and goal-directed fluid therapy.
|
Better-ranked stocks worth a look in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Masimo Corporation ( MASI ) recently announced the results of a study which demonstrated that the company's non-invasive Pleth Variability Index (PVI) parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia (GEN-EPI).
|
6d91a0df-bd39-44ea-8d88-9f25402f5c07
|
715651.0
|
2014-04-10 00:00:00 UTC
|
Delcath Systems Shares Tank on Stock Split - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/delcath-systems-shares-tank-on-stock-split-analyst-blog-2014-04-10
|
nan
|
nan
|
Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. According to an SEC filing, the stock split trimmed Delcath shares to roughly 9.4 million from 150.9 million.
Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device. FDA determined that the risks associated with the company's Melblez device are higher than the benefits for patients with unresectable ocular melanoma metastatic to the liver.
In Oct last year, Delcath's shares turned red after the announcement of raising about $7.5 million through sales of common stock. The New York-based medical device maker also announced several layoffs as part of its restructuring plan.
However, Delcath's financial results for the 2013-fourth quarter showed improvement. The company posted a narrower loss of 4 cents per share for the quarter compared with 14 cents in the fourth quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 5 cents per share. Revenues in the quarter surged 69% to $338 million.
Operating expenses dipped 52% to $5.8 million from $12.0 million for the fourth quarter of 2012. The decline is primarily attributable to a significant reduction in expenses related to the company's NDA submission to the FDA, as well as the cost reduction measures.
Operating loss was narrower at $5.5 million (including non-cash stock-based compensation income of $0.3 million) compared with $11.8 million (including $0.9 million in non-cash stock-based compensation expense) for the fourth quarter of 2012.
Currently, Delcath retains a Zacks Rank #1 (Strong Buy). Other players in the medical instruments industry that are also worth a look include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ), and DexCom, Inc. ( DXCM ). Cynosure and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. Operating loss was narrower at $5.5 million (including non-cash stock-based compensation income of $0.3 million) compared with $11.8 million (including $0.9 million in non-cash stock-based compensation expense) for the fourth quarter of 2012.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. The company posted a narrower loss of 4 cents per share for the quarter compared with 14 cents in the fourth quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 5 cents per share.
|
Shares of Delcath Systems, Inc. ( DCTH ) tanked nearly 20% to $3.73 following its 1-to-16 reverse stock split, which came into effect yesterday. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. According to an SEC filing, the stock split trimmed Delcath shares to roughly 9.4 million from 150.9 million.
|
a77bffe7-0126-49d2-997f-5478de3a4dbd
|
715652.0
|
2014-04-09 00:00:00 UTC
|
Varian Medical Systems Closes Velocity Software Acquisition - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/varian-medical-systems-closes-velocity-software-acquisition-analyst-blog-2014-04-09
|
nan
|
nan
|
California-based medical instruments maker Varian Medical Systems, Inc. ( VAR ) recently completed its acquisition of certain assets of Velocity Medical Solutions, LLC, which was announced last month. However, since the announcement of completion of the acquisition, shares of VAR dropped 1.0% to close at $83.94 yesterday.
Velocity Medical is a privately-held Atlanta-based developer of specialized software for cancer clinics. The acquisition involves the purchase of Velocity's software that enables clinicians to aggregate unstructured treatment and imaging data from diverse systems, which can be used to make more informed treatment decisions. VAR expects this buyout to boost its offering of data-driven clinical decision-making support services for clinicians.
The two companies remain tight-lipped regarding the financial terms of the deal. Nevertheless, VAR announced that it plans to continue the development of this oncology software platform with the Velocity team in Atlanta, GA.
The Velocity software has already been used at over 200 cancer treatment centers globally. Post-acquisition, VAR expects its global sales, service and support network to contribute to faster and deeper market penetration for the Velocity product.
In January this year, VAR also inked a 3-year, $515 million deal with Toshiba Medical Systems to supply its medical imaging components for integration into Toshiba's imaging systems in order to jointly develop new product technologies for the imaging market.
Recent Earnings
For the first quarter of fiscal 2014, VAR reported a 5.8% rise in net earnings per share to 91 cents from 86 cents in the prior-year fiscal quarter, which also inched past the Zacks Consensus Estimate by a penny. With this, VAR also met its own guidance of a 6-7% rise in earnings per share to 87-91 cents for the said quarter.
Revenues in the quarter grew nearly 5.0% to $711.5 million, but lagged the Zacks Consensus Estimate of $718 million.
Growth in revenues was attributable to the continued strong demand for Oncology services as evidenced by a 2.7% rise in net orders for Oncology Systems to $489.6 million during the quarter.
Revenues from X-Ray Products segment went up 9.1% to $145.0 million in the quarter, driven by market traction for VAR's X-Ray Imaging components, also contributing to overall revenue growth.
For fiscal 2014, VAR expects revenues to grow by 6-8% compared with the earlier guidance of 6-7%. However, the company reiterated its earnings per share guidance between $4.22 and $4.34 for the year. The current Zacks Consensus Estimate of $4.29 lies within the guided range.
Zacks Rank
Currently, VAR has a Zacks Rank #2 (Buy). Other stocks performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). All three stocks sport a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other stocks performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. VAR expects this buyout to boost its offering of data-driven clinical decision-making support services for clinicians.
|
Other stocks performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. In January this year, VAR also inked a 3-year, $515 million deal with Toshiba Medical Systems to supply its medical imaging components for integration into Toshiba's imaging systems in order to jointly develop new product technologies for the imaging market.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Other stocks performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). In January this year, VAR also inked a 3-year, $515 million deal with Toshiba Medical Systems to supply its medical imaging components for integration into Toshiba's imaging systems in order to jointly develop new product technologies for the imaging market.
|
Other stocks performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Velocity Medical is a privately-held Atlanta-based developer of specialized software for cancer clinics.
|
a8f2b62e-2576-4d2d-bbf4-01e2cd76e4f6
|
715653.0
|
2014-04-07 00:00:00 UTC
|
Zacks Rank #1 Additions for Monday - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/zacks-rank-1-additions-for-monday-tale-of-the-tape-2014-04-07
|
nan
|
nan
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Companhia Brasileira de Distrib. ( CBD )
Delcath Systems, Inc. ( DCTH )
E TRADE Financial Corporation ( ETFC )
Famous Dave's of America, Inc. ( DAVE )
Farmers Capital Bank Corp ( FFKT )
View the entire Zacks Rank #1 List .
COMPANHIA BRASL (CBD): Free Stock Analysis Report
FAMOUS DAVES (DAVE): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
E TRADE FINL CP (ETFC): Free Stock Analysis Report
FARMERS CAP KY (FFKT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
( CBD ) Delcath Systems, Inc. ( DCTH ) E TRADE Financial Corporation ( ETFC ) Famous Dave's of America, Inc. ( DAVE ) Farmers Capital Bank Corp ( FFKT ) View the entire Zacks Rank #1 List . COMPANHIA BRASL (CBD): Free Stock Analysis Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report E TRADE FINL CP (ETFC): Free Stock Analysis Report FARMERS CAP KY (FFKT): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Companhia Brasileira de Distrib.
|
( CBD ) Delcath Systems, Inc. ( DCTH ) E TRADE Financial Corporation ( ETFC ) Famous Dave's of America, Inc. ( DAVE ) Farmers Capital Bank Corp ( FFKT ) View the entire Zacks Rank #1 List . COMPANHIA BRASL (CBD): Free Stock Analysis Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report E TRADE FINL CP (ETFC): Free Stock Analysis Report FARMERS CAP KY (FFKT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
COMPANHIA BRASL (CBD): Free Stock Analysis Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report E TRADE FINL CP (ETFC): Free Stock Analysis Report FARMERS CAP KY (FFKT): Free Stock Analysis Report To read this article on Zacks.com click here. ( CBD ) Delcath Systems, Inc. ( DCTH ) E TRADE Financial Corporation ( ETFC ) Famous Dave's of America, Inc. ( DAVE ) Farmers Capital Bank Corp ( FFKT ) View the entire Zacks Rank #1 List . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
( CBD ) Delcath Systems, Inc. ( DCTH ) E TRADE Financial Corporation ( ETFC ) Famous Dave's of America, Inc. ( DAVE ) Farmers Capital Bank Corp ( FFKT ) View the entire Zacks Rank #1 List . COMPANHIA BRASL (CBD): Free Stock Analysis Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report E TRADE FINL CP (ETFC): Free Stock Analysis Report FARMERS CAP KY (FFKT): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Companhia Brasileira de Distrib.
|
741b9b82-a239-46ef-af8c-2fbe4a948491
|
715654.0
|
2014-04-07 00:00:00 UTC
|
Echo Therapeutics Slips to Sell - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/echo-therapeutics-slips-to-sell-analyst-blog-2014-04-07
|
nan
|
nan
|
On Apr 3, Zacks Investment Research downgraded Echo Therapeutics, Inc. ( ECTE ) to a Zacks Rank #4 (Sell).
Why the Downgrade?
This Philadelphia-based developer of transdermal skin permeation and diagnostic medical devices reported its fourth-quarter and full-year 2013 results on Mar 27. The fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents. However, adjusted loss per share of 35 cents was narrower than the Zacks Consensus Estimate of a loss of 36 cents.
Echo Therapeutics' selling, general and administrative (SG&A) expenses scaled up 31.3% to $8.4 million during 2013. Factors like increased personnel costs, legal costs and expenses related to prelaunch marketing and manufacturing activities contributed to this hike in SG&A expenses.
In addition, the company's research and development (R&D) expenses for 2013 also increased 29.9% year over year to $11.3 million. This rise was primarily driven by increased engineering and design expenses incurred on account of outside contracts and personnel relating to the Symphony development. As a result of higher R&D and SG&A expenses, Echo Therapeutics saw a 31% year-over-year increase in operating loss to $19.6 million in 2013.
Given broad market fluctuations that have already adversely affected the market price of Echo Therapeutics' common stock, management has announced that the company's stock price is volatile at present and has every possibility to fluctuate in the near future.
The Zacks Consensus Estimate of a loss for 2014 has rose 7.7% to 98 cents per share over the last 30 days. However, for 2015, the Zacks Consensus Estimate of a loss remained flat at $1.07 over the same period.
Other Stocks to Conside r
Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). All these stocks carry a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other Stocks to Conside r Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. This Philadelphia-based developer of transdermal skin permeation and diagnostic medical devices reported its fourth-quarter and full-year 2013 results on Mar 27.
|
Other Stocks to Conside r Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. On Apr 3, Zacks Investment Research downgraded Echo Therapeutics, Inc. ( ECTE ) to a Zacks Rank #4 (Sell).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Conside r Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). On Apr 3, Zacks Investment Research downgraded Echo Therapeutics, Inc. ( ECTE ) to a Zacks Rank #4 (Sell).
|
Other Stocks to Conside r Investors interested in the Medical Instruments space may consider better-ranked stocks like Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. On Apr 3, Zacks Investment Research downgraded Echo Therapeutics, Inc. ( ECTE ) to a Zacks Rank #4 (Sell).
|
2f8e60a3-0f32-418b-81c9-c93ed1c10007
|
715655.0
|
2014-04-03 00:00:00 UTC
|
Zacks Rank #1 Additions for Thursday - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2014-04-03
|
nan
|
nan
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Caesars Acquisition Company ( CACQ )
Delcath Systems, Inc. ( DCTH )
Famous Dave's of America, Inc. ( DAVE )
Glu Mobile Inc. ( GLUU )
Joe's Jeans Inc ( JOEZ )
View the entire Zacks Rank #1 List .
CEASERS ACQ-A (CACQ): Get Free Report
FAMOUS DAVES (DAVE): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
GLU MOBILE INC (GLUU): Free Stock Analysis Report
JOES JEANS INC (JOEZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Caesars Acquisition Company ( CACQ ) Delcath Systems, Inc. ( DCTH ) Famous Dave's of America, Inc. ( DAVE ) Glu Mobile Inc. ( GLUU ) Joe's Jeans Inc ( JOEZ ) View the entire Zacks Rank #1 List . CEASERS ACQ-A (CACQ): Get Free Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GLU MOBILE INC (GLUU): Free Stock Analysis Report JOES JEANS INC (JOEZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Caesars Acquisition Company ( CACQ ) Delcath Systems, Inc. ( DCTH ) Famous Dave's of America, Inc. ( DAVE ) Glu Mobile Inc. ( GLUU ) Joe's Jeans Inc ( JOEZ ) View the entire Zacks Rank #1 List . CEASERS ACQ-A (CACQ): Get Free Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GLU MOBILE INC (GLUU): Free Stock Analysis Report JOES JEANS INC (JOEZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Caesars Acquisition Company ( CACQ ) Delcath Systems, Inc. ( DCTH ) Famous Dave's of America, Inc. ( DAVE ) Glu Mobile Inc. ( GLUU ) Joe's Jeans Inc ( JOEZ ) View the entire Zacks Rank #1 List . CEASERS ACQ-A (CACQ): Get Free Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GLU MOBILE INC (GLUU): Free Stock Analysis Report JOES JEANS INC (JOEZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Caesars Acquisition Company ( CACQ ) Delcath Systems, Inc. ( DCTH ) Famous Dave's of America, Inc. ( DAVE ) Glu Mobile Inc. ( GLUU ) Joe's Jeans Inc ( JOEZ ) View the entire Zacks Rank #1 List . CEASERS ACQ-A (CACQ): Get Free Report FAMOUS DAVES (DAVE): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GLU MOBILE INC (GLUU): Free Stock Analysis Report JOES JEANS INC (JOEZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
6d1497b0-c558-40db-9b66-964e1c56f68b
|
715656.0
|
2014-04-03 00:00:00 UTC
|
DexCom Shares Fall on FDA Warning - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/dexcom-shares-fall-on-fda-warning-analyst-blog-2014-04-03
|
nan
|
nan
|
Shares of San-Diego, CA-based DexCom, Inc. ( DXCM ) tumbled after it revealed the warning letter issued by the U.S. Food and Drug Administration (FDA) regarding administrative deficiencies in its Medical Device Reports (MDR). Although the FDA had sent the warning letter on Mar 14, the company disclosed it only early last week.
Since the revelation of the warning letter, DexCom's shares dropped 5.7% to close at $41.95 yesterday.
FDA's Charges
The federal watchdog agency conducted an inspection of DexCom's San-Diego facility in Nov 2013 after which it determined that the company was not in compliance with the MDR regulations that were recently updated in Jul 2013.
The FDA warning letter held that the glucose monitoring company failed to report at least 4 incidences of low blood sugar (i.e. hypoglycemia) requiring medical treatment that were not correctly detected by the firm's blood glucose monitoring device.
The company also failed to report one instance which reasonably suggests that DexCom's blood glucose monitor malfunctioned and shocked a patient.
The referenced medical interventions to treat hypoglycemia are considered medical interventions necessary to prevent permanent impairment of a body function or permanent damage to a body structure. According to the letter, DexCom failed to submit an MDR for each referenced event. However, the FDA did not impose any sanctions in the warning letter.
DexCom's Claims
Dexcom disclosed the FDA warning letter, saying only that the letter flagged "deficiencies in filing MDRs involving the company's continuous glucose monitoring system."
Before the end of Apr 2014, Dexcom expects to submit all materials necessary to maintain compliance with the FDA's reporting obligations, in an effort to resolve any remaining deficiencies and have the warning letter repealed in due course.
According to Dexcom, the warning is not likely to affect its current operations or its ability to manufacture and sell its G4 Platinum systems and sensors. Neither is it expected to impact any of its pending or future bids for approval from the FDA.
Our Stance
Though the last two weeks have been witness to a downtrend in DexCom's share price, we believe it is well-positioned for future earnings growth.
DexCom reported strong top and bottom-line results for the fourth quarter of 2013, topping the Zacks Consensus Estimates on both fronts. Following the earnings release on Feb 20, shares of this medical device company depicted an uptrend.
Moreover, over the past two months, the company has seen 9 positive estimate revisions for the current year causing the Zacks Consensus Estimate to improve 30.8% to its current level of a loss of 9 cents per share from a loss of 13 cents for 2014. Furthermore, long-term growth for the stock is currently pegged at an impressive 32.5% compared to the industry average of 17.3%.
DexCom currently retains a Zacks Rank #2 (Buy). Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). All the three stocks sport a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. FDA's Charges The federal watchdog agency conducted an inspection of DexCom's San-Diego facility in Nov 2013 after which it determined that the company was not in compliance with the MDR regulations that were recently updated in Jul 2013.
|
Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of San-Diego, CA-based DexCom, Inc. ( DXCM ) tumbled after it revealed the warning letter issued by the U.S. Food and Drug Administration (FDA) regarding administrative deficiencies in its Medical Device Reports (MDR).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Shares of San-Diego, CA-based DexCom, Inc. ( DXCM ) tumbled after it revealed the warning letter issued by the U.S. Food and Drug Administration (FDA) regarding administrative deficiencies in its Medical Device Reports (MDR).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report To read this article on Zacks.com click here. Other players in the medical instruments industry that are also performing well include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). DexCom's Claims Dexcom disclosed the FDA warning letter, saying only that the letter flagged "deficiencies in filing MDRs involving the company's continuous glucose monitoring system."
|
4298dd8c-81ff-4ccb-bb74-6e94bc302141
|
715657.0
|
2014-03-26 00:00:00 UTC
|
Volcano Corporation (VOLC) Crumbles: Stock Falls by 5.7% - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/volcano-corporation-volc-crumbles%3A-stock-falls-by-5.7-tale-of-the-tape-2014-03-26
|
nan
|
nan
|
Volcano Corporation ( VOLC ) saw a big move last session, as the company's shares fell by nearly 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $21.20 to $22.88 in the past one-month time frame.
This slump shouldn't be too much of a surprise to investors, as the company has seen 9 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
VOLC currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the healthcare sector include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). All these stocks carry a Zacks Rank #1 (Strong Buy) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the healthcare sector include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $21.20 to $22.88 in the past one-month time frame.
|
Some better-ranked stocks in the healthcare sector include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). This slump shouldn't be too much of a surprise to investors, as the company has seen 9 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days.
|
Some better-ranked stocks in the healthcare sector include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Syneron Medical Ltd. ( ELOS ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report To read this article on Zacks.com click here. Volcano Corporation ( VOLC ) saw a big move last session, as the company's shares fell by nearly 6% on the day.
|
0df436f9-14b9-4b11-9fb1-a68a37100264
|
715658.0
|
2014-03-26 00:00:00 UTC
|
Teleflex Raised to Buy - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/teleflex-raised-to-buy-analyst-blog-2014-03-26
|
nan
|
nan
|
On Mar 25, Zacks Investment Research upgraded Teleflex Incorporated ( TFX ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
Why the Upgrade?
Teleflex has been witnessing rising estimate revisions over the past 60 days with two upward estimate revisions and no downward revision for 2014. The upward estimate revisions led to a 0.5% rise in Zacks Consensus Estimate to $5.52 per share for the year over the same time frame. Moreover, the company delivered positive earnings surprises in all of the last four quarters with an average beat of 8.6%.
This leading global provider of medical devices for critical care and surgery reported impressive fourth-quarter 2013 results and a promising 2014 guidance on Feb 21, 2014, subsequent to which its shares adopted an upward trend. Shares of Teleflex also hit a new 52-week high of $106.22 in mid-day trading on Mar 21.
Teleflex recently announced receiving the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its restated Indications for Use of the EZ-IO Vascular Access System. The Vascular Access System has been developed by Vidacare Corporation, acquired by Teleflex in December last year.
For the fourth quarter of 2013, Teleflex posted adjusted earnings of $1.36 per share (up 18.6% year over year) which comfortably beat the Zacks Consensus Estimate of $1.27. Net revenue grew 7.5% to $450.5 million, exceeding the Zacks Consensus Estimate of $436 million.
Teleflex is using mergers & acquisitions (M&A) to build out a diverse critical care business. The acquisitions of LMA International in Oct 2012 and Vidacare Corporation in Dec 2013 made significant contributions to revenue growth in the fourth quarter.
Furthermore, Teleflex reported a 50 basis points improvement in its fourth quarter operating margin of 7.8% due to management's focus on operating cost improvement.
For 2014, Teleflex provided revenue growth estimate in the range of 6-8% and adjusted earnings per share guidance in the range of $5.35-$5.55. The current Zacks Consensus Estimate of $5.49 lies within the guided range.
An encouraging guidance, increased M&A activity and stronger operating leverage represent a potential upside for Teleflex going forward.
Other Stocks to Consider
Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). All the three stocks carry a Zacks Rank #1 (Strong Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other Stocks to Consider Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. This leading global provider of medical devices for critical care and surgery reported impressive fourth-quarter 2013 results and a promising 2014 guidance on Feb 21, 2014, subsequent to which its shares adopted an upward trend.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). On Mar 25, Zacks Investment Research upgraded Teleflex Incorporated ( TFX ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). On Mar 25, Zacks Investment Research upgraded Teleflex Incorporated ( TFX ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
|
Other Stocks to Consider Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. ( CYNO ), Syneron Medical Ltd. ( ELOS ) and Delcath Systems, Inc. ( DCTH ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report SYNERON MED LTD (ELOS): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 25, Zacks Investment Research upgraded Teleflex Incorporated ( TFX ) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).
|
7474b1c0-a39d-47aa-8a99-bec0210dc89f
|
715659.0
|
2014-03-25 00:00:00 UTC
|
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/zacks-rank-1-additions-for-tuesday-tale-of-the-tape-2014-03-25
|
nan
|
nan
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Alaska Air Group, Inc. ( ALK )
Amgen, Inc. ( AMGN )
AudioCodes Ltd. ( AUDC )
Cypress Semiconductor Corporation ( CY )
Delcath Systems, Inc. ( DCTH )
View the entire Zacks Rank #1 List .
ALASKA AIR GRP (ALK): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
AUDIOCODES LTD (AUDC): Free Stock Analysis Report
CYPRESS SEMICON (CY): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Alaska Air Group, Inc. ( ALK ) Amgen, Inc. ( AMGN ) AudioCodes Ltd. ( AUDC ) Cypress Semiconductor Corporation ( CY ) Delcath Systems, Inc. ( DCTH ) View the entire Zacks Rank #1 List . ALASKA AIR GRP (ALK): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUDIOCODES LTD (AUDC): Free Stock Analysis Report CYPRESS SEMICON (CY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Alaska Air Group, Inc. ( ALK ) Amgen, Inc. ( AMGN ) AudioCodes Ltd. ( AUDC ) Cypress Semiconductor Corporation ( CY ) Delcath Systems, Inc. ( DCTH ) View the entire Zacks Rank #1 List . ALASKA AIR GRP (ALK): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUDIOCODES LTD (AUDC): Free Stock Analysis Report CYPRESS SEMICON (CY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ALASKA AIR GRP (ALK): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUDIOCODES LTD (AUDC): Free Stock Analysis Report CYPRESS SEMICON (CY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Alaska Air Group, Inc. ( ALK ) Amgen, Inc. ( AMGN ) AudioCodes Ltd. ( AUDC ) Cypress Semiconductor Corporation ( CY ) Delcath Systems, Inc. ( DCTH ) View the entire Zacks Rank #1 List . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Alaska Air Group, Inc. ( ALK ) Amgen, Inc. ( AMGN ) AudioCodes Ltd. ( AUDC ) Cypress Semiconductor Corporation ( CY ) Delcath Systems, Inc. ( DCTH ) View the entire Zacks Rank #1 List . ALASKA AIR GRP (ALK): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUDIOCODES LTD (AUDC): Free Stock Analysis Report CYPRESS SEMICON (CY): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
1437f83e-5926-4171-bfa0-387496cd51d4
|
715660.0
|
2014-03-21 00:00:00 UTC
|
What Makes Tenet (THC) a Strong Sell? - Tale of the Tape
|
DCTH
|
https://www.nasdaq.com/articles/what-makes-tenet-thc-a-strong-sell-tale-of-the-tape-2014-03-21
|
nan
|
nan
|
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Tenet Healthcare Corp. ( THC ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in THC.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 12 estimates moving down in the past 30 days, with no upward revision. This trend has caused the consensus estimate to trend lower, going from $2.72 a share a month ago to its current level of $1.40.
Also, for the current quarter, Tenet has seen 9 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 14 cents a share from a profit of 15 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 10.9% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical sector, you may instead consider some better-ranked stocks including ABIOMED, Inc. ( ABMD ), Actavis plc ( ACT ) and Delcath Systems, Inc. ( DCTH ). All these carry a Zacks Rank #2 (Buy) and may be better selections at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
ABIOMED INC (ABMD): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
TENET HEALTH (THC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If you are still interested in the Medical sector, you may instead consider some better-ranked stocks including ABIOMED, Inc. ( ABMD ), Actavis plc ( ACT ) and Delcath Systems, Inc. ( DCTH ). Click to get this free report >> ABIOMED INC (ABMD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TENET HEALTH (THC): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns.
|
If you are still interested in the Medical sector, you may instead consider some better-ranked stocks including ABIOMED, Inc. ( ABMD ), Actavis plc ( ACT ) and Delcath Systems, Inc. ( DCTH ). Click to get this free report >> ABIOMED INC (ABMD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TENET HEALTH (THC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Click to get this free report >> ABIOMED INC (ABMD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TENET HEALTH (THC): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Medical sector, you may instead consider some better-ranked stocks including ABIOMED, Inc. ( ABMD ), Actavis plc ( ACT ) and Delcath Systems, Inc. ( DCTH ). One such stock that you may want to consider dropping is Tenet Healthcare Corp. ( THC ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
|
If you are still interested in the Medical sector, you may instead consider some better-ranked stocks including ABIOMED, Inc. ( ABMD ), Actavis plc ( ACT ) and Delcath Systems, Inc. ( DCTH ). Click to get this free report >> ABIOMED INC (ABMD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TENET HEALTH (THC): Free Stock Analysis Report To read this article on Zacks.com click here. For the full year, we have seen 12 estimates moving down in the past 30 days, with no upward revision.
|
a0ac2b26-3539-4606-a4e4-c6fe4783850f
|
715661.0
|
2013-10-03 00:00:00 UTC
|
Hologic Scores Well in Brachtherapy Trial - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/hologic-scores-well-in-brachtherapy-trial-analyst-blog-2013-10-03
|
nan
|
nan
|
Hologic, Inc. ( HOLX ), announced the final analysis results of the MammoSite Breast Brachytherapy Registry Trial data, released by the American Society of Breast Surgeons (ASBS).The company reaffirmed that the analysis confirms previously noted "excellent" results which fare favorably when compared with other forms of accelerated partial breast irradiation (APBI) and whole breast irradiation.
The study described Hologic's MammoSite Radiation Therapy as one of the most patient friendly treatment options, enabling women to return to their regular lives after five days of treatment, simultaneously reducing the side effects.
The healthcare professionals who were part of the team that conducted the study also welcomed the successful results. They believe that eventually, their will be a global rise in the choice of accelerated partial breast irradiation as an effective treatment option, among women suffering from breast cancer.
MammoSite Therapy, is a form of targeted radiation therapy that can be applied directly to the area where cancer is most likely to recur. It allows the entire radiation course to be completed within a mere five days as compared to the regular five to seven weeks. Moreover, the targeted therapy of the breast limits radiation exposure to normal and healthy tissue minimizing side effects such as skin discoloration, scarring, burning, fatigue and damage to the surrounding organs.
Equipped with a multi-lumen design, the MammoSite ML system provides radiation oncologists the flexibility to adjust the radiation dose as per the requirement of every individual case. It also allows the oncologists to treat such patients who are not suitable for traditional brachytherapy.
MammoSite Registry Trial as undertaken by the American Society of Breast Surgeons (ASBS) covered 1400 early-stage breast cancer patients over a span of seven years. These patients had undergone breast conserving therapy treatment using Hologic's MammoSite targeted radiation therapy system, between May 2002 and Jun 2004.
Low rates of local recurrence as well as low levels of toxicity post treatment were some of the positive outcomes as stated by the ASBS. The reduced treatment time and the safety and efficacy of brachytherapy-based partial breast irradiation score much higher when rated against other conventional whole breast irradiation systems.
The final analysis results were published online in advance of print in the Aug 22, 2013 issue of the Annals of Surgical Oncology. HOLX was pleased to receive such positive feedback from the highly regarded American Society of Breast Surgeons and hopes to bring forth more such revolutionary treatment solutions for the betterment of women healthcare around the world.
Currently, HOLX carries a Zacks Rank #3 (Hold). Other medical instruments stocks that are worth a look include Delcath Systems, Inc. ( DCTH ), Echo Therapeutics, Inc. ( ECTE ) and Given Imaging Ltd. ( GIVN ), each carrying a Zacks Rank #2 (Buy).
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Get Free Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks that are worth a look include Delcath Systems, Inc. ( DCTH ), Echo Therapeutics, Inc. ( ECTE ) and Given Imaging Ltd. ( GIVN ), each carrying a Zacks Rank #2 (Buy). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report GIVEN IMAGING (GIVN): Get Free Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the targeted therapy of the breast limits radiation exposure to normal and healthy tissue minimizing side effects such as skin discoloration, scarring, burning, fatigue and damage to the surrounding organs.
|
Other medical instruments stocks that are worth a look include Delcath Systems, Inc. ( DCTH ), Echo Therapeutics, Inc. ( ECTE ) and Given Imaging Ltd. ( GIVN ), each carrying a Zacks Rank #2 (Buy). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report GIVEN IMAGING (GIVN): Get Free Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic, Inc. ( HOLX ), announced the final analysis results of the MammoSite Breast Brachytherapy Registry Trial data, released by the American Society of Breast Surgeons (ASBS).The company reaffirmed that the analysis confirms previously noted "excellent" results which fare favorably when compared with other forms of accelerated partial breast irradiation (APBI) and whole breast irradiation.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report GIVEN IMAGING (GIVN): Get Free Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks that are worth a look include Delcath Systems, Inc. ( DCTH ), Echo Therapeutics, Inc. ( ECTE ) and Given Imaging Ltd. ( GIVN ), each carrying a Zacks Rank #2 (Buy). Hologic, Inc. ( HOLX ), announced the final analysis results of the MammoSite Breast Brachytherapy Registry Trial data, released by the American Society of Breast Surgeons (ASBS).The company reaffirmed that the analysis confirms previously noted "excellent" results which fare favorably when compared with other forms of accelerated partial breast irradiation (APBI) and whole breast irradiation.
|
Other medical instruments stocks that are worth a look include Delcath Systems, Inc. ( DCTH ), Echo Therapeutics, Inc. ( ECTE ) and Given Imaging Ltd. ( GIVN ), each carrying a Zacks Rank #2 (Buy). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report GIVEN IMAGING (GIVN): Get Free Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic, Inc. ( HOLX ), announced the final analysis results of the MammoSite Breast Brachytherapy Registry Trial data, released by the American Society of Breast Surgeons (ASBS).The company reaffirmed that the analysis confirms previously noted "excellent" results which fare favorably when compared with other forms of accelerated partial breast irradiation (APBI) and whole breast irradiation.
|
fd176b45-df25-484c-9ebd-3c0fb4453f75
|
715662.0
|
2013-10-03 00:00:00 UTC
|
MAKO Buys Partner, Shares Hit 52-Week High - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/mako-buys-partner-shares-hit-52-week-high-analyst-blog-2013-10-03
|
nan
|
nan
|
MAKO Surgical Corp. ( MAKO ) surprised investors by announcing a deal to acquire its 4-year partner Pipeline Biomedical Holdings when the company itself is in the process of being acquired by leading medical device provider Stryker Corporation ( SYK ).
The transaction is valued at $2.5 million plus 3,953,771 unregistered shares of MAKO stock. Shares of MAKO touched 52-week high of $29.59 and closed at $29.55 yesterday, which represented a whopping year-to-date return of 127.5% and solid one-year return of 66.2%.
Pipeline is attached with robotic assisted surgery developer MAKO Surgical since 2010. It manufactures orthopedic devices and related instruments for both robotic devices and medical procedures and has been supplying implant technologies for MAKO's advanced robotic arm Robotic Arm Interactive Orthopedic System, or RIO, which includes RESTORIS PST Cup and Tapered Stem hip implant system for use with the RIO's MAKOplasty Total Hip Arthroplasty software.
The deal, which is expected to close by Oct 4, to some extent justifies the hefty 85.5% premium paid by Stryker Corporation for MAKO. Based in Fort Lauderdale, Fla., MAKO was founded in Nov 2004 and generated sales of $102.7 million last year. The deal will allow SYK to get hold of MAKO's advanced robotic arm technology, which helps orthopedic surgeons in performing knee and hip joint replacement surgeries, as well as Pipeline Biomedical's implant technologies.
Stryker believes MAKO's robotic technology has long-term potential for human joint reconstruction. MAKO's pioneering RIO system has not been widely adopted as it should be due to inadequate training and marketing efforts. As a result, SYK intends to fill up this gap by utilizing its efficient marketing and training system and gain a competitive edge in the stagnant hip-and-knee replacement market.
Secondly, post-acquisition, Stryker can proceed with the further implant development for MAKO's technologies utilizing its own R&D capabilities. MAKO Surgical lack resources compared to Stryker in developing implants for its systems. Therefore, the acquisition clearly bridges this gap and enables SYK to meet the wider joint reconstruction needs.
Currently, MAKO Surgical retains a Zacks Rank #2 (Buy). Other medical instruments stocks that are also worth a look include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Both of them carry a Zacks Rank #2 (Buy).
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
MAKO SURGICAL (MAKO): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks that are also worth a look include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. The deal, which is expected to close by Oct 4, to some extent justifies the hefty 85.5% premium paid by Stryker Corporation for MAKO.
|
Other medical instruments stocks that are also worth a look include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. It manufactures orthopedic devices and related instruments for both robotic devices and medical procedures and has been supplying implant technologies for MAKO's advanced robotic arm Robotic Arm Interactive Orthopedic System, or RIO, which includes RESTORIS PST Cup and Tapered Stem hip implant system for use with the RIO's MAKOplasty Total Hip Arthroplasty software.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks that are also worth a look include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). MAKO Surgical Corp. ( MAKO ) surprised investors by announcing a deal to acquire its 4-year partner Pipeline Biomedical Holdings when the company itself is in the process of being acquired by leading medical device provider Stryker Corporation ( SYK ).
|
Other medical instruments stocks that are also worth a look include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MAKO SURGICAL (MAKO): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. The transaction is valued at $2.5 million plus 3,953,771 unregistered shares of MAKO stock.
|
ee9ec440-1c19-466e-ada2-8804c3f18846
|
715663.0
|
2013-09-30 00:00:00 UTC
|
Healthcare Stocks Holding Up Relative to Other Sectors; Delcath Systems Wins Another Orphan-Drug Designation
|
DCTH
|
https://www.nasdaq.com/articles/healthcare-stocks-holding-relative-other-sectors-delcath-systems-wins-another-orphan-drug
|
nan
|
nan
|
Top Healthcare Stocks
JNJ -0.25%
PFE -0.83%
ABT -0.11%
MRK -0.96%
AMGN -1.03%
Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication.
Melphalan hydrochloride is being developed as a treatment for patients with hepatocellular carcinoma. The agency previously granted the drug with orphan status in patients with neuroendocrine tumors as well as metastatic cutaneous melanoma and metastatic ocular melanoma.
Orphan drug designation allows up to seven years of marketing exclusivity for drugs intended to treat relatively small patient populations.
DCTH shares climbed as much as 20% today to 36 cents a share.
In other sector news,
(+) BGMD, Centers for Medicare and Medicaid Services preliminarily set the 2014 Medicare payment rate for its BGM Galectin-3 test at the rate of another test with a 2013 limit of $30.24.
(-) ACHN, FDA declines to lift a clinical hold on sovaprevir, deciding any change in the status of the prospective hepatitis C drug is not warranted at this time. The decision prompted a host of analyst downgrades.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. In other sector news, (+) BGMD, Centers for Medicare and Medicaid Services preliminarily set the 2014 Medicare payment rate for its BGM Galectin-3 test at the rate of another test with a 2013 limit of $30.24.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DCTH shares climbed as much as 20% today to 36 cents a share.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
|
27cf6179-b926-4e4e-859a-831e5c17b47b
|
715664.0
|
2013-09-30 00:00:00 UTC
|
Sector Update: Healthcare
|
DCTH
|
https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-30-1
|
nan
|
nan
|
Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication.
Melphalan hydrochloride is being developed as a treatment for patients with hepatocellular carcinoma. The agency previously granted the drug with orphan status in patients with neuroendocrine tumors as well as metastatic cutaneous melanoma and metastatic ocular melanoma.
Orphan drug designation allows up to seven years of marketing exclusivity for drugs intended to treat relatively small patient populations.
DCTH shares climbed as much as 20% today to 36 cents a share.
In other sector news,
(+) BGMD, Centers for Medicare and Medicaid Services preliminarily set the 2014 Medicare payment rate for its BGM Galectin-3 test at the rate of another test with a 2013 limit of $30.24.
(-) ACHN, FDA declines to lift a clinical hold on sovaprevir, deciding any change in the status of the prospective hepatitis C drug is not warranted at this time. The decision prompted a host of analyst downgrades.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. In other sector news, (+) BGMD, Centers for Medicare and Medicaid Services preliminarily set the 2014 Medicare payment rate for its BGM Galectin-3 test at the rate of another test with a 2013 limit of $30.24.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DCTH shares climbed as much as 20% today to 36 cents a share.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
|
In company news, Delcath Systems ( DCTH ) still is trading higher shortly before the closing bell and the the U.S. Food and Drug Administration adding more orphan-drug indications for company's melphalan hydrochloride medication. DCTH shares climbed as much as 20% today to 36 cents a share. Healthcare stocks are moderately lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.2% as a group.
|
bad8e142-9dff-4e31-b448-a2103ce43a03
|
715665.0
|
2013-09-25 00:00:00 UTC
|
Varian Unveils New Oncology Software - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/varian-unveils-new-oncology-software-analyst-blog-2013-09-25
|
nan
|
nan
|
The recent display of a new product by Varian Medical System ( VAR ) at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) should further boost the positive trend demonstrated by VAR's stock over the last couple of weeks.
Varian's latest RapidPlan knowledge-based software provides standard of care models to clinicians to use as a baseline for formulating complex intensity-modulated radiotherapy (IMRT) treatment plans for their patients. However, the product from the company's Oncology Systems business is yet to receive U.S. Food and Drug Administration (FDA) approval and is not yet available for sale.
The RapidPlan tool is integrated within Varian's Eclipse treatment planning system, used for planning all types of external beam radiotherapy. The software helps automate an important part of the treatment planning process, thereby improving the quality and efficiency of care.
Similar products offered by the company include the RapidArc technology and the Smart Segmentation knowledge-based tool. Based on the cost effectiveness of the new softwares, management plans to create more knowledge-driven solutions for the entire oncology continuum.
Recently, VAR completed the first two planned installations of its Edge Radiosurgery Suite in Europe and the U.S. The Radiosurgery Suite is designed to perform advanced radiosurgery using real-time tumor tracking technology and motion management capabilities.
Varian will also launch The Edge Advisory Board to help clinicians perform the procedures. Through this board, VAR will provide clinical education by partnering with leaders in radiosurgery, including neuro- and thoracic surgeons as well as radiation oncologists.
Varian is poised to increase itsglobal marketshare in the radiation oncology market as international markets are still under-equipped to address the growing incidence of cancer. Last month, the company received an order for 20 TrueBeam machines from NHS Supply Chain for NHS hospitals across the U.K.
VAR has a Zacks Rank #2 (Buy). Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ) are worth a look at the moment. All of them carry a Zacks Rank #2 (Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ) are worth a look at the moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Varian's latest RapidPlan knowledge-based software provides standard of care models to clinicians to use as a baseline for formulating complex intensity-modulated radiotherapy (IMRT) treatment plans for their patients.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ) are worth a look at the moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. The recent display of a new product by Varian Medical System ( VAR ) at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) should further boost the positive trend demonstrated by VAR's stock over the last couple of weeks.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ) are worth a look at the moment. The recent display of a new product by Varian Medical System ( VAR ) at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) should further boost the positive trend demonstrated by VAR's stock over the last couple of weeks.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ) are worth a look at the moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Varian's latest RapidPlan knowledge-based software provides standard of care models to clinicians to use as a baseline for formulating complex intensity-modulated radiotherapy (IMRT) treatment plans for their patients.
|
ec3af3d4-50f4-4b7f-8f84-93b6e6b76ad3
|
715666.0
|
2013-09-24 00:00:00 UTC
|
Intuitive Surgical's Firefly Gets FDA Approval - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/intuitive-surgicals-firefly-gets-fda-approval-analyst-blog-2013-09-24
|
nan
|
nan
|
Intuitive Surgical, Inc. ( ISRG ) revealed that its da Vinci Fluorescence Imaging Vision System, well known as Firefly, has received FDA 510(k) clearance for use in gallbladder surgery.
The clearance means surgeons would now be able to identify the biliary duct with the help of the Firefly Imaging system properly for laparoscopic gallbladder removal surgeries. While performing surgeries, there is a higher chance of mistakenly identifying the cystic duct as bile duct leading to injuries due to clipping and division of the common duct.
However, Firefly Fluorescence Imaging Vision System would help surgeons use a specialized video camera to view real-time imaging of bile ducts (cystic duct, common bile duct and common hepatic duct).
Further, it will be able to identify blood flowing in vessels and tissue during minimally invasive surgical procedures. While using the Firefly camera, tissue with blood appears green and the same without blood appears gray.
Intuitive Surgical launched Firefly in 2011 for use with the da Vinci Si Surgical System in the U.S. and Europe. The system combines a fluorescent dye with a specialized camera, endoscope and laser-based illuminator to allow surgeons to identify vasculature in three dimensions beneath tissue surfaces.
ISRG reported earnings per share of $3.90 in the second quarter of 2013, missing the Zacks Consensus Estimate of $4.05 per share but exceeded the year-ago level of $3.75 per share. The company reported revenues of $579 million for the second quarter, up 8% year over year and trailed the Zacks Consensus Estimate of $596 million.
Intuitive Surgical significantly lowered its 2013 guidance based on the company's dismal performance. Due to soft capital sales of the da Vinci system, the company lowered its revenue expectation from flat to 7% for 2013. Previously, ISRG had provided its sales growth guidance in the range of 16% to 19% for 2013. Operating income is forecast in a band of 37% to 38% of sales (earlier 38% to 39%) for 2013.
Currently, ISRG retains a Zacks Rank #3 (Hold). Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). All of them carry a Zacks Rank #2 (Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical, Inc. ( ISRG ) revealed that its da Vinci Fluorescence Imaging Vision System, well known as Firefly, has received FDA 510(k) clearance for use in gallbladder surgery.
|
Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. However, Firefly Fluorescence Imaging Vision System would help surgeons use a specialized video camera to view real-time imaging of bile ducts (cystic duct, common bile duct and common hepatic duct).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). Intuitive Surgical, Inc. ( ISRG ) revealed that its da Vinci Fluorescence Imaging Vision System, well known as Firefly, has received FDA 510(k) clearance for use in gallbladder surgery.
|
Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. However, Firefly Fluorescence Imaging Vision System would help surgeons use a specialized video camera to view real-time imaging of bile ducts (cystic duct, common bile duct and common hepatic duct).
|
97bb28de-5d01-49e0-89a2-715aabac56c7
|
715667.0
|
2013-09-23 00:00:00 UTC
|
Radiosurgery Suite Boosts Varian Medical - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/radiosurgery-suite-boosts-varian-medical-analyst-blog-2013-09-23
|
nan
|
nan
|
Varian Medical Systems ' ( VAR ) share price rose nearly 1% on Sep 20 following the announcement that the company will complete the first two planned installations of its Edge Radiosurgery Suite in Europe and the U.S. The Radiosurgery Suite is designed to perform advanced radiosurgery using real-time tumor tracking technology and motion management capabilities.
In Europe, the system will be installed at the Champalimaud Foundation in Lisbon, Portugal and in the U.S., it will be installed at the Henry Ford Health System in Detroit, Mich. It will meet the need for high-precision stereotactic ablative radiotherapy for treating and eliminating tumors.
Varian will also launch The Edge Advisory Board to help clinicians perform the procedures. Through this board, VAR will provide clinical education by partnering with leaders in radiosurgery, including neuro- and thoracic surgeons as well as radiation oncologists.
Varian is poised to increase its market share in the radiation oncology market as international markets are under-equipped to address the growing incidence of cancer. Last month, the company received an order for 20 TrueBeam machines from NHS Supply Chain for NHS hospitals across the U.K.
Varian's TrueBeam system has been integrated with a host of new technical innovations that includes synchronized imaging, patient positioning, motion management and treatment delivery during a radiotherapy or radiosurgery procedure.
NHS hospitals, spread across the U.K., will benefit from this order as they will get a chance to replace and modernize their base of 300 linear accelerators (100 of these are more than ten years old) with a more advanced and accurate treatment system.
Varian Medical Systems posted third-quarter fiscal 2013 net earnings of $1.03 per share, beating the Zacks Consensus Estimate by a couple of cents. Earnings were better than the year-ago level of 96 cents and the company's previously announced guidance of 98 cents to $1.02 per share for the reported quarter.
Revenues increased 3% year over year to $726.2 million, which were, however, well short of the Zacks Consensus Estimate of $753 million. It also missed VAR's expectations of 7% sales growth in the quarter.
Following the third quarter, Varian revised its expectations for fiscal 2013. Moving ahead, the company envisages revenues to grow by about 5% for fiscal 2013 compared with the prior outlook of 8% sales growth.
Currently, VAR retains a Zacks Rank #3 (Hold). Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ) are worth a look at this moment. All of them carry a Zacks Rank #2 (Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ) are worth a look at this moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems ' ( VAR ) share price rose nearly 1% on Sep 20 following the announcement that the company will complete the first two planned installations of its Edge Radiosurgery Suite in Europe and the U.S.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ) are worth a look at this moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems posted third-quarter fiscal 2013 net earnings of $1.03 per share, beating the Zacks Consensus Estimate by a couple of cents.
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ) are worth a look at this moment. Varian Medical Systems ' ( VAR ) share price rose nearly 1% on Sep 20 following the announcement that the company will complete the first two planned installations of its Edge Radiosurgery Suite in Europe and the U.S.
|
Other medical instruments stocks such as Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ) are worth a look at this moment. CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report VARIAN MEDICAL (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems ' ( VAR ) share price rose nearly 1% on Sep 20 following the announcement that the company will complete the first two planned installations of its Edge Radiosurgery Suite in Europe and the U.S.
|
f692cbf5-ed6f-41bb-813e-6b508151c915
|
715668.0
|
2013-09-20 00:00:00 UTC
|
Thoratec Upped to Neutral - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/thoratec-upped-to-neutral-analyst-blog-2013-09-20
|
nan
|
nan
|
On Sep 19, we have upgraded our recommendation on Thoratec Corporation ( THOR ) to Neutral from Underperform. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong performance in the overseas markets.
Why Upgraded?
On Jul 31, Thoratec Corporation posted a 12.8% rise in adjusted earnings to 44 cents per share in the second quarter of the year from 39 cents a year ago while net earnings improved 9.2% to $25.7 million from $23.6 million in the 2012-quarter. With this, earnings surpassed the Zacks Consensus Estimate by 8 cents per share.
Revenues in the quarter rose 10.0% to $130.5 million, exceeding the Zacks Consensus Estimate of $121 million. Thanks to the company's HeartMate product line that contributed $115.7 million to overall revenues, reflecting a 9% year-over-year increase due to the expansion of its international business, including the recent commercial launch in Japan.
Following the release of second quarter results, the Zacks Consensus Estimate for 2013 earnings remained the same at $1.33 per share. The Zacks Consensus Estimate for 2014 earnings also remained unchanged at $1.45 per share. With the Zacks Consensus Estimates remaining unchanged, THOR now has a Zacks #3 Rank (Hold).
Thoratec has benefited from rapid acceptance of HeartMate II on a global basis. HeartMate II is clinically adequately effective enough to provide favorable long-term survival outcomes for patients who do not have access to donor hearts.
Thoratec also enjoys a monopoly in the U.S. market with this only device of its kind. In the U.S. DT market, the company faces no near-term competitive threat as HeartWare's LVAD is not expected to be launched before 2015.
However, the small size of THOR may restrict its ability to raise resources. The absence of strategic alliances may hinder its ability to develop new products
Other Stocks to Look For
Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). All of them carry a Zacks Rank #2 (Buy).
CYNOSURE INC-A (CYNO): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
THORATEC CORP (THOR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The absence of strategic alliances may hinder its ability to develop new products Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong performance in the overseas markets.
|
The absence of strategic alliances may hinder its ability to develop new products Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. With the Zacks Consensus Estimates remaining unchanged, THOR now has a Zacks #3 Rank (Hold).
|
CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. The absence of strategic alliances may hinder its ability to develop new products Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong performance in the overseas markets.
|
The absence of strategic alliances may hinder its ability to develop new products Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include Cynosure, Inc. ( CYNO ), Delcath Systems, Inc. ( DCTH ), and Echo Therapeutics, Inc. ( ECTE ). CYNOSURE INC-A (CYNO): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong performance in the overseas markets.
|
3aa8ba70-07fb-41bc-92d5-edd1225eb188
|
715669.0
|
2013-09-19 00:00:00 UTC
|
PerkinElmer Upgraded to Neutral - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/perkinelmer-upgraded-to-neutral-analyst-blog-2013-09-19
|
nan
|
nan
|
On Sep 18, we have upgraded our recommendation on PerkinElmer, Inc. ( PKI ) to Neutral from Underperform. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong international presence and high-growth business model.
Why Upgraded?
On Aug 2, PerkinElmer posted adjusted earnings per share of 51 cents in the second quarter of 2013, beating the Zacks Consensus Estimate by 3 cents. Revenues in the quarter rose 4.1% to $543.3 million, exceeding the Zacks Consensus Estimate of $534 million. The increase was driven by improvements in PKI's operating segments.
PerkinElmer expects organic revenues to increase in the low-single digit range in the year compared with 2012. PKI also raised the lower-end of the adjusted earnings per share guidance to $2.03 and $2.10 compared with the prior guidance of $2.00 to $2.10.
Following the release of second quarter results, the Zacks Consensus Estimate for 2013 earnings remained the same at $2.07 per share. The Zacks Consensus Estimate for 2014 earnings also remained unchanged at $2.42 per share.
PerkinElmer has a significant international presence, which provides it with diversified revenues and client base. The company markets its products in more than 150 countries and regions. Further, the company is in the process of transforming its business model to higher-growth offerings through a series of acquisitions and divestitures.
However, PKI operates in a highly competitive industry characterized by rapid technological change and evolving industry standards. Deferred capital expenditures by consumers on account of the constraints in the credit markets may also negatively affect the company.
Other Stocks to Look For
Other stocks that are currently performing well in the medical instruments industry include MELA Sciences, Inc. ( MELA ), Pacific Biosciences of California, Inc. ( PACB ), and Delcath Systems, Inc. ( DCTH ). All of them carry a Zacks Rank #2 (Buy).
DELCATH SYS INC (DCTH): Free Stock Analysis Report
MELA SCIENCES (MELA): Free Stock Analysis Report
PACIFIC BIOSCI (PACB): Free Stock Analysis Report
PERKINELMER INC (PKI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include MELA Sciences, Inc. ( MELA ), Pacific Biosciences of California, Inc. ( PACB ), and Delcath Systems, Inc. ( DCTH ). DELCATH SYS INC (DCTH): Free Stock Analysis Report MELA SCIENCES (MELA): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report PERKINELMER INC (PKI): Free Stock Analysis Report To read this article on Zacks.com click here. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong international presence and high-growth business model.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report MELA SCIENCES (MELA): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report PERKINELMER INC (PKI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include MELA Sciences, Inc. ( MELA ), Pacific Biosciences of California, Inc. ( PACB ), and Delcath Systems, Inc. ( DCTH ). On Aug 2, PerkinElmer posted adjusted earnings per share of 51 cents in the second quarter of 2013, beating the Zacks Consensus Estimate by 3 cents.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report MELA SCIENCES (MELA): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report PERKINELMER INC (PKI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include MELA Sciences, Inc. ( MELA ), Pacific Biosciences of California, Inc. ( PACB ), and Delcath Systems, Inc. ( DCTH ). We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong international presence and high-growth business model.
|
Other Stocks to Look For Other stocks that are currently performing well in the medical instruments industry include MELA Sciences, Inc. ( MELA ), Pacific Biosciences of California, Inc. ( PACB ), and Delcath Systems, Inc. ( DCTH ). DELCATH SYS INC (DCTH): Free Stock Analysis Report MELA SCIENCES (MELA): Free Stock Analysis Report PACIFIC BIOSCI (PACB): Free Stock Analysis Report PERKINELMER INC (PKI): Free Stock Analysis Report To read this article on Zacks.com click here. We are impressed by the company's second quarter results that beat the Zacks Consensus Estimate on both earnings and revenues fronts as well as its strong international presence and high-growth business model.
|
09ac9b35-f305-4afc-87dc-3904ead490c4
|
715670.0
|
2013-09-18 00:00:00 UTC
|
Moody's Changes Outlook of Fresenius - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/moodys-changes-outlook-of-fresenius-analyst-blog-2013-09-18
|
nan
|
nan
|
Moody's Investors Service, the credit rating arm of Moody's Corporation ( MCO ), has changed its outlook of Fresenius SE & Co. KGaA - the parent company of Fresenius Medical Care ( FMS ) - from positive to negative due to the increase in leverage following the recent acquisition of 43 hospitals from Rhoen-Klinikum AG. The outlook has been downgraded despite the fact that the acquisition will lead to improved coverage of Fresenius SE hospitals across Europe.
Moody's Investors Service has also affirmed the Ba1 corporate family rating, Ba1-PD probability of default rating and the Ba1 unsecured bond)Baa3/(P)Baa3 secured bank instrument ratings for Fresenius SE's debt issuing finance subsidiaries.
Fresenius' acquisition of hospitals from private health-care provider Rhoen-Klinikum by its Helios unit is expected to make the company the largest private hospital operator in Europe. Post-acquisition, Fresenius SA will operate 117 hospitals across the continent. Fresenius expects the acquisition of new hospitals, consisting of 11,800 beds and 15 outpatient facilities, to produce synergies leading to a 1%-2% rise in Helios EBITDA margin.
Fresenius will pay €3.07 billion ($4.07 billion) for the Rhoen-Klinikum assets using debt. It anticipates the acquisition to generate annual sales of €2 billion and EBITDA of nearly €250 million. However, the company expects one-time charges of about €80 million before tax due to the acquisition
Later, Helios and Rhoen-Klinikum will also enter a cooperation agreement covering latter's remaining hospitals. The cooperation will be valued at €40 million, of which, Fresenius will contribute 75% and Rhoen the remaining.
Fresenius Medical Care announced second quarter 2013 adjusted earnings of 44 cents per American Depositary Share (ADS), which was flat year-over-year and lower than the Zacks Consensus Estimate of 46 cents per ADS.
Net revenues grew 5% (6% in terms of constant currency) year over year to $3,613 million in the reported quarter. Revenues marginally missed the Zacks Consensus Estimate of $3,615 million. Organic sales growth was 5% on a global basis.
FMS reaffirmed its revenue forecast for 2013. The company expects sales of over $14,600 million for 2013, up 6% year over year. It raised the upper end of its net income guidance (for shareholders) for 2013 to $1,100-$1,500 million from $1,100-$1,200 million.
Currently, FMS carries a Zacks Rank #3 (Hold). Other medical instruments stocks that are performing well include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Both of them carry a Zacks Rank #2 (Buy).
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis Report
MOODYS CORP (MCO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks that are performing well include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report FRESENIUS MED (FMS): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report To read this article on Zacks.com click here. Moody's Investors Service, the credit rating arm of Moody's Corporation ( MCO ), has changed its outlook of Fresenius SE & Co. KGaA - the parent company of Fresenius Medical Care ( FMS ) - from positive to negative due to the increase in leverage following the recent acquisition of 43 hospitals from Rhoen-Klinikum AG.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report FRESENIUS MED (FMS): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks that are performing well include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Moody's Investors Service, the credit rating arm of Moody's Corporation ( MCO ), has changed its outlook of Fresenius SE & Co. KGaA - the parent company of Fresenius Medical Care ( FMS ) - from positive to negative due to the increase in leverage following the recent acquisition of 43 hospitals from Rhoen-Klinikum AG.
|
DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report FRESENIUS MED (FMS): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks that are performing well include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Moody's Investors Service, the credit rating arm of Moody's Corporation ( MCO ), has changed its outlook of Fresenius SE & Co. KGaA - the parent company of Fresenius Medical Care ( FMS ) - from positive to negative due to the increase in leverage following the recent acquisition of 43 hospitals from Rhoen-Klinikum AG.
|
Other medical instruments stocks that are performing well include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report FRESENIUS MED (FMS): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report To read this article on Zacks.com click here. Fresenius' acquisition of hospitals from private health-care provider Rhoen-Klinikum by its Helios unit is expected to make the company the largest private hospital operator in Europe.
|
d85d03be-77cc-4a18-a40d-f0a17ab5f7a3
|
715671.0
|
2013-09-16 00:00:00 UTC
|
Rochester General Gets MASI's Patient SafetyNet - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/rochester-general-gets-masis-patient-safetynet-analyst-blog-2013-09-16
|
nan
|
nan
|
Masimo Corporation ( MASI ) revealed that Rochester General Health System and its 528-bed Rochester General Hospital have installed Masimo Patient SafetyNet system that combines Masimo SET pulse oximetry with ventilation monitoring and wireless clinician notification. The Masimo Patient SafetyNet system has been widely used by health care providers around the world as it is used in ensuring patient's safety need.
Masimo Patient SafetyNet is a remote monitoring and clinician notification system. It measures and monitors patient's physiological conditions and changes that indicate declining health status in real-time. When changes occur in the measured values and indicate deterioration in the patient's condition, the system automatically sends wireless alerts directly to clinicians and immediately leads to lifesaving response to the patient's bedside.
Further, the Masimo SET provides excellent support to clinicians to reduce retinopathy of prematurity (ROP) in neonates, screen newborns for Critical Congenital Heart Disease (CCHD), as well as perform other functions to improve patient outcome in a cost-effective manner.
Masimo Patient SafetyNet has been installed in Rochester General Hospital after an extensive evaluation process that led to standardization of Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry in the organization. The performance of Masimo SET pulse oximetry has been proved by more than 100 independent and objective studies and thousands of clinical evaluations.
According to the U.S. News & World Report Best Hospitals Honor Roll, MASI's popular Masimo SET is used in 8 out of the top 10 hospitals to monitor more than 100 million patients annually. Its accurate measurements, along with increased specificity as well as sensitivity, help identify fatal breathing difficulties even during patient motion and low perfusion rate.
Earlier, Masimo had forged an agreement with University Children's Hospital in Basel, Switzerland. The hospital was the first pediatric institution in the region to utilize the Masimo Patient SafetyNet in its general wards.
Masimo Patient SafetyNet faces strong competition from Covidien 's ( COV ) Nellcor pulse oximeters. The company has started labeling the device to promote the usefulness of the product line for CCHD screening in infants. Moreover, the Food and Drug Administration (FDA) has approved Covidien's Nellcor Bedside SpO2 Patient Monitoring System, Bedside Respiratory Patient Monitoring System, and N-600x Pulse Oximetry Monitoring System for motion tolerance.
Currently, Masimo has a Zacks Rank #3 (Hold). Other medical instruments stocks that are worth considering include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Both of them carry a Zacks Rank #2 (Buy).
COVIDIEN PLC (COV): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
ECHO THERAPEUT (ECTE): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical instruments stocks that are worth considering include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). COVIDIEN PLC (COV): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Further, the Masimo SET provides excellent support to clinicians to reduce retinopathy of prematurity (ROP) in neonates, screen newborns for Critical Congenital Heart Disease (CCHD), as well as perform other functions to improve patient outcome in a cost-effective manner.
|
COVIDIEN PLC (COV): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical instruments stocks that are worth considering include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). Masimo Corporation ( MASI ) revealed that Rochester General Health System and its 528-bed Rochester General Hospital have installed Masimo Patient SafetyNet system that combines Masimo SET pulse oximetry with ventilation monitoring and wireless clinician notification.
|
Other medical instruments stocks that are worth considering include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). COVIDIEN PLC (COV): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Masimo Corporation ( MASI ) revealed that Rochester General Health System and its 528-bed Rochester General Hospital have installed Masimo Patient SafetyNet system that combines Masimo SET pulse oximetry with ventilation monitoring and wireless clinician notification.
|
Other medical instruments stocks that are worth considering include Delcath Systems, Inc. ( DCTH ) and Echo Therapeutics, Inc. ( ECTE ). COVIDIEN PLC (COV): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report MASIMO CORP (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Masimo Corporation ( MASI ) revealed that Rochester General Health System and its 528-bed Rochester General Hospital have installed Masimo Patient SafetyNet system that combines Masimo SET pulse oximetry with ventilation monitoring and wireless clinician notification.
|
7fedfd95-e5d8-4a09-9691-df95bdc21faf
|
715672.0
|
2013-01-29 00:00:00 UTC
|
Hologic Exhibits at Arab Summit - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/hologic-exhibits-at-arab-summit-analyst-blog-2013-01-29
|
nan
|
nan
|
Hologic Inc. ( HOLX ), a leading provider of healthcare products for women, is currently showcasing some of its latest offerings at the 38th Arab Health Congress at the Dubai International Convention and Exhibition Centre. The company undertook this marketing initiative mainly to attract potential customers from the Middle-East. The conference is likely to host 83,000 medical experts from 142 countries.
Some of the Hologic's products displayed at the conference include market leading 2D and 3D mammography systems (Selenia Dimensions) for breast tomosynthesis, the SecurView diagnostic workstation, and the Atec breast biopsy system. Also featured are the Panther system and the associated Aptima assay, which were inducted into Hologic's portfolio with the acquisition of Gen-Probe in August 2012.
The ThinPrep Pap Test and ThinPrep Imaging systems for cervical cancer screening featured at the event are the driving factor behind growth in the company's Diagnostics business. These apart, Hologic's Discovery bone densitometry platform, NovaSure endometrial ablation system and MyoSure tissue removal device are also on display.
In an effort to expand its global reach, Hologic is building on its international infrastructure and fortifying management resources, particularly in the emerging markets of China, Latin America, the Middle East and Eastern Europe. In fiscal 2012, the company generated 27% of its revenues from international operations.
As a part of its growth strategy to focus on international markets and the Middle East, the company is opening a new office in Dubai Healthcare City. The office is scheduled to open in the first quarter of 2013.
However, over the past few quarters, Hologic witnessed several challenges in the form of economic uncertainties in Europe, slower sales cycles and increasing pricing pressure. Moreover, fluctuating foreign currency might adversely affect its international revenues and operating results, particularly in the Diagnostics segment, which has maximum exposure to international markets.
The stock carries a Zacks Rank #3, which translates into a short-term Hold rating. Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems, Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well.
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems, Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic Inc. ( HOLX ), a leading provider of healthcare products for women, is currently showcasing some of its latest offerings at the 38th Arab Health Congress at the Dubai International Convention and Exhibition Centre.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems, Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. As a part of its growth strategy to focus on international markets and the Middle East, the company is opening a new office in Dubai Healthcare City.
|
CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems, Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. Some of the Hologic's products displayed at the conference include market leading 2D and 3D mammography systems (Selenia Dimensions) for breast tomosynthesis, the SecurView diagnostic workstation, and the Atec breast biopsy system.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems, Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. As a part of its growth strategy to focus on international markets and the Middle East, the company is opening a new office in Dubai Healthcare City.
|
1a283c06-3839-4b2b-b2fb-d4e0414cabf4
|
715673.0
|
2013-01-28 00:00:00 UTC
|
FDA Clears Teleflex Needles - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/fda-clears-teleflex-needles-analyst-blog-2013-01-28
|
nan
|
nan
|
Teleflex Incorporated ( TFX ) has obtained the approval of the U.S. Food and Drug Administration (FDA) for its Arrow UltraQuick peripheral nerve block (PNB) needles. The UltraQuik needles enhance block success for single-injection PNBs using the ultrasound approach.
This needle, along with the StimuQuick and StimuQuick Echo needles from the Anesthesia and Respiratory division under the larger Critical Care unit, provides a wide range of clinical solutions for performing PNBs. The company's anesthetic and respiratory product lines are contributing positively to the growth of the Critical Care business, which grew by 4.5% on a constant currency basis in the last reported quarter.
Teleflex has embarked on enhancing its Arrow brand ever since the acquisition of Arrow International in 2007. The acquisition has significantly bolstered single-use product offerings for critical care from Teleflex and expanded its global reach.
Limerick, Pennsylvania-based Teleflex is a global leader in medical devices used in critical care and surgery. The company focuses on profitable and consistent growth and is expected to yield results. The company envisages its sales growth to surpass the market growth. It also plans to gain market share in key product areas.
Product innovation is the driving force for Teleflex. Contributions from new products in the most recent quarter reflect gains from the company's increased focus on research and development. However, the failure to protect its intellectual property and lower-than-expected market adoption of the new products may hinder its growth.
Teleflex operates in a highly competitive medical devices industry and the implementation of the medical devices tax from this year is likely to put additional pressure on its bottom line. Further, the company operates in a stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.
The stock carries a Zacks Rank #3 (Hold). Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems , Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well.
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
TELEFLEX INC (TFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems , Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Teleflex Incorporated ( TFX ) has obtained the approval of the U.S. Food and Drug Administration (FDA) for its Arrow UltraQuick peripheral nerve block (PNB) needles.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems , Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems , Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. The company's anesthetic and respiratory product lines are contributing positively to the growth of the Critical Care business, which grew by 4.5% on a constant currency basis in the last reported quarter.
|
Medical instrument companies, such as Cantel Medical Corp. ( CMN ), Delcath Systems , Inc. ( DCTH ) and Cyberonics Inc. ( CYBX ) with Zacks Rank #1 (Strong Buy), are expected to do well. CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report TELEFLEX INC (TFX): Free Stock Analysis Report To read this article on Zacks.com click here. The company envisages its sales growth to surpass the market growth.
|
3a476d78-6bf4-4ead-af96-2820e2d8bc09
|
715674.0
|
2013-01-23 00:00:00 UTC
|
Hologic Strides on Synergy Track - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/hologic-strides-on-synergy-track-analyst-blog-2013-01-23
|
nan
|
nan
|
Hologic Inc. ( HOLX ) recently announced organizational changes involving radical transformation in the top management for its Diagnostics franchise.
As part of the organizational changes, the Senior Vice President and General Manager of Diagnostics, Carl Hull, announced his retirement. Hull had earlier served as the Chairman, President and Chief Executive Officer of Gen-Probe (erstwhile molecular diagnostic player) until the completion of the acquisition.
Notably, Hologic continues to successfully integrate Gen-Probe, following the closing of the acquisition in Aug 2012. The company is moving forward with several organizational changes to further gain from its solid footing in the Diagnostics business.
Financial Benefits
The successful integration of Gen-Probe with its legacy Diagnostics segment is likely to yield positive results as the company expects to realize cost synergies of over $40 million by the end of the first year of the acquisition. Hologic also envisages an additional $35 million in cost synergies by the end of the third year.
Moreover, the complementary product portfolio, cross-selling opportunities and enhanced global footing should result in potential revenue synergies for Hologic. As the integration process is accelerating, Hologic expects to create significant value from the takeover. The synergies underline the company's attempt to improve its infrastructure and develop its pipeline.
Subsequent to the Gen-Probe deal, Diagnostics became the largest segment at Hologic (representing 44% of the total sales in the fourth quarter of 2012). The contribution is likely to increase further as the organizational changes leverage the franchise growth.
Our Take
Hologic is leaving no stone unturned to consolidate operations and realize potential synergies. While we await updates on the revenue growth potential on the back of synergies, we are encouraged by the company's ability to spot the timing and the value of the cost synergies.
Although Hologic constantly works to create value for its shareholders, several challenges such as economic uncertainties in Europe, slower sales cycles and increasing pricing pressure keeps us on the sidelines. Accordingly, the stock carries a Zacks Rank #3 (Hold). Other medical sector stocks that warrant a look are Cantel Medical ( CMN ), Cyberonics ( CYBX ) and Delcath Systems ( DCTH ) each carrying a Zacks Rank #1 (Strong Buy).
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other medical sector stocks that warrant a look are Cantel Medical ( CMN ), Cyberonics ( CYBX ) and Delcath Systems ( DCTH ) each carrying a Zacks Rank #1 (Strong Buy). CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Hull had earlier served as the Chairman, President and Chief Executive Officer of Gen-Probe (erstwhile molecular diagnostic player) until the completion of the acquisition.
|
Other medical sector stocks that warrant a look are Cantel Medical ( CMN ), Cyberonics ( CYBX ) and Delcath Systems ( DCTH ) each carrying a Zacks Rank #1 (Strong Buy). CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Financial Benefits The successful integration of Gen-Probe with its legacy Diagnostics segment is likely to yield positive results as the company expects to realize cost synergies of over $40 million by the end of the first year of the acquisition.
|
CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Other medical sector stocks that warrant a look are Cantel Medical ( CMN ), Cyberonics ( CYBX ) and Delcath Systems ( DCTH ) each carrying a Zacks Rank #1 (Strong Buy). Financial Benefits The successful integration of Gen-Probe with its legacy Diagnostics segment is likely to yield positive results as the company expects to realize cost synergies of over $40 million by the end of the first year of the acquisition.
|
Other medical sector stocks that warrant a look are Cantel Medical ( CMN ), Cyberonics ( CYBX ) and Delcath Systems ( DCTH ) each carrying a Zacks Rank #1 (Strong Buy). CANTEL MED CORP (CMN): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Hologic Inc. ( HOLX ) recently announced organizational changes involving radical transformation in the top management for its Diagnostics franchise.
|
f1d2e98e-5ff9-4a91-8aa6-3b1a4eed9097
|
715675.0
|
2012-06-11 00:00:00 UTC
|
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO
|
DCTH
|
https://www.nasdaq.com/articles/weekly-cfo-buys-highlight-bwen-emc-ino-dcth-acco-2012-06-11
|
nan
|
nan
|
According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below:
Broadwind Energy ( BWEN ): Executive Vice President and CFO Stephanie K. Kushner Bought 100,000 Shares
Executive Vice President and CFO of Broadwind Energy ( BWEN ) Stephanie K. Kushner bought 100,000 shares on 06/04/2012 at an average price of $0.26. Broadwind Energy Inc., headquartered in Naperville, Ill., owns, supports, grows and strategically positions companies that manufacture, install and maintain components for the energy industry, with a primary emphasis on the wind energy sector. Broadwind Energy has a market cap of $38.1 million; its shares were traded at around $0.27 with and P/S ratio of 0.2.
Broadwind Energy Inc. reported sales of $54.4 million for the first quarter of 2012, a 25% increase compared to $43.5 million in the first quarter of 2011.
Executive Vice President and CFO Stephanie K. Kushner bought shares of BWEN stock.
10% Owner Austin W. Marxe & David Greenhouse sold shares of BWEN stock.
EMC Corp.-Mass ( EMC ): CFO Edward H. Dickinson Bought 30,000 Shares
CFO of EMC Corp.-Mass ( EMC ) Edward H. Dickinson bought 30,000 shares on 05/29/2012 at an average price of $0.08. EMC Corporation and its subsidiaries design, manufacture, market and support a wide range of hardware and software products and provide services for the storage, management, protection and sharing of electronic information. EMC Corp.-mass has a market cap of $48.02 billion; its shares were traded at around $24.64 with a P/E ratio of 17.4 and P/S ratio of 2.4. EMC Corp.-mass had an annual average earnings growth of 29.3% over the past 10 years.
Chairman, President and CEO Joseph M. Tucci , Executive Vice President and CFO David I. Goulden, and Executive Vice President and Chief Marketing Officer Jeremy Burton sold shares of EMC stock.
CFO Edward H. Dickinson bought shares of EMC stock.
Inovio Pharmaceuticals ( INO ): CFO Peter Kies Bought 25,000 Shares
CFO of Inovio Pharmaceuticals ( INO ) Peter Kies bought 25,000 shares on 06/05/2012 at an average price of $0.41. Inovio Pharmaceuticals Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. Inovio Pharmaceuticals has a market cap of $57.8 million; its shares were traded at around $0.42 with and P/S ratio of 5.8.
Inovio Pharmaceuticals Inc. reported financial results for the quarter ended March 31, 2012. Total revenue was $1.7 million for the three months ended March 31, 2012, compared to $3.1 million for the same period in 2011. Total operating expenses were $5.9 million compared to $7.5 million. The net loss attributable to common stockholders was $8.3 million, or $0.06 per share, compared to $2.4 million, or $0.02 per share.
CFO Kenneth D. Misch bought shares of DVOX stock.
Delcath Systems Inc. ( DCTH ): Executive Vice President and CFO Graham G. Miao Bought 20,000 Shares
Executive Vice President and CFO of Delcath Systems Inc. ( DCTH ) Graham G. Miao bought 20,000 shares on 05/31/2012 at an average price of $1.5. Delcath Systems Inc. has developed a system, the Delcath Systems, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. Delcath Systems Inc. has a market cap of $70 million; its shares were traded at around $1.49.
Delcath Systems announced financial results and highlights for its first quarter 2012 ended March 31, 2012 and recent weeks. For the three months ended March 31, 2012, Delcath's operating loss was $14.6 million, which included approximately $0.9 in non-cash stock-based compensation expense. Operating loss for the three months ended March 31, 2011 was $7.8 million, which included approximately $1.3 million in non-cash stock-based compensation expense.
President and CEO Eamonn P. Hobbs, Executive Vice President and CFO Graham G. Miao, and Director Douglas G. Watson bought shares of DCTH stock.
ACCO Brands Corp. ( ACCO ): Executive Vice President and CFO Neal V. Fenwick Bought 18,000 Shares
Executive Vice President and CFO of ACCO Brands Corp. ( ACCO ) Neal V. Fenwick bought 18,000 shares on 06/01/2012 at an average price of $8.67. ACCO Brands Corporation is a world leader in branded office products. ACCO Brands Corp. has a market cap of $476.1 million; its shares were traded at around $9.54 with a P/E ratio of 13.6 and P/S ratio of 0.4.
ACCO Brands Corporation reported its first quarter results for the period ended March 31, 2012. Net sales decreased 3% to $288.9 million, compared to $298.4 million in the prior-year quarter. The first quarter loss from continuing operations was $17.3 million, or $0.31 per share, compared to a loss of $9.0 million, or $0.16 per share, in the prior-year quarter.
Executive Vice President and CFO Neal V. Fenwick, Senior Vice President, Secretary and General Counsel Pamela R. Schneider, and President and COO Boris Elisman bought shares of ACCO stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc. ( DCTH ): Executive Vice President and CFO Graham G. Miao Bought 20,000 Shares Executive Vice President and CFO of Delcath Systems Inc. ( DCTH ) Graham G. Miao bought 20,000 shares on 05/31/2012 at an average price of $1.5. President and CEO Eamonn P. Hobbs, Executive Vice President and CFO Graham G. Miao, and Director Douglas G. Watson bought shares of DCTH stock. The overall trend of CFOs is illustrated in the chart below: Broadwind Energy ( BWEN ): Executive Vice President and CFO Stephanie K. Kushner Bought 100,000 Shares Executive Vice President and CFO of Broadwind Energy ( BWEN ) Stephanie K. Kushner bought 100,000 shares on 06/04/2012 at an average price of $0.26.
|
Delcath Systems Inc. ( DCTH ): Executive Vice President and CFO Graham G. Miao Bought 20,000 Shares Executive Vice President and CFO of Delcath Systems Inc. ( DCTH ) Graham G. Miao bought 20,000 shares on 05/31/2012 at an average price of $1.5. President and CEO Eamonn P. Hobbs, Executive Vice President and CFO Graham G. Miao, and Director Douglas G. Watson bought shares of DCTH stock. The overall trend of CFOs is illustrated in the chart below: Broadwind Energy ( BWEN ): Executive Vice President and CFO Stephanie K. Kushner Bought 100,000 Shares Executive Vice President and CFO of Broadwind Energy ( BWEN ) Stephanie K. Kushner bought 100,000 shares on 06/04/2012 at an average price of $0.26.
|
Delcath Systems Inc. ( DCTH ): Executive Vice President and CFO Graham G. Miao Bought 20,000 Shares Executive Vice President and CFO of Delcath Systems Inc. ( DCTH ) Graham G. Miao bought 20,000 shares on 05/31/2012 at an average price of $1.5. President and CEO Eamonn P. Hobbs, Executive Vice President and CFO Graham G. Miao, and Director Douglas G. Watson bought shares of DCTH stock. The overall trend of CFOs is illustrated in the chart below: Broadwind Energy ( BWEN ): Executive Vice President and CFO Stephanie K. Kushner Bought 100,000 Shares Executive Vice President and CFO of Broadwind Energy ( BWEN ) Stephanie K. Kushner bought 100,000 shares on 06/04/2012 at an average price of $0.26.
|
Delcath Systems Inc. ( DCTH ): Executive Vice President and CFO Graham G. Miao Bought 20,000 Shares Executive Vice President and CFO of Delcath Systems Inc. ( DCTH ) Graham G. Miao bought 20,000 shares on 05/31/2012 at an average price of $1.5. President and CEO Eamonn P. Hobbs, Executive Vice President and CFO Graham G. Miao, and Director Douglas G. Watson bought shares of DCTH stock. The overall trend of CFOs is illustrated in the chart below: Broadwind Energy ( BWEN ): Executive Vice President and CFO Stephanie K. Kushner Bought 100,000 Shares Executive Vice President and CFO of Broadwind Energy ( BWEN ) Stephanie K. Kushner bought 100,000 shares on 06/04/2012 at an average price of $0.26.
|
ba364db9-7341-45b7-b953-d4254836e446
|
715676.0
|
2012-05-29 00:00:00 UTC
|
Delcath Prices Stock and Warrants - Analyst Blog
|
DCTH
|
https://www.nasdaq.com/articles/delcath-prices-stock-and-warrants-analyst-blog-2012-05-29
|
nan
|
nan
|
Specialist producer of pharmaceutical and medical devices for oncology, Delcath Systems Inc. ( DCTH ) recently announced the pricing of an underwritten public offering of 13,333,340 shares of its common stock at $1.50 a share.
The company also priced warrants that entitle holders to purchase up to 4,000,002 shares at an exercise price of $1.65 a share. The offering will generate gross proceeds of $20 million.
After the deduction of underwriters' discounts and estimated offering expenses, this offering will generate net proceeds of about $18.4 million. This excludes any potential cash proceeds by the exercise of the warrants. In a bid to cover over-allotment, the company has also allowed underwriters a 30-day option to purchase an additional 15% of shares of its common stock and warrants.
This is expected to generate gross proceeds of $3 million, if exercised in full. The offering is expected to close on or about May 31, 2012.
Delcath plans to use the proceeds for commercialization of new products, attaining regulatory approvals and to sponsor the clinical trials. The company is on the verge of pitching into a multi-billion dollar global market.
Delcath recently envisaged a commercialization strategy for the European market. It has also submitted applications for regulatory approvals for its products in Hong Kong, South Korea and Singapore and plans to submit the same in India, Russia, China, Canada and Japan. The proceeds will enable the company to focus on its growth strategy in the international market.
The public offering will enable the company to meet its current capital needs. As of March 31, 2012, Delcath Systems' cash position stood at $20.8 million, down 47% year over year. Management believes that its business has not generated sufficient positive cash from operating activities.
It has always operated at a loss since inception and constantly faces liquidity crises. During its first quarterearnings conference call the company revealed a plan to raise additional capital to fund its development efforts and this public offering is an execution of its earlier plan.
The joint book-running managers for this offering are Cowen and Company, a wing of Cowen Group ( COWN ) and Wedbush PacGrow Life Sciences. Roth Capital Partners is acting as co-manager.
Delcath is a provider of oncology solutions. Its business profile includes development and manufacture of pharmaceuticals and medical devices for cancer therapy.
The concern about Delcath profitability still overhangs and the company remains vulnerable compared to its competitors including Mesa Laboratories ( MLAB ), Given Imaging ( GIVN ) and Genmark Diagnostics ( GNMK ).
The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
COWEN GROUP INC (COWN): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
GENMARK DIAGNST (GNMK): Free Stock Analysis Report
(MLAB): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Specialist producer of pharmaceutical and medical devices for oncology, Delcath Systems Inc. ( DCTH ) recently announced the pricing of an underwritten public offering of 13,333,340 shares of its common stock at $1.50 a share. COWEN GROUP INC (COWN): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GIVEN IMAGING (GIVN): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (MLAB): ETF Research Reports To read this article on Zacks.com click here. In a bid to cover over-allotment, the company has also allowed underwriters a 30-day option to purchase an additional 15% of shares of its common stock and warrants.
|
Specialist producer of pharmaceutical and medical devices for oncology, Delcath Systems Inc. ( DCTH ) recently announced the pricing of an underwritten public offering of 13,333,340 shares of its common stock at $1.50 a share. COWEN GROUP INC (COWN): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GIVEN IMAGING (GIVN): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (MLAB): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Specialist producer of pharmaceutical and medical devices for oncology, Delcath Systems Inc. ( DCTH ) recently announced the pricing of an underwritten public offering of 13,333,340 shares of its common stock at $1.50 a share. COWEN GROUP INC (COWN): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GIVEN IMAGING (GIVN): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (MLAB): ETF Research Reports To read this article on Zacks.com click here. During its first quarterearnings conference call the company revealed a plan to raise additional capital to fund its development efforts and this public offering is an execution of its earlier plan.
|
Specialist producer of pharmaceutical and medical devices for oncology, Delcath Systems Inc. ( DCTH ) recently announced the pricing of an underwritten public offering of 13,333,340 shares of its common stock at $1.50 a share. COWEN GROUP INC (COWN): Free Stock Analysis Report DELCATH SYS INC (DCTH): Free Stock Analysis Report GIVEN IMAGING (GIVN): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (MLAB): ETF Research Reports To read this article on Zacks.com click here. The offering will generate gross proceeds of $20 million.
|
fa859f4a-3f43-4e27-aa7a-d5f3bde08afd
|
715677.0
|
2012-05-25 00:00:00 UTC
|
Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer
|
DCTH
|
https://www.nasdaq.com/articles/mid-day-update-stocks-trending-water-ahead-first-holiday-weekend-summer-2012-05-25
|
nan
|
nan
|
U.S. stocks are little changed at mid-day, swinging a few points either side of even in light pre-holiday trading as positive economic data at home fights for dominance with fears of a global slowdown and European debt woes. Industry sectors in the S&P 500 are split between winners and losers, with energy and financial stocks posting the best gains while shares of mining and materials company are down moderately despite small gains for metals and other commodities today. Consumer stocks also are performing relatively well with sentiment data rising to its best levels since 2007.
Stocks briefly ticked higher after a gauge of consumer attitudes climbed to its best level in over four years. The Thomson Reuters/University of Michigan consumer sentiment index climbed to a final 79.3 reading for May, up from 76.4 last month and topping the preliminary 77.8 reading reported earlier this month. Experts polled by Bloomberg, on average, had expected the final reading to match the preliminary 77.8 call.
Americans' perceptions of both current and future conditions rose, with current sentiment rising to 87.2 from 82.9 the prior month. The index of consumer expectations six months from now, often seen as a measure of consumer-spending trends, increased from 72.3 in April to 74.3 this month, its highest reading the highest since July 2007.
Traders, however, still are having a difficult time shaking concerns over global growth and Europe's debt crisis. News Spain's Catalonia state is having problems selling new debt had stocks retreating this morning, with Reuters quoting Deputy Prime Minister Soraya Saenz de Santamaria that the Spanish government is analyzing "with all caution" requests from regional governments to help them regain access to capital markets.
Also today, the U.S. Treasury Department again declined to formally accuse China of currency manipulation while still asserting the yuan remains "significantly undervalued." The department is continuing to "closely monitor" the value of the yuan compared to the dollar and other currencies, according to the Treasury's semi-annual report to Congress on exchange-rate policies. It also will press for changes that yield more exchange-rate flexibility.
In company news, VeriFone Systems ( PAY ) shares are down 15% after Q2 profits for the electronics-payments company declined 42% from year-ago levels on higher acquisition and restructuring costs. The firm also gave Q3 and FY12 guidance that lagged consensus estimates.
Delcath Systems ( DCTH ) shares plunged nearly 37% and hit a new year low $1.46 today after the medical device and drug company announced plans for a public offering of stock and warrants. It did not specify how many shares will be sold although the offering is authorized under the company's Feb. 6 shelf registration allowing it to sell up to $100 million of debt and equity.
Proceeds will be used to further develop and commercialize DCTH's so-called chemosaturation system, designed to administer large doses of chemotherapy and other therapeutic agents to diseased organs or tissues. Its initial focus is treating primary and metastatic liver cancers.
Shipping stocks are sailing today following an encouraging earnings report by Frontline Inc. ( FRO ). The supertanker company rose as much as 15% after posting an unexpected $0.09 a share Q1 profit, which included a $15-million gain from asset sales, and FRO executives saying they anticipate Q2 operating results will top the prior quarter. Shares of Ship Finance International Ltd ( SFL ), Navios Maritime Partners L.P. ( NMM ) and Overseas Shipholding Group Inc. (OSG) are up at least 3% today, including a near 8% advance for SFL.
Commodities are mostly higher. Crude oil for July delivery is up 33 cents at $90.99 a barrel while June natural gas is down 8.2 cents at $2.565 per 1 million BTU. June gold is up $8.20 to $1,565 an ounce with July silver adding 13.3 cents to $28.32 an ounce. July copper is up 2.3 cents at $3.4525.
Among energy ETFs, the United States Oil fund is up 0.18% to $34.32 and the United States Natural Gas fund is down 2.93% to $18.27. Among precious-metal funds, the Market Vectors Gold Miners ETF is up 0.07% to $44.66 while SPDR Gold Shares are up 0.47% to $152.12. The iShares Silver Trust is up 0.22% to $27.50.
Here's where the markets stand this afternoon:
NYSE Composite Index down 0.87 (-0.01%) to 7,551.48
Dow Jones Industrial Average down 16.38 (-0.13%) to 12,513.37
S&P 500 up 2.30 (+0.17%) to 1,322.97
NASDAQ Composite Index up 0.06 (+0.00%) to 2,839.44
GLOBAL SENTIMENT
Nikkei 225 up 0.20%
Hang Seng Index up 0.25%
Shanghai China Composite Index down 0.74%
FTSE 100 down 0.01%
NYSE SECTOR INDICES
NYSE Energy Sector Index up 0.21% to 11,514.77
NYSE Financial Sector Index down 0.28% to 4,244.14
NYSE Healthcare Index up 0.33% to 7,130.02
UPSIDE MOVERS
(+) BLOX (+2.1%) Q3 EPS, revenues beat estimates; guides Q4 above Street.
(+) CHK (+3%) Carl Icahn said to own 4% stake; Blackrock buys another 4 million shares.
(+) GNOM (+23%) No real news but plenty of takeover chatter online.
(+) UPI (+14.9%) Two new R&D initiatives expanding neuromodulation technology.
DOWNSIDE MOVERS
(-) TLB (-38.7%) Breaks off buyout talks with private-equity fund.
(-) ROSG (-15.3%) Plans to sell 570,000 shares in registered direct offering.
(-) NYMT (-4.3%) Launches public offering of 4 million shares.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems ( DCTH ) shares plunged nearly 37% and hit a new year low $1.46 today after the medical device and drug company announced plans for a public offering of stock and warrants. Proceeds will be used to further develop and commercialize DCTH's so-called chemosaturation system, designed to administer large doses of chemotherapy and other therapeutic agents to diseased organs or tissues. U.S. stocks are little changed at mid-day, swinging a few points either side of even in light pre-holiday trading as positive economic data at home fights for dominance with fears of a global slowdown and European debt woes.
|
Delcath Systems ( DCTH ) shares plunged nearly 37% and hit a new year low $1.46 today after the medical device and drug company announced plans for a public offering of stock and warrants. Proceeds will be used to further develop and commercialize DCTH's so-called chemosaturation system, designed to administer large doses of chemotherapy and other therapeutic agents to diseased organs or tissues. The Thomson Reuters/University of Michigan consumer sentiment index climbed to a final 79.3 reading for May, up from 76.4 last month and topping the preliminary 77.8 reading reported earlier this month.
|
Delcath Systems ( DCTH ) shares plunged nearly 37% and hit a new year low $1.46 today after the medical device and drug company announced plans for a public offering of stock and warrants. Proceeds will be used to further develop and commercialize DCTH's so-called chemosaturation system, designed to administer large doses of chemotherapy and other therapeutic agents to diseased organs or tissues. Industry sectors in the S&P 500 are split between winners and losers, with energy and financial stocks posting the best gains while shares of mining and materials company are down moderately despite small gains for metals and other commodities today.
|
Delcath Systems ( DCTH ) shares plunged nearly 37% and hit a new year low $1.46 today after the medical device and drug company announced plans for a public offering of stock and warrants. Proceeds will be used to further develop and commercialize DCTH's so-called chemosaturation system, designed to administer large doses of chemotherapy and other therapeutic agents to diseased organs or tissues. The Thomson Reuters/University of Michigan consumer sentiment index climbed to a final 79.3 reading for May, up from 76.4 last month and topping the preliminary 77.8 reading reported earlier this month.
|
b8cb251e-72f2-429d-9a17-5ca106dd7064
|
715678.0
|
2011-08-15 00:00:00 UTC
|
Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH)
|
DCTH
|
https://www.nasdaq.com/articles/fridays-top-performing-small-cap-stocks-mds-mnkd-fxcm-foe-dcth-2011-08-15
|
nan
|
nan
|
A rough-and-tumble week on Wall Street came to a close Friday on a slightly positive note for both small-cap and large-caps stocks.
Despite the struggles that saw wild day-to-day swings in stocks, as the smoke cleared following the closing bell on Friday, it was revealed there was far less damage during the session than anticipated. And the big surprise was that most popular indexes had posted a two-day rally - something not seen in three weeks.
A flight to large caps was driven by some investors who are worried about the weaknesses they perceive in the U.S. and global economies. They prefer to ride the storm out with the best-known names in their portfolios. But that also opens the door for investors looking to latch onto some small-cap stocks at relative bargain prices.
Earnings continue to be the prevailing driving force in small-cap momentum, as traders sort through data in their search for the best-performing sectors.
The Russell 2000 Index finished the day just above neutral, gaining 0.24 percent in value. The Standard & Poor's Small Cap 600 fared slightly better, adding 0.34 percent. For the week, the Russell was off 2.4 percent, while the S&P indicator shed 2.3 percent.
The year-to-date numbers are less rosy. The Russell 2000 is down 12.4 percent about halfway through August, and is off 10.4 percent for the year. The S&P Small Cap 600 has lost 11.5 percent in value this month, and is down 8.4 percent year-to-date.
Friday's Top Performing Small Cap Stocks (Data provided by Google Finance)
Midas ( MDS ) : Shares surged after the auto repair retailer said it had hired JPMorgan Chase to advise the Illinois company on boosting shareholder value through a sale or other transaction.
MannKind (Nasdaq: MNKD) : The stock was the Russell 2000's best performer, shooting up after the company confirmed with the FDA the design of two clinical studies of Afrezza, its inhaled insulin product for diabetes.
FXCM ( FXCM ) : The online foreign exchange brokerage posted a profit in the third quarter, as its revenue grew 7 percent and trading volume increased 14 percent. The company also has set up a $16 million reserve related to a settlement with the National Futures Association.
Ferro ( FOE ) : The specialty metals producer rebounded a week after the stock hit a 52-week low on the heels of a disappointing earnings report that missed analyst estimates. At the same time, Ferro lowered its profit expectations for the rest of the year.
Delcath Systems (Nasdaq: DCTH) : The company, which has developed a system to deliver chemotherapy and other therapeutic agents to specific parts of the body, continued to bounce back after dropping to a 52-week low on August 8.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems (Nasdaq: DCTH) : The company, which has developed a system to deliver chemotherapy and other therapeutic agents to specific parts of the body, continued to bounce back after dropping to a 52-week low on August 8. Friday's Top Performing Small Cap Stocks (Data provided by Google Finance) Midas ( MDS ) : Shares surged after the auto repair retailer said it had hired JPMorgan Chase to advise the Illinois company on boosting shareholder value through a sale or other transaction. MannKind (Nasdaq: MNKD) : The stock was the Russell 2000's best performer, shooting up after the company confirmed with the FDA the design of two clinical studies of Afrezza, its inhaled insulin product for diabetes.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Delcath Systems (Nasdaq: DCTH) : The company, which has developed a system to deliver chemotherapy and other therapeutic agents to specific parts of the body, continued to bounce back after dropping to a 52-week low on August 8. Friday's Top Performing Small Cap Stocks (Data provided by Google Finance) Midas ( MDS ) : Shares surged after the auto repair retailer said it had hired JPMorgan Chase to advise the Illinois company on boosting shareholder value through a sale or other transaction.
|
Delcath Systems (Nasdaq: DCTH) : The company, which has developed a system to deliver chemotherapy and other therapeutic agents to specific parts of the body, continued to bounce back after dropping to a 52-week low on August 8. For the week, the Russell was off 2.4 percent, while the S&P indicator shed 2.3 percent. The S&P Small Cap 600 has lost 11.5 percent in value this month, and is down 8.4 percent year-to-date.
|
Delcath Systems (Nasdaq: DCTH) : The company, which has developed a system to deliver chemotherapy and other therapeutic agents to specific parts of the body, continued to bounce back after dropping to a 52-week low on August 8. The Russell 2000 Index finished the day just above neutral, gaining 0.24 percent in value. The Russell 2000 is down 12.4 percent about halfway through August, and is off 10.4 percent for the year.
|
b812728d-9c2e-4b9a-94ee-d7b527658454
|
715679.0
|
2011-04-14 00:00:00 UTC
|
Why Phase II Trials Are the Best Time for Biotech Investing
|
DCTH
|
https://www.nasdaq.com/articles/why-phase-ii-trials-are-best-time-biotech-investing-2011-04-14
|
nan
|
nan
|
Marc Lichtenfeld submits:
I recently received a call from an investor relations representative who wanted to know if I'd be interested in hearing about a small biotech company with a drug candidate in Phase II trials.
Would Rory McIlroy have liked a do-over on Sunday at Augusta?
The Three Distinct Phases of Clinical Trials
Before a new experimental drug is tried in humans, it's put to work in test tubes and then animals. Once it's ready for human trials, it's tested in three distinct phases.
The Phase I trial is conducted with a limited number of subjects, usually fewer than 50. In cancer trials, the drug will be given to patients, sometimes as a last resort. For drugs targeting many other diseases, they're given to healthy volunteers so doctors can better understand how the drug reacts inside the human body.
If a drug is deemed safe after this period, the company will proceed to Phase II. This trial usually consists of a few dozen to several hundred patients receiving varying dosage levels of the particular drug.
The data that's considered most accurate is from a trial that's"double blind" (neither the patient nor the doctor know if the patient has received the drug) and placebo controlled (compared to a placebo or standard of care). Some, but not most, Phase II trials are double blind and placebo controlled.
In Phase III, companies test hundreds to thousands of patients. If the data proves that the drug is safe and effective, the company will usually apply for approval.
Naturally, the more patients who take part in a trial, the greater the chance the drug fails. For example, the drug may not work, or there may be unexpected side effects. This is especially common in cancer trials, where the response rates are low, even with approved drugs.
Positive results in Phase III can push a stock higher as investors begin focusing on approval and the sales and profits that could follow. However, it doesn't always work that way. Many drugs with seemingly strong Phase III results have been rejected by the FDA for one reason or another. This can crush investors who followed a drug stock all the way to the end.
For example, MannKind ( MNKD ) has seen its stock rise and fall sharply several times. Investors got their hopes up on the company's inhaled insulin product Afrezza , only to see the FDA reject it time and again over safety issues.
This is one reason why Phase II is the real sweet spot for biotech investing…
Phase II Trials: A Profitable Time to be Involved in Biotech Stocks
Phase II is often the most profitable time to be involved in a small cap biotech stock . Many times, Phase II results are positive. Sometimes it's because the drug works. And other times it's because the trial is rigged to provide positive results.
For example, Cel-Sci ( CVM ), a company that stirs passion (both positive and negative) among biotech investors, ran a Phase II study on the head and neck cancer drug Multikine. However, rather than test the drug against other existing treatments, Multikine was given along with an existing treatment.
At the end of the trial, Cel-Sci boasted of a 12 percent complete response rate. But it was impossible to determine if the two out of 19 patients who had a complete response saw their tumors disappear due to Multikine or due to the other treatment.
So, why would a company do that?
To show good results in the hopes of raising additional capital.
There are also times when the science is conducted properly and Phase II claims are valid, but the drug isn't able to replicate results in a Phase III trial. Remember, a Phase II trial usually contains a much smaller sample size, which can easily distort results.
Very often, when a company reports strong Phase II results, the stock takes off as it is the first real indication that it might be approvable. Investors get excited; potential partners begin sniffing around; and the media begins to cover the drug's potential. Even though at this point things are just starting to get promising, it's often a great time to take the money and run.
Phase III, on the other hand, is fraught with risk. These trials are expensive to run, and there's no guarantee that the drug will again show strong results. For example, there have been some instances where the drug replicated its earlier results, but there was a stronger than expected response from the placebo group, narrowing the difference that the drug made and making it appear less effective.
Phase II Takes Off and Fails in Phase III
There are many instances of stocks that have taken off during or after Phase II results, where investors made lots of money but then suffered losses when the drug failed in Phase III.
A few real world examples - my subscribers made money on Medivation ( MDVN ) despite a disastrous Phase III trial that resulted in the stock plummeting.
Medivation had a drug for Alzheimer's called Dimebon. The Phase II results were outstanding. They showed a slower deterioration and fewer side effects than the existing therapies, including Pfizer's ( PFE ) Aricept. Despite skeptics' doubts, the stock ran in anticipation of Phase III results. If the data was strong and the drug got approved, it would likely be an immediate blockbuster.
After the stock doubled, I recommended that subscribers take half of their profits off of the table. Note, this is not the usual Oxford Club philosophy, but with small-cap biotech stocks that can plummet on one piece of news, I often suggest readers take their risk capital off the table once the stock has risen 100 percent or more.
So with investors now playing with the"house's money" after taking their initial investment back, we waited for the Phase III results.
It turns out, the drug didn't work.
The stock got crushed, and we sold out our remaining position. But because we had sold half at a 100 percent profit, we still pocketed a 37 percent gain. Not bad for a failed drug…
If The Smart Money Leaves … Take Your Profits and Follow
There have been several other instances where something similar has occurred. We made 102 percent gains on Delcath Systems ( DCTH ) and 42 percent gains on MELA Sciences (MELA), despite FDA rejections.
Although in these cases the Phase III trials were not deemed a failure, the FDA has rejected the applications for approval until more questions are answered.
Lastly, after positive Phase II results, you sometimes see the early investors and the venture capitalists exit the position. They've made their money and don't want to stick around for the risky Phase III. If the smart money is leaving, it may be a good idea to follow them out the door. At least with part of your investment.
There's nothing wrong with hanging around and seeing if a small biotech company can get the ball across the goal line and get its drug approved. But considering that less than half of all drugs in Phase II actually make it to the market, it's a smart idea to take profits along the way when you can.
Disclosure: Investment U expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees and agents of Investment U (and affiliated companies) must wait 24 hours after an initial trade recommendation is published on online - or 72 hours after a direct mail publication is sent - before acting on that recommendation.
See also Petrobras Earnings Not Great for Field Service Group on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
We made 102 percent gains on Delcath Systems ( DCTH ) and 42 percent gains on MELA Sciences (MELA), despite FDA rejections. Marc Lichtenfeld submits: I recently received a call from an investor relations representative who wanted to know if I'd be interested in hearing about a small biotech company with a drug candidate in Phase II trials. For example, Cel-Sci ( CVM ), a company that stirs passion (both positive and negative) among biotech investors, ran a Phase II study on the head and neck cancer drug Multikine.
|
We made 102 percent gains on Delcath Systems ( DCTH ) and 42 percent gains on MELA Sciences (MELA), despite FDA rejections. Some, but not most, Phase II trials are double blind and placebo controlled. This is one reason why Phase II is the real sweet spot for biotech investing… Phase II Trials: A Profitable Time to be Involved in Biotech Stocks Phase II is often the most profitable time to be involved in a small cap biotech stock .
|
We made 102 percent gains on Delcath Systems ( DCTH ) and 42 percent gains on MELA Sciences (MELA), despite FDA rejections. This is one reason why Phase II is the real sweet spot for biotech investing… Phase II Trials: A Profitable Time to be Involved in Biotech Stocks Phase II is often the most profitable time to be involved in a small cap biotech stock . There are also times when the science is conducted properly and Phase II claims are valid, but the drug isn't able to replicate results in a Phase III trial.
|
We made 102 percent gains on Delcath Systems ( DCTH ) and 42 percent gains on MELA Sciences (MELA), despite FDA rejections. Positive results in Phase III can push a stock higher as investors begin focusing on approval and the sales and profits that could follow. Many times, Phase II results are positive.
|
58e8427c-f91c-46b2-a32c-f65e4a3f6e11
|
715680.0
|
2011-03-31 00:00:00 UTC
|
14 Highly Shorted Stocks with Decreasing Put/Call Ratios
|
DCTH
|
https://www.nasdaq.com/articles/14-highly-shorted-stocks-decreasing-putcall-ratios-2011-03-31
|
nan
|
nan
|
Below is a list of 14 highly shorted stocks, with short floats above 15% and short ratios greater than 5 days. These stocks have also seen significant decreases in their put/call ratios over the last ten trading days.
Do you think this bullish options sentiment is sustainable?
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize market cap changes for the top stocks mentioned
List sorted by decrease in put/call ratio over the last ten days.
1. Meredith Corp. (MDP): Publishing - Periodicals Industry. Market cap of $1.55B. The stock is a short squeeze candidate, with a short float at 17.91% (equivalent to 10.17 days of average volume). Put/Call ratio decreased 83.93% over the last two weeks (from 2.24 to 0.36). The stock has gained 1.7% over the last year.
2. Liz Claiborne Inc. (LIZ): Textile - Apparel Clothing Industry. Market cap of $519.08M. The stock is a short squeeze candidate, with a short float at 22.75% (equivalent to 6.69 days of average volume). Put/Call ratio decreased 44.44% over the last two weeks (from 0.27 to 0.15). This is a risky stock that is significantly more volatile than the overall market (beta = 2.14). The stock has had a good month, gaining 10.46%.
3. Momenta Pharmaceuticals Inc. (MNTA): Biotechnology Industry. Market cap of $767.08M. The stock is a short squeeze candidate, with a short float at 19.60% (equivalent to 9.07 days of average volume). Put/Call ratio decreased 42.27% over the last two weeks (from 0.97 to 0.56). The stock has had a couple of great days, gaining 7.64% over the last week.
4. Rock-Tenn Co. (RKT): Paper & Paper Products Industry. Market cap of $2.72B. The stock is a short squeeze candidate, with a short float at 24.99% (equivalent to 8.61 days of average volume). Put/Call ratio decreased 39.68% over the last two weeks (from 0.63 to 0.38). The stock has gained 53.11% over the last year.
5. USEC Inc. (USU): Industrial Metals & Minerals Industry. Market cap of $539.55M. The stock is a short squeeze candidate, with a short float at 15.12% (equivalent to 6.89 days of average volume). Put/Call ratio decreased 30.95% over the last two weeks (from 0.42 to 0.29). The stock is currently stuck in a downtrend, trading 9.45% below its SMA20, 17.42% below its SMA50, and 17.43% below its SMA200. USU has lost 8.3% over the last week.
6. Delcath Systems Inc. (DCTH): Drug Delivery Industry. Market cap of $322.35M. The stock is a short squeeze candidate, with a short float at 23.30% (equivalent to 9.54 days of average volume). Put/Call ratio decreased 28.00% over the last two weeks (from 0.5 to 0.36). The stock has had a couple of great days, gaining 7.3% over the last week.
7. hhgregg, Inc. (HGG): Electronics Stores Industry. Market cap of $535.29M. The stock is a short squeeze candidate, with a short float at 27.62% (equivalent to 10.48 days of average volume). Put/Call ratio decreased 26.92% over the last two weeks (from 0.78 to 0.57). The stock has lost 46.59% over the last year.
8. The McClatchy Company (MNI): Publishing - Newspapers Industry. Market cap of $303.52M. The stock is a short squeeze candidate, with a short float at 35.87% (equivalent to 22.66 days of average volume). Put/Call ratio decreased 25.81% over the last two weeks (from 0.31 to 0.23). This is a risky stock that is significantly more volatile than the overall market (beta = 3.2). It's been a rough couple of days for the stock, losing 7.27% over the last week.
9. Skechers USA Inc. (SKX): Textile - Apparel Footwear & Accessories Industry. Market cap of $978.87M. The stock is a short squeeze candidate, with a short float at 17.99% (equivalent to 5.15 days of average volume). Put/Call ratio decreased 19.30% over the last two weeks (from 0.57 to 0.46). The stock has gained 8.85% over the last week.
10. Questcor Pharmaceuticals, Inc. (QCOR): Biotechnology Industry. Market cap of $901.63M. The stock is a short squeeze candidate, with a short float at 19.42% (equivalent to 10.18 days of average volume). Put/Call ratio decreased 17.14% over the last two weeks (from 0.35 to 0.29). QCOR has a relatively low correlation to the market (beta = -0.17), which may be appealing to risk-averse investors. The stock has had a good month, gaining 16.55%.
11. Coinstar Inc. (CSTR): Business Equipment Industry. Market cap of $1.48B. The stock is a short squeeze candidate, with a short float at 41.13% (equivalent to 5.66 days of average volume). Put/Call ratio decreased 16.09% over the last two weeks (from 0.87 to 0.73). Risk-averse investors may appreciate that CSTR has a relatively low correlation to the market (beta = 0.74). The stock has had a good month, gaining 11.37%.
12. The Children's Place Retail Stores, Inc. (PLCE): Apparel Stores Industry. Market cap of $1.31B. The stock is a short squeeze candidate, with a short float at 24.16% (equivalent to 6.52 days of average volume). Put/Call ratio decreased 15.96% over the last two weeks (from 0.94 to 0.79). The stock has had a good month, gaining 13.64%.
13. Rackspace Hosting, Inc (RAX): Internet Software & Services Industry. Market cap of $5.50B. The stock is a short squeeze candidate, with a short float at 17.09% (equivalent to 8.68 days of average volume). Put/Call ratio decreased 13.64% over the last two weeks (from 0.66 to 0.57). RAX is exhibiting strong upside momentum--currently trading 15.37% above its SMA20, 18.84% above its SMA50, and 59.66% above its SMA200. The stock has gained 16.59% over the last week.
14. Power-One Inc. (PWER): Diversified Electronics Industry. Market cap of $929.97M. The stock is a short squeeze candidate, with a short float at 40.28% (equivalent to 6.04 days of average volume). Put/Call ratio decreased 12.31% over the last two weeks (from 0.65 to 0.57). This is a risky stock that is significantly more volatile than the overall market (beta = 2.2). The stock has gained 7.07% over the last week.
*Short data sourced from Schaeffer’s, all other data sourced from Finviz.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems Inc. (DCTH): Drug Delivery Industry. Visualize market cap changes for the top stocks mentioned List sorted by decrease in put/call ratio over the last ten days. Skechers USA Inc. (SKX): Textile - Apparel Footwear & Accessories Industry.
|
Delcath Systems Inc. (DCTH): Drug Delivery Industry. The stock is a short squeeze candidate, with a short float at 17.91% (equivalent to 10.17 days of average volume). The stock is a short squeeze candidate, with a short float at 22.75% (equivalent to 6.69 days of average volume).
|
Delcath Systems Inc. (DCTH): Drug Delivery Industry. The stock is a short squeeze candidate, with a short float at 17.91% (equivalent to 10.17 days of average volume). The stock is a short squeeze candidate, with a short float at 22.75% (equivalent to 6.69 days of average volume).
|
Delcath Systems Inc. (DCTH): Drug Delivery Industry. Below is a list of 14 highly shorted stocks, with short floats above 15% and short ratios greater than 5 days. Visualize market cap changes for the top stocks mentioned List sorted by decrease in put/call ratio over the last ten days.
|
60848bf5-8c5a-4b64-8b3e-1ab7ebdf5586
|
715681.0
|
2010-06-07 00:00:00 UTC
|
Monday Losers: Delcath, CVS Caremark and Coldwater Creek
|
DCTH
|
https://www.nasdaq.com/articles/monday-losers-delcath-cvs-caremark-and-coldwater-creek-2010-06-07
|
nan
|
nan
|
Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) .
Biotech Investors are Dubious of Delcath
Although many biotech firms are seeing nice gains on Monday after this weekend's annual ASCO cancer conference, shares of Delcath (Nasdaq: DCTH) are plunging more than -12% after the company conceded its promising drug delivery system can also prove very toxic and perhaps lethal if it is not administered correctly. That raises concerns that approval by the U.S. Food and Drug Administration ( FDA ) would prove very challenging, and even if approved, might come with heavy restrictions that limit the potential market size for its product.
Delcath has competed key clinical trials and now awaits word from the FDA. Investors could eventually reverse their negative reaction, as the drug delivery system did yield pretty impressive efficacy data.
Action to Take --> Keep an eye on this story as it develops. If it increasingly looks like the FDA will overlook the toxicity issues, then shares could be in for a sharp upward spike. But don't look to bottom-fish these shares just yet, as an FDA rejection would send shares even lower. As with many biotechs, this is a high risk/high reward situation.
Other biotech stocks that are off this morning due to poorly-received date at the ASCO conference include Celldex Therapeutics (Nasdaq: CLDX) and Arqule (Nasdaq: ARQL) .
-------------------------------------
CVS down on Walgreen Move
Shares of CVS Caremark ( CVS ) are down nearly -7% after drugstore rival Walgreen ( WAG ) announced plans to stop using CVS' pharmacy benefit manager ( PBM ) arm, Caremark, for any new customers. CVS merged with Caremark three years ago, and many questioned whether the deal might lead to lost business for CVS, as rivals would essentially be ceding some profits to the merged entity. It may have taken longer than expected, but that finally happened. Walgreen cited other reasons for ending the relationship for any new clients, but no amount of spin could obscure the real reason. Some speculate that MedcoHealth Solutions ( MHS ) might win the contract from Walgreen. Shares of Medco are up nearly +4% today.
CVS took a risk by merging with a PBM. The deal brought in clear potential synergies, but those synergies would be lost if more clients grow uncomfortable doing business with an ostensible rival.
Action to Take --> At this point, the nearly $4 billion drop in CVS' value appears well larger than the impact of the lost Walgreen business. Investors are likely anticipating further pressures on the PBM business. But the core drugstore business looks poised for improvement as management is focusing on improving working capital and boosting free cash flow at the chain. Wait for the dust to settle, but shares are likely to climb higher in coming months if no other PBM clients defect.
-------------------------------------
Coldwater Creek moves Deeper into Value Territory
When we looked at Coldwater Creek (Nasdaq: CWTR) , on Thursday we suggested that shares were cheap but lacked any near-term catalysts. Well, shares fell further on Friday and are shedding another -6% this morning.
Action to Take --> As mutual funds and other holders continue to steadily exit the stock, it is pushing deeper into value territory. Further weakness would have been justified if the retailer were faced with open-ended losses or carried a lot of debt. That's not the case here, and if you have a long-term view, shares should now hold greater appeal as the price/sales ratio is by far the lowest of its peer group, and improved merchandising or an improving employment picture will eventually help to boost the sales and profit picture.
-- David Sterman
Staff Writer
StreetAuthority
Disclosure: David Sterman does not own shares of any security mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Biotech Investors are Dubious of Delcath Although many biotech firms are seeing nice gains on Monday after this weekend's annual ASCO cancer conference, shares of Delcath (Nasdaq: DCTH) are plunging more than -12% after the company conceded its promising drug delivery system can also prove very toxic and perhaps lethal if it is not administered correctly. Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . Investors could eventually reverse their negative reaction, as the drug delivery system did yield pretty impressive efficacy data.
|
Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . Biotech Investors are Dubious of Delcath Although many biotech firms are seeing nice gains on Monday after this weekend's annual ASCO cancer conference, shares of Delcath (Nasdaq: DCTH) are plunging more than -12% after the company conceded its promising drug delivery system can also prove very toxic and perhaps lethal if it is not administered correctly. ------------------------------------- CVS down on Walgreen Move Shares of CVS Caremark ( CVS ) are down nearly -7% after drugstore rival Walgreen ( WAG ) announced plans to stop using CVS' pharmacy benefit manager ( PBM ) arm, Caremark, for any new customers.
|
Biotech Investors are Dubious of Delcath Although many biotech firms are seeing nice gains on Monday after this weekend's annual ASCO cancer conference, shares of Delcath (Nasdaq: DCTH) are plunging more than -12% after the company conceded its promising drug delivery system can also prove very toxic and perhaps lethal if it is not administered correctly. Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . ------------------------------------- CVS down on Walgreen Move Shares of CVS Caremark ( CVS ) are down nearly -7% after drugstore rival Walgreen ( WAG ) announced plans to stop using CVS' pharmacy benefit manager ( PBM ) arm, Caremark, for any new customers.
|
Among the biggest losers in Monday's early trading are Delcath ( DCTH ) , CVS Caremark ( CVS ) and Coldwater Creek (Nasdaq: CWTR) . Biotech Investors are Dubious of Delcath Although many biotech firms are seeing nice gains on Monday after this weekend's annual ASCO cancer conference, shares of Delcath (Nasdaq: DCTH) are plunging more than -12% after the company conceded its promising drug delivery system can also prove very toxic and perhaps lethal if it is not administered correctly. CVS merged with Caremark three years ago, and many questioned whether the deal might lead to lost business for CVS, as rivals would essentially be ceding some profits to the merged entity.
|
7b134e41-5fb2-4aff-a21a-d6e87fafc0c0
|
715682.0
|
2010-04-27 00:00:00 UTC
|
In the News: This Company Is on a Tear, and It's Not Done Yet
|
DCTH
|
https://www.nasdaq.com/articles/news-company-tear-and-its-not-done-yet-2010-04-27
|
nan
|
nan
|
Late last month we recommended looking at Delcath Systems, Inc. (Nasdaq: DCTH) in the article "This Small Biotech Firm's Shares Could Rocket in the Next 30 Days." Well, guess what? DCTH's shares have, in fact, rocketed on positive results in its Phase III trial on its Delcath PHP system, which treats liver cancer. Shares today closed at $14.80, for a +119% gain in about a month. With that much upside behind us, is DCTH still worth buying?
I think so.
Delcath CEO Eammon Hobbe said last week that its proprietary device has a U.S. market potential of $745 million a year. He also said that it could be used as a platform technology to treat other types of cancer and that the potential U.S. market is $5.5 billion.
The company did not discuss -- and Wall Street isn't really considering -- the device's international opportunities. According to curelivercancer.org, 500,000 to 650,000 new cases of liver cancer are diagnosed globally each year, only 2% of which are in the United States.
Additionally, Delcath will announce the full trial data on June 5th, which could propel the shares further upward. The company also plans to submit an FDA application for its first approval by the middle of this year.
Keep in mind, Delcath has no revenue. If the company gets its drug approved -- the ultimate profit catalyst in this industry -- or a major pharmaceutical company buys it, an investment could pay off big time. In the meantime, good news in the coming months could move shares further upward. The company expects its first treatment to be approved in the United States in middle of next year.
Investors looking for big potential upside may still want to consider DCTH. Keep in mind, however, that bad news from its clinical trials or from the FDA could push shares down even quicker.
Anthony Haddad
Staff Writer
StreetAuthority
Disclosure: Anthony Haddad does not own shares of any security mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Late last month we recommended looking at Delcath Systems, Inc. (Nasdaq: DCTH) in the article "This Small Biotech Firm's Shares Could Rocket in the Next 30 Days." DCTH's shares have, in fact, rocketed on positive results in its Phase III trial on its Delcath PHP system, which treats liver cancer. With that much upside behind us, is DCTH still worth buying?
|
DCTH's shares have, in fact, rocketed on positive results in its Phase III trial on its Delcath PHP system, which treats liver cancer. Late last month we recommended looking at Delcath Systems, Inc. (Nasdaq: DCTH) in the article "This Small Biotech Firm's Shares Could Rocket in the Next 30 Days." With that much upside behind us, is DCTH still worth buying?
|
Late last month we recommended looking at Delcath Systems, Inc. (Nasdaq: DCTH) in the article "This Small Biotech Firm's Shares Could Rocket in the Next 30 Days." DCTH's shares have, in fact, rocketed on positive results in its Phase III trial on its Delcath PHP system, which treats liver cancer. With that much upside behind us, is DCTH still worth buying?
|
DCTH's shares have, in fact, rocketed on positive results in its Phase III trial on its Delcath PHP system, which treats liver cancer. Late last month we recommended looking at Delcath Systems, Inc. (Nasdaq: DCTH) in the article "This Small Biotech Firm's Shares Could Rocket in the Next 30 Days." With that much upside behind us, is DCTH still worth buying?
|
df293bdd-238e-443d-b9e6-0cb46521a187
|
715683.0
|
2010-03-25 00:00:00 UTC
|
This Small Biotech Firm's Shares Could Rocket in the Next 30 Days
|
DCTH
|
https://www.nasdaq.com/articles/small-biotech-firms-shares-could-rocket-next-30-days-2010-03-25
|
nan
|
nan
|
Every year, about a quarter million cases of liver cancer are diagnosed in the United States; around the world the number is estimated to exceed two million. According to the American Cancer Society, the five-year survival rate of liver cancer is just 10.8%. This is one of the most fatal of all cancers -- prostate (98.4%), breast (88.6%), and even lung cancer (15.0%) have significantly better survival rates.
Today, surgery is the only option to cure liver cancer, and it comes in two forms: tumor removal and transplant. Completely removing the tumor is not usually possible, as the cancer is often large, in many different parts of the liver, or has spread beyond the liver. Additionally, most people with cirrhosis have too little healthy liver remaining to allow for surgery.
Transplant is no panacea, either, even though survival rates for those that do get one are about 75%, according to the American Liver Foundation. Liver transplants cost over $500,000, and few livers are available. One notable beneficiary is Apple Inc. (Nasdaq: AAPL) co-founder and CEO Steve Jobs, 54, who received a liver transplant about a year ago after suffering complications from pancreatic cancer several years earlier.
In most instances involving liver cancer, transplants are used in only select cases where there are a few small tumors that cannot be removed by surgery. There are also non-surgical treatments, including radiation and chemotherapy, neither of which cures the disease or even helps people live longer.
New treatments are obviously needed for the vast majority of cases that do not qualify for surgery.
One company has a treatment currently in Phase III FDA trials that may change the way doctors treat liver cancer. This treatment has a fast-track designation from the U.S. Food and Drug Administration ( FDA ), meaning that the FDA believes that it shows promise in treating a life-threatening disease that no other treatment currently addresses well.
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. The company expects data from its current clinical trial available in the next month and to submit its FDA application for its first approval, a treatment for metastatic melanoma of the liver -- skin cancer that has spread to the liver -- by the middle of this year.
The treatment isolates the liver from the rest of the body by restricting blood flow. Then, a huge dose of chemotherapy, about ten times what is typically administered intravenously, is given to the liver. But since it is targeted and not spread throughout the body, the liver sees about 100 times more drugs. Blood in the liver is then removed, cleaned of the toxic drugs, and returned to the body. This delivery system allows for much more of the drugs to go where doctors want them while minimizing the amount of drugs that get exposed to the rest of the body.
While focused on the liver, the company's drug delivery technique could be more broadly used. Other organs can be isolated and treated in the same manner, and the company plans to address these in the future, either itself or through partnership deals. The company has received the go-ahead from the FDA to begin Phase III trials for its treatment on primary liver cancer, but it is currently looking for partners in Asia to do the study as it will be less expensive and easier to find patients. In February, Delcath announced an agreement with the Taiwanese company Chi-Fu Trading. The agreement gives Chi-Fu the exclusive right to market Delcath's liver treatment in Taiwan and could bring in up to $10 million for the company, assuming the treatment received the necessary approvals.
As a biotech development company, Delcath has no revenue. If the company gets its drug approved -- the ultimate profit catalyst in this industry -- an investment would likely pay off big time. In the meantime, good news in the coming month could move shares upward.
The company has said that it expects approval of its treatment for metastatic melanoma of the liver in mid-2011. At the end of 2009, the company had about $35.5 million in cash, no debt, and a burn-rate of about $1.8 million per month.
Risk-tolerant investors looking for big potential upside may consider DCTH. Keep in mind, however, that bad news from its clinical trials or from the FDA could push shares down quickly.
Anthony Haddad
Staff Writer
StreetAuthority
Disclosure: Anthony Haddad does not own shares of any security mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. Risk-tolerant investors looking for big potential upside may consider DCTH. One company has a treatment currently in Phase III FDA trials that may change the way doctors treat liver cancer.
|
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. Risk-tolerant investors looking for big potential upside may consider DCTH. One company has a treatment currently in Phase III FDA trials that may change the way doctors treat liver cancer.
|
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. Risk-tolerant investors looking for big potential upside may consider DCTH. The company expects data from its current clinical trial available in the next month and to submit its FDA application for its first approval, a treatment for metastatic melanoma of the liver -- skin cancer that has spread to the liver -- by the middle of this year.
|
Delcath Systems (Nasdaq: DCTH) is a $246.4 million New York-based drug developer focused on treatments for liver cancer. Risk-tolerant investors looking for big potential upside may consider DCTH. One company has a treatment currently in Phase III FDA trials that may change the way doctors treat liver cancer.
|
a207378a-5874-4bf5-902b-6b8042f62631
|
715684.0
|
2023-12-11 00:00:00 UTC
|
Ohio man asks appeals court to revive massive PFAS class action against 3M, DuPont
|
DD
|
https://www.nasdaq.com/articles/ohio-man-asks-appeals-court-to-revive-massive-pfas-class-action-against-3m-dupont
|
nan
|
nan
|
By Clark Mindock
Dec 12 (Reuters) - An Ohio resident has told a U.S. appeals court its recent ruling putting an end to a massive class action lawsuit that accused 3M MMM.N, Corteva Inc CTVA.N subsidiary E.I. du Pont de Nemours and Co and other companies of putting people's health at risk by exposing them to toxic “forever chemicals” could send a dangerous message to chemical manufacturers facing similar claims, and deserves a second look.
Kevin Hardwick, the lead plaintiff in the lawsuit, on Monday asked the full 6th U.S. Circuit Court of Appeals to reconsider a November decision that dismantled the class action that would have allowed roughly all of Ohio's 11.8 million residents to sue the companies as a group.
Hardwick said the decision would allow companies to escape potential liability for per- and polyfluoroalkyl substances, or PFAS, pollution at early stages of litigation if numerous defendants produced the mostly identical chemicals allegedly causing harm.
He said the 6th Circuit's ruling incorrectly concluded he did not sufficiently trace his harms to the companies and the chemicals they produced, and said he provided enough evidence for the case to proceed.
“If the decision stands, the lesson is that companies should conspire together to poison people with the same poison and none of them can be held responsible,” Hardwick said.
PFAS are a family of thousands of chemicals that have been used in a wide range of products including non-stick pans and clothing, and have been tied to cancer and other diseases.
A 3M spokesperson said the company disagrees with Hardwick's arguments. A Corteva representative did not immediately respond to requests for comment on Tuesday.
A three-judge panel had found Hardwick filed too broad a complaint against the manufacturers, and had not shown that the PFAS found in his body could be traced directly to the defendants, noting there are potentially thousands of companies that have manufactured PFAS.
But Hardwick said that was not true, since there are just 10 companies that actually manufactured the specific PFAS at issue in the case. While many other companies may have sold products with the chemicals, each of the 10 defendants is ultimately responsible for contaminating Ohio residents’ blood with those PFAS, Hardwick said.
PFAS are often referred to as forever chemicals because they do not easily break down once released into the environment or absorbed into the human body.
The lawsuit seeks to establish a fund to monitor Ohio residents for health impacts from PFAS exposure, and other relief. It is among thousands that have been filed against 3M, DuPont and others in recent years over alleged PFAS contamination.
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N DuPont de Nemours DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
The U.S. Environmental Protection Agency has called PFAS an “urgent public health and environmental issue," and has taken steps to regulate PFAS, including in drinking water.
The case is Hardwick v. 3M Co, 6th U.S. Circuit Court of Appeals, No. 22-3765.
For Hardwick: Robert Bilott, Aaron Herzig and William Braff of Taft Stettinius & Hollister
For the chemical companies: Theodore Grossman, Louis Chaiten and James Saywell of Jones Day
Read more:
3M, DuPont defeat massive class action over forever chemicals
(Reporting by Clark Mindock)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N DuPont de Nemours DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. By Clark Mindock Dec 12 (Reuters) - An Ohio resident has told a U.S. appeals court its recent ruling putting an end to a massive class action lawsuit that accused 3M MMM.N, Corteva Inc CTVA.N subsidiary E.I. Circuit Court of Appeals to reconsider a November decision that dismantled the class action that would have allowed roughly all of Ohio's 11.8 million residents to sue the companies as a group.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N DuPont de Nemours DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. By Clark Mindock Dec 12 (Reuters) - An Ohio resident has told a U.S. appeals court its recent ruling putting an end to a massive class action lawsuit that accused 3M MMM.N, Corteva Inc CTVA.N subsidiary E.I. For Hardwick: Robert Bilott, Aaron Herzig and William Braff of Taft Stettinius & Hollister For the chemical companies: Theodore Grossman, Louis Chaiten and James Saywell of Jones Day Read more: 3M, DuPont defeat massive class action over forever chemicals (Reporting by Clark Mindock) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N DuPont de Nemours DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. A three-judge panel had found Hardwick filed too broad a complaint against the manufacturers, and had not shown that the PFAS found in his body could be traced directly to the defendants, noting there are potentially thousands of companies that have manufactured PFAS. While many other companies may have sold products with the chemicals, each of the 10 defendants is ultimately responsible for contaminating Ohio residents’ blood with those PFAS, Hardwick said.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N DuPont de Nemours DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. By Clark Mindock Dec 12 (Reuters) - An Ohio resident has told a U.S. appeals court its recent ruling putting an end to a massive class action lawsuit that accused 3M MMM.N, Corteva Inc CTVA.N subsidiary E.I. He said the 6th Circuit's ruling incorrectly concluded he did not sufficiently trace his harms to the companies and the chemicals they produced, and said he provided enough evidence for the case to proceed.
|
c8662452-24c2-4a27-9066-55f258196ddf
|
715685.0
|
2023-12-11 00:00:00 UTC
|
DuPont (DD) Gains on Innovation and Spectrum Plastics Buyout
|
DD
|
https://www.nasdaq.com/articles/dupont-dd-gains-on-innovation-and-spectrum-plastics-buyout-0
|
nan
|
nan
|
DuPont de Nemours, Inc. DD is expected to benefit from its innovation-driven investment, the Spectrum Plastics Group acquisition and productivity and pricing actions amid headwinds including weak demand in specific businesses.
The company’s shares are up 1.5% over a year against a 14% decline of its industry.
Image Source: Zacks Investment Research
DuPont, a Zacks Rank #3 (Hold) stock, remains focused on driving growth though innovation and new product development. Its innovation-driven investment is focused on several high-growth areas. DD remains committed to drive returns from its R&D investment.
The company, in August 2023, completed the buyout of leading manufacturer of specialty medical devices and components, Spectrum Plastics Group from AEA Investors for $1.75 billion. The acquired business, with annual sales of around $500 million, has been integrated into the industrial solutions line of business within the Electronics & Industrial segment.
The acquisition strengthens DuPont’s existing position in stable and fast-growing healthcare end markets. It is also in sync with its focus on high-growth, customer-driven innovation for the healthcare market. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
DuPont is also benefiting from cost synergy savings and productivity improvement actions. Its structural cost actions are contributing to its bottom line. DD also continues to implement strategic price increases in the wake of cost inflation. These actions are likely to support its results in 2023. DuPont is also planning additional restructuring actions and expects savings from these actions to be realized from the first quarter of 2024. It is also managing its portfolio with an aim for value creation. It is divesting non-core assets to focus more on high-growth, high-margin businesses.
However, the company’s water business faces challenges from the slowdown in China. Its water solutions business is expected to see sales moderation in the fourth quarter of 2023 due to softer demand in China resulting from the slowdown in the industrial economy and inventory de-stocking.
Moreover, the weakness in construction end markets is expected to impact the shelter solutions business within the Water & Protection segment in 2023. Also, customer de-stocking in shelter solutions is expected to continue through the fourth quarter.
While the company is seeing a recovery in Interconnect Solutions, the business is expected to continue to be impacted by reduced consumer electronics spending in the near term. Softer smartphone, personal computing and tablet demand is likely to weigh on volumes in this business over the near term.
DuPont de Nemours, Inc. Price and Consensus
DuPont de Nemours, Inc. price-consensus-chart | DuPont de Nemours, Inc. Quote
Stocks to Consider
Better-ranked stocks worth a look in the basic materials space include Denison Mines Corp. DNN, Axalta Coating Systems Ltd. AXTA and The Andersons Inc. ANDE.
Denison Mines has a projected earnings growth rate of 100% for the current year. DNN has a trailing four-quarter earnings surprise of roughly 225%, on average. The stock is up around 58% in a year. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, the Zacks Consensus Estimate for Axalta Coating Systems’ current-year earnings has been revised upward by 8.2%. AXTA, carrying a Zacks Rank #1, beat the Zacks Consensus Estimate in three of the last four quarters while missing in one quarter, with the average earnings surprise being 6.7%. The company’s shares have gained around 27% in the past year.
Andersons currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for ANDE's current-year earnings has been revised 5.1% upward over the past 60 days. Andersons beat the Zacks Consensus Estimate in three of the last four quarters while missed once. It delivered a trailing four-quarter earnings surprise of 32.8%, on average. ANDE shares have rallied roughly 50% in a year.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Andersons, Inc. (ANDE) : Free Stock Analysis Report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
Denison Mine Corp (DNN) : Free Stock Analysis Report
Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DuPont de Nemours, Inc. DD is expected to benefit from its innovation-driven investment, the Spectrum Plastics Group acquisition and productivity and pricing actions amid headwinds including weak demand in specific businesses. DD remains committed to drive returns from its R&D investment. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
|
DuPont de Nemours, Inc. DD is expected to benefit from its innovation-driven investment, the Spectrum Plastics Group acquisition and productivity and pricing actions amid headwinds including weak demand in specific businesses. Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DD remains committed to drive returns from its R&D investment.
|
Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DuPont de Nemours, Inc. DD is expected to benefit from its innovation-driven investment, the Spectrum Plastics Group acquisition and productivity and pricing actions amid headwinds including weak demand in specific businesses. DD remains committed to drive returns from its R&D investment.
|
DuPont de Nemours, Inc. DD is expected to benefit from its innovation-driven investment, the Spectrum Plastics Group acquisition and productivity and pricing actions amid headwinds including weak demand in specific businesses. DD remains committed to drive returns from its R&D investment. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
|
0811dbd8-0750-48a9-9733-b086ee222017
|
715686.0
|
2023-12-08 00:00:00 UTC
|
DuPont (DD) Launches Tedlar PVF Solutions and PVF Coating
|
DD
|
https://www.nasdaq.com/articles/dupont-dd-launches-tedlar-pvf-solutions-and-pvf-coating
|
nan
|
nan
|
DuPont de Nemours Inc. DD announced that Coryor Surface Treatment Company Ltd. and Nippon Paint Taiwan have introduced a range of new offerings in the Taipei Building Show, Taiwan's largest building materials exhibition, including printed Tedlar PVF solutions and PVF coating.
DuPont collaborated closely with Coryor to launch the printed PVF film solutions on display in the show. This innovative Tedlar-based PVF product is part of Coryor's AAMALON applications series, which focuses on better weathering resistance among other performance benefits. Tedlar films have been tested in the harshest environments for more than six decades. From preventing weathering on solar panels to keeping airplane interiors looking clean and new, Tedlar film provides unrivaled UV and weather durability.
DD will also co-launch a PVF coating solution with Nippon Paint at the Taipei show, in addition to the Coryor printed products. Tedlar PVF coatings are designed for building exteriors, including those exposed to harsh environments, and provide long-lasting finishes for a variety of exterior and interior metal applications.
PVF coatings are unique in providing superior chemical resistance, flexibility, hydrolytic stability and UV stability, while outperforming any current coil and extrusion coating resin on the market. It provides excellent chemical resistance and coating bendability performance, making it an ideal solution for surface protection against corrosion, fading and cracking.
Shares of DuPont have gained 2.7% over the past year against a 13.6% decline of its industry.
Image Source: Zacks Investment Research
The company, on its third-quarter call, said that it now sees net sales for 2023 to be around $12,170 million. Adjusted earnings per share for 2023 are forecast to be around $3.45. Also, Operating EBITDA for 2023 is expected to be around $2,975 million.
For the fourth quarter, demand for consumer electronics is anticipated to remain in line with the third quarter, as indicated by consistent order rates from customers. This will likely result in a sequential sales improvement in the Semiconductor Technologies segment. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
DuPont de Nemours, Inc. Price and Consensus
DuPont de Nemours, Inc. price-consensus-chart | DuPont de Nemours, Inc. Quote
Zacks Rank & Key Picks
DuPont currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space include Denison Mines Corp. DNN, Axalta Coating Systems Ltd. AXTA and The Andersons Inc. ANDE.
Denison Mines has a projected earnings growth rate of 100% for the current year. It currently flaunts a Zacks Rank #1 (Strong Buy). DNN has a trailing four-quarter earnings surprise of roughly 225%, on average. The stock is up around 63% in a year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Axalta has a projected earnings growth rate of 5.4% for the current year. It currently sports a Zacks Rank #1. AXTA has a trailing four-quarter earnings surprise of roughly 6.7%, on average. The stock is up around 27.3% in a year.
Andersons currently carries a Zacks Rank #2 (Buy). The stock has gained roughly 47.5% in the past year. ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Andersons, Inc. (ANDE) : Free Stock Analysis Report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
Denison Mine Corp (DNN) : Free Stock Analysis Report
Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DuPont de Nemours Inc. DD announced that Coryor Surface Treatment Company Ltd. and Nippon Paint Taiwan have introduced a range of new offerings in the Taipei Building Show, Taiwan's largest building materials exhibition, including printed Tedlar PVF solutions and PVF coating. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China. DD will also co-launch a PVF coating solution with Nippon Paint at the Taipei show, in addition to the Coryor printed products.
|
DuPont de Nemours Inc. DD announced that Coryor Surface Treatment Company Ltd. and Nippon Paint Taiwan have introduced a range of new offerings in the Taipei Building Show, Taiwan's largest building materials exhibition, including printed Tedlar PVF solutions and PVF coating. Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DD will also co-launch a PVF coating solution with Nippon Paint at the Taipei show, in addition to the Coryor printed products.
|
DuPont de Nemours Inc. DD announced that Coryor Surface Treatment Company Ltd. and Nippon Paint Taiwan have introduced a range of new offerings in the Taipei Building Show, Taiwan's largest building materials exhibition, including printed Tedlar PVF solutions and PVF coating. Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DD will also co-launch a PVF coating solution with Nippon Paint at the Taipei show, in addition to the Coryor printed products.
|
DuPont de Nemours Inc. DD announced that Coryor Surface Treatment Company Ltd. and Nippon Paint Taiwan have introduced a range of new offerings in the Taipei Building Show, Taiwan's largest building materials exhibition, including printed Tedlar PVF solutions and PVF coating. DD will also co-launch a PVF coating solution with Nippon Paint at the Taipei show, in addition to the Coryor printed products. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
|
66016a87-7821-4988-8463-55b85e30d421
|
715687.0
|
2023-12-07 00:00:00 UTC
|
Guru Fundamental Report for DD
|
DD
|
https://www.nasdaq.com/articles/guru-fundamental-report-for-dd-13
|
nan
|
nan
|
Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks for companies returning cash to shareholders via dividends, buybacks and debt paydown.
DUPONT DE NEMOURS INC (DD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
UNIVERSE: PASS
NET PAYOUT YIELD: PASS
QUALITY AND DEBT: PASS
VALUATION: PASS
RELATIVE STRENGTH: PASS
SHAREHOLDER YIELD: PASS
Detailed Analysis of DUPONT DE NEMOURS INC
DD Guru Analysis
DD Fundamental Analysis
More Information on Meb Faber
Meb Faber Portfolio
About Meb Faber: Meb Faber is the founder of Cambria Investments. His research has covered a wide spectrum of the investment world, including topics like shareholder yield, trend following, global asset allocation and home country bias. His shareholder yield strategy, which is based on his book "Shareholder Yield" and forms the basis for an ETF of the same name, looks for companies that are focused on creating value for shareholders by returning cash to them in the form of dividends, share buybacks and debt paydown. Meb is also the author of 4 other books and numerous white papers on investing related topics.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DUPONT DE NEMOURS INC (DD) is a large-cap growth stock in the Biotechnology & Drugs industry. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber.
|
Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD).
|
Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD).
|
Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber.
|
f027e4a3-7450-4e8d-ac5e-53aa2b0461df
|
715688.0
|
2023-12-07 00:00:00 UTC
|
Interesting DD Call Options For January 2024
|
DD
|
https://www.nasdaq.com/articles/interesting-dd-call-options-for-january-2024
|
nan
|
nan
|
Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new January 2024 contracts and identified the following call contract of particular interest.
The call contract at the $72.00 strike price has a current bid of 5 cents. If an investor was to purchase shares of DD stock at the current price level of $71.28/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $72.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 1.08% if the stock gets called away at the January 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red:
Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 0.07% boost of extra return to the investor, or 0.51% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $71.28) to be 24%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
ETFs Holding BEP
SITO market cap history
Funds Holding NGVT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration.
|
Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration.
|
If an investor was to purchase shares of DD stock at the current price level of $71.28/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $72.00. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted).
|
Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new January 2024 contracts and identified the following call contract of particular interest. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.
|
6ea1dbc3-28a1-44c0-98c5-7dcb0525eddc
|
715689.0
|
2023-12-07 00:00:00 UTC
|
BASF gives agriculture, battery units more autonomy but no plan to split
|
DD
|
https://www.nasdaq.com/articles/basf-gives-agriculture-battery-units-more-autonomy-but-no-plan-to-split
|
nan
|
nan
|
By Ludwig Burger and Patricia Weiss
FRANKFURT, Dec 7 (Reuters) - BASF BASFn.DE plans to turn its agriculture, battery materials and coatings businesses into autonomous units to try to boost earnings, a major revamp for the German chemicals giant that has traditionally been highly integrated.
The company, with sales of 87 billion euros ($94 billion) last year, will create legally separate entities for the three units, trade union IGBCE said in a statement on Thursday, which was confirmed by a company spokesperson.
However, "there is no intention to sell these businesses," CEO Martin Brudermueller said during an investor conference. He earlier said external investment partners could be taken on board to share the cost of expanding the battery business.
BASF has already made its catalytic converter business, which relies on combustion-engine powered cars, a standalone subsidiary, which it said in October there were no current plans to sell.
BASF's shares rose as much as 2% before paring gains to close 1.4% higher at 45 euros each.
Other industrial groups in Germany, including ThyssenKruppTKAG.DE, have pursued separation moves, which are typically welcomed by investors who often prefer to buy shares in pure-play companies.
Bayer BAYGn.DE, a rival maker of seeds and crop chemicals, last month said it was considering breaking up its business to improve a battered share price, while chemicals distributor Brenntag BNRGn.DE will reorganise into two independent divisions as it faces pressure from activist investors.
"When something is separated, people draw their own conclusions and expect a sale," the head of BASF's works council, Sinischa Horvat, told Reuters, although he said management had assured him this was not the case.
The revamp comes as Brudermueller gets ready to retire from BASF in April 2024 to become non-executive chairman of Mercedes Benz MBGn.DE. Markus Kamieth, in charge of BASF's Asian operations and chief technology officer Melanie Maas-Brunner are vying to succeed him, a person familiar with the matter has told Reuters.
VERBUND
Unlike major rivals such as Dow DOW.N and Dupont DD.N, BASF has traditionally relied on integrated chemical complexes known as Verbund, producing most of its intermediate substances in house to cut transportation and energy costs and utilise by-products.
"Businesses that are less deeply integrated into the Verbund will gain more space to meet the needs of their specific customer industries while keeping the benefits of an integrated company," BASF said in a statement.
The union said close to 2,500 employees would be affected by the overhaul at BASF's Ludwigshafen headquarters, or almost 10% of staff at the site.
Hit by a subdued European home market, BASF in October mapped out further cost cuts, scaled back investment and said 2023 earnings and sales would be at the lower end of target ranges due to an "extremely uncertain" global macroeconomic outlook.
"The likelihood is that at least 2024 will be another difficult year," Brudermueller said.
Europe's largest chemical company also said that it would stop providing a sales outlook from January, and would guide for earnings before interest, taxes, depreciation and amortisation (EBITDA) before special items rather than EBIT.
BASF's Agricultural Solutions unit had 10.3 billion euros in sales last year, competing with Bayer, Corteva CTVA.N and China's Syngenta, while revenue at the coatings business was 4.2 billion euros, selling mainly to carmakers and repair shops.
Battery materials and related recycling business units generated sales of more than 1 billion but, along with a new chemical complex in Zhanjiang in southern China, it is one of the areas where BASF invests the most.
On China, Brudermueller said clients are starting to restock, "still soft, but definitely a big step forward".
(Reporting by Ludwig Burger and Patricia Weiss, additional reporting by Andrey Sychev Editing by Miranda Murray, Kirsten Donovan)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Unlike major rivals such as Dow DOW.N and Dupont DD.N, BASF has traditionally relied on integrated chemical complexes known as Verbund, producing most of its intermediate substances in house to cut transportation and energy costs and utilise by-products. (Reporting by Ludwig Burger and Patricia Weiss, additional reporting by Andrey Sychev Editing by Miranda Murray, Kirsten Donovan) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. By Ludwig Burger and Patricia Weiss FRANKFURT, Dec 7 (Reuters) - BASF BASFn.DE plans to turn its agriculture, battery materials and coatings businesses into autonomous units to try to boost earnings, a major revamp for the German chemicals giant that has traditionally been highly integrated.
|
Unlike major rivals such as Dow DOW.N and Dupont DD.N, BASF has traditionally relied on integrated chemical complexes known as Verbund, producing most of its intermediate substances in house to cut transportation and energy costs and utilise by-products. (Reporting by Ludwig Burger and Patricia Weiss, additional reporting by Andrey Sychev Editing by Miranda Murray, Kirsten Donovan) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. By Ludwig Burger and Patricia Weiss FRANKFURT, Dec 7 (Reuters) - BASF BASFn.DE plans to turn its agriculture, battery materials and coatings businesses into autonomous units to try to boost earnings, a major revamp for the German chemicals giant that has traditionally been highly integrated.
|
Unlike major rivals such as Dow DOW.N and Dupont DD.N, BASF has traditionally relied on integrated chemical complexes known as Verbund, producing most of its intermediate substances in house to cut transportation and energy costs and utilise by-products. (Reporting by Ludwig Burger and Patricia Weiss, additional reporting by Andrey Sychev Editing by Miranda Murray, Kirsten Donovan) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. By Ludwig Burger and Patricia Weiss FRANKFURT, Dec 7 (Reuters) - BASF BASFn.DE plans to turn its agriculture, battery materials and coatings businesses into autonomous units to try to boost earnings, a major revamp for the German chemicals giant that has traditionally been highly integrated.
|
Unlike major rivals such as Dow DOW.N and Dupont DD.N, BASF has traditionally relied on integrated chemical complexes known as Verbund, producing most of its intermediate substances in house to cut transportation and energy costs and utilise by-products. (Reporting by Ludwig Burger and Patricia Weiss, additional reporting by Andrey Sychev Editing by Miranda Murray, Kirsten Donovan) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. By Ludwig Burger and Patricia Weiss FRANKFURT, Dec 7 (Reuters) - BASF BASFn.DE plans to turn its agriculture, battery materials and coatings businesses into autonomous units to try to boost earnings, a major revamp for the German chemicals giant that has traditionally been highly integrated.
|
bb4e96cd-b7df-4390-99d0-717235e1a9a1
|
715690.0
|
2023-12-07 00:00:00 UTC
|
Why You Should Retain DuPont (DD) Stock in Your Portfolio
|
DD
|
https://www.nasdaq.com/articles/why-you-should-retain-dupont-dd-stock-in-your-portfolio-2
|
nan
|
nan
|
DuPont de Nemours, Inc. DD is expected to gain from its productivity and pricing actions, innovation-driven investment and the Spectrum Plastics Group acquisition amid headwinds including demand softness in certain areas.
The company’s shares are up 1.3% over a year against a 14.5% decline of its industry.
Image Source: Zacks Investment Research
Let’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
Productivity, Innovation & Spectrum Buyout to Aid Results
DuPont remains focused on driving growth though innovation and new product development. Its innovation-driven investment is focused on several high-growth areas. DD remains committed to drive returns from its R&D investment.
The company, in August 2023, completed the buyout of leading manufacturer of specialty medical devices and components, Spectrum Plastics Group from AEA Investors for $1.75 billion. The acquired business, with annual sales of around $500 million, has been integrated into the industrial solutions line of business within the Electronics & Industrial segment.
The acquisition strengthens DuPont’s existing position in stable and fast-growing healthcare end markets. It is also in sync with its focus on high-growth, customer-driven innovation for the healthcare market. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
DuPont is also benefiting from cost synergy savings and productivity improvement actions. Its structural cost actions are contributing to its bottom line. DD also continues to implement strategic price increases in the wake of cost inflation. These actions are likely to support its results in 2023. The company is also managing its portfolio with an aim for value creation. It is divesting non-core assets to focus more on high-growth, high-margin businesses.
Softness in Water Business Ails
The company’s water business faces challenges from the slowdown in China. Its water solutions business is expected to see sales moderation in the fourth quarter of 2023 due to softer demand in China resulting from the slowdown in the industrial economy and inventory de-stocking.
The softness in construction end markets is also expected to impact the shelter solutions business within the Water & Protection segment in 2023. Also, customer de-stocking in shelter solutions is expected to continue through the fourth quarter.
While the company is seeing a recovery in Interconnect Solutions, the business is expected to continue to be impacted by reduced consumer electronics spending in the near term. Interconnect Solutions witnessed an 11% year-over-year decrease in organic sales in the third quarter, partly driven by reduced consumer electronics volumes and inventory de-stocking. Softer smartphone, personal computing and tablet demand is likely to weigh on volumes in this business over the near term.
DuPont de Nemours, Inc. Price and Consensus
DuPont de Nemours, Inc. price-consensus-chart | DuPont de Nemours, Inc. Quote
Stocks to Consider
Better-ranked stocks worth a look in the basic materials space include Denison Mines Corp. DNN, Axalta Coating Systems Ltd. AXTA and The Andersons Inc. ANDE.
Denison Mines has a projected earnings growth rate of 100% for the current year. DNN has a trailing four-quarter earnings surprise of roughly 225%, on average. The stock is up around 64% in a year. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, the Zacks Consensus Estimate for Axalta Coating Systems’ current-year earnings has been revised upward by 8.2%. AXTA, carrying a Zacks Rank #1, beat the Zacks Consensus Estimate in three of the last four quarters while missing in one quarter, with the average earnings surprise being 6.7%. The company’s shares have gained around 24% in the past year.
Andersons currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for ANDE's current-year earnings has been revised 5.1% upward over the past 60 days. Andersons beat the Zacks Consensus Estimate in three of the last four quarters while missed once. It delivered a trailing four-quarter earnings surprise of 32.8%, on average. ANDE shares have rallied roughly 45% in a year.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They've already closed 162 positions with double- and triple-digit gains in 2023 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Andersons, Inc. (ANDE) : Free Stock Analysis Report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
Denison Mine Corp (DNN) : Free Stock Analysis Report
Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DuPont de Nemours, Inc. DD is expected to gain from its productivity and pricing actions, innovation-driven investment and the Spectrum Plastics Group acquisition amid headwinds including demand softness in certain areas. DD remains committed to drive returns from its R&D investment. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
|
DuPont de Nemours, Inc. DD is expected to gain from its productivity and pricing actions, innovation-driven investment and the Spectrum Plastics Group acquisition amid headwinds including demand softness in certain areas. Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DD remains committed to drive returns from its R&D investment.
|
Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DuPont de Nemours, Inc. DD is expected to gain from its productivity and pricing actions, innovation-driven investment and the Spectrum Plastics Group acquisition amid headwinds including demand softness in certain areas. DD remains committed to drive returns from its R&D investment.
|
DuPont de Nemours, Inc. DD is expected to gain from its productivity and pricing actions, innovation-driven investment and the Spectrum Plastics Group acquisition amid headwinds including demand softness in certain areas. DD remains committed to drive returns from its R&D investment. The addition of Spectrum is expected to boost revenues in the Electronics & Industrial segment.
|
f26307be-b81f-40cc-b11c-31bfcf7af6f9
|
715691.0
|
2023-12-04 00:00:00 UTC
|
June 2025 Options Now Available For DuPont (DD)
|
DD
|
https://www.nasdaq.com/articles/june-2025-options-now-available-for-dupont-dd
|
nan
|
nan
|
Investors in DuPont (Symbol: DD) saw new options begin trading today, for the June 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 564 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new June 2025 contracts and identified one put and one call contract of particular interest.
The put contract at the $70.00 strike price has a current bid of $4.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $70.00, but will also collect the premium, putting the cost basis of the shares at $66.00 (before broker commissions). To an investor already interested in purchasing shares of DD, that could represent an attractive alternative to paying $71.20/share today.
Because the $70.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 5.71% return on the cash commitment, or 3.70% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for DuPont, and highlighting in green where the $70.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $72.50 strike price has a current bid of $7.00. If an investor was to purchase shares of DD stock at the current price level of $71.20/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $72.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 11.66% if the stock gets called away at the June 2025 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.50 strike highlighted in red:
Considering the fact that the $72.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 9.83% boost of extra return to the investor, or 6.36% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 250 trading day closing values as well as today's price of $71.20) to be 24%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
ICHR YTD Return
Top Ten Hedge Funds Holding VENA
ESOA market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.50 strike highlighted in red: Considering the fact that the $72.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.50 strike highlighted in red: Considering the fact that the $72.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in DuPont (Symbol: DD) saw new options begin trading today, for the June 2025 expiration.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.50 strike highlighted in red: Considering the fact that the $72.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted).
|
At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new June 2025 contracts and identified one put and one call contract of particular interest. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.50 strike highlighted in red: Considering the fact that the $72.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.
|
a92cd3b1-3a2f-471b-88c3-9a898774371f
|
715692.0
|
2023-12-01 00:00:00 UTC
|
Why Is DuPont de Nemours (DD) Up 5% Since Last Earnings Report?
|
DD
|
https://www.nasdaq.com/articles/why-is-dupont-de-nemours-dd-up-5-since-last-earnings-report
|
nan
|
nan
|
A month has gone by since the last earnings report for DuPont de Nemours (DD). Shares have added about 5% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is DuPont de Nemours due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
DuPont's Q3 Earnings Surpass Estimates, Revenues Lag
DuPont reported earnings from continuing operations of 62 cents per share for third-quarter 2023, down from 69 cents per share in the year-ago quarter.
Barring one-time items, earnings came in at 92 cents per share for the reported quarter, topping the Zacks Consensus Estimate of 84 cents.
DuPont raked in net sales of around $3.06 billion, down 8% from the year-ago quarter. It lagged the Zacks Consensus Estimate of $3.15 billion. The company saw a 10% decline in organic sales in the quarter, modestly offset by a favorable portfolio impact of 2%.
Segment Highlights
The company’s Electronics & Industrial segment recorded net sales of around $1.37 billion in the reported quarter, down 9% on a year-over-year comparison basis. It was above our estimate of $1.34 billion. Organic sales fell 13% due to a 12% decline in volumes and a 1% fall in prices.
The Semiconductor Technologies business reported a high-teen decline in organic sales due to inventory destocking and reduced semiconductor fab utilization caused by weak consumer electronics demand. However, on a reported basis, sales remained flat sequentially. Interconnect Solutions also witnessed an 11% year-over-year decrease in organic sales, driven by reduced consumer electronics volumes, inventory destocking, and lower metals price pass-through, but reported an 8% sequential increase. In the Industrial Solutions business, organic sales were down by a high-single-digit percentage, primarily due to biopharma market inventory destocking and lower demand in electronics-related sectors, partially offset by increased demand for OLED materials.
Net sales in the Water & Protection unit were roughly $1.41 billion, down 8% on a year-over-year comparison basis. The figure was below our estimate of $1.46 billion. Sales fell due to a 9% decline in volume, slightly offset by a 1% increase in price.
Safety Solutions reported a high-single-digit decline in organic sales, primarily due to volume declines resulting from channel inventory destocking. Shelter Solutions also experienced a high-single-digit organic sales decrease, driven by ongoing softness in the construction market, including inventory destocking. Water Solutions saw a mid-single-digit decline in organic sales, mainly due to lower volumes resulting from weaker industrial demand and distributor inventory destocking in China.
Financials
DuPont had cash and cash equivalents of roughly $1.34 billion at the end of the quarter, down around 25% year over year. Long-term debt was around $7.74 billion, down about 26.7% year over year.
The company also generated operating cash flow from continuing operations of $740 million during the quarter.
Guidance
The company now sees net sales for 2023 to be around $12.17 billion. Adjusted earnings per share for 2023 are forecast to be around $3.45. Also, Operating EBITDA for 2023 is expected to be around $2.97 billion.
For the fourth quarter, demand for consumer electronics is anticipated to remain in line with the third quarter, as indicated by consistent order rates from customers. This will likely result in a sequential sales improvement in the Semiconductor Technologies segment. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -5.6% due to these changes.
VGM Scores
Currently, DuPont de Nemours has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, DuPont de Nemours has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
DuPont de Nemours is part of the Zacks Chemical - Diversified industry. Over the past month, Olin (OLN), a stock from the same industry, has gained 7.6%. The company reported its results for the quarter ended September 2023 more than a month ago.
Olin reported revenues of $1.67 billion in the last reported quarter, representing a year-over-year change of -28%. EPS of $0.82 for the same period compares with $2.18 a year ago.
Olin is expected to post earnings of $0.29 per share for the current quarter, representing a year-over-year change of -79.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -23.2%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #5 (Strong Sell) for Olin. Also, the stock has a VGM Score of B.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
Olin Corporation (OLN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A month has gone by since the last earnings report for DuPont de Nemours (DD). Shares have added about 5% in that time frame, underperforming the S&P 500. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
|
Click to get this free report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Olin Corporation (OLN) : Free Stock Analysis Report To read this article on Zacks.com click here. A month has gone by since the last earnings report for DuPont de Nemours (DD). Shares have added about 5% in that time frame, underperforming the S&P 500.
|
Click to get this free report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Olin Corporation (OLN) : Free Stock Analysis Report To read this article on Zacks.com click here. A month has gone by since the last earnings report for DuPont de Nemours (DD). Shares have added about 5% in that time frame, underperforming the S&P 500.
|
A month has gone by since the last earnings report for DuPont de Nemours (DD). Shares have added about 5% in that time frame, underperforming the S&P 500. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
|
85cba695-fc2b-4f12-9a84-89b740ef88df
|
715693.0
|
2023-12-01 00:00:00 UTC
|
DuPont (DD) Attains Full Conversion to Low-GWP Styrofoam
|
DD
|
https://www.nasdaq.com/articles/dupont-dd-attains-full-conversion-to-low-gwp-styrofoam
|
nan
|
nan
|
DuPont de Nemours Inc. DD said that all Styrofoam Brand XPS insulation manufacturing sites in North America now produce a low global warming potential (GWP) formulation, decreasing embodied carbon by 94% and distinguishable by a shift from the original blue to the new grey color.
This new insulation maintains the market-required moisture resistance and thermal performance parameters of Styrofoam Brand XPS. In addition to much lower embodied carbon, this new Styrofoam Brand XPS insulation provides consumers with a variety of benefits, including LEED v4.1 LCA Optimization credit.
This award-winning product personifies the spirit of creativity. The company's joint efforts have considerably reduced the carbon footprint of its Styrofoam portfolio, allowing it to better serve its consumers and communities while also protecting the environment, DD noted.
The new low-GWP Styrofoam Brand XPS Insulation builds on the strengths of more than 80 years of technical innovation. It is already created with 100% renewable electricity and a zero-ozone-depleting formula, and it maintains a minimum R-value of R-5 per inch of thickness for long-term thermal performance.
Additionally, the new formulation has already received honors for sustainable innovation, including the 2023 American Chemistry Council Sustainability Leadership Award in the category of Environmental Protection. The Styrofoam Brand Plazamate XR insulation, which has the best thermal resistance per inch of any XPS roofing insulation, also got a 2023 R&D 100 Award.
Shares of DuPont have lost 0.1% over the past year against a 16.4% decline of its industry.
Image Source: Zacks Investment Research
The company, on its third-quarter call, said that it now sees net sales for 2023 to be around $12,170 million. Adjusted earnings per share for the year are forecast to be about $3.45. Operating EBITDA for 2023 is expected to be roughly $2,975 million.
For the fourth quarter, demand for consumer electronics is anticipated to remain in line with the third quarter, as indicated by consistent order rates from customers. This will likely result in a sequential sales improvement in the Semiconductor Technologies segment. However, compared with the previous guidance, there are additional challenges stemming from channel inventory destocking and decreased industrial water demand in China.
DuPont de Nemours, Inc. Price and Consensus
DuPont de Nemours, Inc. price-consensus-chart | DuPont de Nemours, Inc. Quote
Zacks Rank & Key Picks
DuPont currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the basic materials space include Denison Mines Corp. DNN, Axalta Coating Systems Ltd. AXTA and The Andersons Inc. ANDE.
Denison Mines has a projected earnings growth rate of 100% for the current year. It currently carries a Zacks Rank #1 (Strong Buy). DNN delivered a trailing four-quarter earnings surprise of roughly 225%, on average. The stock is up around 42.7% in a year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Axalta has a projected earnings growth rate of 5.4% for the current year. It currently carries a Zacks Rank #1. AXTA delivered a trailing four-quarter earnings surprise of roughly 6.7%, on average. The stock is up around 15.7% in a year.
Andersons currently carries a Zacks Rank #2. The stock has gained roughly 28.2% in the past year. ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Andersons, Inc. (ANDE) : Free Stock Analysis Report
DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report
Denison Mine Corp (DNN) : Free Stock Analysis Report
Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DuPont de Nemours Inc. DD said that all Styrofoam Brand XPS insulation manufacturing sites in North America now produce a low global warming potential (GWP) formulation, decreasing embodied carbon by 94% and distinguishable by a shift from the original blue to the new grey color. In addition to much lower embodied carbon, this new Styrofoam Brand XPS insulation provides consumers with a variety of benefits, including LEED v4.1 LCA Optimization credit. The company's joint efforts have considerably reduced the carbon footprint of its Styrofoam portfolio, allowing it to better serve its consumers and communities while also protecting the environment, DD noted.
|
Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. DuPont de Nemours Inc. DD said that all Styrofoam Brand XPS insulation manufacturing sites in North America now produce a low global warming potential (GWP) formulation, decreasing embodied carbon by 94% and distinguishable by a shift from the original blue to the new grey color. In addition to much lower embodied carbon, this new Styrofoam Brand XPS insulation provides consumers with a variety of benefits, including LEED v4.1 LCA Optimization credit.
|
DuPont de Nemours Inc. DD said that all Styrofoam Brand XPS insulation manufacturing sites in North America now produce a low global warming potential (GWP) formulation, decreasing embodied carbon by 94% and distinguishable by a shift from the original blue to the new grey color. Click to get this free report The Andersons, Inc. (ANDE) : Free Stock Analysis Report DuPont de Nemours, Inc. (DD) : Free Stock Analysis Report Denison Mine Corp (DNN) : Free Stock Analysis Report Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report To read this article on Zacks.com click here. In addition to much lower embodied carbon, this new Styrofoam Brand XPS insulation provides consumers with a variety of benefits, including LEED v4.1 LCA Optimization credit.
|
DuPont de Nemours Inc. DD said that all Styrofoam Brand XPS insulation manufacturing sites in North America now produce a low global warming potential (GWP) formulation, decreasing embodied carbon by 94% and distinguishable by a shift from the original blue to the new grey color. In addition to much lower embodied carbon, this new Styrofoam Brand XPS insulation provides consumers with a variety of benefits, including LEED v4.1 LCA Optimization credit. The company's joint efforts have considerably reduced the carbon footprint of its Styrofoam portfolio, allowing it to better serve its consumers and communities while also protecting the environment, DD noted.
|
06e50527-47a1-4280-b874-ce16ff394eb4
|
715694.0
|
2023-11-30 00:00:00 UTC
|
Interesting DD Put And Call Options For January 2024
|
DD
|
https://www.nasdaq.com/articles/interesting-dd-put-and-call-options-for-january-2024
|
nan
|
nan
|
Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new January 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $71.00 strike price has a current bid of 80 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $71.00, but will also collect the premium, putting the cost basis of the shares at $70.20 (before broker commissions). To an investor already interested in purchasing shares of DD, that could represent an attractive alternative to paying $71.53/share today.
Because the $71.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.13% return on the cash commitment, or 9.56% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for DuPont, and highlighting in green where the $71.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $72.00 strike price has a current bid of $1.10. If an investor was to purchase shares of DD stock at the current price level of $71.53/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $72.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 2.19% if the stock gets called away at the January 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red:
Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.54% boost of extra return to the investor, or 13.05% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $71.53) to be 24%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
REITs Hedge Funds Are Selling
SBCF YTD Return
Funds Holding IE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Of course, a lot of upside could potentially be left on the table if DD shares really soar, which is why looking at the trailing twelve month trading history for DuPont, as well as studying the business fundamentals becomes important. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in DuPont (Symbol: DD) saw new options begin trading today, for the January 2024 expiration.
|
The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted).
|
At Stock Options Channel, our YieldBoost formula has looked up and down the DD options chain for the new January 2024 contracts and identified one put and one call contract of particular interest. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Below is a chart showing DD's trailing twelve month trading history, with the $72.00 strike highlighted in red: Considering the fact that the $72.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected.
|
169bfd9f-ceee-4375-b1f6-3d1f4174d965
|
715695.0
|
2023-11-29 00:00:00 UTC
|
DuPont, Chemours, Corteva To Pay $110 Mln To Ohio As Natural Resource Restoration Deal Settles
|
DD
|
https://www.nasdaq.com/articles/dupont-chemours-corteva-to-pay-%24110-mln-to-ohio-as-natural-resource-restoration-deal
|
nan
|
nan
|
(RTTNews) - DuPont De Nemours & Co. (DD), Chemours Co. (CC) and Corteva, Inc. (CTVA) announced Wednesday that they have reached a settlement agreement with The State of Ohio regarding natural resource restoration.
As part of the settlement, the companies agreed to pay the State of Ohio a combined total of $110 million. Of this, the State has allocated 80 percent to restoration of natural resources related to operation of the Washington Works facility.
The binding Memorandum of Understanding between the companies were reached in January 2021, under which DuPont's share of the settlement will be around $39 million.
The settlement resolves, among other things, the State's claims relating to releases of per- and polyfluoroalkyl substances, generically referred to as "PFAS", in or into the State from the companies' facilities and claims relating to the manufacture and sale of PFAS-containing products. The settlement also resolves the State's claims related to aqueous film-forming foam or AFFF.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - DuPont De Nemours & Co. (DD), Chemours Co. (CC) and Corteva, Inc. (CTVA) announced Wednesday that they have reached a settlement agreement with The State of Ohio regarding natural resource restoration. As part of the settlement, the companies agreed to pay the State of Ohio a combined total of $110 million. Of this, the State has allocated 80 percent to restoration of natural resources related to operation of the Washington Works facility.
|
(RTTNews) - DuPont De Nemours & Co. (DD), Chemours Co. (CC) and Corteva, Inc. (CTVA) announced Wednesday that they have reached a settlement agreement with The State of Ohio regarding natural resource restoration. Of this, the State has allocated 80 percent to restoration of natural resources related to operation of the Washington Works facility. The settlement also resolves the State's claims related to aqueous film-forming foam or AFFF.
|
(RTTNews) - DuPont De Nemours & Co. (DD), Chemours Co. (CC) and Corteva, Inc. (CTVA) announced Wednesday that they have reached a settlement agreement with The State of Ohio regarding natural resource restoration. The settlement resolves, among other things, the State's claims relating to releases of per- and polyfluoroalkyl substances, generically referred to as "PFAS", in or into the State from the companies' facilities and claims relating to the manufacture and sale of PFAS-containing products. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - DuPont De Nemours & Co. (DD), Chemours Co. (CC) and Corteva, Inc. (CTVA) announced Wednesday that they have reached a settlement agreement with The State of Ohio regarding natural resource restoration. As part of the settlement, the companies agreed to pay the State of Ohio a combined total of $110 million. Of this, the State has allocated 80 percent to restoration of natural resources related to operation of the Washington Works facility.
|
e724268a-c94e-4b50-806d-b025d5767115
|
715696.0
|
2023-11-29 00:00:00 UTC
|
Chemours, DuPont, Corteva reach $110 mln 'forever chemicals' Ohio settlement
|
DD
|
https://www.nasdaq.com/articles/chemours-dupont-corteva-reach-%24110-mln-forever-chemicals-ohio-settlement
|
nan
|
nan
|
Adds details on settlement and background between paragraphs 2-5
Nov 29 (Reuters) - Chemours CC.N, Dupont De Nemours DD.N and Corteva CTVA.N have reached a settlement agreement with the U.S. state of Ohio for $110 million to resolve claims associated with toxic "forever chemicals", the companies said on Wednesday.
Chemours said it would be responsible for half of the settlement costs, while DuPont would provide about $39 million.
The agreement resolves Ohio's claims relating to the release of per- and polyfluoroalkyl substances, or PFAS, from the companies' facilities, including the Washington Works facility located along the Ohio-West Virginia border, Chemours said in a statement.
Chemical makers have faced thousands of lawsuits in recent years over alleged PFAS contamination.
3M MMM.N agreed in June to pay $10.3 billion to settle hundreds of claims that the company polluted public drinking water with the chemicals, while Chemours, DuPont and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
(Reporting by Tanay Dhumal and Sourasis Bose in Bengaluru; Editing by Shilpi Majumdar and Devika Syamnath)
((Tanay.Dhumal@thomsonreuters.com; Twitter: https://twitter.com/TanayDhumal;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Adds details on settlement and background between paragraphs 2-5 Nov 29 (Reuters) - Chemours CC.N, Dupont De Nemours DD.N and Corteva CTVA.N have reached a settlement agreement with the U.S. state of Ohio for $110 million to resolve claims associated with toxic "forever chemicals", the companies said on Wednesday. Chemical makers have faced thousands of lawsuits in recent years over alleged PFAS contamination. 3M MMM.N agreed in June to pay $10.3 billion to settle hundreds of claims that the company polluted public drinking water with the chemicals, while Chemours, DuPont and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
|
Adds details on settlement and background between paragraphs 2-5 Nov 29 (Reuters) - Chemours CC.N, Dupont De Nemours DD.N and Corteva CTVA.N have reached a settlement agreement with the U.S. state of Ohio for $110 million to resolve claims associated with toxic "forever chemicals", the companies said on Wednesday. The agreement resolves Ohio's claims relating to the release of per- and polyfluoroalkyl substances, or PFAS, from the companies' facilities, including the Washington Works facility located along the Ohio-West Virginia border, Chemours said in a statement. 3M MMM.N agreed in June to pay $10.3 billion to settle hundreds of claims that the company polluted public drinking water with the chemicals, while Chemours, DuPont and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
|
Adds details on settlement and background between paragraphs 2-5 Nov 29 (Reuters) - Chemours CC.N, Dupont De Nemours DD.N and Corteva CTVA.N have reached a settlement agreement with the U.S. state of Ohio for $110 million to resolve claims associated with toxic "forever chemicals", the companies said on Wednesday. The agreement resolves Ohio's claims relating to the release of per- and polyfluoroalkyl substances, or PFAS, from the companies' facilities, including the Washington Works facility located along the Ohio-West Virginia border, Chemours said in a statement. 3M MMM.N agreed in June to pay $10.3 billion to settle hundreds of claims that the company polluted public drinking water with the chemicals, while Chemours, DuPont and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
|
Adds details on settlement and background between paragraphs 2-5 Nov 29 (Reuters) - Chemours CC.N, Dupont De Nemours DD.N and Corteva CTVA.N have reached a settlement agreement with the U.S. state of Ohio for $110 million to resolve claims associated with toxic "forever chemicals", the companies said on Wednesday. Chemours said it would be responsible for half of the settlement costs, while DuPont would provide about $39 million. The agreement resolves Ohio's claims relating to the release of per- and polyfluoroalkyl substances, or PFAS, from the companies' facilities, including the Washington Works facility located along the Ohio-West Virginia border, Chemours said in a statement.
|
87319277-dbaa-4995-b37a-aa2b0e9f4578
|
715697.0
|
2023-11-27 00:00:00 UTC
|
3M, DuPont defeat massive class action over forever chemicals
|
DD
|
https://www.nasdaq.com/articles/3m-dupont-defeat-massive-class-action-over-forever-chemicals-0
|
nan
|
nan
|
By Clark Mindock
Nov 27 (Reuters) - A U.S. appeals court on Monday handed 3M MMM.N, Corteva Inc CTVA.N subsidiary E.I. du Pont de Nemours and Co and other manufacturers of toxic so-called "forever chemicals" a big win in their fight against legal liability for the substances, rejecting a lower court's ruling that would have allowed about 11.8 million Ohio residents to sue the companies as a group.
The Cincinnati, Ohio-based 6th U.S. Circuit Court of Appeals vacated a lower court's approval of the massive class action, which included virtually every resident of Ohio and put considerable legal pressure on the chemical manufacturers to settle the plaintiffs' claims.
The court found lead plaintiff Kevin Hardwick filed too broad a complaint against the manufacturers, and had not shown per- and polyfluoroalkyl substances, or PFAS, found in his body could be traced directly to the defendants such as units of 3M, DuPont and others.
The court said Hardwick's complaint “rarely” targeted the actions of any one company, and instead accused the companies collectively of contaminating the environment with the chemicals.
"Seldom is so ambitious a case filed on so slight a basis," wrote Circuit Judge Raymond Kethledge, noting there are thousands of companies that have manufactured PFAS but just 10 listed as defendants in the case.
The appeals court instructed the lower court to dismiss Hardwick's lawsuit, which had aimed to force the companies to pay for studies analyzing the health impacts of PFAS. The chemicals are used in a wide range of consumer products including non-stick pans and clothing and have been tied to cancer and other diseases.
The lawsuit also sought to establish a fund to monitor Ohio residents for health impacts from PFAS exposure.
A 3M spokesperson said the company is pleased with the decision.
Robert Bilott, an attorney for Hardwick, said the court's decision runs "counter to what we know about the history of manufacturing of PFAS in the United States" and said they are evaluating whether to appeal.
The chemicals are often referred to as forever chemicals because they do not easily break down in nature or in the human body.
The lawsuit is among thousands that have been filed against 3M, DuPont and others in recent years over alleged PFAS contamination.
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N, DuPont de Nemours Inc DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion.
The U.S. Environmental Protection Agency has called PFAS an “urgent public health and environmental issue," and has taken steps to regulate PFAS, including in drinking water.
(Reporting by Clark Mindock, Editing by Alexia Garamfalvi, Lincoln Feast and Chris Reese)
((Clark.Mindock@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N, DuPont de Nemours Inc DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. du Pont de Nemours and Co and other manufacturers of toxic so-called "forever chemicals" a big win in their fight against legal liability for the substances, rejecting a lower court's ruling that would have allowed about 11.8 million Ohio residents to sue the companies as a group. The chemicals are used in a wide range of consumer products including non-stick pans and clothing and have been tied to cancer and other diseases.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N, DuPont de Nemours Inc DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. Circuit Court of Appeals vacated a lower court's approval of the massive class action, which included virtually every resident of Ohio and put considerable legal pressure on the chemical manufacturers to settle the plaintiffs' claims. The appeals court instructed the lower court to dismiss Hardwick's lawsuit, which had aimed to force the companies to pay for studies analyzing the health impacts of PFAS.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N, DuPont de Nemours Inc DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. du Pont de Nemours and Co and other manufacturers of toxic so-called "forever chemicals" a big win in their fight against legal liability for the substances, rejecting a lower court's ruling that would have allowed about 11.8 million Ohio residents to sue the companies as a group. Circuit Court of Appeals vacated a lower court's approval of the massive class action, which included virtually every resident of Ohio and put considerable legal pressure on the chemical manufacturers to settle the plaintiffs' claims.
|
3M agreed in June to pay $10.3 billion to settle hundreds of claims the company polluted public drinking water with the chemicals, while Chemours Co CC.N, DuPont de Nemours Inc DD.N and Corteva reached a similar deal with U.S. water providers for $1.19 billion. The appeals court instructed the lower court to dismiss Hardwick's lawsuit, which had aimed to force the companies to pay for studies analyzing the health impacts of PFAS. Robert Bilott, an attorney for Hardwick, said the court's decision runs "counter to what we know about the history of manufacturing of PFAS in the United States" and said they are evaluating whether to appeal.
|
3a789b7a-ecad-4de8-bf86-142786bc93dc
|
715698.0
|
2023-11-27 00:00:00 UTC
|
Ex-Dividend Reminder: Ryerson Holding, Kinross Gold and DuPont
|
DD
|
https://www.nasdaq.com/articles/ex-dividend-reminder%3A-ryerson-holding-kinross-gold-and-dupont
|
nan
|
nan
|
Looking at the universe of stocks we cover at Dividend Channel, on 11/29/23, Ryerson Holding Corp (Symbol: RYI), Kinross Gold Corp. (Symbol: KGC), and DuPont (Symbol: DD) will all trade ex-dividend for their respective upcoming dividends. Ryerson Holding Corp will pay its quarterly dividend of $0.185 on 12/14/23, Kinross Gold Corp. will pay its quarterly dividend of $0.03 on 12/14/23, and DuPont will pay its quarterly dividend of $0.36 on 12/15/23. As a percentage of RYI's recent stock price of $30.12, this dividend works out to approximately 0.61%, so look for shares of Ryerson Holding Corp to trade 0.61% lower — all else being equal — when RYI shares open for trading on 11/29/23. Similarly, investors should look for KGC to open 0.54% lower in price and for DD to open 0.50% lower, all else being equal.
Below are dividend history charts for RYI, KGC, and DD, showing historical dividends prior to the most recent ones declared.
Ryerson Holding Corp (Symbol: RYI):
Kinross Gold Corp. (Symbol: KGC):
DuPont (Symbol: DD):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.46% for Ryerson Holding Corp, 2.15% for Kinross Gold Corp., and 2.01% for DuPont.
Free Report: Top 8%+ Dividends (paid monthly)
In Monday trading, Ryerson Holding Corp shares are currently up about 1.3%, Kinross Gold Corp. shares are up about 0.5%, and DuPont shares are up about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
ETF Fund Flows
Funds Holding TCRZ
GRB Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Looking at the universe of stocks we cover at Dividend Channel, on 11/29/23, Ryerson Holding Corp (Symbol: RYI), Kinross Gold Corp. (Symbol: KGC), and DuPont (Symbol: DD) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for KGC to open 0.54% lower in price and for DD to open 0.50% lower, all else being equal. Below are dividend history charts for RYI, KGC, and DD, showing historical dividends prior to the most recent ones declared.
|
Looking at the universe of stocks we cover at Dividend Channel, on 11/29/23, Ryerson Holding Corp (Symbol: RYI), Kinross Gold Corp. (Symbol: KGC), and DuPont (Symbol: DD) will all trade ex-dividend for their respective upcoming dividends. Ryerson Holding Corp (Symbol: RYI): Kinross Gold Corp. (Symbol: KGC): DuPont (Symbol: DD): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for KGC to open 0.54% lower in price and for DD to open 0.50% lower, all else being equal.
|
Looking at the universe of stocks we cover at Dividend Channel, on 11/29/23, Ryerson Holding Corp (Symbol: RYI), Kinross Gold Corp. (Symbol: KGC), and DuPont (Symbol: DD) will all trade ex-dividend for their respective upcoming dividends. Ryerson Holding Corp (Symbol: RYI): Kinross Gold Corp. (Symbol: KGC): DuPont (Symbol: DD): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for KGC to open 0.54% lower in price and for DD to open 0.50% lower, all else being equal.
|
Looking at the universe of stocks we cover at Dividend Channel, on 11/29/23, Ryerson Holding Corp (Symbol: RYI), Kinross Gold Corp. (Symbol: KGC), and DuPont (Symbol: DD) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for KGC to open 0.54% lower in price and for DD to open 0.50% lower, all else being equal. Below are dividend history charts for RYI, KGC, and DD, showing historical dividends prior to the most recent ones declared.
|
864aa9a7-4d52-406e-980a-64ab9e57931f
|
715699.0
|
2023-11-23 00:00:00 UTC
|
Guru Fundamental Report for DD
|
DD
|
https://www.nasdaq.com/articles/guru-fundamental-report-for-dd-12
|
nan
|
nan
|
Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks for companies returning cash to shareholders via dividends, buybacks and debt paydown.
DUPONT DE NEMOURS INC (DD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
UNIVERSE: PASS
NET PAYOUT YIELD: PASS
QUALITY AND DEBT: PASS
VALUATION: PASS
RELATIVE STRENGTH: PASS
SHAREHOLDER YIELD: PASS
Detailed Analysis of DUPONT DE NEMOURS INC
DD Guru Analysis
DD Fundamental Analysis
More Information on Meb Faber
Meb Faber Portfolio
About Meb Faber: Meb Faber is the founder of Cambria Investments. His research has covered a wide spectrum of the investment world, including topics like shareholder yield, trend following, global asset allocation and home country bias. His shareholder yield strategy, which is based on his book "Shareholder Yield" and forms the basis for an ETF of the same name, looks for companies that are focused on creating value for shareholders by returning cash to them in the form of dividends, share buybacks and debt paydown. Meb is also the author of 4 other books and numerous white papers on investing related topics.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DUPONT DE NEMOURS INC (DD) is a large-cap growth stock in the Biotechnology & Drugs industry. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber.
|
Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD).
|
Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Additional Research Links Top Healthcare Stocks Dividend Aristocrats2023 Wide Moat Stocks2023 High Insider Ownership Stocks Factor-Based Stock Portfolios About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD).
|
Below is Validea's guru fundamental report for DUPONT DE NEMOURS INC (DD). Detailed Analysis of DUPONT DE NEMOURS INC DD Guru Analysis DD Fundamental Analysis More Information on Meb Faber Meb Faber Portfolio About Meb Faber: Meb Faber is the founder of Cambria Investments. Of the 22 guru strategies we follow, DD rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber.
|
25d1544b-3d05-468d-a140-69cd919cdb8e
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.